WCLC 2018 - Disclosure Information - Faculty and Planners · 11/1/2018 · WCLC 2018 - Disclosure Information - Faculty and Planners Final Pr.No. Topic Presentation Title Pres. FirstName

WCLC 2018 - Disclosure Information - Faculty and Planners

Final Pr.No. Topic Presentation Title Pres. FirstName Pres. LastName Pres. Country Relationship Company

Session JCSE01: Perspectives for Lung Cancer Early Detection

Sunday, September 23 ‐ 07:30 ‐ 11:15

Planner

JCSE01 Yi‐long Wu China Speakers or Advisory Board AstraZeneca, Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, Sanofi

JCSE01 Yi‐long Wu China Speakers Bureau AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi

JCSE01 Yi‐long Wu China Honoraria AstraZeneca, Eli Lilly, Pfizer, Roche

JCSE01 Yi‐long Wu China Consultant AstraZeneca, Boehringer Ingelheim, Merck, Roche

JCSE01 Yi‐long Wu China Supported/Contracted Research/Grant Boehringer Ingelheim, Roche

JCSE01 Fred Hirsch USA Consultant AstraZeneca, Genentech, HTG Molecular Diagnostics, Eli Lilly, Merck, Clovis Oncology, Ventana Medical Systems, Bristol‐Meyers Squibb, Pfizer, Roche

JCSE01 Fred Hirsch USA Royalty, Intellectual Property/Patent Holder University of Colorado Cancer Center

JCSE01 Fred Hirsch USA Supported/Contracted Research/Grant Eli Lilly, Genentech, Amgen, Bristol‐Meyers Squibb, Celgene

JCSE01 Fred Hirsch USA Speakers or Advisory Board AbbVie, AstraZeneca, Biocept, Bristol‐Meyers Squibb, HTG, Eli Lilly, Loxo, Merck, Novartis, Pfizer, Roche, Genentech, Ventana, Bayer

JCSE01 Tony Mok Hongkong Speakers or Advisory Board AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Bristol‐Meyers Squibb, Taiho, Takeda Oncology Serono, SFJ Pharma, ACEA Biosciences, Vertex Pharma, geneDecode, OncoGenex Technologies, Celgene, Ignyta, Cirina, Fishawack Facilitate, Janssen, ChiMed

JCSE01 Tony Mok Hongkong Honoraria AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, SFJ Pharma, ACEA Biosciences, Vertex Pharma, Bristol‐Meyers Squibb, OncoGenex Pharma, Celgene, Ignyta, Fishawack Facilitate, Takeda Oncology, Janssen, Cirina, Chimed

JCSE01 Tony Mok Hongkong Ownership Interest (stocks or stock options, or other ownership interest

Sanomics, Cirina

JCSE01 Tony Mok Hongkong Consultant Roche., IASLC, ASCO, ChiMed, Chinese Lung Cancer Research Foundation, Chinese Society of Clinical Oncology, Hong Kong Cancer Therapy Society

JCSE01 Tony Mok Hongkong Supported/Contracted Research/Grant AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmas Group, Roche, Merck, Clovis Oncology, Bristol‐Meyers Squibb, Taiho Pharma, Eisai

JCSE01 Tony Mok Hongkong Employee (full time or part time) The Chinese University of Hong Kong

JCSE01 Caixun Bai China Nothing to disclose

Chairs

JCSE01 Yi‐long Wu China Speakers or Advisory Board AstraZeneca, Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, Sanofi

JCSE01 Yi‐long Wu China Speakers Bureau AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi

JCSE01 Yi‐long Wu China Honoraria AstraZeneca, Eli Lilly, Pfizer, Roche

JCSE01 Yi‐long Wu China Consultant AstraZeneca, Boehringer Ingelheim, Merck, Roche

JCSE01 Yi‐long Wu China Supported/Contracted Research/Grant Boehringer Ingelheim, Roche

JCSE01 Fred Hirsch USA Consultant AstraZeneca, Genentech, HTG Molecular Diagnostics, Eli Lilly, Merck, Clovis Oncology, Ventana Medical Systems, Bristol‐Meyers Squibb, Pfizer, Roche

JCSE01 Fred Hirsch USA Royalty, Intellectual Property/Patent Holder University of Colorado Cancer Center

JCSE01 Fred Hirsch USA Supported/Contracted Research/Grant Eli Lilly, Genentech, Amgen, Bristol‐Meyers Squibb, Celgene

JCSE01 Fred Hirsch USA Speakers or Advisory Board AbbVie, AstraZeneca, Biocept, Bristol‐Meyers Squibb, HTG, Eli Lilly, Loxo, Merck, Novartis, Pfizer, Roche, Genentech, Ventana, Bayer

JCSE01 Tony Mok Hongkong Speakers or Advisory Board AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Bristol‐Meyers Squibb, Taiho, Takeda Oncology Serono, SFJ Pharma, ACEA Biosciences, Vertex Pharma, geneDecode, OncoGenex Technologies, Celgene, Ignyta, Cirina, Fishawack Facilitate, Janssen, ChiMed

JCSE01 Tony Mok Hongkong Honoraria AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, SFJ Pharma, ACEA Biosciences, Vertex Pharma, Bristol‐Meyers Squibb, OncoGenex Pharma, Celgene, Ignyta, Fishawack Facilitate, Takeda Oncology, Janssen, Cirina, Chimed

JCSE01 Tony Mok Hongkong Ownership Interest (stocks or stock options, or other ownership interest

Sanomics, Cirina

JCSE01 Tony Mok Hongkong Consultant Roche., IASLC, ASCO, ChiMed, Chinese Lung Cancer Research Foundation, Chinese Society of Clinical Oncology, Hong Kong Cancer Therapy Society

JCSE01 Tony Mok Hongkong Supported/Contracted Research/Grant AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmas Group, Roche, Merck, Clovis Oncology, Bristol‐Meyers Squibb, Taiho Pharma, Eisai

JCSE01 Tony Mok Hongkong Employee (full time or part time) The Chinese University of Hong Kong

Faculty

JCSE01.02 Screening and Early Detection Necessity for Early Detection in Lung Cancer and Initial Attempts for Early Detection

Annette McWilliams Australia Nothing to disclose

JCSE01.03 Screening and Early Detection CT Screening for Early Detection (NLST, UKLS, NELSON, ITALUNG, DANTE, Others)

Matthijs Oudkerk Netherlands Nothing to disclose

JCSE01.04 Screening and Early Detection Risk Modeling for the Early Detection of Tin Miner Lung Cancer in China You‐lin Qiao China Nothing to disclose

JCSE01.05 Screening and Early Detection Biomarkers and Liquid Biopsy for Early Detection of Lung Cancer K.C. Allen Chan Hongkong Nothing to disclose

JCSE01.06 Screening and Early Detection Incorporating Artificial Intelligence for Early Detection of Lung Cancer Jie Hu Nothing to disclose

JCSE01.07 Screening and Early Detection Discussion

JCSE01.09 Advanced NSCLC Cluster Trial: Ph2 Biomarker‐Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC

Qing Zhou China Nothing to disclose

JCSE01.10 Small Cell Lung Cancer/NET A Ph3 Study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients

Shun Lu China Supported/Contracted Research/Grant AstraZeneca

JCSE01.10 Small Cell Lung Cancer/NET A Ph3 Study of Niraparib as Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients

Shun Lu China Speakers or Advisory Board Eli Lilly, Hutchison MediPharma, Simcere, Bristol‐Meyers Squibb, Roche, Pfizer, AstraZeneca

JCSE01.11 Advanced NSCLC Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC

Jianhua Chang China Nothing to disclose

JCSE01.12 Screening and Early Detection Discussant Oral Abstracts Daniel Tan Singapore Honoraria National Cancer Centre Singapore, Pfizer, Merck, AstraZeneca, Loxo, Boehringer Ingelheim, Bristol‐Meyers Squibb



JCSE01.12 Screening and Early Detection Discussant Oral Abstracts Daniel Tan Singapore Speakers or Advisory Board AstraZeneca, Pfizer, Novartis, Merck

JCSE01.12 Screening and Early Detection Discussant Oral Abstracts Daniel Tan Singapore Supported/Contracted Research/Grant GSK, AstraZeneca, Novartis

JCSE01.13 Screening and Early Detection Discussant Poster Abstracts Bob Li USA Consultant Genentech, Roche, Thermo Fischer Scientific, Guardant Health

JCSE01.13 Screening and Early Detection Discussant Poster Abstracts Bob Li USA Speakers or Advisory Board Genentech, Guardant Health, Mersana Therapeutics

JCSE01.14 Immunooncology Effects of Neoadjuvant Chemotherapy on the Expression of Programmed Death Ligand‐1 and Tumor Infiltrating Lymphocytes in Lung Cancer Tissues

Xu Wang China Nothing to disclose

JCSE01.15 Biology Molecular Characteristics of ALK Primary Point Mutations Non‐Small‐Cell Lung Cancer in Chinese Patients

Chunwei Xu China Nothing to disclose

JCSE01.16 Pathology Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non‐Mucinous Invasive

Zheng Wang China Nothing to disclose

JCSE01.17 Treatment of Early Stage/Localized Disease Weekly Nab‐Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA‐N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study

Changli Wang China Nothing to disclose

JCSE01.18 Advanced NSCLC A Multicenter Survey of One Year Survival Among Chinese Patients with Advanced Nonsquamous Non‐Small Cell Lung Cancer (CTONG1506)


JCSE01.19 Targeted Therapy ALTER‐0303 Study: Tumor Mutation Index (TMI) For Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Baohui Han China Nothing to disclose

JCSE01.20 Small Cell Lung Cancer/NET Outcome in Small Cell Lung Cancer Patients with Cerebral Recurrence After Prior Prophylactic Cranial Irradiation

Lei Zhao China Nothing to disclose

JCSE01.21 Targeted Therapy Different Responses to Osimertinib in Primary and Acquired EGFR T790M‐Mutant NSCLC Patients

Shuyuan Wang China Nothing to disclose

JCSE01.22 Advanced NSCLC Differential Molecular Mechanisms Associated with Dramatic and Gradual Progression in NSCLC Patients with Intrathoracic Dissemination

Ying Chen China Nothing to disclose

JCSE01.22a Immunooncology Tislelizumab Combined With Chemotherapy as First‐Line Treatment in Chinese Patients With Advanced Lung Cancer

Jie Wang China Nothing to disclose

JCSE01.23 Screening and Early Detection Closing Remarks

Session WS01: Cancer Genomics Workshop


Planner

WS01 Natasha Leighl Canada Supported/Contracted Research/Grant Novartis

WS01 Natasha Leighl Canada Honoraria Merck, Bristol‐Meyers Squibb

WS01 Natasha Leighl Canada Consultant Novartis, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Canadian Agency for Drugs and Technologies in Health

WS01 Ramaswamy Govindan USA Speakers or Advisory Board Merck, Baxalta, Roche, Boehringer Ingleheim, Novartis, Pfizer, Celgene, AstraZeneca, MSK, AbbVie Inivata, Pfizer, NeoHealth, Bristol‐Meyers Squibb, Nektar, GlaxcSmithKline

WS01 Ramaswamy Govindan USA Consultant Genentech, Ariad, Astellas, Bristol‐Meyers Squibb, INC Research, AbbVie

WS01 Ramaswamy Govindan USA Honoraria AbbVie, Genentech, Boehringer Ingelheim

Chairs

WS01 Ramaswamy Govindan USA Speakers or Advisory Board Merck, Baxalta, Roche, Boehringer Ingleheim, Novartis, Pfizer, Celgene, AstraZeneca, MSK, AbbVie Inivata, Pfizer, NeoHealth, Bristol‐Meyers Squibb, Nektar, GlaxcSmithKline

WS01 Ramaswamy Govindan USA Consultant Genentech, Ariad, Astellas, Bristol‐Meyers Squibb, INC Research, AbbVie

WS01 Ramaswamy Govindan USA Honoraria AbbVie, Genentech, Boehringer Ingelheim

WS01 Richard Haspel USA Nothing to disclose

Faculty

WS01.01 Introduction to the Workshop Richard Haspel USA Nothing to disclose

WS01.02 Exercise 1: Cancer Gene Panels: Methods and Application Richard Haspel USA Nothing to disclose

WS01.04 Exercise 2: Cancer Gene Panels: Result Interpretation and Clinical Utility Richard Haspel USA Nothing to disclose

WS01.05 Questions/Panel Discussion

Session WS02: Mesothelioma Workshop


Planner

WS02 Mesothelioma Anna Nowak Australia Speakers or Advisory Board Bayer, AstraZeneca, Sellas Life Sciences, Trizell, Boehringer Ingelheim, Epizyme, Roche, Merck

WS02 Mesothelioma Anna Nowak Australia Consultant AstraZeneca, Boehringer Ingelheim, Epizyme

WS02 Mesothelioma Anna Nowak Australia Supported/Contracted Research/Grant AstraZeneca, Douglas Pharma

WS02 Mesothelioma Marc DePerrot Canada Nothing to disclose

WS02 Mesothelioma Paul Baas Netherlands Nothing to disclose

WS02 Mesothelioma Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer

WS02 Mesothelioma Michele Carbone USA Nothing to disclose

WS02 Mesothelioma John Cho Canada Nothing to disclose



WS02 Mesothelioma Lauren Donohoe Canada Nothing to disclose

WS02 Mesothelioma Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche

WS02 Mesothelioma Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex

WS02 Mesothelioma Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca

WS02 Mesothelioma Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

WS02 Mesothelioma Seiki Hasegawa Japan Nothing to disclose

WS02 Mesothelioma Christopher Lee Canada Nothing to disclose

WS02 Mesothelioma Isabelle Opitz Switzerland Nothing to disclose

WS02 Mesothelioma Nick Pavlakis Australia Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Astra Zeneca, Roche, Novartis, Boehringer Ingelheim, Merck, Pfizer, Ipsen, Amgen

WS02 Mesothelioma Nick Pavlakis Australia Supported/Contracted Research/Grant Bayer

WS02 Mesothelioma Kenneth Rosenzweig USA Nothing to disclose

Chair

WS02 Mesothelioma Michele Carbone USA Nothing to disclose

Faculty

WS02.01 Mesothelioma Session 1: Surgery for Mesothelioma Harvey Pass USA Nothing to disclose

WS02.02 Mesothelioma What Are the Most Important Unmet Needs in the Surgical Management of Mesothelioma?

Valerie Rusch USA Consultant Da Vinci Surgery, Bristol‐Meyers Squibb

WS02.02 Mesothelioma What Are the Most Important Unmet Needs in the Surgical Management of Mesothelioma?

Valerie Rusch USA Supported/Contracted Research/Grant Genelux

WS02.03 Mesothelioma Who Are the High Risk Patients for Surgical Failure in Mesothelioma? Harvey Pass USA Nothing to disclose

WS02.04 Mesothelioma SMART, Where It Is Going Marc De Perrot Canada Nothing to disclose

WS02.05 Mesothelioma Reliability of MM Diagnosis and Role of BAP1 Staining Francoise Galateau‐Salle France Nothing to disclose

WS02.06 Mesothelioma Q&A

WS02.07 Mesothelioma Session 2: Immunotherapy in Mesothelioma Paul Baas Netherlands Nothing to disclose

WS02.08 Mesothelioma The Microenvironment and Mesothelioma Prasad Adusumilli USA Nothing to disclose

WS02.09 Mesothelioma PDL‐1 and Mesothelioma Raphael Bueno USA Supported/Contracted Research/Grant NIH U01 SPECS II

WS02.10 Mesothelioma An Overview of Present and Future Immunotherapy Trials in Mesothelioma: Progress and Problems

Aaron Mansfield USA Speakers or Advisory Board Genentech, Bristol‐Meyers Squibb, AbbVie


Aaron Mansfield USA Supported/Contracted Research/Grant Novartis, NIH


Aaron Mansfield USA Consultant Roche

WS02.11 Mesothelioma Window of Opportunity Immunotherapy Trials in Mesothelioma: Design and Translation

Anne Tsao USA Speakers or Advisory Board Bristol‐Meyers Squibb, Eli Lilly, Genentech, Roche, Novartis, Ariad, Merck, Seattle Genetics, Astra‐Zeneca, Boehringer Ingelheim, Sellas Life Science, Takeda, Polaris, Astellas Pharma, Imedex


Anne Tsao USA Supported/Contracted Research/Grant Eli Lilly, Millennium, Polaris, Genentech, Merck, Boehringer Ingelheim, Bristol‐Meyers Squibb, Ariad, Epizyme, Genetics


Anne Tsao USA Consultant Bristol‐Meyers Squibb, Eli Lilly, Genentech, Roche, Novartis, Ariad, Merck, Seattle Genetics, AstraZeneca, Boehringer Ingelheim, Sellas Life Sciences, MedImmune


Anne Tsao USA Honoraria Bristol‐Meyers Squibb, Astra‐Zeneca, Novartis, Boehringer Ingelheim, Genentech, Roche, Takeda, Ariad, Eli Lilly


Anne Tsao USA Royalty, Intellectual Property/Patent Holder John Wiley


WS02.13 Mesothelioma Session 3: Transcriptome Changes and Mutations in Mesothelioma ‐ Somatic, Germline, BAP1 and more

David Jablons USA Consultant Razor Genomics

WS02.14 Mesothelioma BAP1 Mutations: Mechanisms and Significance Michele Carbone USA Nothing to disclose

WS02.15 Mesothelioma Novel Approaches for Targeting BAP1 Marjorie Zauderer USA Nothing to disclose

WS02.16 Mesothelioma Genome‐wide Silencing Screen in Mesothelioma Cells Reveals that Loss of Function of BAP1 Induces Chemoresistance to Ribonucleotide Reductase

Emanuela Felley‐Bosco Switzerland Nothing to disclose

WS02.17 Mesothelioma A Subset of Mesotheliomas with Improved Survival Occurring in Carriers of BAP1 and of other Germline Mutations

Haining Yang USA Nothing to disclose


Session WS03: Endoscopic Diagnosis and Staging of Lung Cancer – Interventional Pulmonology Hands‐On Workshop


Planner

WS03 Kazuhiro Yasufuku Canada Speakers or Advisory Board Concordia, Olympus America

WS03 Kazuhiro Yasufuku Canada Supported/Contracted Research/Grant Olympus Corporation, Siemens, Veran Medical Technologies, Novadaq

WS03 Kazuhiro Yasufuku Canada Consultant Intuitive Surgical, Medtronic, Johnson & Johnson, Auris Surgical Robotics

Chairs



WS03 Kazuhiro Yasufuku Canada Speakers or Advisory Board Concordia, Olympus America

WS03 Kazuhiro Yasufuku Canada Supported/Contracted Research/Grant Olympus Corporation, Siemens, Veran Medical Technologies, Novadaq

WS03 Kazuhiro Yasufuku Canada Consultant Intuitive Surgical, Medtronic, Johnson & Johnson, Auris Surgical Robotics

Faculty

WS03.01 Interventional Diagnostics/Pulmonology Welcome and Introduction

WS03.02 Interventional Diagnostics/Pulmonology EBUS‐TBNA – Role in Invasive Mediastinal Staging Kazuhiro Yasufuku Canada Speakers or Advisory Board Concordia, Olympus America

WS03.02 Interventional Diagnostics/Pulmonology EBUS‐TBNA – Role in Invasive Mediastinal Staging Kazuhiro Yasufuku Canada Supported/Contracted Research/Grant Olympus Corporation, Siemens, Veran Medical Technologies, Novadaq

WS03.02 Interventional Diagnostics/Pulmonology EBUS‐TBNA – Role in Invasive Mediastinal Staging Kazuhiro Yasufuku Canada Consultant Intuitive Surgical, Medtronic, Johnson & Johnson, Auris Surgical Robotics

WS03.03 Interventional Diagnostics/Pulmonology Combined EBUS/EUS Mediastinal Staging Waël Hanna Canada Nothing to disclose

WS03.04 Interventional Diagnostics/Pulmonology Radial Probe EBUS – Methods and Results Kasia Czarnecka‐Kujawa Canada Nothing to disclose

WS03.05 Interventional Diagnostics/Pulmonology Navigational Bronchoscopy Laura Donahoe Canada Nothing to disclose

WS03.06 Interventional Diagnostics/Pulmonology Hands‐On Session on 4 stations

Session YI01: Young Investigator and First Time Attendee Session


Planner

YI01 Young Investigator Track Benjamin Besse France Supported/Contracted Research/Grant Roche, AstraZeneca

YI01 Young Investigator Track Jonathan Yeung Canada Nothing to disclose

YI01 Young Investigator Track Clarissa Baldotto Brazil Nothing to disclose

YI01 Young Investigator Track Vladimir de Lima Brazil Nothing to disclose

YI01 Young Investigator Track Mark Doherty Canada Nothing to disclose

YI01 Young Investigator Track Yoshihisa Kobayashi Japan Speakers Bureau Boehringer Ingelheim

YI01 Young Investigator Track Yoshihisa Kobayashi Japan Supported/Contracted Research/Grant The Japan Society for the Promotion of Science, Osaka Cancer Society, Novartis

YI01 Young Investigator Track Céline Mascaux France Honoraria Boehringer Ingelheim, Eli Lilly, Bristol‐Meyers Squibb, Roche, AstraZeneca

YI01 Young Investigator Track Céline Mascaux France Consultant Roche, Kephren, AstraZeneca, Merck

YI01 Young Investigator Track Céline Mascaux France Speakers or Advisory Board AstraZeneca, Roche, Kephren

YI01 Young Investigator Track Tatiane Montella Brazil Nothing to disclose

YI01 Young Investigator Track Luis Ubillos Uruguay Speakers Bureau Roche, Tecnofarma

YI01 Young Investigator Track Luis Ubillos Uruguay Speakers or Advisory Board Roche, Tecnofarma, Servier, Bayer

YI01 Young Investigator Track Linda Coate USA Nothing to disclose

Chairs

YI01 Jonathan Yeung Canada Nothing to disclose

YI01 Katy Clarke UK Nothing to disclose

Faculty

YI01.01 Introduction to the IASLC ‐ Why You Should be a Member Clarissa Mathias Brazil Nothing to disclose

YI01.02 Planning a Career in Lung Cancer ‐ Clinical Trials Roy Herbst USA Speakers or Advisory Board AstraZeneca, Eli Lilly, Genentech, Roche, Merck, NextCure, Novartis, Pfizer

YI01.02 Planning a Career in Lung Cancer ‐ Clinical Trials Roy Herbst USA Supported/Contracted Research/Grant AstraZeneca, Eli Lilly, Merck, Genentech

YI01.03 Planning a Career in Lung Cancer ‐ Science Yolonda Colson USA Contracted/Support Research Grant Canon USA

YI01.04 Planning a Career in Lung Cancer ‐ Bench to Beside Pasi Jänne USA Consultant Araxes Pharmas, Ariad, AstraZeneca, Boehringer Ingelheim, Chugai, Ignyta, Eli Lilly, Loxo, Merrimack, Mirati Therapeutics, Pfizer, Roche, Dana‐Farber Cancer Institute

YI01.04 Planning a Career in Lung Cancer ‐ Bench to Beside Pasi Jänne USA Speakers or Advisory Board AstraZeneca, Boehringer Ingelheim, Pfizer, Merrimack Pharmas, Roche, Genentech, Chugai Pharmas, Acea Biosciences, Ignyta, Loxo, Ariad, Eli Lilly, Araxes Pharmas

YI01.04 Planning a Career in Lung Cancer ‐ Bench to Beside Pasi Jänne USA Speakers Bureau Loxo

YI01.04 Planning a Career in Lung Cancer ‐ Bench to Beside Pasi Jänne USA Ownership Interest (stocks or stock options, or other ownership interest

Gatekeeper Pharmas

YI01.04 Planning a Career in Lung Cancer ‐ Bench to Beside Pasi Jänne USA Supported/Contracted Research/Grant Astellas Pharmas, AstraZenenca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim

YI01.04 Planning a Career in Lung Cancer ‐ Bench to Beside Pasi Jänne USA Royalty, Intellectual Property/Patent Holder LabCorp

YI01.05 Planning a Career in Lung Cancer ‐ Education Barbara Melosky Canada Nothing to disclose

YI01.06 Community Oncology Parneet Cheema Canada Speakers or Advisory Board Pfizer, AstraZeneca, Roche, Merck, Novartis, Takeda, Boehringer Ingelheim, Bristol‐Meyers Squibb

YI01.07 Making the Most of your Cooperative Group Rolf Stahel Switzerland Speakers Bureau AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Roche



YI01.07 Making the Most of your Cooperative Group Rolf Stahel Switzerland Speakers or Advisory Board AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Pfizer, Roche

YI01.08 Panel Discussion

YI01.10 Knowing your Statistics Mary Redman USA Nothing to disclose

YI01.11 How to get your Paper Published Alex Adjei USA Nothing to disclose

YI01.12 Writing a Successful Abstract Michael Boyer Australia Honoraria Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca, Novartis

YI01.12 Writing a Successful Abstract Michael Boyer Australia Speakers or Advisory Board Merck, Amgen, Roche, Bristol‐Meyers Squibb, Pfizer, AstraZeneca

YI01.12 Writing a Successful Abstract Michael Boyer Australia Contracted/Support Research Grant Merck, Amgen, Genentech, Roche, Bristol‐Meyers Squibb, AstraZeneca, Novartis, Pfizer

YI01.13 How to give a Great Presentation Tony Mok Hongkong Speakers or Advisory Board AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Bristol‐Meyers Squibb, Taiho, Takeda Oncology Serono, SFJ Pharma, ACEA Biosciences, Vertex Pharma, geneDecode, OncoGenex Technologies, Celgene, Ignyta, Cirina, Fishawack Facilitate, Janssen, ChiMed

YI01.13 How to give a Great Presentation Tony Mok Hongkong Honoraria AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, SFJ Pharma, ACEA Biosciences, Vertex Pharma, Bristol‐Meyers Squibb, OncoGenex Pharma, Celgene, Ignyta, Fishawack Facilitate, Takeda Oncology, Janssen, Cirina, Chimed

YI01.13 How to give a Great Presentation Tony Mok Hongkong Ownership Interest (stocks or stock options, or other ownership interest

Sanomics, Cirina

YI01.13 How to give a Great Presentation Tony Mok Hongkong Consultant Roche., IASLC, ASCO, ChiMed, Chinese Lung Cancer Research Foundation, Chinese Society of Clinical Oncology, Hong Kong Cancer Therapy Society

YI01.13 How to give a Great Presentation Tony Mok Hongkong Supported/Contracted Research/Grant AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmas Group, Roche, Merck, Clovis Oncology, Bristol‐Meyers Squibb, Taiho Pharma, Eisai

YI01.13 How to give a Great Presentation Tony Mok Hongkong Employee (full time or part time) The Chinese University of Hong Kong

YI01.14 How to write a Successful Grant Application Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche

YI01.14 How to write a Successful Grant Application Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex

YI01.14 How to write a Successful Grant Application Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca

YI01.14 How to write a Successful Grant Application Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

YI01.15 Panel Discussion

YI01.16 Young investigator Experience Fabio Moraes Brazil Nothing to disclose

YI01.17 Getting the most out of WCLC 2018 Anne‐Marie Baird Australia Nothing to disclose

Session WS05: ITONF Workshop


Planner

WS05 Nursing and Allied Professionals Massey Nematollahi Canada Nothing to disclose

WS05 Nursing and Allied Professionals Patricia Hollen USA Nothing to disclose

WS05 Nursing and Allied Professionals Beth Eaby‐Sandy USA Speakers Bureau Helsinn, Merck, AstraZeneca, Takeda

WS05 Nursing and Allied Professionals Beth Eaby‐Sandy USA Consultant Consultant‐ AbbVie

WS05 Nursing and Allied Professionals Kathleen Gamblin USA Nothing to disclose

WS05 Nursing and Allied Professionals Maria Guerin UK Speakers or Advisory Board AstraZeneca

WS05 Nursing and Allied Professionals Maria Guerin UK Honoraria AstraZeneca

WS05 Nursing and Allied Professionals Pippa Labuc UK Nothing to disclose

WS05 Nursing and Allied Professionals Naz Nouriany Canada Nothing to disclose

WS05 Nursing and Allied Professionals Dianne Zawisza Canada Nothing to disclose

Chairs

WS05 Nursing and Allied Professionals Melissa Culligan USA Nothing to disclose

Faculty

WS05.01 Nursing and Allied Professionals ITONF Membership Meeting & Luncheon Melissa Culligan USA Nothing to disclose

WS05.02 Nursing and Allied Professionals Keynote Speaker: Lung Cancer and Mesothelioma Nursing Care in Canada Massey Nematollahi Canada Nothing to disclose

WS05.03 Nursing and Allied Professionals Panel Discussion: Managing Hope and Expectations in Thoracic Oncology Duncan Colyer Australia Nothing to disclose

WS05.04 Nursing and Allied Professionals Tag, Tweet or Follow: Top Tips for using Social Media in your Clinical Practice

Liz Darlison UK Nothing to disclose

WS05.05 Nursing and Allied Professionals UPDATE: Immunotherapy, Targeted Therapy and Combination Therapy Clinical Trials in Lung Cancer and Mesothelioma

Rebecca Lau Australia Nothing to disclose

WS05.06 Nursing and Allied Professionals Break

WS05.07 Nursing and Allied Professionals Global Issues in Lung Cancer and Mesothelioma in 2018 Lorraine Creech UK Nothing to disclose

WS05.08 Nursing and Allied Professionals UPDATE: Advances in Local Treatments for Lung Cancer and Mesothelioma (Radiation and Surgery)

Anastasia Bykova Canada Nothing to disclose

WS05.09 Nursing and Allied Professionals Break

WS05.10 Nursing and Allied Professionals Nurse‐led TeleHealth in Thoracic Oncology John McPhelim UK Nothing to disclose



WS05.11 Nursing and Allied Professionals UPDATE: Toxicity Management of Immunotherapy Treatments in Lung Cancer and Mesothelioma

Marianne Davies USA Speakers Bureau AstraZeneca, Genentech, Bristol‐Meyers Squibb, Merck

WS05.12 Nursing and Allied Professionals 2017‐18 Year in Review: Scientific Poster Session Angela Tod UK Nothing to disclose

Session MTE01: Preclinical Models of Lung Cancer

Monday, September 24 ‐ 07:00 ‐ 08:00

Planner

MTE01 Biology Wan Lam Canada Nothing to disclose

MTE01 Biology Kwok‐kin Wong USA Nothing to disclose

MTE01 Biology Oscar Arrieta Mexico Nothing to disclose

MTE01 Biology David Beer USA Nothing to disclose

MTE01 Biology Robert Doebele USA Ownership Interest (stocks or stock options, or other ownership interest

Rain Therapeutics

MTE01 Biology Robert Doebele USA Speakers or Advisory Board Ignyta, AstraZeneca, Bayer, Takeda, Bristol‐Meyers Squibb, Ariad

MTE01 Biology Robert Doebele USA Supported/Contracted Research/Grant Ignyta

MTE01 Biology Robert Doebele USA Consultant Pfizer, OncoMed, Trovagene, Ignyta, GreenPeptide, AstraZeneca, Ignyta, Ariad, Guardant Health

MTE01 Biology Robert Doebele USA Honoraria Pfizer, AstraZeneca, Ariad, Guardant Health, Takeda, Spectrum Pharmas, Trovagene

MTE01 Biology Robert Doebele USA Royalty, Intellectual Property/Patent Holder Abbott Molecular, Rain Therapeutics, Igynta

MTE01 Biology Ramaswamy Govindan USA Speakers or Advisory Board Merck, Baxalta, Roche, Boehringer Ingleheim, Novartis, Pfizer, Celgene, AstraZeneca, MSK, AbbVie Inivata, Pfizer, NeoHealth, Bristol‐Meyers Squibb, Nektar, GlaxcSmithKline

MTE01 Biology Ramaswamy Govindan USA Consultant Genentech, Ariad, Astellas, Bristol‐Meyers Squibb, INC Research, AbbVie

MTE01 Biology Ramaswamy Govindan USA Honoraria AbbVie, Genentech, Boehringer Ingelheim

MTE01 Biology Fred Hirsch USA Consultant AstraZeneca, Genentech, HTG Molecular Diagnostics, Eli Lilly, Merck, Clovis Oncology, Ventana Medical Systems, Bristol‐Meyers Squibb, Pfizer, Roche

MTE01 Biology Fred Hirsch USA Royalty, Intellectual Property/Patent Holder University of Colorado Cancer Center

MTE01 Biology Fred Hirsch USA Supported/Contracted Research/Grant Eli Lilly, Genentech, Amgen, Bristol‐Meyers Squibb, Celgene

MTE01 Biology Fred Hirsch USA Speakers or Advisory Board AbbVie, AstraZeneca, Biocept, Bristol‐Meyers Squibb, HTG, Eli Lilly, Loxo, Merck, Novartis, Pfizer, Roche, Genentech, Ventana, Bayer

MTE01 Biology Thomas John Australia Speakers or Advisory Board Bristol‐Meyers Squibb, AstraZeneca, Boehringher Ingelheim, Takeda, Pfizer, Novartis, Merck, Ignyta

MTE01 Biology Thomas John Australia Consultant Bristol‐Meyers Squibb, AstraZeneca, Boehringer Ingelheim, Takeda, Pfizer, Novartis, Merck

MTE01 Biology Geoffrey Liu Canada Honoraria AstraZeneca, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie, Pfizer, Merck

MTE01 Biology Geoffrey Liu Canada Speakers Bureau AstraZeneca

MTE01 Biology Geoffrey Liu Canada Speakers or Advisory Board AstraZeneca, Roche, Merck, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie

MTE01 Biology William Lockwood Canada Nothing to disclose

MTE01 Biology Philip Mack USA Supported/Contracted Research/Grant Boehringer Ingelheim

MTE01 Biology Philip Mack USA Consultant Guardant Health, Apton Biosystems

MTE01 Biology Philip Mack USA Speakers or Advisory Board AstraZeneca, Eli Lilly, Pfizer

MTE01 Biology Matthew Meyerson USA Speakers or Advisory Board OrigiMed

MTE01 Biology Matthew Meyerson USA Ownership Interest (stocks or stock options, or other ownership interest

OrigiMed

MTE01 Biology Matthew Meyerson USA Supported/Contracted Research/Grant Bayer

MTE01 Biology Matthew Meyerson USA Royalty, Intellectual Property/Patent Holder LabCorp

MTE01 Biology Katerina Politi USA Supported/Contracted Research/Grant AstraZeneca, Roche, Kolltan, Symphogen

MTE01 Biology Katerina Politi USA Honoraria AstraZeneca, Merck, Novartis, Tocagen

MTE01 Biology Katerina Politi USA Royalty, Intellectual Property/Patent Holder Molecular MD

MTE01 Biology Daniel Tan Singapore Honoraria National Cancer Centre Singapore, Pfizer, Merck, AstraZeneca, Loxo, Boehringer Ingelheim, Bristol‐Meyers Squibb

MTE01 Biology Daniel Tan Singapore Speakers or Advisory Board AstraZeneca, Pfizer, Novartis, Merck

MTE01 Biology Daniel Tan Singapore Supported/Contracted Research/Grant GSK, AstraZeneca, Novartis

MTE01 Biology Pan‐Chyr Yang Taiwan Nothing to disclose

Faculty

MTE01.01 Biology GEMM of Lung Cancer Sarah Best Australia Nothing to disclose

MTE01.02 Biology Lung Patient Derived Xenograft and Organoid Nadeem Moghal Canada Nothing to disclose



Session MTE02: Update on WHO Classification and Staging of Lung Cancer


Planner

MTE02 Pathology Ming Tsao Canada Honoraria Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Roche, Ventana

MTE02 Pathology Ming Tsao Canada Supported/Contracted Research/Grant Merck, Pfizer, Roche, Ventana, AstraZeneca

MTE02 Pathology Ming Tsao Canada Speakers or Advisory Board AstraZeneca, Pfizer, Merck, Roche, Ventana, Bristol Myers Squibb, AbbVie, Celgene

MTE02 Pathology Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune

MTE02 Pathology Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche

MTE02 Pathology Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen

MTE02 Pathology Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

MTE02 Pathology Alan Borczuk USA Nothing to disclose

MTE02 Pathology Lukas Bubendorf Switzerland Nothing to disclose

MTE02 Pathology Sanja Dacic USA Speakers or Advisory Board Bristol‐Meyers Squibb, Astra‐Zeneca

MTE02 Pathology Sanja Dacic USA Honoraria Bristol‐Meyers Squibb, AstraZeneca

MTE02 Pathology David Hwang Canada Honoraria Merck, Pfizer, Takeda

MTE02 Pathology David Hwang Canada Speakers or Advisory Board Merck

MTE02 Pathology Keith Kerr UK Consultant Bristol‐Meyers Squibb

MTE02 Pathology Keith Kerr UK Speakers or Advisory Board AstraZeneca, Bristol Meyers Squibb, Merck, Roche, Pfizer

MTE02 Pathology Sylvie Lantuejoul France Nothing to disclose

MTE02 Pathology John Longshore USA Speakers Bureau Roche, AstraZeneca, Bristol‐Meyers Squibb, Merck, Genentech

MTE02 Pathology John Longshore USA Speakers or Advisory Board Roche, AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer

MTE02 Pathology John Longshore USA Supported/Contracted Research/Grant Roche, AstraZeneca

MTE02 Pathology Mari Mino‐Kenudson USA Consultant Merrimack Pharmas, H3 Biomedicine

MTE02 Pathology Mari Mino‐Kenudson USA Honoraria Merrimac Pharmas, H3 Biomedicine

MTE02 Pathology Andre Moreira USA Nothing to disclose

MTE02 Pathology Andrew Nicholson UK Consultant Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Bristol‐Meyers Squibb, Roche, AbbVie

MTE02 Pathology Andrew Nicholson UK Supported/Contracted Research/Grant Pfizer, Roche

MTE02 Pathology Andrew Nicholson UK Speakers or Advisory Board Pfizer, Abbvie

MTE02 Pathology Andrew Nicholson UK Ownership Interest (stocks or stock options, or other ownership interest

Merck

MTE02 Pathology Yasushi Yatabe Japan Consultant Merck, Chugai‐Pharma, AstraZeneca, Bristol‐Meyers Squibb, Pfizer, Roche, ThermoFisher, Dako

MTE02 Pathology Yasushi Yatabe Japan Honoraria AstraZeneca, Merck, Bristol Myers, Chugai‐pharma, Pfizer, Roche

Faculty

MTE02.01 Pathology Update on WHO Classification and Staging of Lung Cancer Sanja Dacic USA Speakers or Advisory Board Bristol‐Meyers Squibb, Astra‐Zeneca

MTE02.01 Pathology Update on WHO Classification and Staging of Lung Cancer Sanja Dacic USA Honoraria Bristol‐Meyers Squibb, AstraZeneca

MTE02.02 Pathology Update on WHO Classification and Staging of Lung Cancer Teh‐Ying Chou Taiwan Speakers or Advisory Board Merck, Foundation Medicine, Roche, Novartis

Session MTE03: Clinical Trial Design With Novel Lung Cancer Therapy


Planner

MTE03 Targeted Therapy Janessa Laskin Canada Honoraria Roche, Boehringer Ingelheim, AstraZeneca

MTE03 Targeted Therapy Janessa Laskin Canada Supported/Contracted Research/Grant AstraZeneca, Roche, Pfizer

MTE03 Targeted Therapy Tony Mok China Speakers or Advisory Board AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Bristol‐Meyers Squibb, Taiho, Takeda Oncology Serono, SFJ Pharma, ACEA Biosciences, Vertex Pharma, geneDecode, OncoGenex Technologies, Celgene, Ignyta, Cirina, Fishawack Facilitate, Janssen, ChiMed

MTE03 Targeted Therapy Tony Mok China Honoraria AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, SFJ Pharma, ACEA Biosciences, Vertex Pharma, Bristol‐Meyers Squibb, OncoGenex Pharma, Celgene, Ignyta, Fishawack Facilitate, Takeda Oncology, Janssen, Cirina, Chimed

MTE03 Targeted Therapy Tony Mok China Ownership Interest (stocks or stock options, or other ownership interest

Sanomics, Cirina

MTE03 Targeted Therapy Tony Mok China Consultant Roche., IASLC, ASCO, ChiMed, Chinese Lung Cancer Research Foundation, Chinese Society of Clinical Oncology, Hong Kong Cancer Therapy Society



MTE03 Targeted Therapy Tony Mok China Supported/Contracted Research/Grant AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmas Group, Roche, Merck, Clovis Oncology, Bristol‐Meyers Squibb, Taiho Pharma, Eisai

MTE03 Targeted Therapy Tony Mok China Employee (full time or part time) The Chinese University of Hong Kong

MTE03 Targeted Therapy Ross Camidge USA Honoraria Takeda, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, AstraZeneca, Arrys/Kyn, Genoptix, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera, Lycera, Revolution Med, Orion, Clovis, Celegene, Novartis

MTE03 Targeted Therapy Ross Camidge USA Supported/Contracted Research/Grant Ariad, Takeda, Pfizer

MTE03 Targeted Therapy Ross Camidge USA Speakers or Advisory Board AstraZeneca, Takeda, Arrys/Kyn, Genoptix, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, Takeda, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera DSMB, Lycera, Revolution Med

MTE03 Targeted Therapy Alexander Drilon USA Speakers or Advisory Board Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

MTE03 Targeted Therapy Alexander Drilon USA Honoraria TP Therapeutics, Loxo, Ignyta, Roche, Genentech, Pfizer

MTE03 Targeted Therapy Alexander Drilon USA Supported/Contracted Research/Grant Foundation Medicine

MTE03 Targeted Therapy Alexander Drilon USA Consultant Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

MTE03 Targeted Therapy Enriqueta Felip Spain Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb Celgene, Eli Lilly, Guardant Health, Novartis, Pfizer, Roche, Takeda, Merck

MTE03 Targeted Therapy Enriqueta Felip Spain Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, AstraZeneca, Bristol‐Meyers Squibb, Novartis, AbbVie, Takeda, Celegene, Guardant Health, Merck

MTE03 Targeted Therapy Enriqueta Felip Spain Speakers Bureau AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, MSD, Novartis, Pfizer, Roche, Takeda, AbbVie, Merck, Celegne, Eli Lilly, Guardant Health

MTE03 Targeted Therapy Pilar Garrido Spain Consultant Roche, Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol‐Meyers Squibb, Eli Lilly and Company, AbbVie, Novartis

MTE03 Targeted Therapy Pilar Garrido Spain Speakers Bureau Roche, Merck, Bristol‐Meyers Squibb, Pfizer

MTE03 Targeted Therapy Pilar Garrido Spain Supported/Contracted Research/Grant Guardant

MTE03 Targeted Therapy Shun Lu China Supported/Contracted Research/Grant AstraZeneca

MTE03 Targeted Therapy Shun Lu China Speakers or Advisory Board Eli Lilly, Hutchison MediPharma, Simcere, Bristol‐Meyers Squibb, Roche, Pfizer, AstraZeneca

MTE03 Targeted Therapy Zofia Piotrowska USA Consultant AstraZeneca, Boehringer Ingelheim, Ariad, Novartis, Guardant Health, Takeda, AbbVie

MTE03 Targeted Therapy Zofia Piotrowska USA Speakers or Advisory Board AstraZeneca, Ariad, Takeda, Novartis, Boehringer Ingelheim, AbbVie

MTE03 Targeted Therapy Zofia Piotrowska USA Supported/Contracted Research/Grant Novartis

MTE03 Targeted Therapy Zofia Piotrowska USA Honoraria Guardant Health

MTE03 Targeted Therapy Karen Reckamp USA Consultant Amgen, Ariad, Astellas Pharma, Euclises, Tesaro, Boehringer Ingelheim, Takeda

MTE03 Targeted Therapy Karen Reckamp USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Novartis, Ariad, Clovis Oncology, Xcovery, Gilead Sciences, Pfizer, Adaptimmune, Genentech, Roche, Boehringer Ingelheim, AbbVie

MTE03 Targeted Therapy Lecia Sequist USA Speakers or Advisory Board AstraZeneca, Genentech, Pfizer, Bristol‐Meyers Squibb, Merrimack Pharma, Blueprint Medicines

MTE03 Targeted Therapy Lecia Sequist USA Consultant Merrimack, Novartis, Boehringer Ingelheim

MTE03 Targeted Therapy Lecia Sequist USA Supported/Contracted Research/Grant AstraZeneca, Novartis, Genentech, Boehringer Ingelheim, Merck, Merrimack, Guardant Health

MTE03 Targeted Therapy Benjamin Solomon Australia Speakers or Advisory Board AstraZeneca, Bristol‐Myers Squibb, Merck, Pfizer, Roche, Genentech, Novartis

MTE03 Targeted Therapy Benjamin Solomon Australia Honoraria Bristol‐Myers Squibb, AstraZeneca

MTE03 Targeted Therapy Benjamin Solomon Australia Supported/Contracted Research/Grant Pfizer

MTE03 Targeted Therapy Benjamin Solomon Australia Royalty, Intellectual Property/Patent Holder Veristrat

MTE03 Targeted Therapy Benjamin Solomon Australia Consultant AstraZeneca, Roche, Merck, Bristol‐Myers Squibb, Novartis

MTE03 Targeted Therapy James Chih‐Hsin Yang Taiwan Consultant Boehringer Ingelheim, Eli Lilly, Bayer, Roche, Genentech, Chugai, Astellas, Merck, Novartis, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, Takeda, AstraZeneca, Hansoh Pharma

MTE03 Targeted Therapy James Chih‐Hsin Yang Taiwan Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Roche, Genentech, Chugai, Astellas, Merck, Pfizer, Novartis, Takeda, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, AstraZeneca, Hansoh Pharma

MTE03 Targeted Therapy James Chih‐Hsin Yang Taiwan Honoraria Novartis, Roche, Genentech, Eli Lilly and Company, Merck, Celgene, Pfizer, Ono Pharma, Bristol‐Myers Squibb, Hansoh, Takeda, Boehringer Ingelheim, Astellas, Merimack, Yuhan Pharma

Faculty

MTE03.01 Targeted Therapy Inclusion/Exclusion Updates (CNS Mets, Multiple Prior Cancers, Organ Dysfunction)

Peter Ellis Canada Honoraria AbbVie, AstraZeneca

MTE03.01 Targeted Therapy Inclusion/Exclusion Updates (CNS Mets, Multiple Prior Cancers, Organ Dysfunction)

Peter Ellis Canada Consultant Celegene, Mylan

MTE03.02 Targeted Therapy Novel Trial Design for Precision Medicine Fiona Blackhall UK Nothing to disclose

Session MTE04: Comparison of Various Risk Models


Planner

MTE04 Screening and Early Detection Christine Berg USA Honoraria Medial Early Sign LLC, GRAIL

MTE04 Screening and Early Detection Stephen Lam Canada Nothing to disclose

MTE04 Screening and Early Detection Denise Aberle USA Nothing to disclose

MTE04 Screening and Early Detection John Field UK Speakers Bureau Roche



MTE04 Screening and Early Detection John Field UK Speakers or Advisory Board Epigenomics, VisonGate

MTE04 Screening and Early Detection John Goffin Canada Nothing to disclose

MTE04 Screening and Early Detection Harry Groen Netherlands Consultant Roche‐Genentech, Merck, Novartis, Bristol‐Meyers Squibb

MTE04 Screening and Early Detection Norihiko Ikeda Japan Honoraria AstraZeneca, Chugai, Merck, Ono Pharma, Taiho, Eli Lilly, Pfizer, Johnson & Johnson

MTE04 Screening and Early Detection Garth Nicholas Canada Nothing to disclose

MTE04 Screening and Early Detection Nir Peled Israel Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

MTE04 Screening and Early Detection Nir Peled Israel Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

MTE04 Screening and Early Detection Heidi Schmidt Canada Nothing to disclose

MTE04 Screening and Early Detection Betty Tong Speakers or Advisory Board Medtronic

Faculty

MTE04.01 Screening and Early Detection Comparisons of Risk Models Christine Berg USA Honoraria Medial Early Sign LLC, GRAIL

MTE04.02 Screening and Early Detection Where Should Health Programs Set Threshold for Tailored Screening? James Mulshine USA Nothing to disclose

Session MTE05: Role of Pneumonectomy in N2 Disease


Planner

MTE05 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Supported/Contracted Research/Grant Merck, AstraZeneca, Elekta

MTE05 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Consultant Merck, AstraZeneca, Elekta, Pfizer, Respective Meeting‐Related Travel Support

MTE05 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers or Advisory Board Pfizer, Merck

MTE05 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Honoraria AstraZeneca, Merck

MTE05 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers Bureau AstraZeneca, Merck

MTE05 Treatment of Locoregional Disease ‐ NSCLC Paula Ugalde Canada Nothing to disclose

MTE05 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Honoraria Pfizer, Boehringer Ingelheim, AstaZeneca, Bristol‐Meyers Squibb, Merck, Takeda

MTE05 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Speakers or Advisory Board Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Merck, Takeda

MTE05 Treatment of Locoregional Disease ‐ NSCLC Hiroshi Date Japan Nothing to disclose

MTE05 Treatment of Locoregional Disease ‐ NSCLC Dirk De Ruysscher Netherlands Nothing to disclose

MTE05 Treatment of Locoregional Disease ‐ NSCLC Rui Haddad Brazil Nothing to disclose

MTE05 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Speakers Bureau Varian Medical

MTE05 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Honoraria Varian Medical

MTE05 Treatment of Locoregional Disease ‐ NSCLC Jocelyne Martin Canada Nothing to disclose

MTE05 Treatment of Locoregional Disease ‐ NSCLC Gaetano Rocco Italy Speakers Bureau Baxter, Medtronic

MTE05 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers or Advisory Board AbbVie, AstraZeneca, Spiration

MTE05 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers Bureau Synthes

MTE05 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Consultant Spiration, Olympus

Faculty

MTE05.01 Treatment of Locoregional Disease ‐ NSCLC Role of Pneumonectomy in N2 Disease Jessica Donington USA Honoraria AstraZeneca

MTE05.02 Treatment of Locoregional Disease ‐ NSCLC Role of Pneumonectomy in N2 Disease Paula Ugalde Canada Nothing to disclose

Session MTE06: Symptom Management in Mesothelioma


Planner

MTE06 Mesothelioma Anna Nowak Australia Speakers or Advisory Board Bayer, AstraZeneca, Sellas Life Sciences, Trizell, Boehringer Ingelheim, Epizyme, Roche, Merck

MTE06 Mesothelioma Anna Nowak Australia Consultant AstraZeneca, Boehringer Ingelheim, Epizyme

MTE06 Mesothelioma Anna Nowak Australia Supported/Contracted Research/Grant AstraZeneca, Douglas Pharma

MTE06 Mesothelioma Marc DePerrot Canada Nothing to disclose



MTE06 Mesothelioma Paul Baas Netherlands Nothing to disclose

MTE06 Mesothelioma Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer

MTE06 Mesothelioma Michele Carbone USA Nothing to disclose

MTE06 Mesothelioma John Cho Canada Nothing to disclose

MTE06 Mesothelioma Lauren Donohoe Canada Nothing to disclose

MTE06 Mesothelioma Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche

MTE06 Mesothelioma Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex

MTE06 Mesothelioma Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca

MTE06 Mesothelioma Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

MTE06 Mesothelioma Seiki Hasegawa Japan Nothing to disclose

MTE06 Mesothelioma Christopher Lee Canada Nothing to disclose

MTE06 Mesothelioma Isabelle Opitz Switzerland Nothing to disclose

MTE06 Mesothelioma Nick Pavlakis Australia Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Astra Zeneca, Roche, Novartis, Boehringer Ingelheim, Merck, Pfizer, Ipsen, Amgen

MTE06 Mesothelioma Nick Pavlakis Australia Supported/Contracted Research/Grant Bayer

MTE06 Mesothelioma Kenneth Rosenzweig USA Nothing to disclose

Faculty

MTE06.01 Mesothelioma Role of Pleurectomy in Palliation of Symptoms John Edwards UK Nothing to disclose

MTE06.02 Mesothelioma How to Register Toxicity and Guide Patients Liz Darlison UK Nothing to disclose

Session MTE07: Management of Pleural Recurrence


Planner

MTE07 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Honoraria ACEA, Genentech, Novartis, AstraZeneca

MTE07 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Supported/Contracted Research/Grant Clovis, Exelixis, AstraZeneca, MedImmune, Genentech, Roche, Bristol‐Meyers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Eli Lilly, Acea, Merck

MTE07 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Speakers or Advisory Board ACEA Biosyciences, Pfizer, Novartis, Genentech, Roche, AstraZeneca, Merck

MTE07 Thymoma/Other Thoracic Malignancies Meinoshin Okumura Japan Nothing to disclose

MTE07 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Speakers or Advisory Board AstraZeneca

MTE07 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Consultant Eli Lilly

MTE07 Thymoma/Other Thoracic Malignancies Wentao Fang China Nothing to disclose

MTE07 Thymoma/Other Thoracic Malignancies Pier Luigi Filosso Italy Nothing to disclose

MTE07 Thymoma/Other Thoracic Malignancies Nicolas Girard France Consultant Bristol‐Meyers Squibb, Merck Roche, AstraZeneca

MTE07 Thymoma/Other Thoracic Malignancies Shaf Keshavjee Canada Nothing to disclose

MTE07 Thymoma/Other Thoracic Malignancies Robert Korst USA Nothing to disclose

MTE07 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Supported/Contracted Research/Grant Varian Medical Systems, Boehringer Ingelheim, AstraZeneca, Pfizer

MTE07 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Honoraria Varian Medical Systms, Bristol‐Meyers Squibb, AstraZeneca, Pfizer, Merck

MTE07 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Speakers or Advisory Board AstraZeneca, Merck

MTE07 Thymoma/Other Thoracic Malignancies DAvid Waller UK Nothing to disclose

Faculty

MTE07.01 Thymoma/Other Thoracic Malignancies From Radiation Oncology Perspective Andreas Rimner USA Supported/Contracted Research/Grant Varian Medical Systems, Boehringer Ingelheim, AstraZeneca, Pfizer

MTE07.01 Thymoma/Other Thoracic Malignancies From Radiation Oncology Perspective Andreas Rimner USA Honoraria Varian Medical Systms, Bristol‐Meyers Squibb, AstraZeneca, Pfizer, Merck

MTE07.01 Thymoma/Other Thoracic Malignancies From Radiation Oncology Perspective Andreas Rimner USA Speakers or Advisory Board AstraZeneca, Merck

MTE07.02 Thymoma/Other Thoracic Malignancies From Surgical Perspective Robert Korst USA Nothing to disclose

Session MTE08: Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges




Planner

MTE08 Nursing and Allied Professionals Massey Nematollahi Canada Nothing to disclose

MTE08 Nursing and Allied Professionals Patricia Hollen USA Nothing to disclose

MTE08 Nursing and Allied Professionals Beth Eaby‐Sandy USA Speakers Bureau Helsinn, Merck, AstraZeneca, Takeda

MTE08 Nursing and Allied Professionals Beth Eaby‐Sandy USA Consultant Consultant‐ AbbVie

MTE08 Nursing and Allied Professionals Kathleen Gamblin USA Nothing to disclose

MTE08 Nursing and Allied Professionals Maria Guerin UK Speakers or Advisory Board AstraZeneca

MTE08 Nursing and Allied Professionals Maria Guerin UK Honoraria AstraZeneca

MTE08 Nursing and Allied Professionals Pippa Labuc UK Nothing to disclose

MTE08 Nursing and Allied Professionals Naz Nouriany Canada Nothing to disclose

MTE08 Nursing and Allied Professionals Dianne Zawisza Canada Nothing to disclose

Faculty

MTE08.01 Nursing and Allied Professionals Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges

Linda Sarna USA Nothing to disclose

Session MTE09: Management of Advanced Wild‐Type Lung Cancer in Special Situations


Planner

MTE09 Advanced NSCLC Scott Laurie Canada Consultant Bristol‐Meyers Squibb, Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca, BBI

MTE09 Advanced NSCLC Scott Laurie Canada Honoraria Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca

MTE09 Advanced NSCLC Leora Horn Canada Consultant AbbVie, AstraZeneca, Genentech, Merck, Incyte, Xcovery, Roche

MTE09 Advanced NSCLC Leora Horn Canada Supported/Contracted Research/Grant Xcovery Holding Company, Bristol‐Meyers Squibb, Boehringer Ingelheim, AbbVie, Genentech, Merck

MTE09 Advanced NSCLC Carlos Gil Ferreira Brazil Nothing to disclose

MTE09 Advanced NSCLC Glenn Goss USA Nothing to disclose

MTE09 Advanced NSCLC Pasi Jänne USA Consultant Araxes Pharmas, Ariad, AstraZeneca, Boehringer Ingelheim, Chugai, Ignyta, Eli Lilly, Loxo, Merrimack, Mirati Therapeutics, Pfizer, Roche, Dana‐Farber Cancer Institute

MTE09 Advanced NSCLC Pasi Jänne USA Speakers or Advisory Board AstraZeneca, Boehringer Ingelheim, Pfizer, Merrimack Pharmas, Roche, Genentech, Chugai Pharmas, Acea Biosciences, Ignyta, Loxo, Ariad, Eli Lilly, Araxes Pharmas

MTE09 Advanced NSCLC Pasi Jänne USA Speakers Bureau Loxo

MTE09 Advanced NSCLC Pasi Jänne USA Ownership Interest (stocks or stock options, or other ownership interest

Gatekeeper Pharmas

MTE09 Advanced NSCLC Pasi Jänne USA Supported/Contracted Research/Grant Astellas Pharmas, AstraZenenca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim

MTE09 Advanced NSCLC Pasi Jänne USA Royalty, Intellectual Property/Patent Holder LabCorp

MTE09 Advanced NSCLC Clarissa Mathias Brazil Nothing to disclose

MTE09 Advanced NSCLC Keunchil Park Korea Consultant Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Hanmi, Kyowa Kakko Kirin, Novartis, Ono Pharma, Roche, Bristol‐Meyers Squibb, GlaxoSmithKline, Merck, GlaxoSmithKline

MTE09 Advanced NSCLC Keunchil Park Korea Supported/Contracted Research/Grant AstraZeneca

MTE09 Advanced NSCLC Keunchil Park Korea Speakers or Advisory Board AstraZeneca, Astellas, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Hanmi, KHK, Merck, Novartis, Roche

MTE09 Advanced NSCLC Suresh Ramalingam USA Consultant AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

MTE09 Advanced NSCLC Suresh Ramalingam USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

MTE09 Advanced NSCLC Noemi Reguart Spain Nothing to disclose

MTE09 Advanced NSCLC Christian Rolfo USA Nothing to disclose

MTE09 Advanced NSCLC Qing Zhou China Nothing to disclose

Faculty

MTE09.01 Advanced NSCLC Evidence Based Management of the Patient over 80 Elisabeth Quoix France Advisory Board BMS, Novartis

MTE09.01 Advanced NSCLC Evidence Based Management of the Patient over 80 Elisabeth Quoix France Consultant Travel grants for meetings: Astra zeneca, BMS, Takeda

MTE09.02 Advanced NSCLC Management of the PS 2 Patient Joan Schiller USA Speakers or Advisory Board AstraZeneca, Roche, Merck

MTE09.02 Advanced NSCLC Management of the PS 2 Patient Joan Schiller USA Supported/Contracted Research/Grant Merck, Genetech, Bristol‐Meyers Squibb, Xcovery

MTE09.02 Advanced NSCLC Management of the PS 2 Patient Joan Schiller USA Consultant Lung Cancer Research Foundation



Session MTE10: Emerging Technologies for Small and Smaller Lesions ‐ Update on Ablation via Endoscopy vs Percutaneous


Planner

MTE10 Interventional Diagnostics/Pulmonology Kazuhiro Yasufuku Canada Speakers or Advisory Board Concordia, Olympus America

MTE10 Interventional Diagnostics/Pulmonology Kazuhiro Yasufuku Canada Supported/Contracted Research/Grant Olympus Corporation, Siemens, Veran Medical Technologies, Novadaq

MTE10 Interventional Diagnostics/Pulmonology Kazuhiro Yasufuku Canada Consultant Intuitive Surgical, Medtronic, Johnson & Johnson, Auris Surgical Robotics

MTE10 Interventional Diagnostics/Pulmonology Kwun Fong Australia Nothing to disclose

MTE10 Interventional Diagnostics/Pulmonology Jason Agulnik Canada Honoraria Merck, Pfizer, Bristol‐Meyers Squibb, AstraZeneca

MTE10 Interventional Diagnostics/Pulmonology Nicole Bouchard Canada Supported/Contracted Research/Grant Pfizer, Bristol‐Meyers Squibb, Merck

MTE10 Interventional Diagnostics/Pulmonology Nicole Bouchard Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche

MTE10 Interventional Diagnostics/Pulmonology Eric Edell Canada Nothing to disclose

MTE10 Interventional Diagnostics/Pulmonology Wael Hannah Canada Nothing to disclose

MTE10 Interventional Diagnostics/Pulmonology Felix Herth Germany Nothing to disclose

MTE10 Interventional Diagnostics/Pulmonology Hojoong Kim Korea Nothing to disclose

MTE10 Interventional Diagnostics/Pulmonology Moishe Liberman Canada Nothing to disclose

MTE10 Interventional Diagnostics/Pulmonology Navneet Singh India Nothing to disclose

MTE10 Interventional Diagnostics/Pulmonology Egbert Smit Netherlands Nothing to disclose

Faculty

MTE10.01 Interventional Diagnostics/Pulmonology Emerging Technologies for Small and Smaller Lesions ‐ Update on Ablation via Endoscopy vs Percutaneous

Felix Herth Germany Nothing to disclose

Session PL01: Plenary Session ‐ Patients First


Planner

PL01 Natasha Leighl Canada Supported/Contracted Research/Grant Novartis

PL01 Natasha Leighl Canada Honoraria Merck, Bristol‐Meyers Squibb

PL01 Natasha Leighl Canada Consultant Novartis, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Canadian Agency for Drugs and Technologies in Health

PL01 Gail Darling Canada Nothing to disclose

PL01 Andrea Bezjak Canada Nothing to disclose

PL01 Frances Shepherd Canada Honoraria Bristol‐Myers Squibb, Eli Lilly, AstraZeneca, Roche, Genentech, Merck, Novartis, Pfizer

PL01 Frances Shepherd Canada Consultant Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack

PL01 Frances Shepherd Canada Ownership Interest (stocks or stock options, or other ownership interest

Eli Lilly, AstraZeneca

PL01 Frances Shepherd Canada Speakers or Advisory Board Eli Lilly, AstraZeneca, Merck

Chairs


PL01 Paul Bunn, Jr. USA Consultant AstraZeneca, Bristol‐Meyers Squibb, Genentech, Eli Lilly, Pfizer, Merck, Novartis, Merrimack, Daiichi

PL01 Paul Bunn, Jr. USA Supported/Contracted Research/Grant Genentech, Roche

PL01 Paul Bunn, Jr. USA Honoraria AstraZeneca, Guardant Health

PL01 Paul Bunn, Jr. USA Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Genentech, Merck, MerckSerono, Takeda

Faculty

PL01.01 When Breath Becomes Air Lucy Kalanithi USA Nothing to disclose

PL01.02 Science that Matters David Carbone USA Consultant Genentech

PL01.02 Science that Matters David Carbone USA Supported/Contracted Research/Grant Merck, Bristol‐Meyers Squibb

PL01.02 Science that Matters David Carbone USA Speakers or Advisory Board AbbVie, Adaptimmune, Agenus, Amgen, Ariad, AstraZeneca, Biocept, Boehringer Ingelheim, Bristol‐Meyers Squibb, Celgene, EMD Serono, Inc, Foundation Medicine, Genentech, Roche, Gritstone, Guardant Health, Inovio, Merck, Novartis, Palobiofarma, Pfizer, prIME Oncology, Stemcentrx, Takeda

PL01.02 Science that Matters David Carbone USA Honoraria AbbVie, Adaptimmune, Agenus, Amgen, Ariad, AstraZeneca, Biocept, Boehringer Ingelheim, Bristol‐Meyers Squibb, Celgene, Foundation Medicine, Genentech, Roche, Gritstone, Guardant Health, Inovio, Merck, Novartis, Palobiofarma, Pfizer, prIME Oncology, Stemcentrx, Takeda

PL01.03 Trials that Matter! Tony Mok Hongkong Speakers or Advisory Board AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Bristol‐Meyers Squibb, Taiho, Takeda Oncology Serono, SFJ Pharma, ACEA Biosciences, Vertex Pharma, geneDecode, OncoGenex Technologies, Celgene, Ignyta, Cirina, Fishawack Facilitate, Janssen, ChiMed

PL01.03 Trials that Matter! Tony Mok Hongkong Honoraria AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, SFJ Pharma, ACEA Biosciences, Vertex Pharma, Bristol‐Meyers Squibb, OncoGenex Pharma, Celgene, Ignyta, Fishawack Facilitate, Takeda Oncology, Janssen, Cirina, Chimed



PL01.03 Trials that Matter! Tony Mok Hongkong Ownership Interest (stocks or stock options, or other ownership interest

Sanomics, Cirina

PL01.03 Trials that Matter! Tony Mok Hongkong Consultant Roche., IASLC, ASCO, ChiMed, Chinese Lung Cancer Research Foundation, Chinese Society of Clinical Oncology, Hong Kong Cancer Therapy Society

PL01.03 Trials that Matter! Tony Mok Hongkong Supported/Contracted Research/Grant AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmas Group, Roche, Merck, Clovis Oncology, Bristol‐Meyers Squibb, Taiho Pharma, Eisai

PL01.03 Trials that Matter! Tony Mok Hongkong Employee (full time or part time) The Chinese University of Hong Kong

PL01.04 Getting Drugs to Patients Faster: A Global View Solange Peters Switzerland Speakers or Advisory Board Amgen, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Roche, Janssen, Merck, Pfizer, Regeneron, Takeda

PL01.05 Conquering Lung Cancer ‐ The IASLC Vision Giorgio Scagliotti Italy Honoraria AstraZeneca, Roche, Pfizer, Merck, Eli Lilly, AbbVie, Novartis, Clovis

PL01.05 Conquering Lung Cancer ‐ The IASLC Vision Giorgio Scagliotti Italy Speakers or Advisory Board Eli Lilly, Merck

PL01.05 Conquering Lung Cancer ‐ The IASLC Vision Giorgio Scagliotti Italy Speakers Bureau Eli Lilly, Merck

PL01.05 Conquering Lung Cancer ‐ The IASLC Vision Giorgio Scagliotti Italy Consultant Bayer

PL01.06 Patients First Tish Vigna Canada Nothing to disclose

Session MA01: Early Stage Lung Cancer: Questions and Controversies


Planner

MA01 Treatment of Early/Locoregional/Oligo Yee Ung Canada Nothing to disclose

MA01 Treatment of Early/Locoregional/Oligo Benjamin Lok Canada Nothing to disclose

MA01 Treatment of Early/Locoregional/Oligo Patrick Cheung Canada Nothing to disclose

MA01 Treatment of Early/Locoregional/Oligo Frances Shepherd Canada Honoraria Bristol‐Myers Squibb, Eli Lilly, AstraZeneca, Roche, Genentech, Merck, Novartis, Pfizer

MA01 Treatment of Early/Locoregional/Oligo Frances Shepherd Canada Other Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack

MA01 Treatment of Early/Locoregional/Oligo Frances Shepherd Canada Ownership Interest (stocks or stock options, or other ownership interest


MA01 Treatment of Early/Locoregional/Oligo Frances Shepherd Canada Speakers or Advisory Board Eli Lilly, AstraZeneca, Merck

MA01 Treatment of Early/Locoregional/Oligo Harvey Pass USA Nothing to disclose

MA01 Treatment of Early/Locoregional/Oligo Wael Hannah Canada Nothing to disclose

MA01 Treatment of Early/Locoregional/Oligo Paula Ugalde Canada Nothing to disclose

MA01 Treatment of Early/Locoregional/Oligo Charles Butts Canada Honoraria Pfizer, Boehringer Ingelheim, AstaZeneca, Bristol‐Meyers Squibb, Merck, Takeda

MA01 Treatment of Early/Locoregional/Oligo Charles Butts Canada Speakers or Advisory Board Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Merck, Takeda

Chairs

MA01 Wael Hannah Canada Nothing to disclose

MA01 Masahiro Tsuboi Japan Speakers or Advisory Board Merck, AstraZeneca

MA01 Masahiro Tsuboi Japan Honoraria AstraZeneca KK, Eli Lilly, Boehringer Ingelheim, Daikichi‐Sankyo, Chudai Pharma, Taiho Pharma, Teijin Pharma, Johnson & Johnson

Faculty

MA01.01 Treatment of Early Stage/Localized Disease Proposal on Incorporating Lymphovascular Invasion as a T‐Descriptor for Stage I Non‐Small Cell Lung Cancer


MA01.02 Treatment of Early Stage/Localized Disease Histologic Subtyping in Pathologic Stage I Lung Adenocarcinoma Provides Risk‐Based Stratification for Surveillance

Yusuke Takahashi USA Nothing to disclose

MA01.03 Treatment of Early Stage/Localized Disease An Externally Validated Nomogram for Predicting Distant Metastasis After SBRT for Early Stage Non‐Small Cell Lung Cancer

Aditya Juloori USA Nothing to disclose

MA01.04 Treatment of Early Stage/Localized Disease Discussant ‐ MA01.01, MA01.02, MA01.03 Deepali Jain India Nothing to disclose

MA01.05 Treatment of Early Stage/Localized Disease Opioids and Sleep Medication Use After Surgery for Early Stage Lung Cancer: A SEER‐Medicare Analysis

Stephanie Tuminello USA Nothing to disclose

MA01.06 Treatment of Early Stage/Localized Disease Evaluation of Safety and Efficacy in Surgical Treatment for Octogenarian Lung Cancer Patients by Multicenter Prospective Study: JACS1303

Tomohiro Haruki Japan Nothing to disclose

MA01.07 Treatment of Early Stage/Localized Disease Validation of RTOG 0813 Normal Tissue Constraints for Pulmonary Toxicity in SBRT for Central Non‐Small Cell Lung Cancer

Kyle Verdecchia USA Nothing to disclose

MA01.08 Treatment of Early Stage/Localized Disease Discussant ‐ MA01.05, MA01.06, MA01.07 Biniam Kidane Canada Nothing to disclose

MA01.09 Treatment of Early Stage/Localized Disease Risk Factors of Radiation‐Induced Lymphopenia (RIL) and Its Prognostic Significance in Small Lung Cancer Patients Treated with Stereotactic Body

Xiaomei Gong China Nothing to disclose

MA01.10 Treatment of Early Stage/Localized Disease Toxicity and Local Control in “Ultra‐Central” Lung Tumors Treated With SBRT or High‐Dose Hypofractionated RT

Chunyu Wang USA Nothing to disclose

MA01.11 Treatment of Early Stage/Localized Disease Salvage SBRT for Local Recurrence After Primary Surgical Resection of Early Stage Non‐Small Cell Lung Cancer

Sarah Sittenfeld USA Nothing to disclose

MA01.12 Treatment of Early Stage/Localized Disease Discussant ‐ MA01.09, MA01.10, MA01.11 Drew Moghanaki USA Honoraria Varian Medical Systems

Session MA02: Improving Outcomes for Patients with Lung Cancer


Planner



MA02 Advanced NSCLC/TT/Immunooncology Normand Blais Canada Speakers or Advisory Board AstraZeneca, Merck, Sanofi Canada, Bristol‐Meyers Squibb, Roche Canada, Boehringer Ingelheim, Bayer, Pfizer

MA02 Advanced NSCLC/TT/Immunooncology Desiree Hao Canada Nothing to disclose

MA02 Advanced NSCLC/TT/Immunooncology Ross Camidge USA Honoraria Takeda, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, AstraZeneca, Arrys/Kyn, Genoptix, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera, Lycera, Revolution Med, Orion, Clovis, Celegene, Novartis

MA02 Advanced NSCLC/TT/Immunooncology Ross Camidge USA Supported/Contracted Research/Grant Ariad, Takeda, Pfizer

MA02 Advanced NSCLC/TT/Immunooncology Ross Camidge USA Speakers or Advisory Board AstraZeneca, Takeda, Arrys/Kyn, Genoptix, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, Takeda, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera DSMB, Lycera, Revolution Med

MA02 Advanced NSCLC/TT/Immunooncology Adrian Sacher USA Nothing to disclose

MA02 Advanced NSCLC/TT/Immunooncology Natasha Leighl Canada Supported/Contracted Research/Grant Novartis

MA02 Advanced NSCLC/TT/Immunooncology Natasha Leighl Canada Honoraria Merck, Bristol‐Meyers Squibb

MA02 Advanced NSCLC/TT/Immunooncology Natasha Leighl Canada Consultant Novartis, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Canadian Agency for Drugs and Technologies in Health

Chairs

MA02 Ronald Burkes Advisory Board AZ, Roche, BI, Merck, Eli Lilly, Amgen,

MA02 Ronald Burkes Honoraria AZ, Roche, BI, Merck, Eli Lilly, Amgen,

Faculty

MA02.01 Advanced NSCLC ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri‐Diagnosis Thromboembolic Events

Terry Ng USA Nothing to disclose

MA02.02 Advanced NSCLC Multistate Healthcare Network Underutilizes Valuable End‐of‐Life Resources in Stage IV Non‐Small Cell Lung Cancer

Candice Wilshire USA Nothing to disclose

MA02.03 Advanced NSCLC ASTRIS: A Real World Treatment Study of Osimertinib in Patients with EGFR T790M‐Positive NSCLC

Yi‐Long Wu China Speakers or Advisory Board AstraZeneca, Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, Sanofi


Yi‐Long Wu China Speakers Bureau AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi


Yi‐Long Wu China Honoraria AstraZeneca, Eli Lilly, Pfizer, Roche


Yi‐Long Wu China Consultant AstraZeneca, Boehringer Ingelheim, Merck, Roche


Yi‐Long Wu China Supported/Contracted Research/Grant Boehringer Ingelheim, Roche

MA02.04 Advanced NSCLC Discussant ‐ MA 02.01, MA 02.02, MA 02.03 Alona Zer Israel Honoraria Bristol‐Meyers Squibb, Eli Lilly, Roche

MA02.05 Advanced NSCLC A Double‐Blind, Randomized, Placebo‐Controlled Phase 3 Noninferiority Study of Darbepoetin Alfa for Anemia in Advanced NSCLC

Rajnish Nagarkar India Nothing to disclose

MA02.06 Advanced NSCLC A Randomized, Double‐Blind, Placebo‐Controlled Trial of Chemotherapy Combined with Yangzheng Xiaoji in Advanced NSCLC

Ligang Xing China Nothing to disclose

MA02.07 Advanced NSCLC Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial

Kumar Prabhash India Nothing to disclose

MA02.08 Advanced NSCLC The Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double‐Blind Clinical Trial

Jenny Turcott Mexico Nothing to disclose

MA02.09 Advanced NSCLC Discussant ‐ MA 02.05, MA 02.06, MA 02.07, MA 02.08 Paul Wheatley‐Price Canada Speakers or Advisory Board AstraZeneca, Novartis, Eli Lilly Oncology, Bristol‐Meyers Squibb, Merck, Takeda

MA02.10 Screening and Early Detection The First Year of Implementing a Lung Cancer Screening Program in an Urban Safety‐Net Health System

Heidi Hamann USA Nothing to disclose

MA02.11 Advanced NSCLC Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling ‐ A Prospective Canadian Study (VALUE)

Doreen Ezeife Canada Nothing to disclose

MA02.12 Advanced NSCLC Discussant ‐ MA 02.10, MA 02.11 William Evans Canada Speakers or Advisory Board AbbVie, Astellas, Bristol‐Meyers Squibb, Eisai, Eli Lilly, Janseen, Gilead, Takeda, AstraZeneca, Janssen, Boehringer Ingelheim, Roche, Celgene

MA02.12 Advanced NSCLC Discussant ‐ MA 02.10, MA 02.11 William Evans Canada Consultant AstraZeneca, Janssen, Boehringer Ingelheim, Roche, Celgene

Session MA03: Lung Cancer Screening ‐ Next Step


Planner

MA03 Screening/Pulmonology/Prevention/Tobacco Control

Kazuhiro Yasufuku Canada Speakers or Advisory Board Concordia, Olympus America


Kazuhiro Yasufuku Canada Supported/Contracted Research/Grant Olympus Corporation, Siemens, Veran Medical Technologies, Novadaq


Kazuhiro Yasufuku Canada Consultant Intuitive Surgical, Medtronic, Johnson & Johnson, Auris Surgical Robotics


Jason Agulnik Canada Honoraria Merck, Pfizer, Bristol‐Meyers Squibb, AstraZeneca


Carolyn Dresler USA Nothing to disclose


Stephen Lam Canada Nothing to disclose


Heidi Schmidt Canada Nothing to disclose

Chairs

MA03 Alain Tremblay Canada Nothing to disclose

MA03 Sam Janes UK Advisory Board Astra Zeneca

MA03 Sam Janes UK Honoraria Astra Zeneca

MA03 Sam Janes UK Contracted/Support Research Grant GRAIL Inc

Faculty



MA03.01 Screening and Early Detection Manchester Lung Cancer Screening: Results of the First Incidence Screening Round

Haval Balata UK Nothing to disclose

MA03.02 Screening and Early Detection Prospective Evaluation of the Clinical Utility of the International Lung Screen Trial Lung Nodule Management Protocol


MA03.03 Screening and Early Detection Prolonged Low‐Dose Computed Tomography (LDCT) Screening Beyond 5 Years Reduces Overall and Lung Cancer Specific Mortality

Ugo Pastorino Italy Royalty, Intellectual Property/Patent Holder Gensignia Life Science

MA03.04 Screening and Early Detection Discussant ‐ MA 03.01, MA 03.02, MA 03.03 Denise Aberle USA Nothing to disclose

MA03.05 Screening and Early Detection New Subsolid Pulmonary Nodules in Lung Cancer Screening: The NELSON Trial

Marjolein Heuvelmans Netherlands Nothing to disclose

MA03.06 Screening and Early Detection Descriptive Epidemiology of Significant Incidental Findings in a Large Clinical Lung Cancer Screening Program

Shawn Regis USA Nothing to disclose

MA03.07 Screening and Early Detection Development and Validation of Deep Learning Model for Recognition of Histologic Subtype of Lung Adenocarcinoma from CT Images

Yunlang She China Nothing to disclose

MA03.08 Screening and Early Detection Discussant ‐ MA 03.05, MA 03.06, MA 03.07 Richard Booton UK Nothing to disclose

MA03.10 Screening and Early Detection Population‐Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer

Shamus Carr USA Nothing to disclose

MA03.11 Screening and Early Detection Trained Dogs Can Identify Malignant Pulmonary Nodules in Exhaled Gas Angela Guirao Spain Nothing to disclose

MA03.12 Screening and Early Detection Discussant ‐ MA 03.10, MA 03.11 Luis Montuenga Spain Nothing to disclose

MA03.12a Screening and Early Detection Q&A

Session MS01: Cancer Pathways, Targeted Therapy and Resistance


Planner

MS01 Biology Wan Lam Canada Nothing to disclose

MS01 Biology Kwok‐kin Wong USA Nothing to disclose

MS01 Biology Oscar Arrieta Mexico Nothing to disclose

MS01 Biology David Beer USA Nothing to disclose

MS01 Biology Robert Doebele USA Ownership Interest (stocks or stock options, or other ownership interest

Rain Therapeutics

MS01 Biology Robert Doebele USA Speakers or Advisory Board Ignyta, AstraZeneca, Bayer, Takeda, Bristol‐Meyers Squibb, Ariad

MS01 Biology Robert Doebele USA Supported/Contracted Research/Grant Ignyta

MS01 Biology Robert Doebele USA Consultant Pfizer, OncoMed, Trovagene, Ignyta, GreenPeptide, AstraZeneca, Ignyta, Ariad, Guardant Health

MS01 Biology Robert Doebele USA Honoraria Pfizer, AstraZeneca, Ariad, Guardant Health, Takeda, Spectrum Pharmas, Trovagene

MS01 Biology Robert Doebele USA Royalty, Intellectual Property/Patent Holder Abbott Molecular, Rain Therapeutics, Igynta

MS01 Biology Ramaswamy Govindan USA Speakers or Advisory Board Merck, Baxalta, Roche, Boehringer Ingleheim, Novartis, Pfizer, Celgene, AstraZeneca, MSK, AbbVie Inivata, Pfizer, NeoHealth, Bristol‐Meyers Squibb, Nektar, GlaxcSmithKline

MS01 Biology Ramaswamy Govindan USA Consultant Genentech, Ariad, Astellas, Bristol‐Meyers Squibb, INC Research, AbbVie

MS01 Biology Ramaswamy Govindan USA Honoraria AbbVie, Genentech, Boehringer Ingelheim

MS01 Biology Fred Hirsch USA Consultant AstraZeneca, Genentech, HTG Molecular Diagnostics, Eli Lilly, Merck, Clovis Oncology, Ventana Medical Systems, Bristol‐Meyers Squibb, Pfizer, Roche

MS01 Biology Fred Hirsch USA Royalty, Intellectual Property/Patent Holder University of Colorado Cancer Center

MS01 Biology Fred Hirsch USA Supported/Contracted Research/Grant Eli Lilly, Genentech, Amgen, Bristol‐Meyers Squibb, Celgene

MS01 Biology Fred Hirsch USA Speakers or Advisory Board AbbVie, AstraZeneca, Biocept, Bristol‐Meyers Squibb, HTG, Eli Lilly, Loxo, Merck, Novartis, Pfizer, Roche, Genentech, Ventana, Bayer

MS01 Biology Thomas John Australia Speakers or Advisory Board Bristol‐Meyers Squibb, AstraZeneca, Boehringher Ingelheim, Takeda, Pfizer, Novartis, Merck, Ignyta

MS01 Biology Thomas John Australia Consultant Bristol‐Meyers Squibb, AstraZeneca, Boehringer Ingelheim, Takeda, Pfizer, Novartis, Merck

MS01 Biology Geoffrey Liu Canada Honoraria AstraZeneca, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie, Pfizer, Merck

MS01 Biology Geoffrey Liu Canada Speakers Bureau AstraZeneca

MS01 Biology Geoffrey Liu Canada Speakers or Advisory Board AstraZeneca, Roche, Merck, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie

MS01 Biology William Lockwood Canada Nothing to disclose

MS01 Biology Philip Mack USA Supported/Contracted Research/Grant Boehringer Ingelheim

MS01 Biology Philip Mack USA Consultant Guardant Health, Apton Biosystems

MS01 Biology Philip Mack USA Speakers or Advisory Board AstraZeneca, Eli Lilly, Pfizer

MS01 Biology Matthew Meyerson USA Speakers or Advisory Board OrigiMed

MS01 Biology Matthew Meyerson USA Ownership Interest (stocks or stock options, or other ownership interest

OrigiMed

MS01 Biology Matthew Meyerson USA Supported/Contracted Research/Grant Bayer

MS01 Biology Matthew Meyerson USA Royalty, Intellectual Property/Patent Holder LabCorp

MS01 Biology Katerina Politi USA Supported/Contracted Research/Grant AstraZeneca, Roche, Kolltan, Symphogen



MS01 Biology Katerina Politi USA Honoraria AstraZeneca, Merck, Novartis, Tocagen

MS01 Biology Katerina Politi USA Royalty, Intellectual Property/Patent Holder Molecular MD

MS01 Biology Daniel Tan Singapore Honoraria National Cancer Centre Singapore, Pfizer, Merck, AstraZeneca, Loxo, Boehringer Ingelheim, Bristol‐Meyers Squibb

MS01 Biology Daniel Tan Singapore Speakers or Advisory Board AstraZeneca, Pfizer, Novartis, Merck

MS01 Biology Daniel Tan Singapore Supported/Contracted Research/Grant GSK, AstraZeneca, Novartis

MS01 Biology Pan‐Chyr Yang Taiwan Nothing to disclose

Chairs


MS01 Biology Gregory Riely USA Supported/Contracted Research/Grant Novartis, Genentech Roche, Millennium, GlaxoSmithKline, Pfizer, Infinity Pharmas, Ariad

MS01 Biology Gregory Riely USA Speakers or Advisory Board Genetech

MS01 Biology Gregory Riely USA Consultant Ariad Pharmas, GlaxoSmithKline, Infinity Pharmas, Millennium Pharmas, Inc., Novartis Pharmas Corporation, Pfizer, Roche Laboratories, Genentech, Merck

Faculty

MS01.01 Biology Defects of the SWI/SNF OR MYC/MAX Pathways: Effects in Cell Differentiation and Therapeutic Opportunities

Montse Sanchez‐Cespedes Spain Nothing to disclose

MS01.02 Biology Targeting Negative Feedback Regulators to Hyperactivate Oncogenic Signaling

William Lockwood Canada Nothing to disclose

MS01.03 Biology Stimulating Anti‐Tumor Immunity Through Enhancing T‐Cell Activation Kwok‐Kin Wong USA Nothing to disclose

MS01.04 Biology Addressing Drug Resistance Beyond Kinase Domain Mutations Robert Doebele USA Ownership Interest (stocks or stock options, or other ownership interest

Rain Therapeutics

MS01.04 Biology Addressing Drug Resistance Beyond Kinase Domain Mutations Robert Doebele USA Speakers or Advisory Board Ignyta, AstraZeneca, Bayer, Takeda, Bristol‐Meyers Squibb, Ariad

MS01.04 Biology Addressing Drug Resistance Beyond Kinase Domain Mutations Robert Doebele USA Supported/Contracted Research/Grant Ignyta

MS01.04 Biology Addressing Drug Resistance Beyond Kinase Domain Mutations Robert Doebele USA Consultant Pfizer, OncoMed, Trovagene, Ignyta, GreenPeptide, AstraZeneca, Ignyta, Ariad, Guardant Health

MS01.04 Biology Addressing Drug Resistance Beyond Kinase Domain Mutations Robert Doebele USA Honoraria Pfizer, AstraZeneca, Ariad, Guardant Health, Takeda, Spectrum Pharmas, Trovagene

MS01.04 Biology Addressing Drug Resistance Beyond Kinase Domain Mutations Robert Doebele USA Royalty, Intellectual Property/Patent Holder Abbott Molecular, Rain Therapeutics, Igynta

MS01.05 Q&A

Session MS02: The Future of IO


Planner

MS02 Immunooncology Desiree Hao Canada Nothing to disclose

MS02 Immunooncology Solange Peters Switzerland Speakers or Advisory Board Amgen, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Roche, Janssen, Merck, Pfizer, Regeneron, Takeda

MS02 Immunooncology Myung‐Ju Ahn Korea Consultant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Merck, Novartis, Alpha BioPharmas

MS02 Immunooncology Myung‐Ju Ahn Korea Speakers or Advisory Board AstraZeneca, Eli Lilly, Bristol‐Meyers Squibb, Merck, Ono Pharma, Roche

MS02 Immunooncology Fabrice Barlesi France Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda

MS02 Immunooncology Fabrice Barlesi France Consultant Roche, Genentech., AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda

MS02 Immunooncology Fabrice Barlesi France Supported/Contracted Research/Grant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda

MS02 Immunooncology Fabrice Barlesi France Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda, Serono

MS02 Immunooncology Julie Brahmer USA Speakers or Advisory Board Merck, Genetech, Bristol‐Meyers Squibb, Syndax, AstraZeneca, Celgene, Amgen Oncology

MS02 Immunooncology Julie Brahmer USA Consultant Celgene, Eli Lilly, MedImmune, AstraZeneca, Bristol‐Meyers Squibb

MS02 Immunooncology Julie Brahmer USA Supported/Contracted Research/Grant Medimmune, AstraZeneca, Bristol‐Meyers Squibb

MS02 Immunooncology Edward Garon USA Consultant Bristol‐Meyers Squibb, Eli Lilly, AstraZeneca, Genentech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax

MS02 Immunooncology Edward Garon USA Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Genetech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax

MS02 Immunooncology Edward Garon USA Supported/Contracted Research/Grant Merck, Genentech, AstraZeneca, Novartis, Pfizer, Eli Lilly, Bristol‐Meyers Squibb, Boehringer Ingelheim, Mirati Therapeutics, Dyanvax

MS02 Immunooncology Rina Hui Australia Honoraria Bristol‐Meyers Squibb, Boehringer Ingelheim, Merck, AstraZeneca, Novartis, Roche

MS02 Immunooncology Rina Hui Australia Speakers or Advisory Board AstraZeneca, Merck, Novartis, Pfizer, Roche, Bristol‐Meyers Squibb

MS02 Immunooncology Rina Hui Australia Consultant Merck, AstraZeneca, Novartis, Roche, Bristol‐Meyers Squibb, Boehringer Ingelheim, Pfizer

MS02 Immunooncology Rosalyn Juergens Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Amgen, Novartis, AstraZeneca, Takeda

MS02 Immunooncology Rosalyn Juergens Canada Honoraria Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, AstraZeneca, MedImmune, Eli Lilly, Takeda, Novartis, Amgen Pfizer

MS02 Immunooncology Rosalyn Juergens Canada Speakers Bureau Amgen

MS02 Immunooncology Rosalyn Juergens Canada Consultant Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Amgen, Roche, AstraZeneca, MedImmune,



MS02 Immunooncology Rosalyn Juergens Canada Supported/Contracted Research/Grant AstraZeneca, MedImmune, Merck, Bristol‐Meyers Squibb

MS02 Immunooncology Martin Reck Germany Speakers Bureau Roche, Eli Lilly, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Merck, Boehringer‐Ingelheim, Novartis, Pfizer, Abbot

MS02 Immunooncology Martin Reck Germany Speakers or Advisory Board Roche, Eli Lilly, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Merck, Boehringer Ingelheim, Novartis, Pfizer, Abbot

MS02 Immunooncology Martin Reck Germany Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Lilly, Merck, Practa, Roche

MS02 Immunooncology Martin Reck Germany Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Celgene, Eli Lilly, Merck, Pfizer, Proacta, Novartis, Roche, Abbott

MS02 Immunooncology Naiyer Rizvi USA Honoraria Roche, AstraZeneca, Novartis, Merck, Pfizer, Lilly, Bristol‐Meyers Squibb

MS02 Immunooncology Naiyer Rizvi USA Ownership Interest (stocks or stock options, or other ownership interest

Gritsone Oncology, Armo Biosciences

MS02 Immunooncology Naiyer Rizvi USA Speakers or Advisory Board Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

MS02 Immunooncology Naiyer Rizvi USA Consultant Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

MS02 Immunooncology Adrian Sacher USA Nothing to disclose

MS02 Immunooncology Ross Soo Singapore Supported/Contracted Research/Grant AstraZeneca

MS02 Immunooncology Ross Soo Singapore Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Celgene, Ignyta, Roche, Taiho

MS02 Immunooncology Yi‐Long Wu China Speakers or Advisory Board AstraZeneca, Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, Sanofi

MS02 Immunooncology Yi‐Long Wu China Speakers Bureau AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi

MS02 Immunooncology Yi‐Long Wu China Honoraria AstraZeneca, Eli Lilly, Pfizer, Roche

MS02 Immunooncology Yi‐Long Wu China Consultant AstraZeneca, Boehringer Ingelheim, Merck, Roche

MS02 Immunooncology Yi‐Long Wu China Supported/Contracted Research/Grant Boehringer Ingelheim, Roche

Chairs

MS02 Yuichiro Ohe Japan Advisory Board AstraZeneca, Chugai, Lilly, ONO, Kissei, Kyorin

MS02 Yuichiro Ohe Japan Honoraria AstraZeneca, Chugai, Lilly, ONO, BMS, Boehringer Ingelheim, Bayer, Pfizer, MSD, Taiho, Sanofi, Kyorin, Kissei

MS02 Yuichiro Ohe Japan Contracted/Support Research Grant AstraZeneca, Chugai, Lilly, ONO, BMS, Kyorin, Dainippon‐ Sumitomo, Pfizer, Taiho, Novartis, Kissei, Ignyta

MS02 Rina Hui Australia Advisory Board Merck Sharp & Dohme, AstraZeneca, Novartis, Roche, Bristol‐Myers Squibb

MS02 Rina Hui Australia Honoraria Merck Sharp & Dohme, AstraZeneca, Novartis, Roche

Faculty

MS02.01 Immunooncology What Is/Will Be the Optimal Duration of Therapy with IO? David Spigel USA Consultant Genentech, Roche, Celgene, Bristol‐Myers Squibb, Eli Lilly, AstraZeneca, Pfizer, Clovis Oncology, Novartis, Boehringer Ingelheim

MS02.01 Immunooncology What Is/Will Be the Optimal Duration of Therapy with IO? David Spigel USA Supported/Contracted Research/Grant Genentech, Roche, Novartis, Celgene, Bristol‐ Myers Squibb, Eli Lilly, AstraZeneca, Pfizer, Clovis Oncology, Boehringer Ingelheim, Peregrine Pharma, Oncogenex, OncoMed, Amgen, Verastem, Daiichi Sankyo, University of Texas Southwestern Medical Center‐Simmons Cancer Center, Merck

MS02.02 Immunooncology Combination Therapies: Where Are We in 2018? Martin Reck Germany Speakers Bureau Roche, Eli Lilly, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Merck, Boehringer‐Ingelheim, Novartis, Pfizer, Abbot

MS02.02 Immunooncology Combination Therapies: Where Are We in 2018? Martin Reck Germany Speakers or Advisory Board Roche, Eli Lilly, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Merck, Boehringer Ingelheim, Novartis, Pfizer, Abbot

MS02.02 Immunooncology Combination Therapies: Where Are We in 2018? Martin Reck Germany Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Lilly, Merck, Practa, Roche

MS02.02 Immunooncology Combination Therapies: Where Are We in 2018? Martin Reck Germany Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Celgene, Eli Lilly, Merck, Pfizer, Proacta, Novartis, Roche, Abbott

MS02.03 Immunooncology Next Generation IO in Lung Cancer Solange Peters Switzerland Speakers or Advisory Board Amgen, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Roche, Janssen, Merck, Pfizer, Regeneron, Takeda

MS02.04 Immunooncology Optimizing Clinical Trial Designs in Immunotherapy Vassiliki Papadimitrakopoulou USA Speakers or Advisory Board Nektar Therapeutics, AstraZeneca, Arrys, Merck, Loxo, Araxes Pharma, Roche, Janssen Research Foundation, Bristol‐Meyers Squibb, Clovis Oncology, Eli Lilly, Novartis, Takeda Pharma, AbbVie, TRM Oncology, Pfizer

MS02.04 Immunooncology Optimizing Clinical Trial Designs in Immunotherapy Vassiliki Papadimitrakopoulou USA Supported/Contracted Research/Grant Eli Lilly, Novartis, Merck, AstraZeneca, Roche, Nektar Therapeutics, Janssen, Bristol‐Meyers Squibb, Checkmate, Incyte, Oregon Health Science, ACEA Biosciences, American Association of Cancer Research, Hope Foundation, Cancer Prevention and Research Institute of Texas, Genentech, Guardant Health

MS02.05 Immunooncology Convincing Policy Makers to Afford Immunotherapy Carlos Gil Ferreira Brazil Nothing to disclose

MS02.06 Q&A

Session MS03: New Frontiers in Oligometastases


Planner

MS03 Oligometastatic NSCLC David Palma Canada Nothing to disclose

MS03 Oligometastatic NSCLC Joseph Salama USA Nothing to disclose

MS03 Oligometastatic NSCLC Hak Choy USA Speakers Bureau AstraZeneca

MS03 Oligometastatic NSCLC Hak Choy USA Honoraria AstraZeneca, Merck

MS03 Oligometastatic NSCLC Laurie Gaspar USA Nothing to disclose

MS03 Oligometastatic NSCLC Matthias Guckenberger Switzerland Nothing to disclose

MS03 Oligometastatic NSCLC David Jones USA Nothing to disclose

MS03 Oligometastatic NSCLC Mary Macneil Canada Nothing to disclose



MS03 Oligometastatic NSCLC Boris Sepesi USA Nothing to disclose

Chairs

MS03 Eric Lim UK Speakers Bureau Abbott Molecular, Pfizer, Roche, Eli Lily, Boehringer Ingelheim, Ethicon

MS03 Eric Lim UK Supported/Contracted Research/Grant Medela, ScreenCell, Clearbridge Biomedics, Illumina, Guardant Health

MS03 Jyoti Patel USA Speakers or Advisory Board AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Takeda, Roche

MS03 Jyoti Patel USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb

MS03 Jyoti Patel USA Consultant Genentech

Faculty

MS03.01 Oligometastatic NSCLC The Biology of Oligometastases: What Have We learned? David Palma Canada Nothing to disclose

MS03.02 Oligometastatic NSCLC Biomarkers in Oligometastatic Patients i. Monitoring Diseases Response ‐ Imaging vs Serum

Max Diehn USA Ownership Interest (stocks or stock options, or other ownership interest

CiberMed


Max Diehn USA Honoraria Roche


Max Diehn USA Supported/Contracted Research/Grant Varian Medical Systems


Max Diehn USA Royalty, Intellectual Property/Patent Holder Patents on Cancer Biomarkers

MS03.03 Oligometastatic NSCLC Investigations into Alternative Clinical Endpoints for OM Beyond Survival Alexander Louie Canada Honoraria Varian Medical Systems, AstraZeneca

MS03.04 Oligometastatic NSCLC Treatment of Oligoprogression: Real Progress or False Hope? Fiona McDonald UK Nothing to disclose

MS03.05 Oligometastatic NSCLC Integration of Immunotherapy in the Oligometastatic Paradigm Shankar Siva Australia Speakers Bureau Varian, Astellas, Bristol‐Meyers Squibb

MS03.05 Oligometastatic NSCLC Integration of Immunotherapy in the Oligometastatic Paradigm Shankar Siva Australia Speakers or Advisory Board Janssen, Astellas

MS03.05 Oligometastatic NSCLC Integration of Immunotherapy in the Oligometastatic Paradigm Shankar Siva Australia Supported/Contracted Research/Grant Varian, Merck

MS03.05 Oligometastatic NSCLC Integration of Immunotherapy in the Oligometastatic Paradigm Shankar Siva Australia Consultant Bristol‐Meyers Squibb, AstraZeneca

MS03.06 Q&A

Session MS04: Joint GLCC/IASLC Session: Exploring Hot Topics for Advocates


Planner

MS04 Advocacy Paul Wheatley‐Price Canada Speakers or Advisory Board AstraZeneca, Novartis, Eli Lilly Oncology, Bristol‐Meyers Squibb, Merck, Takeda

MS04 Advocacy Jesme Fox UK Nothing to disclose

MS04 Advocacy Bonnie Addario USA Nothing to disclose

MS04 Advocacy Andrea Ferris USA Nothing to disclose

MS04 Advocacy Kazuo Hasegawa Japan Nothing to disclose

MS04 Advocacy Kim Norris USA Speakers or Advisory Board Takeda

MS04 Advocacy Kim Norris USA Consultant Takeda

MS04 Advocacy Silvia Novello Italy Speakers or Advisory Board Takeda

MS04 Advocacy Silvia Novello Italy Speakers Bureau Boehringer Ingelheim, AstraZeneca, Roche, Merck, Bristol‐Meyers Squibb, Eli Lilly, Takeda, Pfizer

MS04 Advocacy Christina Sit Canada Nothing to disclose

MS04 Advocacy Howard (Jack) West USA Consultant Ariad, Genentech, Roche, Takeda

MS04 Advocacy Howard (Jack) West USA Speakers Bureau Ariad, Bristol‐Myers Squibb, Eli Lilly

MS04 Advocacy Howard (Jack) West USA Speakers or Advisory Board AbbVie, Ariad, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Merck, Roche, Genentech, Takeda, Spectrum

Chairs

MS04 Advocacy Carolyn Aldige USA Nothing to disclose

MS04 Advocacy Christina Sit Canada Nothing to disclose

Faculty

MS04.01 Advocacy Collecting Data in the Real World ‐ How Can Patient Groups Work with Researchers in Defining and Collecting Real‐World Evidence?

Taofeek Owonikoko USA Speakers or Advisory Board AbbVie, Bristol‐Meyers Squibb, G1 Therapeutics

MS04.01 Advocacy Collecting Data in the Real World ‐ How Can Patient Groups Work with Researchers in Defining and Collecting Real‐World Evidence?

Taofeek Owonikoko USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, AbbVie, United Pharma, G1 Therapeutics

MS04.02 Advocacy How Is Lung Cancer Screening Evolving to Be More Efficient and Effective? David Baldwin UK Honoraria AstraZeneca

MS04.03 Advocacy Exploring Smoking Stigma, Negativity and Lung Cancer ‐ What Can Be Done?

Stefania Vallone Italy Nothing to disclose

MS04.04 Advocacy E‐Cigarettes ‐ What Do Lung Cancer Advocates Need to Know? Carolyn Dresler USA Nothing to disclose

MS04.05 Panel Discussion



Session OA01: Improving Outcomes in Locoregional NSCLC I


Planner

OA01 Treatment of Early/Locoregional/Oligo Yee Ung Canada Nothing to disclose

OA01 Treatment of Early/Locoregional/Oligo Benjamin Lok Canada Nothing to disclose

OA01 Treatment of Early/Locoregional/Oligo Patrick Cheung Canada Nothing to disclose

OA01 Treatment of Early/Locoregional/Oligo Frances Shepherd Canada Honoraria Bristol‐Myers Squibb, Eli Lilly, AstraZeneca, Roche, Genentech, Merck, Novartis, Pfizer

OA01 Treatment of Early/Locoregional/Oligo Frances Shepherd Canada Other Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack

OA01 Treatment of Early/Locoregional/Oligo Frances Shepherd Canada Ownership Interest (stocks or stock options, or other ownership interest


OA01 Treatment of Early/Locoregional/Oligo Frances Shepherd Canada Speakers or Advisory Board Eli Lilly, AstraZeneca, Merck

OA01 Treatment of Early/Locoregional/Oligo Harvey Pass USA Nothing to disclose

OA01 Treatment of Early/Locoregional/Oligo Wael Hannah Canada Nothing to disclose

OA01 Treatment of Early/Locoregional/Oligo Paula Ugalde Canada Nothing to disclose

OA01 Treatment of Early/Locoregional/Oligo Charles Butts Canada Honoraria Pfizer, Boehringer Ingelheim, AstaZeneca, Bristol‐Meyers Squibb, Merck, Takeda

OA01 Treatment of Early/Locoregional/Oligo Charles Butts Canada Speakers or Advisory Board Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Merck, Takeda

Chairs

OA01 Ryan Carlson Canada Nothing to disclose

OA01 Gaetano Rocco Italy Speakers Bureau Baxter, Medtronic

Faculty

OA01.01 Treatment of Locoregional Disease ‐ NSCLC 10‐Year Updated Analysis of NRG Oncology/RTOG 0214: A Phase III Comparison of PCI vs. Observation in Patients with LA‐NSCLC.

Alexander Sun Canada Nothing to disclose

OA01.02 Treatment of Locoregional Disease ‐ NSCLC The Estimate of Shrinking Field and SIB Radiotherapy Guided by 18F‐FDG PET/CT in Locally Advanced NSCLC Patients: A Phase 2 Randomized Clinical

Yaping Xu China Nothing to disclose

OA01.03 Treatment of Locoregional Disease ‐ NSCLC Interaction Between Dose and Calcifications Is a Predictor for Overall Survival in Lung Cancer Patients Receiving Radiotherapy

Alan McWilliam UK Nothing to disclose

OA01.04 Treatment of Locoregional Disease ‐ NSCLC Discussant ‐ OA 01.01, OA 01.02, OA 01.03 John Armstrong Ireland Nothing to disclose

OA01.05 Treatment of Locoregional Disease ‐ NSCLC Phase II Study of Neo‐Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non‐Small Cell Lung Cancer‐ Nadim Study‐SLCG

Mariano Provencio Spain Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Fabre, Merck, Pierre, Roche


Mariano Provencio Spain Consultant Bristol‐Meyers Squibb


Mariano Provencio Spain Supported/Contracted Research/Grant Bristol‐Meyers Squibb

OA01.06 Treatment of Locoregional Disease ‐ NSCLC DETERRED: Phase II Trial Combining Atezolizumab Concurrently with Chemoradiation Therapy in Locally Advanced Non‐Small Cell Lung Cancer

Steven Lin USA Nothing to disclose

OA01.07 Treatment of Locoregional Disease ‐ NSCLC Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III

Greg Durm USA Nothing to disclose

OA01.08 Treatment of Locoregional Disease ‐ NSCLC Discussant ‐ OA 01.05, OA 01.06, OA 01.07 Corey Langer USA Supported/Contracted Research/Grant Pfizer, Eli Lilly, Genentech, OSI Pharmas, GlaxoSmithKline, Clovis, Merck, Advantagene, Inovio, Takeda, AbbVie, Celgene, Incyte, Macrogenics

OA01.08 Treatment of Locoregional Disease ‐ NSCLC Discussant ‐ OA 01.05, OA 01.06, OA 01.07 Corey Langer USA Honoraria Bristol‐Meyers Squibb, Imclone Systems, Pfizer, Eli Lilly, AstraZeneca, Merck, Novartis, Genentech, Bayer, Celgene, Abbott Labs, Biodesix, Clariant, CarisDx, Ariad, Boehringer Ingelheim, Synta, Clovis

OA01.08 Treatment of Locoregional Disease ‐ NSCLC Discussant ‐ OA 01.05, OA 01.06, OA 01.07 Corey Langer USA Consultant Amgen, Synta, Peregrine, SWOG, Incyte, VA, Eli Lilly, PIK, PER, NOCR, CCO, RTP

Session OA02: Novel Therapies in ROS1, HER2 and EGFR


Planner

OA02 Advanced NSCLC/TT/Immunooncology Normand Blais Canada Speakers or Advisory Board AstraZeneca, Merck, Sanofi Canada, Bristol‐Meyers Squibb, Roche Canada, Boehringer Ingelheim, Bayer, Pfizer

OA02 Advanced NSCLC/TT/Immunooncology Desiree Hao Canada Nothing to disclose

OA02 Advanced NSCLC/TT/Immunooncology Ross Camidge USA Honoraria Takeda, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, AstraZeneca, Arrys/Kyn, Genoptix, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera, Lycera, Revolution Med, Orion, Clovis, Celegene, Novartis

OA02 Advanced NSCLC/TT/Immunooncology Ross Camidge USA Supported/Contracted Research/Grant Ariad, Takeda, Pfizer

OA02 Advanced NSCLC/TT/Immunooncology Ross Camidge USA Speakers or Advisory Board AstraZeneca, Takeda, Arrys/Kyn, Genoptix, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, Takeda, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera DSMB, Lycera, Revolution Med

OA02 Advanced NSCLC/TT/Immunooncology Adrian Sacher USA Nothing to disclose

OA02 Advanced NSCLC/TT/Immunooncology Natasha Leighl Canada Supported/Contracted Research/Grant Novartis

OA02 Advanced NSCLC/TT/Immunooncology Natasha Leighl Canada Honoraria Merck, Bristol‐Meyers Squibb

OA02 Advanced NSCLC/TT/Immunooncology Natasha Leighl Canada Consultant Novartis, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Canadian Agency for Drugs and Technologies in Health

Chairs

OA02 Rebecca Heist USA Honoraria Boehringer Ingelheim



OA02 Rebecca Heist USA Supported/Contracted Research/Grant Genentech, Roche, Millenium, Novartis, Celgene, Peregrine, Mirati, Corvus, Incyte, AbbVie, Agios, Debiopharm

OA02 Bing Xia USA Advisory Board regeneron pharmaceuticals

Faculty

OA02.01 Targeted Therapy Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion‐Positive Non‐Small Cell Lung Cancer (NSCLC)

Robert Doebele USA Ownership Interest (stocks or stock options, or other ownership interest

Rain Therapeutics


Robert Doebele USA Speakers or Advisory Board Ignyta, AstraZeneca, Bayer, Takeda, Bristol‐Meyers Squibb, Ariad


Robert Doebele USA Supported/Contracted Research/Grant Ignyta


Robert Doebele USA Consultant Pfizer, OncoMed, Trovagene, Ignyta, GreenPeptide, AstraZeneca, Ignyta, Ariad, Guardant Health


Robert Doebele USA Honoraria Pfizer, AstraZeneca, Ariad, Guardant Health, Takeda, Spectrum Pharmas, Trovagene


Robert Doebele USA Royalty, Intellectual Property/Patent Holder Abbott Molecular, Rain Therapeutics, Igynta

OA02.02 Targeted Therapy Safety and Preliminary Clinical Activity of Ropotrectinib (TPX‐0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion‐Positive NSCLC

Jessica Lin USA Honoraria Chugai, Boehringer Ingelheim

OA02.03 Targeted Therapy Clinical Activity of Lorlatinib in Patients with ROS1+ Advanced Non‐Small Cell Lung Cancer: Phase 2 Study Cohort EXP‐6

Sai‐Hong Ou USA Speakers Bureau Roche, Genentech, AstraZeneca, Takeda


Sai‐Hong Ou USA Speakers or Advisory Board Pfizer, Roche, Genentech, Novartis, AstraZeneca, Takeda, Foundation Medicine


Sai‐Hong Ou USA Honoraria Pfizer, Genentech, Roche, Ariad, Takeda, Novartis, AstraZeneca, Foundation Medicine


Sai‐Hong Ou USA Ownership Interest (stocks or stock options, or other ownership interest

TP Therapeutics


Sai‐Hong Ou USA Supported/Contracted Research/Grant Pfizer, Roche, MedImmune, AstraZeneca, Clovis Oncology, Ariad, Ignyta, Peregrine Pharma, GlaxoSmithKline, Astellas Pharma, Chugai Pharma

OA02.04 Targeted Therapy Discussant ‐ OA 02.01, OA 02.02, OA 02.03 Shengxiang Ren China Nothing to disclose

OA02.05 Targeted Therapy CK‐101 (RX518), a Third Generation Mutant‐Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial

Melissa Johnson USA Supported/Contracted Research/Grant BerGenBio, Eli Lilly, Merck Serono, Janssen, Mirati Therapeutics, Genmab, Pfizer, AstraZeneca, Genentech, Roche, Stemcentrix, Novartis, Checkpoint Therapeutics, Array BioPharma, Regeneron, Apexigen, AbbVie, Tarveda, Adaptimmune, Syndax, Neovia, Boehringer Ingelheim, Sanofi, Hengrui Therapeutics, Daiichi – Sankyo, Lycera, G1 Therapeutics, Dynavax, OncoMed,


Melissa Johnson USA Speakers or Advisory Board Astellas, Otsuka Pharmas, Genentech, Roche, Celgene, Boehringer Ingelheim, Sanofi, Mirati, Loxo, AstraZeneca, Mersana


Melissa Johnson USA Consultant Astellas, Otsuka Pharmas, Roche

OA02.06 Targeted Therapy A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non‐Small Cell Lung Cancer (NSCLC)

John Heymach USA Royalty, Intellectual Property/Patent Holder Spectrum Pharmas


John Heymach USA Consultant AstraZeneca, AbbVie, Boehringer Ingelheim, Medivation, Ariad, Synta, Oncomed, Novartis, Genentech, Calithera Biosciences


John Heymach USA Ownership Interest (stocks or stock options, or other ownership interest

Cardinal Spine, Bio‐Tree, Spectrum Pharmas


John Heymach USA Supported/Contracted Research/Grant AstraZeneca, Bayer, GlaxoSmithKline, Threshold Pharmas


John Heymach USA Honoraria Ariad


John Heymach USA Speakers or Advisory Board AstraZeneca

OA02.07 Targeted Therapy Updated Results of Phase 1 Study of DS‐8201a in HER2‐Expressing or –Mutated Advanced Non‐Small‐Cell Lung Cancer

Junji Tsurutani Japan Nothing to disclose

OA02.08 Targeted Therapy Discussant ‐ OA 02.05, OA 02.06, OA 02.07 Daniel Costa USA Speakers or Advisory Board Tadeka, AstraZeneca

OA02.08 Targeted Therapy Discussant ‐ OA 02.05, OA 02.06, OA 02.07 Daniel Costa USA Honoraria Pfizer, Tadeka

OA02.08 Targeted Therapy Discussant ‐ OA 02.05, OA 02.06, OA 02.07 Daniel Costa USA Supported/Contracted Research/Grant Pfizer

OA02.08 Targeted Therapy Discussant ‐ OA 02.05, OA 02.06, OA 02.07 Daniel Costa USA Consultant Ariad

Session OA03: Advances in Lung Cancer Pathology


Planner

OA03 Biology/Pathology Geoffrey Liu Canada Honoraria AstraZeneca, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie, Pfizer, Merck

OA03 Biology/Pathology Geoffrey Liu Canada Speakers Bureau AstraZeneca

OA03 Biology/Pathology Geoffrey Liu Canada Speakers or Advisory Board AstraZeneca, Roche, Merck, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie

OA03 Biology/Pathology Robert Doebele USA Ownership Interest (stocks or stock options, or other ownership interest

Rain Therapeutics

OA03 Biology/Pathology Robert Doebele USA Speakers or Advisory Board Ignyta, AstraZeneca, Bayer, Takeda, Bristol‐Meyers Squibb, Ariad

OA03 Biology/Pathology Robert Doebele USA Supported/Contracted Research/Grant Ignyta

OA03 Biology/Pathology Robert Doebele USA Consultant Pfizer, OncoMed, Trovagene, Ignyta, GreenPeptide, AstraZeneca, Ignyta, Ariad, Guardant Health

OA03 Biology/Pathology Robert Doebele USA Honoraria Pfizer, AstraZeneca, Ariad, Guardant Health, Takeda, Spectrum Pharmas, Trovagene

OA03 Biology/Pathology Robert Doebele USA Royalty, Intellectual Property/Patent Holder Abbott Molecular, Rain Therapeutics, Igynta

OA03 Biology/Pathology Ramaswamy Govindan USA Speakers or Advisory Board Merck, Baxalta, Roche, Boehringer Ingleheim, Novartis, Pfizer, Celgene, AstraZeneca, MSK, AbbVie Inivata, Pfizer, NeoHealth, Bristol‐Meyers Squibb, Nektar, GlaxcSmithKline

OA03 Biology/Pathology Ramaswamy Govindan USA Consultant Genentech, Ariad, Astellas, Bristol‐Meyers Squibb, INC Research, AbbVie

OA03 Biology/Pathology Ramaswamy Govindan USA Honoraria AbbVie, Genentech, Boehringer Ingelheim

OA03 Biology/Pathology Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune



OA03 Biology/Pathology Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche

OA03 Biology/Pathology Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen

OA03 Biology/Pathology Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

OA03 Biology/Pathology David Hwang Canada Honoraria Merck, Pfizer, Takeda

OA03 Biology/Pathology David Hwang Canada Speakers or Advisory Board Merck

Chairs

OA03 Gang Chen China Nothing to disclose

OA03 Giuseppe Pelosi Italy Nothing to disclose

Faculty

OA03.01 Pathology The Immunophenotyping and Genomic Characteristics of Pulmonary Sarcomatoid Carcinoma: Pleomorphic, Spindle Cell and Giant Cell

Chunyan Wu China Nothing to disclose

OA03.02 Pathology Nationwide Comparative Study Of PD‐L1 IHC Assays on Lung Cancer: Initial Report Of LC‐SCRUM‐IBIS Project

Noriko Motoi Japan Speakers Bureau Bristol‐Meyers Squibb


Noriko Motoi Japan Speakers or Advisory Board Bristol‐Meyers Squibb, Ono Pharmas, Miraca, AstraZeneca, Merck


Noriko Motoi Japan Honoraria Bristol‐Meyers Squibb, Ono Pharmas, AstraZeneca, Merck, Novartis, Roche, Agilent, Chugai


Noriko Motoi Japan Supported/Contracted Research/Grant Roche

OA03.03 Pathology Phase 2B of Blueprint PD‐L1 Immunohistochemistry Assay Comparability Study

Keith Kerr UK Consultant Bristol‐Meyers Squibb

OA03.03 Pathology Phase 2B of Blueprint PD‐L1 Immunohistochemistry Assay Comparability Study

Keith Kerr UK Speakers or Advisory Board AstraZeneca, Bristol Meyers Squibb, Merck, Roche, Pfizer

OA03.04 Pathology Discussant ‐ OA 03.01, OA 03.02, OA 03.03 Julien Adam France Advisory Board AstraZeneca, BMS, Merck, Roche, Pfizer

OA03.05 Pathology Characterization of the Immunologic Intra‐Tumor Heterogeneity in Early Stages of Non‐Small Cell Lung Cancer by Multiplex Immunofluorescence

Alejandro Francisco Cruz USA Nothing to disclose

OA03.06 Pathology Extraction of Radiomic Values from Lung Adenocarcinoma with Near‐Pure Histological Subtypes

Mong‐Wei Lin Taiwan Nothing to disclose

OA03.07 Pathology Three‐Dimensional Immunofluorescence Analysis of Dynamic Vessel Co‐Option of Spread Through Air Spaces (STAS) in Lung Cancer

Yukako Yagi USA Nothing to disclose

OA03.08 Pathology Discussant ‐ OA 03.05, OA 03.06, OA 03.07 David Rimm USA Speakers or Advisory Board AstraZeneca, Agendia, Agilent, Bethyl Labs, Biocept, Bristol‐Meyers Squibb, Cell signaling technology, Cepheid, Merck, Optrascan, Perkin Elmer, Ultivue

OA03.08 Pathology Discussant ‐ OA 03.05, OA 03.06, OA 03.07 David Rimm USA Ownership Interest (stocks or stock options, or other ownership interest

PixelGear

OA03.08 Pathology Discussant ‐ OA 03.05, OA 03.06, OA 03.07 David Rimm USA Supported/Contracted Research/Grant Navigate, Novartis, Gilead Sciences, Perkin Elmer

Session OA04: Improving Access and Outcomes in Lung Cancer Management


Planner

OA04 Real World/Advocacy/Nursing/AHP Paul Wheatley‐Price Canada Speakers or Advisory Board AstraZeneca, Novartis, Eli Lilly Oncology, Bristol‐Meyers Squibb, Merck, Takeda

OA04 Real World/Advocacy/Nursing/AHP Christina Sit Canada Nothing to disclose

OA04 Real World/Advocacy/Nursing/AHP Dianne Zawisza Canada Nothing to disclose

OA04 Real World/Advocacy/Nursing/AHP Naz Nouriany Canada Nothing to disclose

OA04 Real World/Advocacy/Nursing/AHP Alexander Louie Canada Honoraria Varian Medical Systems, AstraZeneca

OA04 Real World/Advocacy/Nursing/AHP Melissa Culligan USA Nothing to disclose

Chairs

OA04 Pilar Garrido Spain Consultant Roche, Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol‐Meyers Squibb, Eli Lilly and Company, AbbVie, Novartis

OA04 Pilar Garrido Spain Speakers Bureau Roche, Merck, Bristol‐Meyers Squibb, Pfizer

OA04 Pilar Garrido Spain Supported/Contracted Research/Grant Guardant

OA04 Melissa Culligan USA Nothing to disclose

Faculty

OA04.01 Nursing and Allied Professionals What is the Cost of a Strong Evidence for the Treatment of Advanced Non‐Small Cell Lung Cancer?

Pedro Aguiar Jr Brazil Nothing to disclose

OA04.02 Nursing and Allied Professionals Demographic, Psychosocial, and Behavioral Associations with Cancer Screening Among a Homeless Population

Lovoria Williams USA Nothing to disclose

OA04.03 Nursing and Allied Professionals The Role of Comprehensive Genomic Profiling in the Community Setting Kimberly Rohan USA Speakers Bureau Merck, Genentech, AstraZeneca

OA04.03 Nursing and Allied Professionals The Role of Comprehensive Genomic Profiling in the Community Setting Kimberly Rohan USA Speakers or Advisory Board AstraZeneca

OA04.04 Nursing and Allied Professionals Discussant ‐ OA 04.01, OA 04.02, OA 04.03 Jhanelle Gray USA Supported/Contracted Research/Grant AstraZeneca, Celgene, Eli Lilly, Janssen, Merck, Genentech, Boehringer Ingelheim, Bristol‐Meyers Squibb, Array

OA04.04 Nursing and Allied Professionals Discussant ‐ OA 04.01, OA 04.02, OA 04.03 Jhanelle Gray USA Speakers or Advisory Board AstraZeneca

OA04.04 Nursing and Allied Professionals Discussant ‐ OA 04.01, OA 04.02, OA 04.03 Jhanelle Gray USA Honoraria Celgene, Eli Lilly, Janssen, AstraZeneca

OA04.05 Nursing and Allied Professionals An Early Rehabilitation Intervention for Enhancing Oxygenation From Lung Cancer Surgery

Wei Ling Hsiao Taiwan Nothing to disclose



OA04.06 Nursing and Allied Professionals Perceptions of Non‐Participation in a Rehabilitation Intervention After Surgery for Non‐Small Cell Lung Cancer

Mai Schoenau Denmark Nothing to disclose

OA04.07 Nursing and Allied Professionals Early Initiated Postoperative Rehabilitation Reduces Fatigue in Patients with Operable Lung Cancer: A Randomized Trial

Morten Quist Denmark Nothing to disclose

OA04.08 Nursing and Allied Professionals Discussant ‐ OA 04.05, OA 04.06, OA 04.07 Pippa Labuc UK Nothing to disclose

Session PC01: Controversies in Mesothelioma


Planner

PC01 Mesothelioma Anna Nowak Australia Speakers or Advisory Board Bayer, AstraZeneca, Sellas Life Sciences, Trizell, Boehringer Ingelheim, Epizyme, Roche, Merck

PC01 Mesothelioma Anna Nowak Australia Consultant AstraZeneca, Boehringer Ingelheim, Epizyme

PC01 Mesothelioma Anna Nowak Australia Supported/Contracted Research/Grant AstraZeneca, Douglas Pharma

PC01 Mesothelioma Marc DePerrot Canada Nothing to disclose

PC01 Mesothelioma Paul Baas Netherlands Nothing to disclose

PC01 Mesothelioma Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer

PC01 Mesothelioma Michele Carbone USA Nothing to disclose

PC01 Mesothelioma John Cho Canada Nothing to disclose

PC01 Mesothelioma Lauren Donohoe Canada Nothing to disclose

PC01 Mesothelioma Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche

PC01 Mesothelioma Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex

PC01 Mesothelioma Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca

PC01 Mesothelioma Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

PC01 Mesothelioma Seiki Hasegawa Japan Nothing to disclose

PC01 Mesothelioma Christopher Lee Canada Nothing to disclose

PC01 Mesothelioma Isabelle Opitz Switzerland Nothing to disclose

PC01 Mesothelioma Nick Pavlakis Australia Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Astra Zeneca, Roche, Novartis, Boehringer Ingelheim, Merck, Pfizer, Ipsen, Amgen

PC01 Mesothelioma Nick Pavlakis Australia Supported/Contracted Research/Grant Bayer

PC01 Mesothelioma Kenneth Rosenzweig USA Nothing to disclose

Chairs

PC01 Nicole Bouchard Canada Supported/Contracted Research/Grant Pfizer, Bristol‐Meyers Squibb, Merck

PC01 Nicole Bouchard Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche

PC01 Nico Van Zandwijk Australia Nothing to disclose

Faculty

PC01.01 Mesothelioma PRO Intrapleural Chemotherapy Is It the Future? Alessandra Curioni Fontecedro Switzerland Consultant Bristol‐Meyers Squibb, Merck, Roche, AstraZeneca, Pfizer, Takeda, Novartis, Boehringer Ingelheim

PC01.01 Mesothelioma PRO Intrapleural Chemotherapy Is It the Future? Alessandra Curioni Fontecedro Switzerland Speakers or Advisory Board Roche, Merck, Bristol‐Meyers Squibb, Boehringer‐Ingelheim, Pfizer, AstraZeneca, Takeda

PC01.01 Mesothelioma PRO Intrapleural Chemotherapy Is It the Future? Alessandra Curioni Fontecedro Switzerland Supported/Contracted Research/Grant Novartis

PC01.02 Mesothelioma CON Intrapleural Chemotherapy Is It the Future? David Rice USA Nothing to disclose

PC01.03 Mesothelioma PRO IO in Mesothelioma Should Only Be Given on Clinical Trials Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer

PC01.04 Mesothelioma CON in Mesothelioma Should Only Be Given on Clinical Trials Evan Alley USA Nothing to disclose

PC01.05 Mesothelioma PRO Radiation Options: Are We SMART Enough? John Cho Canada Nothing to disclose

PC01.06 Mesothelioma CON Radiation Options: Are We SMART Enough? Charles Simone USA Nothing to disclose

Session ES01: Advances in Lung Cancer Screening Through Imaging


Planner

ES01 Screening and Early Detection Christine Berg USA Honoraria Medial Early Sign LLC, GRAIL

ES01 Screening and Early Detection Stephen Lam Canada Nothing to disclose

ES01 Screening and Early Detection Denise Aberle USA Nothing to disclose



ES01 Screening and Early Detection John Field UK Speakers Bureau Roche

ES01 Screening and Early Detection John Field UK Speakers or Advisory Board Epigenomics, VisonGate

ES01 Screening and Early Detection John Goffin Canada Nothing to disclose

ES01 Screening and Early Detection Harry Groen Netherlands Consultant Roche‐Genentech, Merck, Novartis, Bristol‐Meyers Squibb

ES01 Screening and Early Detection Norihiko Ikeda Japan Honoraria AstraZeneca, Chugai, Merck, Ono Pharma, Taiho, Eli Lilly, Pfizer, Johnson & Johnson

ES01 Screening and Early Detection Garth Nicholas Canada Nothing to disclose

ES01 Screening and Early Detection Nir Peled Israel Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

ES01 Screening and Early Detection Nir Peled Israel Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

ES01 Screening and Early Detection Heidi Schmidt Canada Nothing to disclose

ES01 Screening and Early Detection Betty Tong Speakers or Advisory Board Medtronic

Chairs

ES01 Denise Aberle USA Nothing to disclose

ES01 Heidi Schmidt Canada Nothing to disclose

Faculty

ES01.01 Screening and Early Detection Image Quality Characteristics and Nodule Growth Measurement, Medical Physics and Machine Parameters

Ricardo Avila USA Ownership Interest Accumetra, Paraxial

ES01.01 Screening and Early Detection Image Quality Characteristics and Nodule Growth Measurement, Medical Physics and Machine Parameters

Ricardo Avila USA Employee Accumetra, Paraxial

ES01.02 Screening and Early Detection Image Interpretation and Advances from the Perspective of the Radiologist

David Yankelevitz USA Advisory Board Grail


David Yankelevitz USA Ownership Interest Accumetra LLC


David Yankelevitz USA Royalty, Intellectual Property/Patent Holder General Electric through Cornell Research Foundation

ES01.03 Screening and Early Detection Deep Machine Learning for Screening LDCT Bram Van Ginneken Netherlands Ownership Interest (stocks or stock options, or other ownership interest

Thirona

ES01.03 Screening and Early Detection Deep Machine Learning for Screening LDCT Bram Van Ginneken Netherlands Supported/Contracted Research/Grant MeVis Medical Systems

ES01.04 Screening and Early Detection Multi‐Phasic Screening ‐ Can We Address Competing Causes of Morbidity * Mortality Such as Coronary Artery Disease and COPD

Rozemarijn Vliegenthart Netherlands Nothing to disclose

ES01.05 Q&A

Session MA04: Novel Approaches with IO


Planner










Chairs

MA04 Tatiane Montella Brazil Nothing to disclose

MA04 Randeep Sangha Canada Advisory Board Boehringer‐Ingelheim; AstraZeneca, Roche/Genentech, Lundbeck, BMS, Merck, Novartis, Abbvie, Takeda

MA04 Randeep Sangha Canada Honoraria Boehringer‐Ingelheim; AstraZeneca, Roche/Genentech, Lundbeck, BMS, Merck, Novartis, Abbvie, Takeda, Pfizer

Faculty

MA04.01 Immunooncology Cemiplimab, a Human Monoclonal Anti‐PD‐1, Alone or in Combination with Radiotherapy: Phase 1 NSCLC Expansion Cohorts

Victor Moreno Spain Nothing to disclose

MA04.02 Immunooncology Responses and Durability in NSCLC Treated With Pegilodecakin and Anti‐PD‐1

Edward Garon USA Consultant Bristol‐Meyers Squibb, Eli Lilly, AstraZeneca, Genentech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax


Edward Garon USA Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Genetech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax


Edward Garon USA Supported/Contracted Research/Grant Merck, Genentech, AstraZeneca, Novartis, Pfizer, Eli Lilly, Bristol‐Meyers Squibb, Boehringer Ingelheim, Mirati Therapeutics, Dyanvax



MA04.03 Immunooncology Immunotherapy for Non‐Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry

Oliver Gautschi Switzerland Nothing to disclose

MA04.04 Immunooncology Discussant ‐ MA 04.01, MA 04.02, MA 04.03 Jose Pacheco USA Speakers or Advisory Board AstraZeneca, Novartis

MA04.04 Immunooncology Discussant ‐ MA 04.01, MA 04.02, MA 04.03 Jose Pacheco USA Honoraria Ariad Pharma

MA04.04 Immunooncology Discussant ‐ MA 04.01, MA 04.02, MA 04.03 Jose Pacheco USA Supported/Contracted Research/Grant Janssen, AstraZeneca and Pfizer

MA04.05 Immunooncology Outcomes in NSCLC Patients Treated with First‐Line Pembrolizumab and a PD‐L1 TPS of 50‐74% vs 75‐100% or 50‐89% vs 90‐100%

Mark Awad USA Consultant Genentech, Merck, Pfizer, Boehringer Ingelheim, AbbVie, AstraZeneca, MedImmune, Clovis Oncology, Nektar, Bristol‐Meyers Squibb, Ariad, Foundation Medicine, Syndax, Novartis

MA04.06 Immunooncology PD‐1 Blockade Promotes Hyperprogressive Disease in NSCLC Through Macrophages Activation via Antibody‐Fc/FcR Interaction

Gabriella Sozzi Italy Nothing to disclose

MA04.07 Immunooncology MicroRNA‐Based Liquid Biopsy Combines with PD‐L1 Tumor Expression to Predict Response to Immunotherapy in Advance NSCLC Patients

Mattia Boeri Italy Nothing to disclose

MA04.08 Immunooncology Discussant ‐ MA 04.05, MA 04.06, MA 04.07 Patrick Forde USA Supported/Contracted Research/Grant AstraZeneca, Bristol‐Meyers Squibb, Novartis, Kyowa, Janssen

MA04.08 Immunooncology Discussant ‐ MA 04.05, MA 04.06, MA 04.07 Patrick Forde USA Consultant Merck, Inivata, AbbVie, Boehringer Ingelheim

MA04.08 Immunooncology Discussant ‐ MA 04.05, MA 04.06, MA 04.07 Patrick Forde USA Speakers or Advisory Board Bristol‐Meyers Squibb, AstraZeneca, Novartis, Merck

MA04.09 Immunooncology Neoadjuvant Atezolizumab in Resectable Non‐Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)


MA04.09 Immunooncology Neoadjuvant Atezolizumab in Resectable Non‐Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)


MA04.10 Immunooncology Comprehensive Peripheral Blood Immunophenotyping and T‐Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC

Filiz Oezkan USA Consultant Epigenomics, Genentech, Roche


Filiz Oezkan USA Honoraria Novartis


Filiz Oezkan USA Supported/Contracted Research/Grant Genentech, Roche

MA04.11 Immunooncology Neoantigen Targeting and T Cell Reshaping in Resectable NSCLC Patients Treated with Neoadjuvant PD‐1 Blockade

Kellie Smith USA Nothing to disclose

MA04.12 Immunooncology Discussant ‐ MA 04.09, MA 04.10, MA 04.11 Alex Adjei USA Nothing to disclose

Session MA05: Improving Outcomes in Locoregional NSCLC II


Planner














Chairs

MA05 Jocelyne Martin Canada Nothing to disclose

MA05 Devin Schellenberg Canada Advisory Board Astra Zeneca

MA05 Devin Schellenberg Canada Honoraria Pfizer

MA05 Devin Schellenberg Canada Contracted/Support Research Grant Varian Medical Systems

Faculty

MA05.01 Treatment of Locoregional Disease ‐ NSCLC E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS‐NSCLC

Jyoti Patel USA Speakers or Advisory Board AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Takeda, Roche


Jyoti Patel USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb


Jyoti Patel USA Consultant Genentech

MA05.02 Treatment of Locoregional Disease ‐ NSCLC PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated with Durvalumab vs. Placebo After CRT

Johan Vansteenkiste Belgium Supported/Contracted Research/Grant University Hospitals KU Leuven, Merck


Johan Vansteenkiste Belgium Speakers or Advisory Board Apotex, AstraZeneca, Apotex, Boehringer Ingelheim, Merck, Novartis, Roche


Johan Vansteenkiste Belgium Consultant AstraZeneca, Merck, Bristol‐Meyers Squibb, Roche


Johan Vansteenkiste Belgium Honoraria AstraZeneca, Bristol‐Meyers Squibb, Merck, Roche



MA05.03 Treatment of Locoregional Disease ‐ NSCLC Immune Microenvironment and its Association with Adjuvant Chemotherapy Benefit in Locoregionally Advanced Lung Adenocarcinoma

Raj Vaghjiani USA Nothing to disclose

MA05.04 Treatment of Locoregional Disease ‐ NSCLC Discussant ‐ MA 05.01, MA 05.02, MA 05.03 Scott Gettinger USA Speakers Bureau Guardant

MA05.05 Treatment of Locoregional Disease ‐ NSCLC Photon‐Based Cardiac Sparing Via Volumetric Modulated Arc Therapy in Thoracic Radiation Therapy for Locally Advanced Non‐Small Cell Lung

Matthew Ferris USA Nothing to disclose

MA05.06 Treatment of Locoregional Disease ‐ NSCLC Locally Advanced Lung Cancer Radiotherapy in Deep Inspiration Breath Hold: Dosimetric Benefits from a Prospective Trial

Mirjana Josipovic Denmark Consultant Varian Medical Systems

MA05.07 Treatment of Locoregional Disease ‐ NSCLC Dose Escalated Chemo‐RT to 84 Gy in Stage III NSCLC Appears Excessively Toxic: Results from a Randomized Phase II Trial

Jan Nyman Sweden Nothing to disclose

MA05.08 Treatment of Locoregional Disease ‐ NSCLC Discussant ‐ MA 05.05, MA 05.06, MA 05.07 Benjamin Lok Canada Nothing to disclose

MA05.09 Treatment of Locoregional Disease ‐ NSCLC PFS and Cardiac‐Toxicity‐Adjusted‐PFS As Predictors of OS in Locally Advanced NSCLC Treated with Concurrent Chemoradiation

Chen Hu USA Nothing to disclose

MA05.10 Treatment of Locoregional Disease ‐ NSCLC The Pathologic Response of Locally Advanced NSCLC Treated with Concomitant Chemoradiation to 60 Gy in Image Guided Radiation Therapy

Sarit Appel Israel Nothing to disclose

MA05.11 Treatment of Locoregional Disease ‐ NSCLC Radiomics Analysis Using SVM Predicts Mediastinal Lymph Nodes Status of Squamous Cell Lung Cancer by Pre‐Treatment Chest CT Scan

Wu Nan China Nothing to disclose

MA05.12 Treatment of Locoregional Disease ‐ NSCLC Discussant ‐ MA 05.09, MA 05.10, MA 05.11 Matthew Hatton UK Speakers or Advisory Board AstraZeneca

Session MA06: PDL1, TMB and DNA Repair


Planner

MA06 Biology/Pathology Geoffrey Liu Canada Honoraria AstraZeneca, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie, Pfizer, Merck

MA06 Biology/Pathology Geoffrey Liu Canada Speakers Bureau AstraZeneca

MA06 Biology/Pathology Geoffrey Liu Canada Speakers or Advisory Board AstraZeneca, Roche, Merck, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie

MA06 Biology/Pathology Robert Doebele USA Ownership Interest (stocks or stock options, or other ownership interest

Rain Therapeutics

MA06 Biology/Pathology Robert Doebele USA Speakers or Advisory Board Ignyta, AstraZeneca, Bayer, Takeda, Bristol‐Meyers Squibb, Ariad

MA06 Biology/Pathology Robert Doebele USA Supported/Contracted Research/Grant Ignyta

MA06 Biology/Pathology Robert Doebele USA Consultant Pfizer, OncoMed, Trovagene, Ignyta, GreenPeptide, AstraZeneca, Ignyta, Ariad, Guardant Health

MA06 Biology/Pathology Robert Doebele USA Honoraria Pfizer, AstraZeneca, Ariad, Guardant Health, Takeda, Spectrum Pharmas, Trovagene

MA06 Biology/Pathology Robert Doebele USA Royalty, Intellectual Property/Patent Holder Abbott Molecular, Rain Therapeutics, Igynta

MA06 Biology/Pathology Ramaswamy Govindan USA Speakers or Advisory Board Merck, Baxalta, Roche, Boehringer Ingleheim, Novartis, Pfizer, Celgene, AstraZeneca, MSK, AbbVie Inivata, Pfizer, NeoHealth, Bristol‐Meyers Squibb, Nektar, GlaxcSmithKline

MA06 Biology/Pathology Ramaswamy Govindan USA Consultant Genentech, Ariad, Astellas, Bristol‐Meyers Squibb, INC Research, AbbVie

MA06 Biology/Pathology Ramaswamy Govindan USA Honoraria AbbVie, Genentech, Boehringer Ingelheim

MA06 Biology/Pathology Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune

MA06 Biology/Pathology Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche

MA06 Biology/Pathology Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen

MA06 Biology/Pathology Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

MA06 Biology/Pathology David Hwang Canada Honoraria Merck, Pfizer, Takeda

MA06 Biology/Pathology David Hwang Canada Speakers or Advisory Board Merck

Chairs

MA06 Noriko Motoi Japan Speakers Bureau Bristol‐Meyers Squibb

MA06 Noriko Motoi Japan Speakers or Advisory Board Bristol‐Meyers Squibb, Ono Pharmas, Miraca, AstraZeneca, Merck

MA06 Noriko Motoi Japan Honoraria Bristol‐Meyers Squibb, Ono Pharmas, AstraZeneca, Merck, Novartis, Roche, Agilent, Chugai

MA06 Noriko Motoi Japan Supported/Contracted Research/Grant Roche

MA06 Julien Adam France Advisory Board AstraZeneca, BMS, Merck, Roche, Pfizer

Faculty

MA06.01 Biology The Intrinsic PD‐L1 Promotes Cellular Invasiveness Via their PD‐1 Receptor in Lung Adenocarcinoma Cells

Wen‐Pin Su Taiwan Nothing to disclose

MA06.02 Biology Prospective Immunogenomic Profiling of Non‐Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON

Marcelo Negrao USA Nothing to disclose

MA06.03 Biology PD‐1 and Id‐1 Combined Blockade Impacts Tumor Growth and Survival Through PD‐L1 Expression and Tumor Infiltration by Immune‐Related Cells

Ignacio Gil‐Bazo Spain Nothing to disclose

MA06.04 Biology Discussant ‐ MA 06.01, MA 06.02, MA 06.03 Akihiko Yoshida Japan Nothing to disclose

MA06.05 Biology The Micro‐Environmental Cross Talk Between Mast Cells and Lung Cancer Cells Through Cell‐to‐Cell Contact

Rachel Shemesh Israel Nothing to disclose

MA06.06 Biology An Ex‐Vivo Patient‐Derived, Immunocompetent (PDI) Culture System to Evaluate Immunotherapeutic Agents’ Anti‐Tumor Efficacy

Zachary Tano USA Nothing to disclose

MA06.07 Biology Genetic and Epigenetic Alterations are Associated with Tumor Mutation Burden in Non‐Small Cell Lung Cancer

Liang‐Liang Cai China Nothing to disclose



MA06.08 Biology Discussant ‐ MA 06.05, MA 06.06, MA 06.07 Jyoti Patel USA Speakers or Advisory Board AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Takeda, Roche

MA06.08 Biology Discussant ‐ MA 06.05, MA 06.06, MA 06.07 Jyoti Patel USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb

MA06.08 Biology Discussant ‐ MA 06.05, MA 06.06, MA 06.07 Jyoti Patel USA Consultant Genentech

MA06.09 Biology XRCC6BP1: A DNA Repair Gene in Cisplatin Resistant Lung Cancer Stem Cells That May Predict Survival Outcomes in Patients

Martin Barr Ireland Nothing to disclose

MA06.10 Biology Germline Mutation in ATM Affect Lung Cancer Risk with High Effect Xuemei Ji USA Nothing to disclose

MA06.11 Biology Distinct Origins of Lymphatic and Brain Metastasis in Lung Cancer Tao Jiang China Nothing to disclose

MA06.12 Biology Discussant ‐ MA 06.09, MA 06.10, MA 06.11 Rebecca Heist USA Honoraria Boehringer Ingelheim

MA06.12 Biology Discussant ‐ MA 06.09, MA 06.10, MA 06.11 Rebecca Heist USA Supported/Contracted Research/Grant Genentech, Roche, Millenium, Novartis, Celgene, Peregrine, Mirati, Corvus, Incyte, AbbVie, Agios, Debiopharm

Session MA07: Towards Survivorship: The Landscape, Supports and Barriers


Planner

MA07 Real World/Advocacy/Nursing/AHP Paul Wheatley‐Price Canada Speakers or Advisory Board AstraZeneca, Novartis, Eli Lilly Oncology, Bristol‐Meyers Squibb, Merck, Takeda

MA07 Real World/Advocacy/Nursing/AHP Christina Sit Canada Nothing to disclose

MA07 Real World/Advocacy/Nursing/AHP Dianne Zawisza Canada Nothing to disclose

MA07 Real World/Advocacy/Nursing/AHP Naz Nouriany Canada Nothing to disclose

MA07 Real World/Advocacy/Nursing/AHP Alexander Louie Canada Honoraria Varian Medical Systems, AstraZeneca

MA07 Real World/Advocacy/Nursing/AHP Melissa Culligan USA Nothing to disclose

Chairs

MA07 Kazuo Hasegawa Japan Nothing to disclose

MA07 Paul Wheatley‐Price Canada Speakers or Advisory Board AstraZeneca, Novartis, Eli Lilly Oncology, Bristol‐Meyers Squibb, Merck, Takeda

Faculty

MA07.01 Advocacy No Longer Outliers: Understanding the Needs of Long‐Term Lung Cancer Survivors

Maureen Rigney USA Nothing to disclose

MA07.02 Advocacy Line of Therapy and Patient Preferences Treating Lung Cancer: A Discrete‐Choice Experiment

Andrea Ferris USA Nothing to disclose

MA07.03 Advocacy Attitudes to Lung Cancer in Europe: Findings from a Global Consumer Survey

Jesme Fox UK Nothing to disclose

MA07.04 Advocacy Discussant ‐ MA 07.01, MA 07.02, MA 07.03 Kim Norris USA Speakers or Advisory Board Takeda

MA07.04 Advocacy Discussant ‐ MA 07.01, MA 07.02, MA 07.03 Kim Norris USA Consultant Takeda

MA07.05 Advocacy Psychosocial Needs and Programs of Cancer Patients/Survivors and Their Relatives: Unmet Needs from an International Study

Csaba Dégi Romania Nothing to disclose

MA07.06 Advocacy Telephonic Communication In Palliative Care For Better Management Of Terminal Cancer Patients In Rural India ‐ An NGO Based Approach.

Nabanita Mandal India Nothing to disclose

MA07.07 Advocacy Identifying the Severity of Psychosocial Symptoms Among Patients Diagnosed with Lung Cancer. Do We Really Need Emotional Support

Arooj Fatima Pakistan Nothing to disclose

MA07.08 Advocacy Discussant ‐ MA 07.05, MA 07.06, MA 07.07 Jennifer King USA Speakers or Advisory Board Grail, AstraZeneca, Genentech, Tesaro, AbbVie

MA07.08 Advocacy Discussant ‐ MA 07.05, MA 07.06, MA 07.07 Jennifer King USA Supported/Contracted Research/Grant AstraZeneca

MA07.08 Advocacy Discussant ‐ MA 07.05, MA 07.06, MA 07.07 Jennifer King USA Speakers Bureau AstraZeneca

MA07.09 Advocacy Willingness to Perform Multiple Biopsies to Improve Quality of Lung Cancer Care: Understanding the Oncologists’ Perspective

Upal Basu Roy USA Nothing to disclose

MA07.10 Advocacy Utilizing a Personalized Navigation Program to Identify Barriers and Increase Clinical Trial Participation Among Lung Cancer Patients

Andrew Ciupek USA Speakers or Advisory Board Takeda Pharmas, AbbVie, Grail, Genentech

MA07.11 Advocacy Drug Price Comparison in Advanced Lung Cancer – High Cost Prices is Accompanied by Patient Benefits?

Luciene Bonan Brazil Nothing to disclose

MA07.12 Advocacy Discussant ‐ MA 07.09, MA 07.10, MA 07.11 Govind Babu Kanakasetty India Nothing to disclose

Session MS05: Diagnostic Dilemma in Lung Cancer


Planner

MS05 Pathology Ming Tsao Canada Honoraria Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Roche, Ventana

MS05 Pathology Ming Tsao Canada Supported/Contracted Research/Grant Merck, Pfizer, Roche, Ventana, AstraZeneca

MS05 Pathology Ming Tsao Canada Speakers or Advisory Board AstraZeneca, Pfizer, Merck, Roche, Ventana, Bristol Myers Squibb, AbbVie, Celgene

MS05 Pathology Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune

MS05 Pathology Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche



MS05 Pathology Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen

MS05 Pathology Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

MS05 Pathology Alan Borczuk USA Nothing to disclose

MS05 Pathology Lukas Bubendorf Switzerland Nothing to disclose

MS05 Pathology Sanja Dacic USA Speakers or Advisory Board Bristol‐Meyers Squibb, Astra‐Zeneca

MS05 Pathology Sanja Dacic USA Honoraria Bristol‐Meyers Squibb, AstraZeneca

MS05 Pathology David Hwang Canada Honoraria Merck, Pfizer, Takeda

MS05 Pathology David Hwang Canada Speakers or Advisory Board Merck

MS05 Pathology Keith Kerr UK Consultant Bristol‐Meyers Squibb

MS05 Pathology Keith Kerr UK Speakers or Advisory Board AstraZeneca, Bristol Meyers Squibb, Merck, Roche, Pfizer

MS05 Pathology Sylvie Lantuejoul France Nothing to disclose

MS05 Pathology John Longshore USA Speakers Bureau Roche, AstraZeneca, Bristol‐Meyers Squibb, Merck, Genentech

MS05 Pathology John Longshore USA Speakers or Advisory Board Roche, AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer

MS05 Pathology John Longshore USA Supported/Contracted Research/Grant Roche, AstraZeneca

MS05 Pathology Mari Mino‐Kenudson USA Consultant Merrimack Pharmas, H3 Biomedicine

MS05 Pathology Mari Mino‐Kenudson USA Honoraria Merrimac Pharmas, H3 Biomedicine

MS05 Pathology Andre Moreira USA Nothing to disclose

MS05 Pathology Andrew Nicholson UK Consultant Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Bristol‐Meyers Squibb, Roche, AbbVie

MS05 Pathology Andrew Nicholson UK Supported/Contracted Research/Grant Pfizer, Roche

MS05 Pathology Andrew Nicholson UK Speakers or Advisory Board Pfizer, Abbvie

MS05 Pathology Andrew Nicholson UK Ownership Interest (stocks or stock options, or other ownership interest

Merck

MS05 Pathology Yasushi Yatabe Japan Consultant Merck, Chugai‐Pharma, AstraZeneca, Bristol‐Meyers Squibb, Pfizer, Roche, ThermoFisher, Dako

MS05 Pathology Yasushi Yatabe Japan Honoraria AstraZeneca, Merck, Bristol Myers, Chugai‐pharma, Pfizer, Roche

Chairs

MS05 Johan Botling Sweden Advisory Board BMS

MS05 Johan Botling Sweden Honoraria Astra Zeneca, BMS, Boehringer Ingelheim

MS05 Johan Botling Sweden Contracted/Support Research Grant BMS

MS05 David Hwang Canada Honoraria Merck, Pfizer, Takeda

MS05 David Hwang Canada Speakers or Advisory Board Merck

Faculty

MS05.01 Pathology Staging and Pathology of Multiple Lung Nodules Alain Borczuk USA Nothing to disclose

MS05.02 Pathology Defining Invasion in Minimally Invasive Adenocarcinoma Masayuki Noguchi Japan Nothing to disclose

MS05.03 Pathology Tumor Heterogeneity in Lung Cancer Elisabeth Brambilla France Nothing to disclose

MS05.04 Pathology Diagnosis and Classification in Biopsies Andre Moreira USA Nothing to disclose

MS05.05 Q&A

Session MS06: Practical Issues in the Management of Oligometastatic NSCLC


Planner

MS06 Oligometastatic NSCLC David Palma Canada Nothing to disclose

MS06 Oligometastatic NSCLC Joseph Salama USA Nothing to disclose

MS06 Oligometastatic NSCLC Hak Choy USA Speakers Bureau AstraZeneca

MS06 Oligometastatic NSCLC Hak Choy USA Honoraria AstraZeneca, Merck

MS06 Oligometastatic NSCLC Laurie Gaspar USA Nothing to disclose

MS06 Oligometastatic NSCLC Matthias Guckenberger Switzerland Nothing to disclose

MS06 Oligometastatic NSCLC David Jones USA Nothing to disclose



MS06 Oligometastatic NSCLC Mary Macneil Canada Nothing to disclose

MS06 Oligometastatic NSCLC Boris Sepesi USA Nothing to disclose

Chairs

MS06 Mary Macneil Canada Nothing to disclose

MS06 Ugo Pastorino Italy Royalty, Intellectual Property/Patent Holder Gensignia Life Science

Faculty

MS06.01 Oligometastatic NSCLC The Role of Radiation in Treating the Mets Hak Choy USA Speakers Bureau AstraZeneca

MS06.01 Oligometastatic NSCLC The Role of Radiation in Treating the Mets Hak Choy USA Honoraria AstraZeneca, Merck

MS06.02 Oligometastatic NSCLC The Role of Interventional Pulmonology and Radiology Kwun Fong Australia Nothing to disclose

MS06.03 Oligometastatic NSCLC The Role of Surgical Resection Boris Sepesi USA Nothing to disclose

MS06.04 Oligometastatic NSCLC Systemic Therapy for Oligomets: Before, During, or After Local Therapies? Ross Camidge USA Honoraria Takeda, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, AstraZeneca, Arrys/Kyn, Genoptix, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera, Lycera, Revolution Med, Orion, Clovis, Celegene, Novartis

MS06.04 Oligometastatic NSCLC Systemic Therapy for Oligomets: Before, During, or After Local Therapies? Ross Camidge USA Supported/Contracted Research/Grant Ariad, Takeda, Pfizer

MS06.04 Oligometastatic NSCLC Systemic Therapy for Oligomets: Before, During, or After Local Therapies? Ross Camidge USA Speakers or Advisory Board AstraZeneca, Takeda, Arrys/Kyn, Genoptix, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, Takeda, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera DSMB, Lycera, Revolution Med

MS06.05 Oligometastatic NSCLC The Special Case of Brain Metastases: Systemic Therapy, Radiation or Both?

Laurie Gaspar USA Nothing to disclose

MS06.06 Q&A

Session MS07: Antibody‐Drug Conjugates in Advanced NSCLC


Planner

MS07 Advanced NSCLC Scott Laurie Canada Consultant Bristol‐Meyers Squibb, Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca, BBI

MS07 Advanced NSCLC Scott Laurie Canada Honoraria Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca

MS07 Advanced NSCLC Leora Horn Canada Consultant AbbVie, AstraZeneca, Genentech, Merck, Incyte, Xcovery, Roche

MS07 Advanced NSCLC Leora Horn Canada Supported/Contracted Research/Grant Xcovery Holding Company, Bristol‐Meyers Squibb, Boehringer Ingelheim, AbbVie, Genentech, Merck

MS07 Advanced NSCLC Carlos Gil Ferreira Brazil Nothing to disclose

MS07 Advanced NSCLC Glenn Goss USA Nothing to disclose

MS07 Advanced NSCLC Pasi Jänne USA Consultant Araxes Pharmas, Ariad, AstraZeneca, Boehringer Ingelheim, Chugai, Ignyta, Eli Lilly, Loxo, Merrimack, Mirati Therapeutics, Pfizer, Roche, Dana‐Farber Cancer Institute

MS07 Advanced NSCLC Pasi Jänne USA Speakers or Advisory Board AstraZeneca, Boehringer Ingelheim, Pfizer, Merrimack Pharmas, Roche, Genentech, Chugai Pharmas, Acea Biosciences, Ignyta, Loxo, Ariad, Eli Lilly, Araxes Pharmas

MS07 Advanced NSCLC Pasi Jänne USA Speakers Bureau Loxo

MS07 Advanced NSCLC Pasi Jänne USA Ownership Interest (stocks or stock options, or other ownership interest

Gatekeeper Pharmas

MS07 Advanced NSCLC Pasi Jänne USA Supported/Contracted Research/Grant Astellas Pharmas, AstraZenenca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim

MS07 Advanced NSCLC Pasi Jänne USA Royalty, Intellectual Property/Patent Holder LabCorp

MS07 Advanced NSCLC Clarissa Mathias Brazil Nothing to disclose

MS07 Advanced NSCLC Keunchil Park Korea Consultant Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Hanmi, Kyowa Kakko Kirin, Novartis, Ono Pharma, Roche, Bristol‐Meyers Squibb, GlaxoSmithKline, Merck, GlaxoSmithKline

MS07 Advanced NSCLC Keunchil Park Korea Supported/Contracted Research/Grant AstraZeneca

MS07 Advanced NSCLC Keunchil Park Korea Speakers or Advisory Board AstraZeneca, Astellas, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Hanmi, KHK, Merck, Novartis, Roche

MS07 Advanced NSCLC Suresh Ramalingam USA Consultant AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

MS07 Advanced NSCLC Suresh Ramalingam USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

MS07 Advanced NSCLC Noemi Reguart Spain Nothing to disclose

MS07 Advanced NSCLC Christian Rolfo USA Nothing to disclose

MS07 Advanced NSCLC Qing Zhou China Nothing to disclose

Chairs

MS07 Normand Blais Canada Speakers or Advisory Board AstraZeneca, Merck, Sanofi Canada, Bristol‐Meyers Squibb, Roche Canada, Boehringer Ingelheim, Bayer, Pfizer

MS07 Edgardo Santos USA Speakers Bureau Genentech, Pfizer, Novartis, Amgen, Takeda, Boehringer Ingelheim, Celgene, Merck, AstraZeneca

Faculty

MS07.01 Advanced NSCLC Basic Science David Gerber USA Ownership Interest (stocks or stock options, or other ownership interest

Gilead



MS07.01 Advanced NSCLC Basic Science David Gerber USA Speakers or Advisory Board Bristol‐Meyers Squibb, Samsung‐Bioepis

MS07.01 Advanced NSCLC Basic Science David Gerber USA Speakers Bureau Guardant

MS07.01 Advanced NSCLC Basic Science David Gerber USA Consultant Karyopharm

MS07.01 Advanced NSCLC Basic Science David Gerber USA Supported/Contracted Research/Grant Karyopharm, BerGenBio

MS07.02 Advanced NSCLC Pharmacology Christian Rolfo USA Nothing to disclose

MS07.03 Advanced NSCLC Clinical Data Thomas Stinchcombe USA Speakers or Advisory Board Genentech, AstraZeneca, Novartis, Takeda

MS07.04 Advanced NSCLC Future Directions Silvia Novello Italy Speakers or Advisory Board Takeda

MS07.04 Advanced NSCLC Future Directions Silvia Novello Italy Speakers Bureau Boehringer Ingelheim, AstraZeneca, Roche, Merck, Bristol‐Meyers Squibb, Eli Lilly, Takeda, Pfizer

MS07.05 Q&A

Session MS08: Lung Cancer in the Real World


Planner

MS08 Treatment in the Real World ‐ Support, Survivorship, Systems Research

Meredith Giuliani Canada Nothing to disclose


Martin Stockler Australia Supported/Contracted Research/Grant AbbVie, Amgen, AstraZeneca, Bayer, Bristol‐Meyers Squibb, Celgene, Merck, Pfizer, Roche


Carlos Barrios Brazil Honoraria Novartis, Roche, Genentech, Pfizer, GlaxoSmithKline, Sanofi, Boehringer Ingelheim, Eisai


Carlos Barrios Brazil Consultant Boehringer Ingelheim, Roche, Genentech, Novartis, GlaxoSmithKline, Eisai, Pfizer


Carlos Barrios Brazil Supported/Contracted Research/Grant Pfizer, Novartis, Amgen Inc., AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche, Genentech, Eli Lilly, Sanofi, Taiho Pharma, Mylan, Merrimack, Merck, AbbVie, Astellas Pharma, Biomarin, Bristol‐Meyers Squibb, Daiichi Sankyo, Abraxis BioScience, AB Science, Asana Biosciences, Medivation, Exelixis, ImClone Systems, Leo Pharma, Millennium


David Dawe Canada Nothing to disclose


William Evans Canada Speakers or Advisory Board AbbVie, Astellas, Bristol‐Meyers Squibb, Eisai, Eli Lilly, Janseen, Gilead, Takeda, AstraZeneca, Janssen, Boehringer Ingelheim, Roche, Celgene


William Evans Canada Consultant AstraZeneca, Janssen, Boehringer Ingelheim, Roche, Celgene


David Gerber USA Ownership Interest (stocks or stock options, or other ownership interest

Gilead


David Gerber USA Speakers or Advisory Board Bristol‐Meyers Squibb, Samsung‐Bioepis


David Gerber USA Speakers Bureau Guardant


David Gerber USA Consultant Karyopharm


David Gerber USA Supported/Contracted Research/Grant Karyopharm, BerGenBio


Cheryl Ho Canada Supported/Contracted Research/Grant BC Cancer Foundation


Cheryl Ho Canada Honoraria AstraZeneca


Cheryl Ho Canada Consultant Roche


Ronan Kelly USA Nothing to disclose


Biniam Kidane Canada Nothing to disclose


Gilberto Lopes Brazil Nothing to disclose


Alexander Louie Canada Honoraria Varian Medical Systems, AstraZeneca


Jarushka Naidoo USA Supported/Contracted Research/Grant Merck, AstraZeneca


Jarushka Naidoo USA Consultant Bristol‐Meyers Squibb, Takeda, AstraZeneca






Sadeesh Srinathan Canada Nothing to disclose

Chairs

MS08 Antoinette Wozniak USA Speakers or Advisory Board AstraZeneca, Takeda, Boehringer Ingelheim, HUYA, BeyondSpring

MS08 Antoinette Wozniak USA Supported/Contracted Research/Grant Boehringer Ingelheim

MS08 Ronan Kelly USA Nothing to disclose

Faculty

MS08.01 Treatment in the Real World ‐ Support, Survivorship, Systems Research

How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies ‐ European Perspective

Yolande Lievens Belgium Nothing to disclose


How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies – US Perspective

Gideon Blumenthal USA Nothing to disclose


Sources of Real World Data: Research Designs, Statistical Modelling and Quality Assurance Requirements

Mary Redman USA Nothing to disclose




The ASCO Perspective Bruce Johnson USA Royalty, Intellectual Property/Patent Holder Dana‐Farber Cancer Institute


The ASCO Perspective Bruce Johnson USA Consultant KEW


The ASCO Perspective Bruce Johnson USA Supported/Contracted Research/Grant Novartis, Toshiba, Genentech, Roche, Medical Systems


The ESTRO Perspective Umberto Ricardi Italy Nothing to disclose

MS08.06 Discussion

Session OA05: Clinical Trials in IO


Planner










Chairs

OA05 Scott Owen Canada Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Roche, Merck

OA05 Scott Owen Canada Honoraria AstraZeneca

OA05 Scott Owen Canada Consultant Roche Canada

OA05 Denis Moro‐Sibilot France Speakers or Advisory Board Roche, Eli Lilly, Sanofi, Novartis, Amgen, Pfizer, AstraZeneca, Clovis Oncology, Merck, Ariad, AbbVie, Bristol‐Meyers Squibb, Boehringer Ingelheim, Takeda

Faculty

OA05.01 Advanced NSCLC Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti‐PD‐(L)1 Therapy

Matthew Hellmann USA Consultant Bristol‐Meyers Squibb, Merck, Genentech Roche, AstraZeneca, MedImmune, Novartis, Janseen, Shattuck Lab, Syndax


Matthew Hellmann USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb


Matthew Hellmann USA Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Genentech, AstraZeneca, MedImmune, Novartis, Janssen Pharmas, Mirati Therapeutics, Shattuck Labs


Matthew Hellmann USA Royalty, Intellectual Property/Patent Holder Memorial Sloan Kettering Cancer Center

OA05.02 Advanced NSCLC Epacadostat Plus Pembrolizumab in Patients with Non‐Small Cell Lung Cancer: Phase 1/2 Results from ECHO‐202/KEYNOTE‐037

Liza Villaruz USA Speakers or Advisory Board Pfizer

OA05.03 Advanced NSCLC Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC

Ben Creelan USA Nothing to disclose

OA05.04 Advanced NSCLC Discussant ‐ OA 05.01, OA 05.02, OA 05.03 Scott Owen Canada Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Roche, Merck

OA05.04 Advanced NSCLC Discussant ‐ OA 05.01, OA 05.02, OA 05.03 Scott Owen Canada Honoraria AstraZeneca

OA05.04 Advanced NSCLC Discussant ‐ OA 05.01, OA 05.02, OA 05.03 Scott Owen Canada Consultant Roche Canada

OA05.05 Advanced NSCLC Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Fabrice Barlesi France Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda


Fabrice Barlesi France Consultant Roche, Genentech., AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda


Fabrice Barlesi France Supported/Contracted Research/Grant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda


Fabrice Barlesi France Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda, Serono

OA05.06 Advanced NSCLC CheckMate 227: Patient‐Reported Outcomes of First‐Line Nivolumab + Ipilimumab in High Tumor Mutational Burden Advanced NSCLC

Julie Brahmer USA Speakers or Advisory Board Merck, Genetech, Bristol‐Meyers Squibb, Syndax, AstraZeneca, Celgene, Amgen Oncology


Julie Brahmer USA Consultant Celgene, Eli Lilly, MedImmune, AstraZeneca, Bristol‐Meyers Squibb


Julie Brahmer USA Supported/Contracted Research/Grant Medimmune, AstraZeneca, Bristol‐Meyers Squibb

OA05.07 Advanced NSCLC IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non‐Squamous NSCLC

Vassiliki Papadimitrakopoulou USA Speakers or Advisory Board Nektar Therapeutics, AstraZeneca, Arrys, Merck, Loxo, Araxes Pharma, Roche, Janssen Research Foundation, Bristol‐Meyers Squibb, Clovis Oncology, Eli Lilly, Novartis, Takeda Pharma, AbbVie, TRM Oncology, Pfizer

OA05.07 Advanced NSCLC IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non‐Squamous NSCLC

Vassiliki Papadimitrakopoulou USA Supported/Contracted Research/Grant Eli Lilly, Novartis, Merck, AstraZeneca, Roche, Nektar Therapeutics, Janssen, Bristol‐Meyers Squibb, Checkmate, Incyte, Oregon Health Science, ACEA Biosciences, American Association of Cancer Research, Hope Foundation, Cancer Prevention and Research Institute of Texas, Genentech, Guardant Health

OA05.08 Advanced NSCLC Discussant ‐ OA 05.05, OA 05.06, OA 05.07 Hossein Borghaei USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Eli Lilly, Genentech, Celgene, Merck, Pfizer, Millennium

OA05.08 Advanced NSCLC Discussant ‐ OA 05.05, OA 05.06, OA 05.07 Hossein Borghaei USA Speakers or Advisory Board Bristol‐Meyers Squibb, Eli Lilly, Genentech, Celgene, Merck, Pfizer, Boerhinger Ingelheim, AstraZeneca, Genmab, Trovagene, Novartis, Regeneron, Cantargia AB, BioNTech

OA05.08 Advanced NSCLC Discussant ‐ OA 05.05, OA 05.06, OA 05.07 Hossein Borghaei USA Consultant University of Pennsylvania MIllennium



Session OA06: Early Stage Lung Cancer: Outcomes and Interventions


Planner














Chairs

OA06 Paul Van Schil Belgium Nothing to disclose

OA06 Harubumi Kato Japan Nothing to disclose

Faculty

OA06.01 Treatment of Early Stage/Localized Disease Case‐Series Study in Ever‐ and Never‐Smoking Females and Males with NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424)

Kathy Albain USA Advisory Board Geneutech/Roche, Genomic Health

OA06.02 Treatment of Early Stage/Localized Disease Video‐Assisted Thoracoscopic Surgery vs. Thoracotomy for Non‐Small Cell Lung Cancer: Oncologic Outcome of a Randomized Trial

Dongrong Situ China Nothing to disclose

OA06.03 Treatment of Early Stage/Localized Disease Sublobar Resection is Equivalent to Lobectomy for Screen Detected Lung Cancer

Brendon Stiles USA Employee (full time or part time) Pfizer, Pharmaceutical Product Development


Brendon Stiles USA Speakers or Advisory Board Merck, AstraZeneca, Lung Cancer Research Foundation


Brendon Stiles USA Ownership Interest (stocks or stock options, or other ownership interest

Pfizer, Pharmaceutical Product Development


Brendon Stiles USA Consultant Lung Cancer Research Foundation

OA06.04 Treatment of Early Stage/Localized Disease Discussant ‐ OA 06.01, OA 06.02, OA 06.03 Valerie Rusch USA Consultant Da Vinci Surgery, Bristol‐Meyers Squibb

OA06.04 Treatment of Early Stage/Localized Disease Discussant ‐ OA 06.01, OA 06.02, OA 06.03 Valerie Rusch USA Supported/Contracted Research/Grant Genelux

OA06.05 Treatment of Early Stage/Localized Disease Do SBRT Planning and Delivery Factors Influence Local Control for Early Stage Non‐Small Cell Lung Cancer (e‐NSCLC)?

Gregory Videtic USA Nothing to disclose

OA06.06 Treatment of Early Stage/Localized Disease MISSILE‐NSCLC: A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early‐Stage Non‐Small Cell Lung Cancer

David Palma Canada Nothing to disclose

OA06.07 Treatment of Early Stage/Localized Disease Predictors and Consequences of Refusing Surgery for Clinical Stage I NSCLC: A National Cancer Database Analysis

Brendon Stiles USA Employee (full time or part time) Pfizer, Pharmaceutical Product Development


Brendon Stiles USA Speakers or Advisory Board Merck, AstraZeneca, Lung Cancer Research Foundation


Brendon Stiles USA Ownership Interest (stocks or stock options, or other ownership interest

Pfizer, Pharmaceutical Product Development


Brendon Stiles USA Consultant Lung Cancer Research Foundation

OA06.08 Treatment of Early Stage/Localized Disease Discussant ‐ OA 06.05, OA 06.06, OA 06.07 Steven Lin USA Advisory Board AstraZeneca

OA06.08 Treatment of Early Stage/Localized Disease Discussant ‐ OA 06.05, OA 06.06, OA 06.07 Steven Lin USA Contracted/Support Research Grant Genentech, Hitachi Chemical Diagnostic, New River Labs, Beyond Spring Pharmaceuticals

Session PC02: Debate on Local Therapies for Limited Small Cell Lung Cancer? Surgery PRO/CON and BID Radiation PRO/CON


Planner

PC02 Small Cell Lung Cancer/NET Fiona Blackhall UK Nothing to disclose

PC02 Small Cell Lung Cancer/NET Peter Ellis Canada Honoraria AbbVie, AstraZeneca

PC02 Small Cell Lung Cancer/NET Peter Ellis Canada Consultant Celegene, Mylan

PC02 Small Cell Lung Cancer/NET Jeffrey Bogart USA Nothing to disclose

PC02 Small Cell Lung Cancer/NET Lauren Byers USA Nothing to disclose

PC02 Small Cell Lung Cancer/NET Quincy Chu Canada Nothing to disclose

PC02 Small Cell Lung Cancer/NET Eric Lim UK Speakers Bureau Abbott Molecular, Pfizer, Roche, Eli Lily, Boehringer Ingelheim, Ethicon



PC02 Small Cell Lung Cancer/NET Eric Lim UK Supported/Contracted Research/Grant Medela, ScreenCell, Clearbridge Biomedics, Illumina, Guardant Health

PC02 Small Cell Lung Cancer/NET Francoise Mornex France Nothing to disclose

PC02 Small Cell Lung Cancer/NET Charles Rudin USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Genentech, Harpoon, Genetics

PC02 Small Cell Lung Cancer/NET Charles Rudin USA Consultant Bristol‐Meyers Squibb, AbbVie, Seattle Genetics, Harpoon Therapeutics, Genentech Roche, AstraZeneca

PC02 Small Cell Lung Cancer/NET Ben Slotman Netherlands Nothing to disclose

PC02 Small Cell Lung Cancer/NET Sumitra Thongprasert Thailand Nothing to disclose

PC02 Small Cell Lung Cancer/NET Jie Wang China Nothing to disclose

PC02 Small Cell Lung Cancer/NET Mauro Zukin Brazil Nothing to disclose

Chairs

PC02 Wilfried Eberhardt Germany Speakers or Advisory Board Bristol‐Meyers Squibb, Roche, AstraZeneca, Merck, Boehringer Ingelheim, Celgene, Eli Lilly, Pfizer, Novartis, Takeda, AbbVie

PC02 Wilfried Eberhardt Germany Honoraria Bristol‐Meyers Squibb, Roche, AstraZeneca, Merck, Boehringer Ingelheim, Celgene, Eli Lilly, Pfizer, Novartis, Takeda, AbbVie

PC02 Wilfried Eberhardt Germany Supported/Contracted Research/Grant Eli Lilly, Bristol‐Meyers Squibb, AstraZeneca

PC02 Wilfried Eberhardt Germany Consultant Bristol‐Meyers Squibb, Roche, AstraZeneca, Boehringer Ingelheim

PC02 Quincy Chu Canada Nothing to disclose

Faculty

PC02.00 Small Cell Lung Cancer/NET Introduction with Poll Questions Wilfried Eberhardt Germany Speakers or Advisory Board Bristol‐Meyers Squibb, Roche, AstraZeneca, Merck, Boehringer Ingelheim, Celgene, Eli Lilly, Pfizer, Novartis, Takeda, AbbVie

PC02.00 Small Cell Lung Cancer/NET Introduction with Poll Questions Wilfried Eberhardt Germany Honoraria Bristol‐Meyers Squibb, Roche, AstraZeneca, Merck, Boehringer Ingelheim, Celgene, Eli Lilly, Pfizer, Novartis, Takeda, AbbVie

PC02.00 Small Cell Lung Cancer/NET Introduction with Poll Questions Wilfried Eberhardt Germany Supported/Contracted Research/Grant Eli Lilly, Bristol‐Meyers Squibb, AstraZeneca

PC02.00 Small Cell Lung Cancer/NET Introduction with Poll Questions Wilfried Eberhardt Germany Consultant Bristol‐Meyers Squibb, Roche, AstraZeneca, Boehringer Ingelheim

PC02.01 Small Cell Lung Cancer/NET Surgery ‐ PRO Elliot Wakeam Canada Nothing to disclose

PC02.02 Small Cell Lung Cancer/NET Surgery ‐ CON Cecile Le Pechoux France Speakers or Advisory Board AstraZeneca

PC02.02a Small Cell Lung Cancer/NET Poll Questions Wilfried Eberhardt Germany Speakers or Advisory Board Bristol‐Meyers Squibb, Roche, AstraZeneca, Merck, Boehringer Ingelheim, Celgene, Eli Lilly, Pfizer, Novartis, Takeda, AbbVie

PC02.02a Small Cell Lung Cancer/NET Poll Questions Wilfried Eberhardt Germany Honoraria Bristol‐Meyers Squibb, Roche, AstraZeneca, Merck, Boehringer Ingelheim, Celgene, Eli Lilly, Pfizer, Novartis, Takeda, AbbVie

PC02.02a Small Cell Lung Cancer/NET Poll Questions Wilfried Eberhardt Germany Supported/Contracted Research/Grant Eli Lilly, Bristol‐Meyers Squibb, AstraZeneca

PC02.02a Small Cell Lung Cancer/NET Poll Questions Wilfried Eberhardt Germany Consultant Bristol‐Meyers Squibb, Roche, AstraZeneca, Boehringer Ingelheim

PC02.03 Small Cell Lung Cancer/NET BID Radiation ‐ CON Ben Slotman Netherlands Nothing to disclose

PC02.04 Small Cell Lung Cancer/NET BID Radiation ‐ PRO Jeffrey Bogart USA Nothing to disclose

Session MA08: Clinical Trials in Brain Metastases


Planner










Chairs

MA08 Edith Filion Canada Nothing to disclose

MA08 Barbara Melosky Canada Nothing to disclose

Faculty

MA08.01 Advanced NSCLC Phase 3 Trial of Whole Brain Radiotherapy with Concurrent Erlotinib Versus WBRT Alone for NSCLC with Brain Metastases (ENTER)

ZhenZhou Yang China Nothing to disclose



MA08.02 Advanced NSCLC Prophylactic Cranial Irradiation Reduces the Risk of Brain Metastases in High‐Risk Lung Cancer Patients: EGFR and ALK Mutations

Oscar Arrieta Mexico Nothing to disclose

MA08.03 Advanced NSCLC EGFR‐TKI Plus Brain Radiotherapy Versus EGFR‐TKI Alone in the Management of EGFR Mutated NSCLC Patients with Brain Metastases: A

Wenhua Liang China Nothing to disclose

MA08.04 Advanced NSCLC Discussant ‐ MA 08.01, MA 08.02, MA 08.03 Nasser Hanna USA Supported/Contracted Research/Grant Merck, Bristol‐Meyers Squibb, Genentech, AstraZeneca

MA08.05 Advanced NSCLC Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study

Todd Bauer USA Speakers or Advisory Board Ignyta, Guardant Health, Loxo, Pfizer, Moderna Therapeutics


Todd Bauer USA Employee (full time or part time) Tennessee Oncology, Sarah Cannon Research Institute


Todd Bauer USA Supported/Contracted Research/Grant Daiichi Sankyo, Medpacto, Incyte, Mirati Therapeutics, MedImmune, AbbVie, AstraZeneca, Leap Therapeutics, MabVax, Stemline Therapeutics, Merck, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Principa Biopharma, Genentech, Roche, Deciphera, Merrimack, Immunogen, Millennium, Ignyta, Calithera Biosciences, Kolltan Pharmas, Principa Biopharma, Peleton, Immunocore,

MA08.07 Advanced NSCLC Real World Data of Osimertinib in Patients with Central Nervous System (CNS) Metastasis in ASTRIS Korean Subset.

Jin‐Hyoung Kang Korea Nothing to disclose

MA08.08 Advanced NSCLC Discussant ‐ MA 08.05, MA 08.07 Myung‐Ju Ahn Korea Consultant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Merck, Novartis, Alpha BioPharmas

MA08.08 Advanced NSCLC Discussant ‐ MA 08.05, MA 08.07 Myung‐Ju Ahn Korea Speakers or Advisory Board AstraZeneca, Eli Lilly, Bristol‐Meyers Squibb, Merck, Ono Pharma, Roche

MA08.09 Advanced NSCLC Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non‐Small Cell Lung Cancer (NSCLC) Patients

Lizza Hendriks Netherlands Nothing to disclose

MA08.10 Advanced NSCLC Real‐Life Intracerebral Efficacy of Nivolumab in Non‐Small Cell Lung Cancer Patients with Brain Metastases

Margaux Geier France Nothing to disclose

MA08.11 Advanced NSCLC Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with

Raafat Alameddine Canada Nothing to disclose

MA08.12 Advanced NSCLC Discussant ‐ MA 08.09, MA 08.10, MA 08.11 Arjun Sahgal Canada Contracted/Support Research Grant Elekta AB

MA08.12 Advanced NSCLC Discussant ‐ MA 08.09, MA 08.10, MA 08.11 Arjun Sahgal Canada Other(please specify) Past educational seminars with Elekta AB, Accuray Inc., and Varian medical systems; travel accommodations/expenses by Elekta and Varian; Dr. Sahgal also belongs to the Elekta MR Linac Research Consortium

MA08.12a Advanced NSCLC Q&A

Session MA09: Lung Cancer Surgical and Molecular Pathology


Planner





Rain Therapeutics















Chairs

MA09 Deepali Jain India Nothing to disclose

MA09 Dongmei Lin China Nothing to disclose

Faculty

MA09.01 Pathology Correlation of Pre‐Operative Cancer Imaging Techniques with Post‐Operative Macro and Microscopic Lung Pathology Images

Stephen Harrow UK Honoraria AstraZeneca

MA09.01 Pathology Correlation of Pre‐Operative Cancer Imaging Techniques with Post‐Operative Macro and Microscopic Lung Pathology Images

Stephen Harrow UK Speakers or Advisory Board AstraZeneca

MA09.02 Pathology Tumor Size and Frozen Section Should Be Considered Jointly to Predict the Final Pathology for Lung Adenocarcinoma

Erjia Zhu China Nothing to disclose

MA09.03 Pathology Multiple Pathological Variables Predict Efficacy of Adjuvant Chemotherapy in Primary Lung Adenocarcinoma

John Le Quesne UK Nothing to disclose

MA09.04 Pathology Discussant ‐ MA 09.01, MA 09.02, MA 09.03 Natasha Rekhtman USA Nothing to disclose



MA09.05 Pathology Can We Predict Radiosensitivity in Non‐Small Cell Lung Cancer? Juvenal Baena UK Nothing to disclose

MA09.06 Pathology The Newly Recognized Filigree Pattern of Micropapillary (MIP) Lung Adenocarcinoma (LADC) is as Clinically Important as the Classical Pattern

Katsura Emoto USA Nothing to disclose

MA09.07 Pathology Developing a Pathological Grading System in Predicting Prognosis for Invasive Mucinous Adenocarcinomas

Wei‐Chin Chang Taiwan Nothing to disclose

MA09.08 Pathology Discussant ‐ MA 09.05, MA 09.06, MA 09.07 Lucian Chirieac USA Nothing to disclose

MA09.09 Pathology EBUS‐TBNA in Assessing PD‐L1 Expression in NSCLC Jason Agulnik Canada Honoraria Merck, Pfizer, Bristol‐Meyers Squibb, AstraZeneca

MA09.10 Pathology Molecular Profiling and PD‐L1 Status in 900 Cases of Surgically Resected Non‐Small Cell Lung Cancer with Clinical and Pathological Correlation

Zhaolin Xu Canada Nothing to disclose

MA09.11 Pathology Genomic Landscape and its Correlation with TMB, CD8 TILs and PD‐L1 Expression in Chinese Lung Squamous Cell Carcinoma

Tao Jiang China Nothing to disclose

MA09.12 Pathology Discussant ‐ MA 09.09, MA 09.10, MA 09.11 Philippe Joubert Canada Nothing to disclose

Session MS09: Tumour Board ‐ Tissue Acquisition and Staging


Planner

MS09 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Honoraria ACEA, Genentech, Novartis, AstraZeneca

MS09 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Supported/Contracted Research/Grant Clovis, Exelixis, AstraZeneca, MedImmune, Genentech, Roche, Bristol‐Meyers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Eli Lilly, Acea, Merck

MS09 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Speakers or Advisory Board ACEA Biosyciences, Pfizer, Novartis, Genentech, Roche, AstraZeneca, Merck

MS09 Thymoma/Other Thoracic Malignancies Meinoshin Okumura Japan Nothing to disclose

MS09 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Speakers or Advisory Board AstraZeneca

MS09 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Consultant Eli Lilly

MS09 Thymoma/Other Thoracic Malignancies Wentao Fang China Nothing to disclose

MS09 Thymoma/Other Thoracic Malignancies Pier Luigi Filosso Italy Nothing to disclose

MS09 Thymoma/Other Thoracic Malignancies Nicolas Girard France Consultant Bristol‐Meyers Squibb, Merck Roche, AstraZeneca

MS09 Thymoma/Other Thoracic Malignancies Shaf Keshavjee Canada Nothing to disclose

MS09 Thymoma/Other Thoracic Malignancies Robert Korst USA Nothing to disclose

MS09 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Supported/Contracted Research/Grant Varian Medical Systems, Boehringer Ingelheim, AstraZeneca, Pfizer

MS09 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Honoraria Varian Medical Systms, Bristol‐Meyers Squibb, AstraZeneca, Pfizer, Merck

MS09 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Speakers or Advisory Board AstraZeneca, Merck

MS09 Thymoma/Other Thoracic Malignancies DAvid Waller UK Nothing to disclose

Chairs

MS09 Eric Edell Canada Nothing to disclose

MS09 Septimiu Murgu USA Honoraria Boston Scientific, Olympus, Cook Inc, Pinnacle Biologics, Auris Robotics

MS09 Septimiu Murgu USA Other(please specify) educational consultant

Faculty

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu Eric Edell Canada Nothing to disclose

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu Septimiu Murgu USA Honoraria Boston Scientific, Olympus, Cook Inc, Pinnacle Biologics, Auris Robotics

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu Septimiu Murgu USA Other(please specify) educational consultant

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu Neal Navani UK Nothing to disclose

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu Karin Steinke Australia Nothing to disclose

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu Kazuhiro Yasufuku Canada Speakers or Advisory Board Concordia, Olympus America

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu Kazuhiro Yasufuku Canada Supported/Contracted Research/Grant Olympus Corporation, Siemens, Veran Medical Technologies, Novadaq

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu Kazuhiro Yasufuku Canada Consultant Intuitive Surgical, Medtronic, Johnson & Johnson, Auris Surgical Robotics

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu David Hwang Canada Honoraria Merck, Pfizer, Takeda

MS09.01 Thymoma/Other Thoracic Malignancies Cases Prepared by Drs. Edell/Murgu David Hwang Canada Speakers or Advisory Board Merck

MS09.02 Thymoma/Other Thoracic Malignancies Q&A

Session MS10: Part Solid Nodules, GGN and STAS




Planner

MS10 Treatment of Early Stage/Localized Disease Hisao Asamura Japan Honoraria Lecturer of seminar ‐ Johnson & Johnson, Covidien, Eli Lilly, Taiho, Boehringer Ingelheim, Ono Pharmaceuticals

MS10 Treatment of Early Stage/Localized Disease Patrick Cheung Canada Nothing to disclose

MS10 Treatment of Early Stage/Localized Disease Thomas D'Amico USA Consultant Consultant for Scanlan Instruments

MS10 Treatment of Early Stage/Localized Disease Jessica Donington USA Honoraria AstraZeneca

MS10 Treatment of Early Stage/Localized Disease Janet Edwards Canada Nothing to disclose

MS10 Treatment of Early Stage/Localized Disease Bob Li USA Consultant Genentech, Roche, Thermo Fischer Scientific, Guardant Health

MS10 Treatment of Early Stage/Localized Disease Bob Li USA Speakers or Advisory Board Genentech, Guardant Health, Mersana Therapeutics

MS10 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Speakers or Advisory Board Eli LIlly

MS10 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Supported/Contracted Research/Grant Eli Lilly, Boehringer Ingelheim, AstraZeneca, Chugai, The Japan Society for the Promotion of Science

MS10 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Consultant Bristol‐Meyers Squibb, Ono Pharma

MS10 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Speakers Bureau AstraZeneca, Chug, Pfizer, Boehringer Ingelheim

MS10 Treatment of Early Stage/Localized Disease Luis Raez USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Roche, Genentech, Syndax, Novartis

MS10 Treatment of Early Stage/Localized Disease Ramon Rami‐Porta Spain Nothing to disclose

MS10 Treatment of Early Stage/Localized Disease Tomohito Saito Japan Supported/Contracted Research/Grant Ono Pharma, Bristol‐Myers Squibb

MS10 Treatment of Early Stage/Localized Disease Tomohito Saito Japan Consultant Ono Pharma

MS10 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Speakers or Advisory Board AstraZeneca, Eli Lilly, Merck

MS10 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Employee (full time or part time) VU University Medical Center

MS10 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Honoraria Eli Lilly

MS10 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Supported/Contracted Research/Grant Varian Medical Systems, ViewRay

Chairs

MS10 Paul Van Schil Belgium Nothing to disclose

MS10 Nir Peled Israel Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

MS10 Nir Peled Israel Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

Faculty

MS10.01 Treatment of Early Stage/Localized Disease Radiographic Differences Between Presumed AIS and MIA Mini Pakkal Canada Nothing to disclose

MS10.02 Treatment of Early Stage/Localized Disease Importance of CT in the Pathologic Assessment of Tumor Sized in Subsolid and Part‐Solid Adenocarcinoma

Erik Thunnissen Netherlands Speakers or Advisory Board Pfizer, Bristol‐Meyers Squibb, Merck


Erik Thunnissen Netherlands Consultant Diaceutics


Erik Thunnissen Netherlands Supported/Contracted Research/Grant Pfizer


Erik Thunnissen Netherlands Honoraria Oncologia, Histogenix, AstraZeneca, Ventana

MS10.03 Treatment of Early Stage/Localized Disease CT Versus Needle Biopsy Assessment Before Resection of Part Solid Nodules

Young Tae Kim Korea Nothing to disclose

MS10.04 Treatment of Early Stage/Localized Disease Therapeutic Implications of Spread Through Air Spaces (STAS) William Travis USA Nothing to disclose

MS10.05 Treatment of Early Stage/Localized Disease Should We Resect GGNs Kenji Suzuki Japan Nothing to disclose

MS10.06 Q&A

Session MS11: Stigma and Lung Cancer: Unintended Translational Consequences of Effective Tobacco Control


Planner

MS11 Prevention and Tobacco Control Matthew Steliga USA Nothing to disclose

MS11 Prevention and Tobacco Control Michael Cummings USA Nothing to disclose

MS11 Prevention and Tobacco Control Eric Bedard Canada Nothing to disclose

MS11 Prevention and Tobacco Control Wanda De Kanter Netherlands Nothing to disclose

MS11 Prevention and Tobacco Control Carolyn Dresler USA Nothing to disclose

MS11 Prevention and Tobacco Control Rayjean Hung Canada Nothing to disclose

MS11 Prevention and Tobacco Control Jacek Jassem Poland Nothing to disclose

MS11 Prevention and Tobacco Control Jamie Ostroff USA Nothing to disclose



MS11 Prevention and Tobacco Control Emily Stone Australia Nothing to disclose

MS11 Prevention and Tobacco Control Nise Yamaguchi Brazil Nothing to disclose

MS11 Prevention and Tobacco Control Li Zhang China Speakers or Advisory Board Merck, Boehringer Ingelheim

Chairs

MS11 Antoni Rosell Spain Nothing to disclose

MS11 Li Zhang China Speakers or Advisory Board Merck, Boehringer Ingelheim

Faculty

MS11.01 Prevention and Tobacco Control Identifying Consequences of Stigma on Lung Cancer Care Delivery and Patient Outcomes

Heidi Hamann USA Nothing to disclose

MS11.02 Prevention and Tobacco Control Stigma of Tobacco and Lung Cancer: A South American Perspective Clarissa Baldotto Brazil Nothing to disclose

MS11.03 Prevention and Tobacco Control Prevalence of Perceived Lung Cancer Stigma Among Medical and Nursing Students

Jamie Studts USA Nothing to disclose

MS11.04 Prevention and Tobacco Control Taking a Smoking History in the Context of Lung Cancer Treatment: Missed Opportunities for Stigma‐Reducing Empathic Encounters with Throacic

Peter Harper UK Nothing to disclose

MS11.05 Q&A

Session MS12: Immunotherapy and RT


Planner

MS12 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Supported/Contracted Research/Grant Merck, AstraZeneca, Elekta

MS12 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Consultant Merck, AstraZeneca, Elekta, Pfizer, Respective Meeting‐Related Travel Support

MS12 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers or Advisory Board Pfizer, Merck

MS12 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Honoraria AstraZeneca, Merck

MS12 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers Bureau AstraZeneca, Merck

MS12 Treatment of Locoregional Disease ‐ NSCLC Paula Ugalde Canada Nothing to disclose

MS12 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Honoraria Pfizer, Boehringer Ingelheim, AstaZeneca, Bristol‐Meyers Squibb, Merck, Takeda

MS12 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Speakers or Advisory Board Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Merck, Takeda

MS12 Treatment of Locoregional Disease ‐ NSCLC Hiroshi Date Japan Nothing to disclose

MS12 Treatment of Locoregional Disease ‐ NSCLC Dirk De Ruysscher Netherlands Nothing to disclose

MS12 Treatment of Locoregional Disease ‐ NSCLC Rui Haddad Brazil Nothing to disclose

MS12 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Speakers Bureau Varian Medical

MS12 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Honoraria Varian Medical

MS12 Treatment of Locoregional Disease ‐ NSCLC Jocelyne Martin Canada Nothing to disclose

MS12 Treatment of Locoregional Disease ‐ NSCLC Gaetano Rocco Italy Speakers Bureau Baxter, Medtronic

MS12 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers or Advisory Board AbbVie, AstraZeneca, Spiration

MS12 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers Bureau Synthes

MS12 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Consultant Spiration, Olympus

Chairs

MS12 Joseph Salama USA Nothing to disclose

MS12 Yi‐Long Wu China Speakers or Advisory Board AstraZeneca, Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, Sanofi

MS12 Yi‐Long Wu China Speakers Bureau AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi

MS12 Yi‐Long Wu China Honoraria AstraZeneca, Eli Lilly, Pfizer, Roche

MS12 Yi‐Long Wu China Consultant AstraZeneca, Boehringer Ingelheim, Merck, Roche

MS12 Yi‐Long Wu China Supported/Contracted Research/Grant Boehringer Ingelheim, Roche

Faculty

MS12.01 Treatment of Locoregional Disease ‐ NSCLC Biology IO+RT Dirk De Ruysscher Netherlands Nothing to disclose

MS12.02 Treatment of Locoregional Disease ‐ NSCLC Clinical Data Available Feng‐Ming (Spring) Kong USA Speakers Bureau Varian Medical

MS12.02 Treatment of Locoregional Disease ‐ NSCLC Clinical Data Available Feng‐Ming (Spring) Kong USA Honoraria Varian Medical



MS12.03 Treatment of Locoregional Disease ‐ NSCLC Ongoing Studies Francoise Mornex France Nothing to disclose

MS12.04 Treatment of Locoregional Disease ‐ NSCLC Implications for Routine Practice Paul Mitchell Australia Advisory Board Roche, BMS, AstraZeneca, Merck KGa, MSD

MS12.04 Treatment of Locoregional Disease ‐ NSCLC Implications for Routine Practice Paul Mitchell Australia Honoraria Roche, Merck KGa

MS12.04 Treatment of Locoregional Disease ‐ NSCLC Implications for Routine Practice Paul Mitchell Australia Other(please specify) Travel Grant (conference): Roche, BMS, AstraZeneca

MS12.05 Q&A

Session OA07: Oligometastasis: What Should Be the State‐Of‐The‐Art?


Planner














Chairs

OA07 Yee Ung Canada Nothing to disclose

OA07 Paula Mulvenna UK Nothing to disclose

Faculty

OA07.01 Oligometastatic NSCLC Phase II Study of Pembrolizumab for Oligometastatic Non‐Small Cell Lung Cancer (NSCLC) Following Completion of Locally Ablative Therapy (LAT)

Joshua Bauml USA Supported/Contracted Research/Grant Merck, Novartis, Carevive Systems, Janssen, Bayer


Joshua Bauml USA Consultant Merck, Bristol‐Meyers Squibb, Celgene, Boehringer‐Ingelheim, AstraZeneca, Genentech, Guardant Health


Joshua Bauml USA Honoraria Clovis, Bristol‐Meyers Squibb, Celgene, Boehringer Ingleheim, AstraZeneca, Genentech, Guardant Health

OA07.02 Oligometastatic NSCLC ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI

Oscar S.H. Chan Hongkong Speakers or Advisory Board AstraZeneca, Merck

OA07.02 Oligometastatic NSCLC ATOM: A Phase II Study to Assess Efficacy of Preemptive Local Ablative Therapy to Residual Oligometastases After EGFR TKI

Oscar S.H. Chan Hongkong Honoraria Bristol‐Meyers Squibb, AstraZeneca

OA07.03 Oligometastatic NSCLC Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR‐Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver


OA07.04 Oligometastatic NSCLC Discussant ‐ OA 07.01, OA 07.02, OA 07.03 Gregory Videtic USA Nothing to disclose

OA07.05 Oligometastatic NSCLC Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated with EGFR‐TKIs

Yaping Xu China Nothing to disclose

OA07.06 Oligometastatic NSCLC Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.

Fang Hu China Nothing to disclose

OA07.07 Oligometastatic NSCLC PFS and OS Beyond 5 years of NSCLC Patients with Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)

Dirk De Ruysscher Netherlands Nothing to disclose

OA07.08 Oligometastatic NSCLC Discussant ‐ OA 07.05, OA 07.06, OA 07.07 Sue Yom USA Supported/Contracted Research/Grant Bristol‐Myers Squibb, Merck, Genentech

OA07.08 Oligometastatic NSCLC Discussant ‐ OA 07.05, OA 07.06, OA 07.07 Sue Yom USA Royalty, Intellectual Property/Patent Holder Springer, UpToDate

Session OA08: Mesothelioma: Immunotherapy and microRNA for Diagnosis and Treatment


Planner

OA08 SCLC/Thymoma/Mesothelioma Marc De Perrot Canada Nothing to disclose

OA08 SCLC/Thymoma/Mesothelioma Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer

OA08 SCLC/Thymoma/Mesothelioma Quincy Chu Canada Nothing to disclose

OA08 SCLC/Thymoma/Mesothelioma Anthony Brade Canada Speakers or Advisory Board AstraZeneca

OA08 SCLC/Thymoma/Mesothelioma Anthony Brade Canada Consultant Eli Lilly



OA08 SCLC/Thymoma/Mesothelioma Gail Darling Canada Nothing to disclose

Chairs

OA08 Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche

OA08 Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex

OA08 Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca

OA08 Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

OA08 John Cho Canada Nothing to disclose

Faculty

OA08.01 Mesothelioma Long‐Term Efficacy and Safety of Nivolumab in Second‐ or Third‐Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)

Takashi Nakano Japan Honoraria Merck, Olympus, Ishihara Sangyo, Kyorin, Pharma, Boehringer Ingelheim, Ono Pharma

OA08.02 Mesothelioma DREAM ‐ A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result

Anna Nowak Australia Speakers or Advisory Board Bayer, AstraZeneca, Sellas Life Sciences, Trizell, Boehringer Ingelheim, Epizyme, Roche, Merck


Anna Nowak Australia Consultant AstraZeneca, Boehringer Ingelheim, Epizyme


Anna Nowak Australia Supported/Contracted Research/Grant AstraZeneca, Douglas Pharma

OA08.03 Mesothelioma Phase II Trial of Pembrolizumab (NCT02399371) In Previously‐Treated Malignant Mesothelioma (MM): Final Analysis

Arpita Desai USA Nothing to disclose

OA08.04 Mesothelioma Discussant ‐ OA 08.01, OA 08.02, OA 08.03 Thomas John Australia Speakers or Advisory Board Bristol‐Meyers Squibb, AstraZeneca, Boehringher Ingelheim, Takeda, Pfizer, Novartis, Merck, Ignyta

OA08.04 Mesothelioma Discussant ‐ OA 08.01, OA 08.02, OA 08.03 Thomas John Australia Consultant Bristol‐Meyers Squibb, AstraZeneca, Boehringer Ingelheim, Takeda, Pfizer, Novartis, Merck

OA08.05 Mesothelioma Quantifying Tumour Infiltrating Lymphocytes (TILs) in Malignant Pleural Mesothelioma (MPM) ‐Defining the Hot, the Warm and the Cold Tumours.

Thomas John Australia Speakers or Advisory Board Bristol‐Meyers Squibb, AstraZeneca, Boehringher Ingelheim, Takeda, Pfizer, Novartis, Merck, Ignyta

OA08.05 Mesothelioma Quantifying Tumour Infiltrating Lymphocytes (TILs) in Malignant Pleural Mesothelioma (MPM) ‐Defining the Hot, the Warm and the Cold Tumours.

Thomas John Australia Consultant Bristol‐Meyers Squibb, AstraZeneca, Boehringer Ingelheim, Takeda, Pfizer, Novartis, Merck

OA08.06 Mesothelioma Tumour Suppressor MicroRNAs Modulate Drug Resistance by Targeting Anti‐Apoptotic Pathways in Malignant Pleural Mesothelioma (MPM)

Yuen Yee Cheng Australia Nothing to disclose

OA08.07 Mesothelioma In Silico Discovery of Unannotated miRNAs in Malignant Pleural Mesothelioma Reveals Novel Tissue‐of‐Origin Markers

Brenda Minatel Canada Nothing to disclose

OA08.08 Mesothelioma Discussant ‐ OA 08.05, OA 08.06, OA 08.07 Emanuela Felley‐Bosco Switzerland Nothing to disclose

Session OA09: Prevention and Cessation


Planner

OA09 Screening/Pulmonology/Prevention/Tobacco Control














Chairs

OA09 James Jett USA Employee Oncimmune LLC

OA09 James Jett USA Other(please specify) Salary

OA09 Paula Ugalde Canada Nothing to disclose

Faculty

OA09.01 Prevention and Tobacco Control 5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario’s Regional Cancer Centres


OA09.01 Prevention and Tobacco Control 5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario’s Regional Cancer Centres


OA09.02 Prevention and Tobacco Control Acceptance of Smoking Cessation Services in Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk


OA09.02 Prevention and Tobacco Control Acceptance of Smoking Cessation Services in Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk


OA09.03 Prevention and Tobacco Control Discussions Between Health Professionals and Smokers About E‐Cigarettes: Results from the ITC Policy Evaluation Project

Shannon Gravely Canada Nothing to disclose

OA09.04 Prevention and Tobacco Control Discussant ‐ OA 09.01, OA 09.02, OA 09.03 Betty Tong USA Speakers or Advisory Board Medtronic

OA09.05 Prevention and Tobacco Control Potential Reduction in Lung Cancer Mortality in the US from 2015‐2065: A Comparative Modeling Approach

Jihyoun Jeon USA Nothing to disclose

OA09.06 Prevention and Tobacco Control Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study

Laura Mezquita France Nothing to disclose

OA09.07 Prevention and Tobacco Control Association Between Outdoor Air Pollution And Lung Cancer in Female Never Smokers

Renelle Myers Canada Nothing to disclose



OA09.08 Prevention and Tobacco Control Discussant ‐ OA 09.05, OA 09.06, OA 09.07 Douglas Arenberg USA Nothing to disclose

Session PC03: Controversies in Management of Resectable Thymoma


Planner

PC03 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Honoraria ACEA, Genentech, Novartis, AstraZeneca

PC03 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Supported/Contracted Research/Grant Clovis, Exelixis, AstraZeneca, MedImmune, Genentech, Roche, Bristol‐Meyers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Eli Lilly, Acea, Merck

PC03 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Speakers or Advisory Board ACEA Biosyciences, Pfizer, Novartis, Genentech, Roche, AstraZeneca, Merck

PC03 Thymoma/Other Thoracic Malignancies Meinoshin Okumura Japan Nothing to disclose

PC03 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Speakers or Advisory Board AstraZeneca

PC03 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Consultant Eli Lilly

PC03 Thymoma/Other Thoracic Malignancies Wentao Fang China Nothing to disclose

PC03 Thymoma/Other Thoracic Malignancies Pier Luigi Filosso Italy Nothing to disclose

PC03 Thymoma/Other Thoracic Malignancies Nicolas Girard France Consultant Bristol‐Meyers Squibb, Merck Roche, AstraZeneca

PC03 Thymoma/Other Thoracic Malignancies Shaf Keshavjee Canada Nothing to disclose

PC03 Thymoma/Other Thoracic Malignancies Robert Korst USA Nothing to disclose

PC03 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Supported/Contracted Research/Grant Varian Medical Systems, Boehringer Ingelheim, AstraZeneca, Pfizer

PC03 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Honoraria Varian Medical Systms, Bristol‐Meyers Squibb, AstraZeneca, Pfizer, Merck

PC03 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Speakers or Advisory Board AstraZeneca, Merck

PC03 Thymoma/Other Thoracic Malignancies DAvid Waller UK Nothing to disclose

Chairs

PC03 Andrea Bezjak Canada Nothing to disclose

PC03 Norihiko Ikeda Japan Honoraria AstraZeneca, Chugai, Merck, Ono Pharma, Taiho, Eli Lilly, Pfizer, Johnson & Johnson

Faculty

PC03.01 Thymoma/Other Thoracic Malignancies Post‐Operative Radiation Therapy or NOT: PRO Conrad Falkson Canada Nothing to disclose

PC03.02 Thymoma/Other Thoracic Malignancies Post‐Operative Radiation Therapy or NOT: CON Daniel Gomez USA Honoraria Merck, Bristol‐Meyers Squibb, AstraZeneca, Varian, Reflexion

PC03.02 Thymoma/Other Thoracic Malignancies Post‐Operative Radiation Therapy or NOT: CON Daniel Gomez USA Speakers or Advisory Board AstraZeneca, Merck

PC03.03 Discussion

PC03.04 Thymoma/Other Thoracic Malignancies Debate on Standard Surgical Approaches ‐ Minimally Invasive Thymectomy Shaf Keshavjee Canada Nothing to disclose

PC03.05 Thymoma/Other Thoracic Malignancies Debate on Standard Surgical Approaches ‐ Open Thymectomy Meinoshin Okumura Japan Nothing to disclose

PC03.06 Discussion

PC03.07 Thymoma/Other Thoracic Malignancies Adjuvant Chemotherapy for Thymic Carcinoma ‐ YES Giulia Pasello Italy Nothing to disclose

PC03.08 Thymoma/Other Thoracic Malignancies Adjuvant Chemotherapy for Thymic Carcinoma ‐ NO Sukhmani Padda USA Supported/Contracted Research/Grant Forty‐Seven, EpicentRx

PC03.08 Thymoma/Other Thoracic Malignancies Adjuvant Chemotherapy for Thymic Carcinoma ‐ NO Sukhmani Padda USA Speakers or Advisory Board G1 therapeutics, Janssen, AstraZeneca, AbbVie

PC03.08 Thymoma/Other Thoracic Malignancies Adjuvant Chemotherapy for Thymic Carcinoma ‐ NO Sukhmani Padda USA Consultant Physician Education Resource, MedScape

PC03.09 Discussion

Session PC04: Targeted Therapy for NSCLC


Planner

PC04 Targeted Therapy Janessa Laskin Canada Honoraria Roche, Boehringer Ingelheim, AstraZeneca

PC04 Targeted Therapy Janessa Laskin Canada Supported/Contracted Research/Grant AstraZeneca, Roche, Pfizer

PC04 Targeted Therapy Tony Mok China Speakers or Advisory Board AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Bristol‐Meyers Squibb, Taiho, Takeda Oncology Serono, SFJ Pharma, ACEA Biosciences, Vertex Pharma, geneDecode, OncoGenex Technologies, Celgene, Ignyta, Cirina, Fishawack Facilitate, Janssen, ChiMed

PC04 Targeted Therapy Tony Mok China Honoraria AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, SFJ Pharma, ACEA Biosciences, Vertex Pharma, Bristol‐Meyers Squibb, OncoGenex Pharma, Celgene, Ignyta, Fishawack Facilitate, Takeda Oncology, Janssen, Cirina, Chimed

PC04 Targeted Therapy Tony Mok China Ownership Interest (stocks or stock options, or other ownership interest

Sanomics, Cirina

PC04 Targeted Therapy Tony Mok China Consultant Roche., IASLC, ASCO, ChiMed, Chinese Lung Cancer Research Foundation, Chinese Society of Clinical Oncology, Hong Kong Cancer Therapy Society



PC04 Targeted Therapy Tony Mok China Supported/Contracted Research/Grant AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmas Group, Roche, Merck, Clovis Oncology, Bristol‐Meyers Squibb, Taiho Pharma, Eisai

PC04 Targeted Therapy Tony Mok China Employee (full time or part time) The Chinese University of Hong Kong

PC04 Targeted Therapy Ross Camidge USA Honoraria Takeda, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, AstraZeneca, Arrys/Kyn, Genoptix, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera, Lycera, Revolution Med, Orion, Clovis, Celegene, Novartis

PC04 Targeted Therapy Ross Camidge USA Supported/Contracted Research/Grant Ariad, Takeda, Pfizer

PC04 Targeted Therapy Ross Camidge USA Speakers or Advisory Board AstraZeneca, Takeda, Arrys/Kyn, Genoptix, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, Takeda, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera DSMB, Lycera, Revolution Med

PC04 Targeted Therapy Alexander Drilon USA Speakers or Advisory Board Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

PC04 Targeted Therapy Alexander Drilon USA Honoraria TP Therapeutics, Loxo, Ignyta, Roche, Genentech, Pfizer

PC04 Targeted Therapy Alexander Drilon USA Supported/Contracted Research/Grant Foundation Medicine

PC04 Targeted Therapy Alexander Drilon USA Consultant Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

PC04 Targeted Therapy Enriqueta Felip Spain Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb Celgene, Eli Lilly, Guardant Health, Novartis, Pfizer, Roche, Takeda, Merck

PC04 Targeted Therapy Enriqueta Felip Spain Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, AstraZeneca, Bristol‐Meyers Squibb, Novartis, AbbVie, Takeda, Celegene, Guardant Health, Merck

PC04 Targeted Therapy Enriqueta Felip Spain Speakers Bureau AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, MSD, Novartis, Pfizer, Roche, Takeda, AbbVie, Merck, Celegne, Eli Lilly, Guardant Health

PC04 Targeted Therapy Pilar Garrido Spain Consultant Roche, Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol‐Meyers Squibb, Eli Lilly and Company, AbbVie, Novartis

PC04 Targeted Therapy Pilar Garrido Spain Speakers Bureau Roche, Merck, Bristol‐Meyers Squibb, Pfizer

PC04 Targeted Therapy Pilar Garrido Spain Supported/Contracted Research/Grant Guardant

PC04 Targeted Therapy Shun Lu China Supported/Contracted Research/Grant AstraZeneca

PC04 Targeted Therapy Shun Lu China Speakers or Advisory Board Eli Lilly, Hutchison MediPharma, Simcere, Bristol‐Meyers Squibb, Roche, Pfizer, AstraZeneca

PC04 Targeted Therapy Zofia Piotrowska USA Consultant AstraZeneca, Boehringer Ingelheim, Ariad, Novartis, Guardant Health, Takeda, AbbVie

PC04 Targeted Therapy Zofia Piotrowska USA Speakers or Advisory Board AstraZeneca, Ariad, Takeda, Novartis, Boehringer Ingelheim, AbbVie

PC04 Targeted Therapy Zofia Piotrowska USA Supported/Contracted Research/Grant Novartis

PC04 Targeted Therapy Zofia Piotrowska USA Honoraria Guardant Health

PC04 Targeted Therapy Karen Reckamp USA Consultant Amgen, Ariad, Astellas Pharma, Euclises, Tesaro, Boehringer Ingelheim, Takeda

PC04 Targeted Therapy Karen Reckamp USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Novartis, Ariad, Clovis Oncology, Xcovery, Gilead Sciences, Pfizer, Adaptimmune, Genentech, Roche, Boehringer Ingelheim, AbbVie

PC04 Targeted Therapy Lecia Sequist USA Speakers or Advisory Board AstraZeneca, Genentech, Pfizer, Bristol‐Meyers Squibb, Merrimack Pharma, Blueprint Medicines

PC04 Targeted Therapy Lecia Sequist USA Consultant Merrimack, Novartis, Boehringer Ingelheim

PC04 Targeted Therapy Lecia Sequist USA Supported/Contracted Research/Grant AstraZeneca, Novartis, Genentech, Boehringer Ingelheim, Merck, Merrimack, Guardant Health

PC04 Targeted Therapy Benjamin Solomon Australia Speakers or Advisory Board AstraZeneca, Bristol‐Myers Squibb, Merck, Pfizer, Roche, Genentech, Novartis

PC04 Targeted Therapy Benjamin Solomon Australia Honoraria Bristol‐Myers Squibb, AstraZeneca

PC04 Targeted Therapy Benjamin Solomon Australia Supported/Contracted Research/Grant Pfizer

PC04 Targeted Therapy Benjamin Solomon Australia Royalty, Intellectual Property/Patent Holder Veristrat

PC04 Targeted Therapy Benjamin Solomon Australia Consultant AstraZeneca, Roche, Merck, Bristol‐Myers Squibb, Novartis

PC04 Targeted Therapy James Chih‐Hsin Yang Taiwan Consultant Boehringer Ingelheim, Eli Lilly, Bayer, Roche, Genentech, Chugai, Astellas, Merck, Novartis, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, Takeda, AstraZeneca, Hansoh Pharma

PC04 Targeted Therapy James Chih‐Hsin Yang Taiwan Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Roche, Genentech, Chugai, Astellas, Merck, Pfizer, Novartis, Takeda, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, AstraZeneca, Hansoh Pharma

PC04 Targeted Therapy James Chih‐Hsin Yang Taiwan Honoraria Novartis, Roche, Genentech, Eli Lilly and Company, Merck, Celgene, Pfizer, Ono Pharma, Bristol‐Myers Squibb, Hansoh, Takeda, Boehringer Ingelheim, Astellas, Merimack, Yuhan Pharma

Chairs

PC04 Zofia Piotrowska USA Consultant AstraZeneca, Boehringer Ingelheim, Ariad, Novartis, Guardant Health, Takeda, AbbVie

PC04 Zofia Piotrowska USA Speakers or Advisory Board AstraZeneca, Ariad, Takeda, Novartis, Boehringer Ingelheim, AbbVie

PC04 Zofia Piotrowska USA Supported/Contracted Research/Grant Novartis

PC04 Zofia Piotrowska USA Honoraria Guardant Health

PC04 Benjamin Solomon Australia Speakers or Advisory Board AstraZeneca, Bristol‐Myers Squibb, Merck, Pfizer, Roche, Genentech, Novartis

PC04 Benjamin Solomon Australia Honoraria Bristol‐Myers Squibb, AstraZeneca

PC04 Benjamin Solomon Australia Supported/Contracted Research/Grant Pfizer

PC04 Benjamin Solomon Australia Royalty, Intellectual Property/Patent Holder Veristrat

PC04 Benjamin Solomon Australia Consultant AstraZeneca, Roche, Merck, Bristol‐Myers Squibb, Novartis

Faculty

PC04.01 Targeted Therapy Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First versus Osimertinib First)

James Chih‐Hsin Yang Taiwan Consultant Boehringer Ingelheim, Eli Lilly, Bayer, Roche, Genentech, Chugai, Astellas, Merck, Novartis, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, Takeda, AstraZeneca, Hansoh Pharma




James Chih‐Hsin Yang Taiwan Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Roche, Genentech, Chugai, Astellas, Merck, Pfizer, Novartis, Takeda, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, AstraZeneca, Hansoh Pharma


James Chih‐Hsin Yang Taiwan Honoraria Novartis, Roche, Genentech, Eli Lilly and Company, Merck, Celgene, Pfizer, Ono Pharma, Bristol‐Myers Squibb, Hansoh, Takeda, Boehringer Ingelheim, Astellas, Merimack, Yuhan Pharma

PC04.02 Targeted Therapy Optimal Sequencing of EGFR TKI Therapy ‐ 3rd Generation First Karen Reckamp USA Consultant Amgen, Ariad, Astellas Pharma, Euclises, Tesaro, Boehringer Ingelheim, Takeda

PC04.02 Targeted Therapy Optimal Sequencing of EGFR TKI Therapy ‐ 3rd Generation First Karen Reckamp USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Novartis, Ariad, Clovis Oncology, Xcovery, Gilead Sciences, Pfizer, Adaptimmune, Genentech, Roche, Boehringer Ingelheim, AbbVie

PC04.03 Targeted Therapy Adjuvant Targeted Therapy for pts with Genomic Alterations ‐ Yes Shun Lu China Supported/Contracted Research/Grant AstraZeneca

PC04.03 Targeted Therapy Adjuvant Targeted Therapy for pts with Genomic Alterations ‐ Yes Shun Lu China Speakers or Advisory Board Eli Lilly, Hutchison MediPharma, Simcere, Bristol‐Meyers Squibb, Roche, Pfizer, AstraZeneca

PC04.04 Targeted Therapy Adjuvant Targeted Therapy for pts with Genomic Alterations ‐ No Lecia Sequist USA Speakers or Advisory Board AstraZeneca, Genentech, Pfizer, Bristol‐Meyers Squibb, Merrimack Pharma, Blueprint Medicines

PC04.04 Targeted Therapy Adjuvant Targeted Therapy for pts with Genomic Alterations ‐ No Lecia Sequist USA Consultant Merrimack, Novartis, Boehringer Ingelheim

PC04.04 Targeted Therapy Adjuvant Targeted Therapy for pts with Genomic Alterations ‐ No Lecia Sequist USA Supported/Contracted Research/Grant AstraZeneca, Novartis, Genentech, Boehringer Ingelheim, Merck, Merrimack, Guardant Health

PC04.05 Targeted Therapy NGS/Whole Exome Sequencing for Routine Use Daniel Tan Singapore Honoraria National Cancer Centre Singapore, Pfizer, Merck, AstraZeneca, Loxo, Boehringer Ingelheim, Bristol‐Meyers Squibb

PC04.05 Targeted Therapy NGS/Whole Exome Sequencing for Routine Use Daniel Tan Singapore Speakers or Advisory Board AstraZeneca, Pfizer, Novartis, Merck

PC04.05 Targeted Therapy NGS/Whole Exome Sequencing for Routine Use Daniel Tan Singapore Supported/Contracted Research/Grant GSK, AstraZeneca, Novartis

PC04.06 Targeted Therapy Focused Panels for Molecular Profiling for Routine Use Fernando Lopez‐Rios Spain Supported/Contracted Research/Grant Roche

PC04.06 Targeted Therapy Focused Panels for Molecular Profiling for Routine Use Fernando Lopez‐Rios Spain Speakers or Advisory Board Roche, Life Technologies, Bristol‐Meyers Squibb, AbbVie, AstraZeneca, Merck, Pfizer

PC04.06 Targeted Therapy Focused Panels for Molecular Profiling for Routine Use Fernando Lopez‐Rios Spain Speakers Bureau AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Life Technologies, Merck, Pfizer, Roche

PC04.06 Targeted Therapy Focused Panels for Molecular Profiling for Routine Use Fernando Lopez‐Rios Spain Honoraria AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Life Technologies, Merck, Pfizer, Roche

PC04.07 Q&A

Session MTE11: Biology of Small Cell Lung Cancer

Tuesday, September 25 ‐ 07:00 ‐ 08:00

Planner

MTE11 Biology Wan Lam Canada Nothing to disclose

MTE11 Biology Kwok‐kin Wong USA Nothing to disclose

MTE11 Biology Oscar Arrieta Mexico Nothing to disclose

MTE11 Biology David Beer USA Nothing to disclose

MTE11 Biology Robert Doebele USA Ownership Interest (stocks or stock options, or other ownership interest

Rain Therapeutics

MTE11 Biology Robert Doebele USA Speakers or Advisory Board Ignyta, AstraZeneca, Bayer, Takeda, Bristol‐Meyers Squibb, Ariad

MTE11 Biology Robert Doebele USA Supported/Contracted Research/Grant Ignyta

MTE11 Biology Robert Doebele USA Consultant Pfizer, OncoMed, Trovagene, Ignyta, GreenPeptide, AstraZeneca, Ignyta, Ariad, Guardant Health

MTE11 Biology Robert Doebele USA Honoraria Pfizer, AstraZeneca, Ariad, Guardant Health, Takeda, Spectrum Pharmas, Trovagene

MTE11 Biology Robert Doebele USA Royalty, Intellectual Property/Patent Holder Abbott Molecular, Rain Therapeutics, Igynta

MTE11 Biology Ramaswamy Govindan USA Speakers or Advisory Board Merck, Baxalta, Roche, Boehringer Ingleheim, Novartis, Pfizer, Celgene, AstraZeneca, MSK, AbbVie Inivata, Pfizer, NeoHealth, Bristol‐Meyers Squibb, Nektar, GlaxcSmithKline

MTE11 Biology Ramaswamy Govindan USA Consultant Genentech, Ariad, Astellas, Bristol‐Meyers Squibb, INC Research, AbbVie

MTE11 Biology Ramaswamy Govindan USA Honoraria AbbVie, Genentech, Boehringer Ingelheim

MTE11 Biology Fred Hirsch USA Consultant AstraZeneca, Genentech, HTG Molecular Diagnostics, Eli Lilly, Merck, Clovis Oncology, Ventana Medical Systems, Bristol‐Meyers Squibb, Pfizer, Roche

MTE11 Biology Fred Hirsch USA Royalty, Intellectual Property/Patent Holder University of Colorado Cancer Center

MTE11 Biology Fred Hirsch USA Supported/Contracted Research/Grant Eli Lilly, Genentech, Amgen, Bristol‐Meyers Squibb, Celgene

MTE11 Biology Fred Hirsch USA Speakers or Advisory Board AbbVie, AstraZeneca, Biocept, Bristol‐Meyers Squibb, HTG, Eli Lilly, Loxo, Merck, Novartis, Pfizer, Roche, Genentech, Ventana, Bayer

MTE11 Biology Thomas John Australia Speakers or Advisory Board Bristol‐Meyers Squibb, AstraZeneca, Boehringher Ingelheim, Takeda, Pfizer, Novartis, Merck, Ignyta

MTE11 Biology Thomas John Australia Consultant Bristol‐Meyers Squibb, AstraZeneca, Boehringer Ingelheim, Takeda, Pfizer, Novartis, Merck

MTE11 Biology Geoffrey Liu Canada Honoraria AstraZeneca, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie, Pfizer, Merck

MTE11 Biology Geoffrey Liu Canada Speakers Bureau AstraZeneca

MTE11 Biology Geoffrey Liu Canada Speakers or Advisory Board AstraZeneca, Roche, Merck, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie

MTE11 Biology William Lockwood Canada Nothing to disclose

MTE11 Biology Philip Mack USA Supported/Contracted Research/Grant Boehringer Ingelheim

MTE11 Biology Philip Mack USA Consultant Guardant Health, Apton Biosystems

MTE11 Biology Philip Mack USA Speakers or Advisory Board AstraZeneca, Eli Lilly, Pfizer



MTE11 Biology Matthew Meyerson USA Speakers or Advisory Board OrigiMed

MTE11 Biology Matthew Meyerson USA Ownership Interest (stocks or stock options, or other ownership interest

OrigiMed

MTE11 Biology Matthew Meyerson USA Supported/Contracted Research/Grant Bayer

MTE11 Biology Matthew Meyerson USA Royalty, Intellectual Property/Patent Holder LabCorp

MTE11 Biology Katerina Politi USA Supported/Contracted Research/Grant AstraZeneca, Roche, Kolltan, Symphogen

MTE11 Biology Katerina Politi USA Honoraria AstraZeneca, Merck, Novartis, Tocagen

MTE11 Biology Katerina Politi USA Royalty, Intellectual Property/Patent Holder Molecular MD

MTE11 Biology Daniel Tan Singapore Honoraria National Cancer Centre Singapore, Pfizer, Merck, AstraZeneca, Loxo, Boehringer Ingelheim, Bristol‐Meyers Squibb

MTE11 Biology Daniel Tan Singapore Speakers or Advisory Board AstraZeneca, Pfizer, Novartis, Merck

MTE11 Biology Daniel Tan Singapore Supported/Contracted Research/Grant GSK, AstraZeneca, Novartis

MTE11 Biology Pan‐Chyr Yang Taiwan Nothing to disclose

Faculty

MTE11.01 Biology Novel Therapeutic Targets in SCLC Julien Sage USA Nothing to disclose

MTE11.02 Biology Biological Subsets of SCLC Charles Rudin USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Genentech, Harpoon, Genetics

MTE11.02 Biology Biological Subsets of SCLC Charles Rudin USA Consultant Bristol‐Meyers Squibb, AbbVie, Seattle Genetics, Harpoon Therapeutics, Genentech Roche, AstraZeneca

Session MTE12: IO in the Real World ‐ High Risk Populations And Patient Support


Planner

MTE12 Immunooncology Desiree Hao Canada Nothing to disclose

MTE12 Immunooncology Solange Peters Switzerland Speakers or Advisory Board Amgen, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Roche, Janssen, Merck, Pfizer, Regeneron, Takeda

MTE12 Immunooncology Myung‐Ju Ahn Korea Consultant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Merck, Novartis, Alpha BioPharmas

MTE12 Immunooncology Myung‐Ju Ahn Korea Speakers or Advisory Board AstraZeneca, Eli Lilly, Bristol‐Meyers Squibb, Merck, Ono Pharma, Roche

MTE12 Immunooncology Fabrice Barlesi France Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda

MTE12 Immunooncology Fabrice Barlesi France Consultant Roche, Genentech., AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda

MTE12 Immunooncology Fabrice Barlesi France Supported/Contracted Research/Grant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda

MTE12 Immunooncology Fabrice Barlesi France Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda, Serono

MTE12 Immunooncology Julie Brahmer USA Speakers or Advisory Board Merck, Genetech, Bristol‐Meyers Squibb, Syndax, AstraZeneca, Celgene, Amgen Oncology

MTE12 Immunooncology Julie Brahmer USA Consultant Celgene, Eli Lilly, MedImmune, AstraZeneca, Bristol‐Meyers Squibb

MTE12 Immunooncology Julie Brahmer USA Supported/Contracted Research/Grant Medimmune, AstraZeneca, Bristol‐Meyers Squibb

MTE12 Immunooncology Edward Garon USA Consultant Bristol‐Meyers Squibb, Eli Lilly, AstraZeneca, Genentech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax

MTE12 Immunooncology Edward Garon USA Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Genetech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax

MTE12 Immunooncology Edward Garon USA Supported/Contracted Research/Grant Merck, Genentech, AstraZeneca, Novartis, Pfizer, Eli Lilly, Bristol‐Meyers Squibb, Boehringer Ingelheim, Mirati Therapeutics, Dyanvax

MTE12 Immunooncology Rina Hui Australia Honoraria Bristol‐Meyers Squibb, Boehringer Ingelheim, Merck, AstraZeneca, Novartis, Roche

MTE12 Immunooncology Rina Hui Australia Speakers or Advisory Board AstraZeneca, Merck, Novartis, Pfizer, Roche, Bristol‐Meyers Squibb

MTE12 Immunooncology Rina Hui Australia Consultant Merck, AstraZeneca, Novartis, Roche, Bristol‐Meyers Squibb, Boehringer Ingelheim, Pfizer

MTE12 Immunooncology Rosalyn Juergens Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Amgen, Novartis, AstraZeneca, Takeda

MTE12 Immunooncology Rosalyn Juergens Canada Honoraria Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, AstraZeneca, MedImmune, Eli Lilly, Takeda, Novartis, Amgen Pfizer

MTE12 Immunooncology Rosalyn Juergens Canada Speakers Bureau Amgen

MTE12 Immunooncology Rosalyn Juergens Canada Consultant Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Amgen, Roche, AstraZeneca, MedImmune,

MTE12 Immunooncology Rosalyn Juergens Canada Supported/Contracted Research/Grant AstraZeneca, MedImmune, Merck, Bristol‐Meyers Squibb

MTE12 Immunooncology Martin Reck Germany Speakers Bureau Roche, Eli Lilly, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Merck, Boehringer‐Ingelheim, Novartis, Pfizer, Abbot

MTE12 Immunooncology Martin Reck Germany Speakers or Advisory Board Roche, Eli Lilly, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Merck, Boehringer Ingelheim, Novartis, Pfizer, Abbot

MTE12 Immunooncology Martin Reck Germany Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Lilly, Merck, Practa, Roche

MTE12 Immunooncology Martin Reck Germany Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Celgene, Eli Lilly, Merck, Pfizer, Proacta, Novartis, Roche, Abbott

MTE12 Immunooncology Naiyer Rizvi USA Honoraria Roche, AstraZeneca, Novartis, Merck, Pfizer, Lilly, Bristol‐Meyers Squibb



MTE12 Immunooncology Naiyer Rizvi USA Ownership Interest (stocks or stock options, or other ownership interest


MTE12 Immunooncology Naiyer Rizvi USA Speakers or Advisory Board Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

MTE12 Immunooncology Naiyer Rizvi USA Consultant Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

MTE12 Immunooncology Adrian Sacher USA Nothing to disclose

MTE12 Immunooncology Ross Soo Singapore Supported/Contracted Research/Grant AstraZeneca

MTE12 Immunooncology Ross Soo Singapore Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Celgene, Ignyta, Roche, Taiho

MTE12 Immunooncology Yi‐Long Wu China Speakers or Advisory Board AstraZeneca, Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, Sanofi

MTE12 Immunooncology Yi‐Long Wu China Speakers Bureau AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi

MTE12 Immunooncology Yi‐Long Wu China Honoraria AstraZeneca, Eli Lilly, Pfizer, Roche

MTE12 Immunooncology Yi‐Long Wu China Consultant AstraZeneca, Boehringer Ingelheim, Merck, Roche

MTE12 Immunooncology Yi‐Long Wu China Supported/Contracted Research/Grant Boehringer Ingelheim, Roche

Faculty

MTE12.01 Immunooncology Is IO an Option for Patients with Contraindications (Auto‐immune Disease, Pulmonary Fibrosis, HIV, Hepatitis, Transplant etc)

Andrew Robinson Canada Speakers or Advisory Board Merck, Kirkland

MTE12.01 Immunooncology Is IO an Option for Patients with Contraindications (Auto‐immune Disease, Pulmonary Fibrosis, HIV, Hepatitis, Transplant etc)

Andrew Robinson Canada Consultant Merck, Kirkland,

MTE12.02 Immunooncology How can we Minimize Toxicity for our High Risk Patients? Massey Nematollahi Canada Nothing to disclose

Session MTE13: Clonal Evolution and Targeted Therapy


Planner

MTE13 Targeted Therapy Janessa Laskin Canada Honoraria Roche, Boehringer Ingelheim, AstraZeneca

MTE13 Targeted Therapy Janessa Laskin Canada Supported/Contracted Research/Grant AstraZeneca, Roche, Pfizer

MTE13 Targeted Therapy Tony Mok China Speakers or Advisory Board AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Bristol‐Meyers Squibb, Taiho, Takeda Oncology Serono, SFJ Pharma, ACEA Biosciences, Vertex Pharma, geneDecode, OncoGenex Technologies, Celgene, Ignyta, Cirina, Fishawack Facilitate, Janssen, ChiMed

MTE13 Targeted Therapy Tony Mok China Honoraria AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, SFJ Pharma, ACEA Biosciences, Vertex Pharma, Bristol‐Meyers Squibb, OncoGenex Pharma, Celgene, Ignyta, Fishawack Facilitate, Takeda Oncology, Janssen, Cirina, Chimed

MTE13 Targeted Therapy Tony Mok China Ownership Interest (stocks or stock options, or other ownership interest

Sanomics, Cirina

MTE13 Targeted Therapy Tony Mok China Consultant Roche., IASLC, ASCO, ChiMed, Chinese Lung Cancer Research Foundation, Chinese Society of Clinical Oncology, Hong Kong Cancer Therapy Society

MTE13 Targeted Therapy Tony Mok China Supported/Contracted Research/Grant AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmas Group, Roche, Merck, Clovis Oncology, Bristol‐Meyers Squibb, Taiho Pharma, Eisai

MTE13 Targeted Therapy Tony Mok China Employee (full time or part time) The Chinese University of Hong Kong

MTE13 Targeted Therapy Ross Camidge USA Honoraria Takeda, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, AstraZeneca, Arrys/Kyn, Genoptix, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera, Lycera, Revolution Med, Orion, Clovis, Celegene, Novartis

MTE13 Targeted Therapy Ross Camidge USA Supported/Contracted Research/Grant Ariad, Takeda, Pfizer

MTE13 Targeted Therapy Ross Camidge USA Speakers or Advisory Board AstraZeneca, Takeda, Arrys/Kyn, Genoptix, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, Takeda, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera DSMB, Lycera, Revolution Med

MTE13 Targeted Therapy Alexander Drilon USA Speakers or Advisory Board Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

MTE13 Targeted Therapy Alexander Drilon USA Honoraria TP Therapeutics, Loxo, Ignyta, Roche, Genentech, Pfizer

MTE13 Targeted Therapy Alexander Drilon USA Supported/Contracted Research/Grant Foundation Medicine

MTE13 Targeted Therapy Alexander Drilon USA Consultant Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

MTE13 Targeted Therapy Enriqueta Felip Spain Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb Celgene, Eli Lilly, Guardant Health, Novartis, Pfizer, Roche, Takeda, Merck

MTE13 Targeted Therapy Enriqueta Felip Spain Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, AstraZeneca, Bristol‐Meyers Squibb, Novartis, AbbVie, Takeda, Celegene, Guardant Health, Merck

MTE13 Targeted Therapy Enriqueta Felip Spain Speakers Bureau AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, MSD, Novartis, Pfizer, Roche, Takeda, AbbVie, Merck, Celegne, Eli Lilly, Guardant Health

MTE13 Targeted Therapy Pilar Garrido Spain Consultant Roche, Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol‐Meyers Squibb, Eli Lilly and Company, AbbVie, Novartis

MTE13 Targeted Therapy Pilar Garrido Spain Speakers Bureau Roche, Merck, Bristol‐Meyers Squibb, Pfizer

MTE13 Targeted Therapy Pilar Garrido Spain Supported/Contracted Research/Grant Guardant

MTE13 Targeted Therapy Shun Lu China Supported/Contracted Research/Grant AstraZeneca

MTE13 Targeted Therapy Shun Lu China Speakers or Advisory Board Eli Lilly, Hutchison MediPharma, Simcere, Bristol‐Meyers Squibb, Roche, Pfizer, AstraZeneca

MTE13 Targeted Therapy Zofia Piotrowska USA Consultant AstraZeneca, Boehringer Ingelheim, Ariad, Novartis, Guardant Health, Takeda, AbbVie

MTE13 Targeted Therapy Zofia Piotrowska USA Speakers or Advisory Board AstraZeneca, Ariad, Takeda, Novartis, Boehringer Ingelheim, AbbVie

MTE13 Targeted Therapy Zofia Piotrowska USA Supported/Contracted Research/Grant Novartis

MTE13 Targeted Therapy Zofia Piotrowska USA Honoraria Guardant Health



MTE13 Targeted Therapy Karen Reckamp USA Consultant Amgen, Ariad, Astellas Pharma, Euclises, Tesaro, Boehringer Ingelheim, Takeda

MTE13 Targeted Therapy Karen Reckamp USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Novartis, Ariad, Clovis Oncology, Xcovery, Gilead Sciences, Pfizer, Adaptimmune, Genentech, Roche, Boehringer Ingelheim, AbbVie

MTE13 Targeted Therapy Lecia Sequist USA Speakers or Advisory Board AstraZeneca, Genentech, Pfizer, Bristol‐Meyers Squibb, Merrimack Pharma, Blueprint Medicines

MTE13 Targeted Therapy Lecia Sequist USA Consultant Merrimack, Novartis, Boehringer Ingelheim

MTE13 Targeted Therapy Lecia Sequist USA Supported/Contracted Research/Grant AstraZeneca, Novartis, Genentech, Boehringer Ingelheim, Merck, Merrimack, Guardant Health

MTE13 Targeted Therapy Benjamin Solomon Australia Speakers or Advisory Board AstraZeneca, Bristol‐Myers Squibb, Merck, Pfizer, Roche, Genentech, Novartis

MTE13 Targeted Therapy Benjamin Solomon Australia Honoraria Bristol‐Myers Squibb, AstraZeneca

MTE13 Targeted Therapy Benjamin Solomon Australia Supported/Contracted Research/Grant Pfizer

MTE13 Targeted Therapy Benjamin Solomon Australia Royalty, Intellectual Property/Patent Holder Veristrat

MTE13 Targeted Therapy Benjamin Solomon Australia Consultant AstraZeneca, Roche, Merck, Bristol‐Myers Squibb, Novartis

MTE13 Targeted Therapy James Chih‐Hsin Yang Taiwan Consultant Boehringer Ingelheim, Eli Lilly, Bayer, Roche, Genentech, Chugai, Astellas, Merck, Novartis, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, Takeda, AstraZeneca, Hansoh Pharma

MTE13 Targeted Therapy James Chih‐Hsin Yang Taiwan Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Roche, Genentech, Chugai, Astellas, Merck, Pfizer, Novartis, Takeda, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, AstraZeneca, Hansoh Pharma

MTE13 Targeted Therapy James Chih‐Hsin Yang Taiwan Honoraria Novartis, Roche, Genentech, Eli Lilly and Company, Merck, Celgene, Pfizer, Ono Pharma, Bristol‐Myers Squibb, Hansoh, Takeda, Boehringer Ingelheim, Astellas, Merimack, Yuhan Pharma

Faculty

MTE13.01 Targeted Therapy Clonal Evolution and Targeted Therapy Ramaswamy Govindan USA Speakers or Advisory Board Merck, Baxalta, Roche, Boehringer Ingleheim, Novartis, Pfizer, Celgene, AstraZeneca, MSK, AbbVie Inivata, Pfizer, NeoHealth, Bristol‐Meyers Squibb, Nektar, GlaxcSmithKline

MTE13.01 Targeted Therapy Clonal Evolution and Targeted Therapy Ramaswamy Govindan USA Consultant Genentech, Ariad, Astellas, Bristol‐Meyers Squibb, INC Research, AbbVie

MTE13.01 Targeted Therapy Clonal Evolution and Targeted Therapy Ramaswamy Govindan USA Honoraria AbbVie, Genentech, Boehringer Ingelheim

MTE13.02 Targeted Therapy Clonal Evolution and Targeted Therapy Janessa Laskin Canada Honoraria Roche, Boehringer Ingelheim, AstraZeneca

MTE13.02 Targeted Therapy Clonal Evolution and Targeted Therapy Janessa Laskin Canada Supported/Contracted Research/Grant AstraZeneca, Roche, Pfizer

Session MTE14: Nodule Management (Pro Con Debate and Case Presentations)


Planner

MTE14 Screening and Early Detection Christine Berg USA Honoraria Medial Early Sign LLC, GRAIL

MTE14 Screening and Early Detection Stephen Lam Canada Nothing to disclose

MTE14 Screening and Early Detection Denise Aberle USA Nothing to disclose

MTE14 Screening and Early Detection John Field UK Speakers Bureau Roche

MTE14 Screening and Early Detection John Field UK Speakers or Advisory Board Epigenomics, VisonGate

MTE14 Screening and Early Detection John Goffin Canada Nothing to disclose

MTE14 Screening and Early Detection Harry Groen Netherlands Consultant Roche‐Genentech, Merck, Novartis, Bristol‐Meyers Squibb

MTE14 Screening and Early Detection Norihiko Ikeda Japan Honoraria AstraZeneca, Chugai, Merck, Ono Pharma, Taiho, Eli Lilly, Pfizer, Johnson & Johnson

MTE14 Screening and Early Detection Garth Nicholas Canada Nothing to disclose

MTE14 Screening and Early Detection Nir Peled Israel Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

MTE14 Screening and Early Detection Nir Peled Israel Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

MTE14 Screening and Early Detection Heidi Schmidt Canada Nothing to disclose

MTE14 Screening and Early Detection Betty Tong Speakers or Advisory Board Medtronic

Faculty

MTE14.01 Screening and Early Detection Nodule Management (Pro Con Debate and Case Presentations) Matthijs Oudkerk Netherlands Nothing to disclose

Session MTE15: Who is Too High Risk for a VATS Resection?


Planner

MTE15 Treatment of Early Stage/Localized Disease Hisao Asamura Japan Honoraria Lecturer of seminar ‐ Johnson & Johnson, Covidien, Eli Lilly, Taiho, Boehringer Ingelheim, Ono Pharmaceuticals

MTE15 Treatment of Early Stage/Localized Disease Patrick Cheung Canada Nothing to disclose

MTE15 Treatment of Early Stage/Localized Disease Thomas D'Amico USA Consultant Consultant for Scanlan Instruments



MTE15 Treatment of Early Stage/Localized Disease Jessica Donington USA Honoraria AstraZeneca

MTE15 Treatment of Early Stage/Localized Disease Janet Edwards Canada Nothing to disclose

MTE15 Treatment of Early Stage/Localized Disease Bob Li USA Consultant Genentech, Roche, Thermo Fischer Scientific, Guardant Health

MTE15 Treatment of Early Stage/Localized Disease Bob Li USA Speakers or Advisory Board Genentech, Guardant Health, Mersana Therapeutics

MTE15 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Speakers or Advisory Board Eli LIlly

MTE15 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Supported/Contracted Research/Grant Eli Lilly, Boehringer Ingelheim, AstraZeneca, Chugai, The Japan Society for the Promotion of Science

MTE15 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Consultant Bristol‐Meyers Squibb, Ono Pharma

MTE15 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Speakers Bureau AstraZeneca, Chug, Pfizer, Boehringer Ingelheim

MTE15 Treatment of Early Stage/Localized Disease Luis Raez USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Roche, Genentech, Syndax, Novartis

MTE15 Treatment of Early Stage/Localized Disease Ramon Rami‐Porta Spain Nothing to disclose

MTE15 Treatment of Early Stage/Localized Disease Tomohito Saito Japan Supported/Contracted Research/Grant Ono Pharma, Bristol‐Myers Squibb

MTE15 Treatment of Early Stage/Localized Disease Tomohito Saito Japan Consultant Ono Pharma

MTE15 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Speakers or Advisory Board AstraZeneca, Eli Lilly, Merck

MTE15 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Employee (full time or part time) VU University Medical Center

MTE15 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Honoraria Eli Lilly

MTE15 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Supported/Contracted Research/Grant Varian Medical Systems, ViewRay

Faculty

MTE15.01 Treatment of Early Stage/Localized Disease Identifying High Risk Patients: What Makes a Patient Too High Risk for Surgery and Who Decides?

Hisao Asamura Japan Honoraria Lecturer of seminar ‐ Johnson & Johnson, Covidien, Eli Lilly, Taiho, Boehringer Ingelheim, Ono Pharmaceuticals

MTE15.02 Treatment of Early Stage/Localized Disease Who is Too High Risk for a VATS Resection? Pieter E. Postmus Netherlands Speakers or Advisory Board Celgene, AstraZeneca, Roche, Bristol‐Meyers Squibb, Boehringer Ingelheim, Janssen, Merck, Clovis

Session MTE16: What Is Changing in the Management of Pulmonary Neuroendocrine Tumours?


Planner

MTE16 Small Cell Lung Cancer/NET Fiona Blackhall UK Nothing to disclose

MTE16 Small Cell Lung Cancer/NET Peter Ellis Canada Honoraria AbbVie, AstraZeneca

MTE16 Small Cell Lung Cancer/NET Peter Ellis Canada Consultant Celegene, Mylan

MTE16 Small Cell Lung Cancer/NET Jeffrey Bogart USA Nothing to disclose

MTE16 Small Cell Lung Cancer/NET Lauren Byers USA Nothing to disclose

MTE16 Small Cell Lung Cancer/NET Quincy Chu Canada Nothing to disclose

MTE16 Small Cell Lung Cancer/NET Eric Lim UK Speakers Bureau Abbott Molecular, Pfizer, Roche, Eli Lily, Boehringer Ingelheim, Ethicon

MTE16 Small Cell Lung Cancer/NET Eric Lim UK Supported/Contracted Research/Grant Medela, ScreenCell, Clearbridge Biomedics, Illumina, Guardant Health

MTE16 Small Cell Lung Cancer/NET Francoise Mornex France Nothing to disclose

MTE16 Small Cell Lung Cancer/NET Charles Rudin USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Genentech, Harpoon, Genetics

MTE16 Small Cell Lung Cancer/NET Charles Rudin USA Consultant Bristol‐Meyers Squibb, AbbVie, Seattle Genetics, Harpoon Therapeutics, Genentech Roche, AstraZeneca

MTE16 Small Cell Lung Cancer/NET Ben Slotman Netherlands Nothing to disclose

MTE16 Small Cell Lung Cancer/NET Sumitra Thongprasert Thailand Nothing to disclose

MTE16 Small Cell Lung Cancer/NET Jie Wang China Nothing to disclose

MTE16 Small Cell Lung Cancer/NET Mauro Zukin Brazil Nothing to disclose

Faculty

MTE16.01 Small Cell Lung Cancer/NET Proper Treatment of LCNEC; Chemotherapy or Targeted Therapy Sumitra Thongprasert Thailand Nothing to disclose

MTE16.02 Small Cell Lung Cancer/NET The Management of Small Cell Lung Cancer following First Line Treatment Failure

Glenwood Goss Canada Nothing to disclose

Session MTE17: Living with and Beyond Lung Cancer: An Education for Advocates


Planner



MTE17 Advocacy Paul Wheatley‐Price Canada Speakers or Advisory Board AstraZeneca, Novartis, Eli Lilly Oncology, Bristol‐Meyers Squibb, Merck, Takeda

MTE17 Advocacy Jesme Fox UK Nothing to disclose

MTE17 Advocacy Bonnie Addario USA Nothing to disclose

MTE17 Advocacy Andrea Ferris USA Nothing to disclose

MTE17 Advocacy Kazuo Hasegawa Japan Nothing to disclose

MTE17 Advocacy Kim Norris USA Speakers or Advisory Board Takeda

MTE17 Advocacy Kim Norris USA Consultant Takeda

MTE17 Advocacy Silvia Novello Italy Speakers or Advisory Board Takeda

MTE17 Advocacy Silvia Novello Italy Speakers Bureau Boehringer Ingelheim, AstraZeneca, Roche, Merck, Bristol‐Meyers Squibb, Eli Lilly, Takeda, Pfizer

MTE17 Advocacy Christina Sit Canada Nothing to disclose

MTE17 Advocacy Howard (Jack) West USA Consultant Ariad, Genentech, Roche, Takeda

MTE17 Advocacy Howard (Jack) West USA Speakers Bureau Ariad, Bristol‐Myers Squibb, Eli Lilly

MTE17 Advocacy Howard (Jack) West USA Speakers or Advisory Board AbbVie, Ariad, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Merck, Roche, Genentech, Takeda, Spectrum

Faculty

MTE17.01 Advocacy Living with and Beyond Lung Cancer: An Education for Advocates Maureen Rigney USA Nothing to disclose

Session MTE18: Case‐Based Management of Patients with Inadequate Tissue for Molecular Tests


Planner

MTE18 Advanced NSCLC Scott Laurie Canada Consultant Bristol‐Meyers Squibb, Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca, BBI

MTE18 Advanced NSCLC Scott Laurie Canada Honoraria Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca

MTE18 Advanced NSCLC Leora Horn Canada Consultant AbbVie, AstraZeneca, Genentech, Merck, Incyte, Xcovery, Roche

MTE18 Advanced NSCLC Leora Horn Canada Supported/Contracted Research/Grant Xcovery Holding Company, Bristol‐Meyers Squibb, Boehringer Ingelheim, AbbVie, Genentech, Merck

MTE18 Advanced NSCLC Carlos Gil Ferreira Brazil Nothing to disclose

MTE18 Advanced NSCLC Glenn Goss USA Nothing to disclose

MTE18 Advanced NSCLC Pasi Jänne USA Consultant Araxes Pharmas, Ariad, AstraZeneca, Boehringer Ingelheim, Chugai, Ignyta, Eli Lilly, Loxo, Merrimack, Mirati Therapeutics, Pfizer, Roche, Dana‐Farber Cancer Institute

MTE18 Advanced NSCLC Pasi Jänne USA Speakers or Advisory Board AstraZeneca, Boehringer Ingelheim, Pfizer, Merrimack Pharmas, Roche, Genentech, Chugai Pharmas, Acea Biosciences, Ignyta, Loxo, Ariad, Eli Lilly, Araxes Pharmas

MTE18 Advanced NSCLC Pasi Jänne USA Speakers Bureau Loxo

MTE18 Advanced NSCLC Pasi Jänne USA Ownership Interest (stocks or stock options, or other ownership interest

Gatekeeper Pharmas

MTE18 Advanced NSCLC Pasi Jänne USA Supported/Contracted Research/Grant Astellas Pharmas, AstraZenenca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim

MTE18 Advanced NSCLC Pasi Jänne USA Royalty, Intellectual Property/Patent Holder LabCorp

MTE18 Advanced NSCLC Clarissa Mathias Brazil Nothing to disclose

MTE18 Advanced NSCLC Keunchil Park Korea Consultant Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Hanmi, Kyowa Kakko Kirin, Novartis, Ono Pharma, Roche, Bristol‐Meyers Squibb, GlaxoSmithKline, Merck, GlaxoSmithKline

MTE18 Advanced NSCLC Keunchil Park Korea Supported/Contracted Research/Grant AstraZeneca

MTE18 Advanced NSCLC Keunchil Park Korea Speakers or Advisory Board AstraZeneca, Astellas, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Hanmi, KHK, Merck, Novartis, Roche

MTE18 Advanced NSCLC Suresh Ramalingam USA Consultant AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

MTE18 Advanced NSCLC Suresh Ramalingam USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

MTE18 Advanced NSCLC Noemi Reguart Spain Nothing to disclose

MTE18 Advanced NSCLC Christian Rolfo USA Nothing to disclose

MTE18 Advanced NSCLC Qing Zhou China Nothing to disclose

Faculty

MTE18.01 Advanced NSCLC Case‐Based Management of Patients with Inadequate Tissue for Molecular Tests

Adrian Sacher Canada Nothing to disclose


Benjamin Levy USA Advisory Board AstraZeneca, Merck, Celgene, Eli Lilly, Takeda, Genentech


Benjamin Levy USA Contracted/Support Research Grant Celgene, Boehringer Ingleheim



Session SH01: Scientific Highlights of the Previous Day


Planner

SH01 Natasha Leighl Canada Supported/Contracted Research/Grant Novartis

SH01 Natasha Leighl Canada Honoraria Merck, Bristol‐Meyers Squibb

SH01 Natasha Leighl Canada Consultant Novartis, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Canadian Agency for Drugs and Technologies in Health

SH01 Gail Darling Canada Nothing to disclose

SH01 Andrea Bezjak Canada Nothing to disclose

SH01 Frances Shepherd Canada Honoraria Bristol‐Myers Squibb, Eli Lilly, AstraZeneca, Roche, Genentech, Merck, Novartis, Pfizer

SH01 Frances Shepherd Canada Consultant Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack

SH01 Frances Shepherd Canada Ownership Interest (stocks or stock options, or other ownership interest


SH01 Frances Shepherd Canada Speakers or Advisory Board Eli Lilly, AstraZeneca, Merck

Chairs

SH01 Wilfried Eberhardt Germany Speakers or Advisory Board Bristol‐Meyers Squibb, Roche, AstraZeneca, Merck, Boehringer Ingelheim, Celgene, Eli Lilly, Pfizer, Novartis, Takeda, AbbVie

SH01 Wilfried Eberhardt Germany Honoraria Bristol‐Meyers Squibb, Roche, AstraZeneca, Merck, Boehringer Ingelheim, Celgene, Eli Lilly, Pfizer, Novartis, Takeda, AbbVie

SH01 Wilfried Eberhardt Germany Supported/Contracted Research/Grant Eli Lilly, Bristol‐Meyers Squibb, AstraZeneca

SH01 Wilfried Eberhardt Germany Consultant Bristol‐Meyers Squibb, Roche, AstraZeneca, Boehringer Ingelheim

SH01 Rina Hui Australia Honoraria Bristol‐Meyers Squibb, Boehringer Ingelheim, Merck, AstraZeneca, Novartis, Roche

SH01 Rina Hui Australia Speakers or Advisory Board AstraZeneca, Merck, Novartis, Pfizer, Roche, Bristol‐Meyers Squibb

SH01 Rina Hui Australia Consultant Merck, AstraZeneca, Novartis, Roche, Bristol‐Meyers Squibb, Boehringer Ingelheim, Pfizer

Faculty

SH01.01 Advances in Radiation Robert Macrae Canada Nothing to disclose

SH01.02 Surgery Masahiro Tsuboi Japan Speakers or Advisory Board Merck, AstraZeneca

SH01.02 Surgery Masahiro Tsuboi Japan Honoraria AstraZeneca KK, Eli Lilly, Boehringer Ingelheim, Daikichi‐Sankyo, Chudai Pharma, Taiho Pharma, Teijin Pharma, Johnson & Johnson

SH01.03 Access, Outcomes, Survivorship Viola Zhu USA Speakers or Advisory Board AstraZeneca, Biocept, Roche, Genentech, Takeda

SH01.03 Access, Outcomes, Survivorship Viola Zhu USA Ownership Interest (stocks or stock options, or other ownership interest

TP Therapeutics

SH01.04 Advanced Lung Cancer Luis Raez USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Roche, Genentech, Syndax, Novartis

SH01.05 Q&A



Planner







SH02 Frances Shepherd Canada Consultant Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack




Chairs

SH02 Barbara Melosky Canada Nothing to disclose

SH02 Nico Van Zandwijk Australia Nothing to disclose

Faculty



SH02.01 Targeted tx Robert Pirker Austria Speakers Bureau Boehringer Ingelheim

SH02.01 Targeted tx Robert Pirker Austria Speakers or Advisory Board Boehringer Ingelheim, AstraZeneca, Eli Lilly

SH02.01 Targeted tx Robert Pirker Austria Honoraria Merck, Genmab and Regeneron

SH02.02 Mesothelioma Anne Tsao USA Speakers or Advisory Board Bristol‐Meyers Squibb, Eli Lilly, Genentech, Roche, Novartis, Ariad, Merck, Seattle Genetics, Astra‐Zeneca, Boehringer Ingelheim, Sellas Life Science, Takeda, Polaris, Astellas Pharma, Imedex

SH02.02 Mesothelioma Anne Tsao USA Supported/Contracted Research/Grant Eli Lilly, Millennium, Polaris, Genentech, Merck, Boehringer Ingelheim, Bristol‐Meyers Squibb, Ariad, Epizyme, Genetics

SH02.02 Mesothelioma Anne Tsao USA Consultant Bristol‐Meyers Squibb, Eli Lilly, Genentech, Roche, Novartis, Ariad, Merck, Seattle Genetics, AstraZeneca, Boehringer Ingelheim, Sellas Life Sciences, MedImmune

SH02.02 Mesothelioma Anne Tsao USA Honoraria Bristol‐Meyers Squibb, Astra‐Zeneca, Novartis, Boehringer Ingelheim, Genentech, Roche, Takeda, Ariad, Eli Lilly

SH02.02 Mesothelioma Anne Tsao USA Royalty, Intellectual Property/Patent Holder John Wiley

SH02.03 IO Gregory Riely USA Supported/Contracted Research/Grant Novartis, Genentech Roche, Millennium, GlaxoSmithKline, Pfizer, Infinity Pharmas, Ariad

SH02.03 IO Gregory Riely USA Speakers or Advisory Board Genetech

SH02.03 IO Gregory Riely USA Consultant Ariad Pharmas, GlaxoSmithKline, Infinity Pharmas, Millennium Pharmas, Inc., Novartis Pharmas Corporation, Pfizer, Roche Laboratories, Genentech, Merck

SH02.04 Pathology/Biology/Diagnostics Rafael Rosell Spain Nothing to disclose

SH02.05 Q&A

Session PL02: Presidential Symposium including Top 5 Abstracts


Planner











Chairs

PL02 Giorgio Scagliotti Italy Honoraria AstraZeneca, Roche, Pfizer, Merck, Eli Lilly, AbbVie, Novartis, Clovis

PL02 Giorgio Scagliotti Italy Speakers or Advisory Board Eli Lilly, Merck

PL02 Giorgio Scagliotti Italy Speakers Bureau Eli Lilly, Merck

PL02 Giorgio Scagliotti Italy Consultant Bayer

PL02 Ming Tsao Canada Honoraria Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Roche, Ventana

PL02 Ming Tsao Canada Supported/Contracted Research/Grant Merck, Pfizer, Roche, Ventana, AstraZeneca

PL02 Ming Tsao Canada Speakers or Advisory Board AstraZeneca, Pfizer, Merck, Roche, Ventana, Bristol Myers Squibb, AbbVie, Celgene






Faculty

PL02.01 Treatment of Early Stage/Localized Disease Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC

Scott Antonia USA Speakers or Advisory Board Bristol‐Meyers Squibb, Novartis, Merck, Cellular Biomedicine Group, Boehringer Ingelheim, AstraZeneca, MedImmune, Memgen, FLX Bio

PL02.01 Treatment of Early Stage/Localized Disease Overall Survival with Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results from PACIFIC

Scott Antonia USA Supported/Contracted Research/Grant Novartis

PL02.02 Treatment of Early Stage/Localized Disease Discussant ‐ PL02.01 Everett Vokes USA Consultant Genentech

PL02.03 Advanced NSCLC Brigatinib vs Crizotinib in Patients With ALK Inhibitor‐Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA‐1L)

Ross Camidge USA Honoraria Takeda, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, AstraZeneca, Arrys/Kyn, Genoptix, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera, Lycera, Revolution Med, Orion, Clovis, Celegene, Novartis


Ross Camidge USA Supported/Contracted Research/Grant Ariad, Takeda, Pfizer


Ross Camidge USA Speakers or Advisory Board AstraZeneca, Takeda, Arrys/Kyn, Genoptix, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, Takeda, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera DSMB, Lycera, Revolution Med

PL02.04 Advanced NSCLC Discussant ‐ PL02.03 Fiona Blackhall UK Nothing to disclose



PL02.05 Screening and Early Detection Effects of Volume CT Lung Cancer Screening: Mortality Results of the NELSON Randomised‐Controlled Population Based Trial

Harry De Koning Netherlands Nothing to disclose

PL02.06 Screening and Early Detection Discussant ‐ PL02.05 John Field UK Speakers Bureau Roche

PL02.06 Screening and Early Detection Discussant ‐ PL02.05 John Field UK Speakers or Advisory Board Epigenomics, VisonGate

PL02.07 Small Cell Lung Cancer/NET IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive‐Stage SCLC

Stephen Liu USA Speakers or Advisory Board Genentech, Pfizer, Takeda, Celgene, Eli Lilly, Taiho, Bristol‐Meyers Squibb, AstraZeneca, Ignyta


Stephen Liu USA Supported/Contracted Research/Grant Genentech, Pfizer, Threshold, Clovis, Corvus, Esanex, Bayer, OncoMed, Ignyta, Merck, Lycera, AstraZeneca, Molecular Partners


Stephen Liu USA Consultant Roche

PL02.08 Small Cell Lung Cancer/NET Discussant ‐ PL02.07 Natasha Leighl Canada Supported/Contracted Research/Grant Novartis

PL02.08 Small Cell Lung Cancer/NET Discussant ‐ PL02.07 Natasha Leighl Canada Honoraria Merck, Bristol‐Meyers Squibb

PL02.08 Small Cell Lung Cancer/NET Discussant ‐ PL02.07 Natasha Leighl Canada Consultant Novartis, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Canadian Agency for Drugs and Technologies in Health

PL02.09 Mesothelioma Nintedanib + Pemetrexed/Cisplatin in Patients with Unresectable MPM: Phase III Results from the LUME‐Meso Trial

Giorgio Scagliotti Italy Honoraria AstraZeneca, Roche, Pfizer, Merck, Eli Lilly, AbbVie, Novartis, Clovis


Giorgio Scagliotti Italy Speakers or Advisory Board Eli Lilly, Merck


Giorgio Scagliotti Italy Speakers Bureau Eli Lilly, Merck


Giorgio Scagliotti Italy Consultant Bayer

PL02.10 Mesothelioma Discussant ‐ PL02.09 Ross Soo Singapore Supported/Contracted Research/Grant AstraZeneca

PL02.10 Mesothelioma Discussant ‐ PL02.09 Ross Soo Singapore Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Celgene, Ignyta, Roche, Taiho

PL02.11 Advanced NSCLC Q&A

Session ES02: Quality Care in Lung Cancer


Planner

ES02 Nursing and Allied Professionals Massey Nematollahi Canada Nothing to disclose

ES02 Nursing and Allied Professionals Patricia Hollen USA Nothing to disclose

ES02 Nursing and Allied Professionals Beth Eaby‐Sandy USA Speakers Bureau Helsinn, Merck, AstraZeneca, Takeda

ES02 Nursing and Allied Professionals Beth Eaby‐Sandy USA Consultant Consultant‐ AbbVie

ES02 Nursing and Allied Professionals Kathleen Gamblin USA Nothing to disclose

ES02 Nursing and Allied Professionals Maria Guerin UK Speakers or Advisory Board AstraZeneca

ES02 Nursing and Allied Professionals Maria Guerin UK Honoraria AstraZeneca

ES02 Nursing and Allied Professionals Pippa Labuc UK Nothing to disclose

ES02 Nursing and Allied Professionals Naz Nouriany Canada Nothing to disclose

ES02 Nursing and Allied Professionals Dianne Zawisza Canada Nothing to disclose

Chairs

ES02 Pippa Labuc UK Nothing to disclose

ES02 Nazanin Nouriany Canada Nothing to disclose

Faculty

ES02.01 Nursing and Allied Professionals Expanding PROs in Daily Practice Kahren White Australia Nothing to disclose

ES02.02 Nursing and Allied Professionals PRO: To Medicate: Managing Breathlessness Alexandre Chan Singapore Nothing to disclose

ES02.03 Nursing and Allied Professionals CON: Not to Medicate: Managing Breathlessness Catherine Granger Australia Nothing to disclose

ES02.04 Nursing and Allied Professionals Molecular Testing 101 for Nurses Beth Eaby‐Sandy USA Speakers Bureau Helsinn, Merck, AstraZeneca, Takeda

ES02.04 Nursing and Allied Professionals Molecular Testing 101 for Nurses Beth Eaby‐Sandy USA Consultant Consultant‐ AbbVie

ES02.05 Nursing and Allied Professionals Structured Approach For Developing and Implementing and Advanced Practice Nursing Role in Lung Cancer

Andrea Serena Switzerland Nothing to disclose

ES02.06 Q&A

Session GR01: Thymic Malignancies Tumor Board


Planner

GR01 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Honoraria ACEA, Genentech, Novartis, AstraZeneca



GR01 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Supported/Contracted Research/Grant Clovis, Exelixis, AstraZeneca, MedImmune, Genentech, Roche, Bristol‐Meyers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Eli Lilly, Acea, Merck

GR01 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Speakers or Advisory Board ACEA Biosyciences, Pfizer, Novartis, Genentech, Roche, AstraZeneca, Merck

GR01 Thymoma/Other Thoracic Malignancies Meinoshin Okumura Japan Nothing to disclose

GR01 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Speakers or Advisory Board AstraZeneca

GR01 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Consultant Eli Lilly

GR01 Thymoma/Other Thoracic Malignancies Wentao Fang China Nothing to disclose

GR01 Thymoma/Other Thoracic Malignancies Pier Luigi Filosso Italy Nothing to disclose

GR01 Thymoma/Other Thoracic Malignancies Nicolas Girard France Consultant Bristol‐Meyers Squibb, Merck Roche, AstraZeneca

GR01 Thymoma/Other Thoracic Malignancies Shaf Keshavjee Canada Nothing to disclose

GR01 Thymoma/Other Thoracic Malignancies Robert Korst USA Nothing to disclose

GR01 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Supported/Contracted Research/Grant Varian Medical Systems, Boehringer Ingelheim, AstraZeneca, Pfizer

GR01 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Honoraria Varian Medical Systms, Bristol‐Meyers Squibb, AstraZeneca, Pfizer, Merck

GR01 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Speakers or Advisory Board AstraZeneca, Merck

GR01 Thymoma/Other Thoracic Malignancies DAvid Waller UK Nothing to disclose

Chairs

GR01 Thymoma/Other Thoracic Malignancies Vincent (Wentao) Fang China Nothing to disclose

GR01 Thymoma/Other Thoracic Malignancies Giuseppe Giaccone USA Nothing to disclose

Faculty

GR01.01 Thymoma/Other Thoracic Malignancies Pathology Anja Roden USA Nothing to disclose

GR01.02 Thymoma/Other Thoracic Malignancies Surgical Oncology Pier Luigi Filosso Italy Nothing to disclose

GR01.03 Thymoma/Other Thoracic Malignancies Surgical Oncology David Waller UK Nothing to disclose

GR01.04 Thymoma/Other Thoracic Malignancies Medical Oncology Nicolas Girard France Consultant Bristol‐Meyers Squibb, Merck Roche, AstraZeneca

GR01.05 Thymoma/Other Thoracic Malignancies Radiation Oncology Anthony Brade Canada Speakers or Advisory Board AstraZeneca

GR01.05 Thymoma/Other Thoracic Malignancies Radiation Oncology Anthony Brade Canada Consultant Eli Lilly

GR01.06 Discussion

Session MA10: Considerations in Immunotherapy / Real World


Planner










Chairs

MA10 Kevin Jao Canada Nothing to disclose

MA10 Rosalyn Juergens Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Amgen, Novartis, AstraZeneca, Takeda

MA10 Rosalyn Juergens Canada Honoraria Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, AstraZeneca, MedImmune, Eli Lilly, Takeda, Novartis, Amgen Pfizer

MA10 Rosalyn Juergens Canada Speakers Bureau Amgen

MA10 Rosalyn Juergens Canada Consultant Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Amgen, Roche, AstraZeneca, MedImmune,

MA10 Rosalyn Juergens Canada Supported/Contracted Research/Grant AstraZeneca, MedImmune, Merck, Bristol‐Meyers Squibb



Faculty

MA10.01 Advanced NSCLC Antibiotic Use and PD‐1 Inhibitors: Shorter Survival in Lung Cancer, Especially When Given Intravenously. Type of Infection Also Matters

Xabier Mielgo‐Rubio Spain Nothing to disclose

MA10.02 Advanced NSCLC Impact of Antibiotics on Outcome of Metastatic Non Small Cell Lung Cancer Patients Treated with Immunotherapy

Giulia Galli Italy Nothing to disclose

MA10.03 Advanced NSCLC Plasmatic Evaluation of the Intestinal Barrier and Blood Microbiota, and Antibiotic Use in Non‐Small Cell Lung Cancer Patients Treated with

Etienne Giroux Leprieur France Speakers or Advisory Board AstraZeneca, Novartis, Roche, Merck

MA10.04 Advanced NSCLC Discussant ‐ MA 10.01, MA 10.02, MA 10.03 Bertrand Routy Canada Nothing to disclose

MA10.05 Advanced NSCLC Effect of Early Steroids use in Advanced NSCLC Patients Treated with Immunotherapy

Giovanni Fucà Italy Nothing to disclose

MA10.06 Advanced NSCLC Impact of Immune‐Related Adverse Events on Survival in Patients with Advanced Non‐Small Cell Lung Cancer Treated with Nivolumab

Biagio Ricciuti Italy Nothing to disclose

MA10.07 Advanced NSCLC Discussant ‐ MA 10.05, MA 10.06 Kenneth O’Byrne Australia Honoraria Pfizer, Roche, AstraZeneca, Boehringer‐Ingelheim, Bristol‐Meyers Squibb, Merck, Eli Lilly, Novartis, Teva

MA10.07 Advanced NSCLC Discussant ‐ MA 10.05, MA 10.06 Kenneth O’Byrne Australia Speakers Bureau Pfizer, Roche, AstraZeneca, Boehringer‐Ingelheim, Bristol‐Meyers Squibb, Merck

MA10.07 Advanced NSCLC Discussant ‐ MA 10.05, MA 10.06 Kenneth O’Byrne Australia Royalty, Intellectual Property/Patent Holder Queensland University of Technology

MA10.07 Advanced NSCLC Discussant ‐ MA 10.05, MA 10.06 Kenneth O’Byrne Australia Supported/Contracted Research/Grant Tesaro

MA10.07 Advanced NSCLC Discussant ‐ MA 10.05, MA 10.06 Kenneth O’Byrne Australia Speakers or Advisory Board Pfizer, Roche, AstraZeneca, Boehringer‐Ingelheim, Bristol‐Meyers Squibb, Merck, Lilly Oncology, Novartis, Teva

MA10.08 Advanced NSCLC Choice of Taxane and Outcomes in the KEYNOTE‐407 Study of Pembrolizumab Plus Chemotherapy for Metastatic Squamous NSCLC

Balazs Halmos USA Speakers or Advisory Board AstraZeneca, Boehringer Ingelheim, Genentech, Pfizer, Eli Lilly, Foundation Medicine, Guardant Health, Takeda, Novartis, Merck, Bristol‐Meyers Squibb


Balazs Halmos USA Supported/Contracted Research/Grant Merck, AstraZeneca, Mirati Therapeutics, Boehringer Ingelheim, Pfizer, Takeda, Novartis, Eli Lilly


Balazs Halmos USA Consultant Foundation Medicine, Guardant Health


Balazs Halmos USA Honoraria AstraZeneca, Novartis, Takeda, Pfizer, Eli Lilly, Foundation One, Guardant Health, Boehringer Ingelheim, Genentech

MA10.09 Treatment in the Real World ‐ Support, Survivorship, Systems Research

NECPAL 2: A Multicentre Descriptive Study of Primary and Continuous Attention in Palliative Care in Argentina: Lung Cancer Cohort

Carolina Gabay Argentina Nothing to disclose


Lung Cancer Stigma: A Ten‐Year View of Patient, Provider, and Public Attitudes About Lung Cancer.

Jennifer King USA Speakers or Advisory Board Grail, AstraZeneca, Genentech, Tesaro, AbbVie



Jennifer King USA Supported/Contracted Research/Grant AstraZeneca



Jennifer King USA Speakers Bureau AstraZeneca

MA10.11 Advanced NSCLC Discussant ‐ MA 10.08, MA 10.09, MA 10.10 Antoinette Wozniak USA Speakers or Advisory Board AstraZeneca, Takeda, Boehringer Ingelheim, HUYA, BeyondSpring

MA10.11 Advanced NSCLC Discussant ‐ MA 10.08, MA 10.09, MA 10.10 Antoinette Wozniak USA Supported/Contracted Research/Grant Boehringer Ingelheim

MA10.12 Advanced NSCLC Q&A

Session MA11: Biomarkers of IO Response


Planner










Chairs

MA11 Govind Babu Kanakasetty India Nothing to disclose

MA11 Shirish Gadgeel USA Speakers or Advisory Board Astra‐Zeneca, Genentech, Roche, Ariad, Takeda, AbbVie, Bristol Meyers‐Squibb

Faculty

MA11.01 Immunooncology Comparative Efficacy of T‐Cell Intrinsic Versus Extrinsic PD‐1 Blockade to Overcome PD‐L1+ Tumor‐Mediated Exhaustion

Jordan Dozier USA Nothing to disclose

MA11.02 Immunooncology Increased CD3+ TIL Infiltration and Low FOXP3+/CD8+ TIL Ratio Can Predict Anti‐PD‐1 Therapeutic Response in Non‐Small Cell Lung Cancer Patients

Hyojin Kim Korea Nothing to disclose

MA11.03 Immunooncology Interaction of Tumor Infiltrating Lymphocytes and Cancer Nuclei Predicts Response to Nivolumab in Non‐Small Cell Lung Cancer (NSCLC)

Xiangxue Wang USA Nothing to disclose

MA11.04 Immunooncology Discussant ‐ MA 11.01, MA 11.02, MA 11.03 Donald Morris Canada Honoraria Roche, AstraZeneca, Bristol‐Meyers Squibb, Cellgene, Takada, Boehringer Ingelheim, Pfizer, Novartis

MA11.04 Immunooncology Discussant ‐ MA 11.01, MA 11.02, MA 11.03 Donald Morris Canada Speakers or Advisory Board Roche, AstraZeneca, Bristol‐Meyers Squibb, Cellgene, Takada, Boehringer Ingelheim, Pfizer, Novartis

MA11.05 Immunooncology Indoleamine 2,3‐Dioxygenase Expression in Non‐Small‐Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact

Francesco Agustoni USA Nothing to disclose



MA11.06 Immunooncology Prognostic Value of Complement System in NSCLC and its Association with PD‐1 and PD‐L1 Expression

Luis Montuenga Spain Nothing to disclose

MA11.07 Immunooncology Expression of LAG‐3 and NY‐ESO‐1 In Tumor Cells is Promising Biomarker Predicting Durable Clinical Benefit of PD‐1 Blockade in Advanced NSCLC

Hee Ryeong Jang Korea Nothing to disclose

MA11.08 Immunooncology Discussant ‐ MA 11.05, MA 11.06, MA 11.07 Erin Schenk USA Consultant Elsevier

MA11.09 Immunooncology Single‐Cell Characterization of the Immunologic Microenvironment in Advanced‐Stage, Oncogene‐Driven NSCLC

Julia Rotow USA Consultant Revolution Medicines

MA11.10 Immunooncology Identification of Mismatch Repair Deficient Lung Adenocarcinomas Using Targeted Next‐Generation Sequencing

Navin Mahadevan USA Nothing to disclose

MA11.11 Immunooncology Discrepancy of Tumor Neoantigen Burden Between Primary Lesions and Matched Metastases in Lung Cancer


MA11.12 Immunooncology Discussant ‐ MA 11.09, MA 11.10, MA 11.11 Ignacio Gil‐Bazo Spain Nothing to disclose

Session MA12: Mesothelioma Surgery and Novel Targets for Prognosis and Therapy


Planner

MA12 SCLC/Thymoma/Mesothelioma Marc De Perrot Canada Nothing to disclose

MA12 SCLC/Thymoma/Mesothelioma Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer

MA12 SCLC/Thymoma/Mesothelioma Quincy Chu Canada Nothing to disclose

MA12 SCLC/Thymoma/Mesothelioma Anthony Brade Canada Speakers or Advisory Board AstraZeneca

MA12 SCLC/Thymoma/Mesothelioma Anthony Brade Canada Consultant Eli Lilly

MA12 SCLC/Thymoma/Mesothelioma Gail Darling Canada Nothing to disclose

Chairs

MA12 Gerard Zalcman France Advisory Board BMS, MSD

MA12 Gerard Zalcman France Honoraria BMS, MSD, Roche, Borhinger, Pfizer, Astra‐Zeneca

MA12 Gerard Zalcman France Contracted/Support Research Grant Roche

MA12 Carmela Pepe Canada Nothing to disclose

Faculty

MA12.01 Mesothelioma The Information Pathway to Randomisation: Patients Experience of the Mesothelioma and Radical Surgery (MARS2) Feasibility Trial

Angela Tod UK Nothing to disclose

MA12.02 Mesothelioma Quality of Life Following Pleurectomy Decortication and Extrapleural Pneumonectomy for Pleural Malignant Mesothelioma

Wil Lieberman‐Cribbin USA Nothing to disclose

MA12.03 Mesothelioma The Impact of Malignant Pleural Mesothelioma Histology on the Use of Surgery and Survival in a Population‐Based Analysis

Chi‐Fu Yang USA Nothing to disclose

MA12.04 Mesothelioma Discussant ‐ MA 12.01, MA 12.02, MA 12.03 Marc De Perrot Canada Nothing to disclose

MA12.05 Mesothelioma Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma

Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche


Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex


Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca


Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

MA12.06 Mesothelioma STELLAR – Final Results of a Phase 2 Trial of TTFields with Chemotherapy for First‐Line Treatment of Malignant Pleural Mesothelioma

Giovanni Ceresoli Italy Supported/Contracted Research/Grant Bayer

MA12.07 Mesothelioma gC1qR Expression is Independently Prognostic for Survival Benefit Following Chemotherapy in Mesothelioma

Xiaoyu Li USA Nothing to disclose

MA12.08 Mesothelioma Discussant ‐ MA 12.05, MA 12.06, MA 12.07 Quincy Chu Canada Nothing to disclose

MA12.09 Mesothelioma Preclinical Investigations of Folate Receptor Targeted Nanoparticles for Photodynamic Therapy of Malignant Pleural Mesothelioma

Tatsuya Kato Canada Supported/Contracted Research/Grant Ono Pharmas, Bristol‐Meyers Squibb, AstraZeneca, Boehringer Ingerheim, Chugai, Eli Lilly, Kirin Kyowa, Merck, Pfixer, Quintiles, Taiho, Parexel, AbbVie, Astellas


Tatsuya Kato Canada Honoraria Ono Pharma, Bristol‐Meyers Squibb, AstraZeneca, Boehringer Ingerheim, Chugai, Eli Lilly, Merck, Novartis, Pfizer, Quintiles, Roche, Taiho, Parexel, AbbVie


Tatsuya Kato Canada Speakers or Advisory Board Chugai, Eli Lilly, Merck

MA12.10 Mesothelioma Long‐Term Impact of Radiotherapy Before Surgery for Mesothelioma on the Distribution of Memory T Cell Subsets

Junichi Murakami Canada Nothing to disclose

MA12.11 Mesothelioma Analysis of Angiogenic and Stromal Biomarkers in a Large Malignant Mesothelioma Cohort

Puey Ling Chia Australia Nothing to disclose

MA12.12 Mesothelioma Discussant ‐ MA 12.09, MA 12.10, MA 12.11 Masaki Anraku Japan Nothing to disclose

Session MA13: Interventional Pulmonology


Planner

















Chairs

MA13 Jason Agulnik Canada Honoraria Merck, Pfizer, Bristol‐Meyers Squibb, AstraZeneca

MA13 Kwun Fong Australia Nothing to disclose

Faculty

MA13.01 Interventional Diagnostics/Pulmonology CT‐Guided Transthoracic Needle Biopsy for Evaluation of PD‐L1 Expression: Comparison of 22C3 and SP263 Assays

Kyongmin Beck Korea Nothing to disclose

MA13.02 Interventional Diagnostics/Pulmonology PD‐L1 Expression in EBUS‐Guided Cytology Specimens of Non‐Small Cell Lung Cancer is Not Affected by Type of Fixation: A Study of Matched Pairs

Alexander Haragan UK Nothing to disclose

MA13.03 Interventional Diagnostics/Pulmonology Heterogeneity Analysis of EBUS‐TBNA‐Derived Specimens for Evaluation of PD‐L1 Expression and Copy Number Alterations in Patients with NSCLC

Katsuhiro Yoshimura Japan Nothing to disclose

MA13.04 Interventional Diagnostics/Pulmonology Discussant ‐ MA 13.01, MA 13.02, MA 13.03 John Gosney UK Speakers or Advisory Board AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Roche

MA13.04 Interventional Diagnostics/Pulmonology Discussant ‐ MA 13.01, MA 13.02, MA 13.03 John Gosney UK Consultant AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Roche

MA13.05 Interventional Diagnostics/Pulmonology The Canada Lymph Node Sonographic Score: National Validation of a Sonographic Score to Determine Mediastinal Lymph Node Malignancy

Danielle Hylton Canada Nothing to disclose

MA13.06 Interventional Diagnostics/Pulmonology Endosonography with Lymph Nodes Sampling for Restaging the Mediastinum in Lung Cancer: A Systematic Review and Pooled‐Data

Long Jiang China Nothing to disclose

MA13.07 Interventional Diagnostics/Pulmonology Diagnostic Yield of N3 Hilar Staging by Endobronchial Ultrasonography (EBUS) in Lung Cancer

Antoni Rosell Spain Nothing to disclose

MA13.08 Interventional Diagnostics/Pulmonology Discussant ‐ MA 13.05, MA 13.06, MA 13.07 Nicole Bouchard Canada Supported/Contracted Research/Grant Pfizer, Bristol‐Meyers Squibb, Merck

MA13.08 Interventional Diagnostics/Pulmonology Discussant ‐ MA 13.05, MA 13.06, MA 13.07 Nicole Bouchard Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche

MA13.09 Interventional Diagnostics/Pulmonology Electromagnetic Navigation Bronchoscopy as an Integrated Approach to Aid in Diagnosis and Treatment of Pulmonary Lesions

Sandeep Khandhar USA Consultant Medtronic


Sandeep Khandhar USA Supported/Contracted Research/Grant Medtronic


Sandeep Khandhar USA Speakers or Advisory Board Medtronic

MA13.10 Interventional Diagnostics/Pulmonology Comparison of Pulmonary Nodule Location Between Preprocedural CT and Intra‐Procedural Cone‐Beam CT During Guided Bronchoscopy

Michael Pritchett USA Honoraria Biodesix, Medtronic, AstraZeneca, Johnson & Johnson


Michael Pritchett USA Speakers or Advisory Board Biodesix, Medtronic, AstraZeneca


Michael Pritchett USA Speakers Bureau Medtronic, AstraZeneca

MA13.11 Interventional Diagnostics/Pulmonology Photodynamic Therapy for Peripheral‐Type Lung Cancer in a Multi‐Center Clinical Trial

Jitsuo Usuda Japan Nothing to disclose

MA13.12 Interventional Diagnostics/Pulmonology Discussant ‐ MA 13.09, MA 13.10, MA 13.11 Antoni Rosell Spain Nothing to disclose

Session MA14: Survivorship, Socioeconomic and End‐of‐Life Considerations


Planner







Chairs

MA14 Taofeek Owonikoko USA Speakers or Advisory Board AbbVie, Bristol‐Meyers Squibb, G1 Therapeutics

MA14 Taofeek Owonikoko USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, AbbVie, United Pharma, G1 Therapeutics

MA14 Pablo Munoz Schuffenegger Canada Nothing to disclose

Faculty


Life Sustaining Procedures, Palliative Care and Hospital Cost Trends in Dying Lung Cancer Patients in U.S. Hospitals: 2005‐2014

Jinwook Hwang Korea Nothing to disclose


Use and Impact of A Systematic Advanced Care Planning in Hospitalized Lung Cancer Patients: A Prospective Study.

Anne Claire Toffart France Nothing to disclose


Aggressiveness of Cares on the Month Before Death of Patients with Lung Cancer: A French National Database Survey

Olivier Bylicki France Nothing to disclose




Discussant ‐ MA 14.01, MA 14.02, MA 14.03 Gouri Shankar Bhattacharyya India Nothing to disclose


Social Isolation Increases Psychological Distress in Patients With NSCLC Cheryl Ho Canada Supported/Contracted Research/Grant BC Cancer Foundation


Social Isolation Increases Psychological Distress in Patients With NSCLC Cheryl Ho Canada Honoraria AstraZeneca


Social Isolation Increases Psychological Distress in Patients With NSCLC Cheryl Ho Canada Consultant Roche


Predictors of Financial Toxicity, an Under‐Recognized Patient‐Reported Outcome

Doreen Ezeife Canada Nothing to disclose


The Impact of Socioeconomic Status and Geographic Location on Palliative Chemotherapy Uptake in Patients with Metastatic NSCLC

Zamzam Al‐Hashami Canada Nothing to disclose


Discussant ‐ MA 14.05, MA 14.06, MA 14.07 Christos Chouaid France Speakers or Advisory Board Roche, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Novartis, Merck, Bristol‐Meyers Squibb, GlaxoSmithKline, Amgen


Mortality of Lung Cancer as a Second Primary Malignancy among Cancer Survivors: A Study of Surveillance, Epidemiology, and End Results Database

Lei Deng USA Nothing to disclose


QTc Interval‐Prolonging Medications in Lung Cancer: Implications for Clinical Trial Eligibility and Routine Clinical Care


Gilead











Factors Associated with Early Mortality in Non‐Small Cell Lung Cancer Patients Following Systemic Anti‐Cancer Treatment

Amanda Gibson Canada Nothing to disclose


Discussant ‐ MA 14.09, MA 14.10, MA 14.11 Amanda Tufman Germany Nothing to disclose

Session MS13: Novel Mediators of Lung Cancer Metastasis


Planner






Rain Therapeutics
























OrigiMed












Chairs



Faculty

MS13.01 Biology Liquid Biopsy‐mediated Identification of Metastatic Variants Philip Mack USA Supported/Contracted Research/Grant Boehringer Ingelheim

MS13.01 Biology Liquid Biopsy‐mediated Identification of Metastatic Variants Philip Mack USA Consultant Guardant Health, Apton Biosystems

MS13.01 Biology Liquid Biopsy‐mediated Identification of Metastatic Variants Philip Mack USA Speakers or Advisory Board AstraZeneca, Eli Lilly, Pfizer

MS13.02 Biology Capicua Inactivation Drives Lung Cancer Metastasis Trever Bivona USA Nothing to disclose

MS13.03 Biology Ubiquilin as a Novel Mediator of Lung Cancer Invasion and Metastasis Levi Beverly USA Nothing to disclose

MS13.04 Biology Tracking the Evolution of Non‐Small‐Cell Lung Cancer Charles Swanton UK Ownership Interest ACHILLES (CO‐FOUNDER)

MS13.04 Biology Tracking the Evolution of Non‐Small‐Cell Lung Cancer Charles Swanton UK Honoraria CELGENE, GENENTECH, ROCHE VENTANA, NOVARTIS, BMS

MS13.04 Biology Tracking the Evolution of Non‐Small‐Cell Lung Cancer Charles Swanton UK Contracted/Support Research Grant PFIZER, ASTRAZENECA

MS13.04 Biology Tracking the Evolution of Non‐Small‐Cell Lung Cancer Charles Swanton UK Other(please specify) STOCK OPTIONS IN APOGEN BIOTECH AND EPIC BIOSCIENCES AND GRAIL

MS13.05 Biology Discussant David Beer USA Nothing to disclose

MS13.06 Q&A

Session MS14: IO in Early Stage NSCLC


Planner










































Chairs

MS14 Janet Edwards Canada Nothing to disclose

MS14 Mark Kris USA Honoraria AstraZeneca

Faculty

MS14.01 Immunooncology Basic Science Rationale of IO in Early Stage NSCLC? Johan Vansteenkiste Belgium Supported/Contracted Research/Grant University Hospitals KU Leuven, Merck

MS14.01 Immunooncology Basic Science Rationale of IO in Early Stage NSCLC? Johan Vansteenkiste Belgium Speakers or Advisory Board Apotex, AstraZeneca, Apotex, Boehringer Ingelheim, Merck, Novartis, Roche

MS14.01 Immunooncology Basic Science Rationale of IO in Early Stage NSCLC? Johan Vansteenkiste Belgium Consultant AstraZeneca, Merck, Bristol‐Meyers Squibb, Roche

MS14.01 Immunooncology Basic Science Rationale of IO in Early Stage NSCLC? Johan Vansteenkiste Belgium Honoraria AstraZeneca, Bristol‐Meyers Squibb, Merck, Roche

MS14.02 Immunooncology Adjuvant / Neoadjuvant IO Therapy Julie Brahmer USA Speakers or Advisory Board Merck, Genetech, Bristol‐Meyers Squibb, Syndax, AstraZeneca, Celgene, Amgen Oncology

MS14.02 Immunooncology Adjuvant / Neoadjuvant IO Therapy Julie Brahmer USA Consultant Celgene, Eli Lilly, MedImmune, AstraZeneca, Bristol‐Meyers Squibb

MS14.02 Immunooncology Adjuvant / Neoadjuvant IO Therapy Julie Brahmer USA Supported/Contracted Research/Grant Medimmune, AstraZeneca, Bristol‐Meyers Squibb

MS14.03 Immunooncology Concerns About IO for the Thoracic Surgeon? Bernward Passlick Germany Nothing to disclose

MS14.04 Immunooncology IO ‐ New Standards in Stage III NSCLC Rafal Dziadziuszko Poland Speakers or Advisory Board Roche, AstraZeneca, Pfizer, Bristol Meyers‐Squibb, Ignyta

MS14.04 Immunooncology IO ‐ New Standards in Stage III NSCLC Rafal Dziadziuszko Poland Honoraria Roche, Pfizer, Novartis, Ignyta, AstraZeneca, Bristol‐Meyers Squibb

MS14.04 Immunooncology IO ‐ New Standards in Stage III NSCLC Rafal Dziadziuszko Poland Speakers Bureau Roche, Bristol‐Meyers Squibb, AstraZeneca

MS14.05 Immunooncology Do Biomarkers used in Metastatic Setting Apply in Earlier Stages Naiyer Rizvi USA Honoraria Roche, AstraZeneca, Novartis, Merck, Pfizer, Lilly, Bristol‐Meyers Squibb

MS14.05 Immunooncology Do Biomarkers used in Metastatic Setting Apply in Earlier Stages Naiyer Rizvi USA Ownership Interest (stocks or stock options, or other ownership interest


MS14.05 Immunooncology Do Biomarkers used in Metastatic Setting Apply in Earlier Stages Naiyer Rizvi USA Speakers or Advisory Board Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

MS14.05 Immunooncology Do Biomarkers used in Metastatic Setting Apply in Earlier Stages Naiyer Rizvi USA Consultant Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

MS14.06 Q&A

Session MS15: Disruptive Technology and Lung Cancer Risk


Planner














Chairs

MS15 Douglas Arenberg USA Nothing to disclose

MS15 Biniam Kidane Canada Nothing to disclose

Faculty

MS15.01 Prevention and Tobacco Control Just Water Vapor? Toxicology Perspectives on Electronic Cigarettes Maciej Goniewicz USA Speakers or Advisory Board Johnson & Johnson

MS15.02 Prevention and Tobacco Control PRO‐ Electronic Cigarettes: A Cessation Tool K. Michael Cummings USA Nothing to disclose

MS15.03 Prevention and Tobacco Control CON‐ Electronic Cigarettes: Not Evidence Based Cessation Alison Wallace Canada Nothing to disclose

MS15.04 Prevention and Tobacco Control The Rise of Heat‐Not Burn Tobacco in Japan: A “Hot” Issue for Tobacco Control

Junji Yoshida Japan Nothing to disclose

MS15.05 Prevention and Tobacco Control Heat‐Not‐Burn Tobacco: Real Risk Reduction or Industry’s Next Promise Carolyn Dresler USA Nothing to disclose

MS15.06 Q&A

Session OA10: Right Patient, Right Target & Right Drug ‐ Novel Treatments and Research Partnerships


Planner










Chairs

OA10 Howard West USA Consultant Ariad, Genentech, Roche, Takeda

OA10 Howard West USA Speakers Bureau Ariad, Bristol‐Myers Squibb, Eli Lilly

OA10 Howard West USA Speakers or Advisory Board AbbVie, Ariad, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Merck, Roche, Genentech, Takeda, Spectrum

OA10 Jyoti Patel USA Speakers or Advisory Board AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Takeda, Roche

OA10 Jyoti Patel USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb

OA10 Jyoti Patel USA Consultant Genentech

Faculty

OA10.01 Targeted Therapy Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC

John Bridges USA Consultant ICON


John Bridges USA Supported/Contracted Research/Grant Lungevity


John Bridges USA Honoraria Bayer, Boehringer Ingelheim

OA10.02 Targeted Therapy Oncogene‐Driven Patient Groups: A New Era For Research Partnerships Janet Freeman‐Daily USA Nothing to disclose

OA10.03 Targeted Therapy Discussant ‐ OA 10.01, OA 10.02 Zofia Piotrowska USA Consultant AstraZeneca, Boehringer Ingelheim, Ariad, Novartis, Guardant Health, Takeda, AbbVie

OA10.03 Targeted Therapy Discussant ‐ OA 10.01, OA 10.02 Zofia Piotrowska USA Speakers or Advisory Board AstraZeneca, Ariad, Takeda, Novartis, Boehringer Ingelheim, AbbVie



OA10.03 Targeted Therapy Discussant ‐ OA 10.01, OA 10.02 Zofia Piotrowska USA Supported/Contracted Research/Grant Novartis

OA10.03 Targeted Therapy Discussant ‐ OA 10.01, OA 10.02 Zofia Piotrowska USA Honoraria Guardant Health

OA10.04 Targeted Therapy Afatinib With or Without Cetuximab for EGFR‐Mutant Non‐Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403

Sarah Goldberg USA Supported/Contracted Research/Grant AstraZeneca


Sarah Goldberg USA Honoraria AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Boehringer Ingelheim


Sarah Goldberg USA Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Boehringer Ingelheim Daiichi

OA10.05 Targeted Therapy An Open‐Label, Multicenter, Phase II Single Arm Trial of Osimertinib in NSCLC Patients with Uncommon EGFR Mutation(KCSG‐LU15‐09)

Jang Ho Cho Korea Nothing to disclose

OA10.06 Targeted Therapy A First‐in‐Human Phase 1 Trial of the EGFR‐cMET Bispecific Antibody JNJ‐61186372 in Patients with Advanced Non‐Small Cell Lung Cancer (NSCLC)

Keunchil Park Korea Consultant Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Hanmi, Kyowa Kakko Kirin, Novartis, Ono Pharma, Roche, Bristol‐Meyers Squibb, GlaxoSmithKline, Merck, GlaxoSmithKline


Keunchil Park Korea Supported/Contracted Research/Grant AstraZeneca


Keunchil Park Korea Speakers or Advisory Board AstraZeneca, Astellas, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Hanmi, KHK, Merck, Novartis, Roche

OA10.07 Targeted Therapy Resistance Mechanisms of Osimertinib in Chinese Non‐Small Cell Lung Cancer Patients: Analysis from AURA17 Trial

Caicun Zhou China Honoraria Roche, Eli Lilly, Boehringer Ingelheim, Merck, Hengrui, Qiru, Sanofi, Pfizer

OA10.08 Targeted Therapy Discussant ‐ OA 10.04, OA 10.05, OA 10.06, OA 10.07 Linda Coate Ireland Nothing to disclose

Session PC05: Optimizing Clinical Trial Design in NSCLC


Planner

PC05 Advanced NSCLC Scott Laurie Canada Consultant Bristol‐Meyers Squibb, Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca, BBI

PC05 Advanced NSCLC Scott Laurie Canada Honoraria Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca

PC05 Advanced NSCLC Leora Horn Canada Consultant AbbVie, AstraZeneca, Genentech, Merck, Incyte, Xcovery, Roche

PC05 Advanced NSCLC Leora Horn Canada Supported/Contracted Research/Grant Xcovery Holding Company, Bristol‐Meyers Squibb, Boehringer Ingelheim, AbbVie, Genentech, Merck

PC05 Advanced NSCLC Carlos Gil Ferreira Brazil Nothing to disclose

PC05 Advanced NSCLC Glenn Goss USA Nothing to disclose

PC05 Advanced NSCLC Pasi Jänne USA Consultant Araxes Pharmas, Ariad, AstraZeneca, Boehringer Ingelheim, Chugai, Ignyta, Eli Lilly, Loxo, Merrimack, Mirati Therapeutics, Pfizer, Roche, Dana‐Farber Cancer Institute

PC05 Advanced NSCLC Pasi Jänne USA Speakers or Advisory Board AstraZeneca, Boehringer Ingelheim, Pfizer, Merrimack Pharmas, Roche, Genentech, Chugai Pharmas, Acea Biosciences, Ignyta, Loxo, Ariad, Eli Lilly, Araxes Pharmas

PC05 Advanced NSCLC Pasi Jänne USA Speakers Bureau Loxo

PC05 Advanced NSCLC Pasi Jänne USA Ownership Interest (stocks or stock options, or other ownership interest

Gatekeeper Pharmas

PC05 Advanced NSCLC Pasi Jänne USA Supported/Contracted Research/Grant Astellas Pharmas, AstraZenenca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim

PC05 Advanced NSCLC Pasi Jänne USA Royalty, Intellectual Property/Patent Holder LabCorp

PC05 Advanced NSCLC Clarissa Mathias Brazil Nothing to disclose

PC05 Advanced NSCLC Keunchil Park Korea Consultant Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Hanmi, Kyowa Kakko Kirin, Novartis, Ono Pharma, Roche, Bristol‐Meyers Squibb, GlaxoSmithKline, Merck, GlaxoSmithKline

PC05 Advanced NSCLC Keunchil Park Korea Supported/Contracted Research/Grant AstraZeneca

PC05 Advanced NSCLC Keunchil Park Korea Speakers or Advisory Board AstraZeneca, Astellas, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Hanmi, KHK, Merck, Novartis, Roche

PC05 Advanced NSCLC Suresh Ramalingam USA Consultant AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

PC05 Advanced NSCLC Suresh Ramalingam USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

PC05 Advanced NSCLC Noemi Reguart Spain Nothing to disclose

PC05 Advanced NSCLC Christian Rolfo USA Nothing to disclose

PC05 Advanced NSCLC Qing Zhou China Nothing to disclose

Chairs

PC05 Pilar Garrido Spain Consultant Roche, Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol‐Meyers Squibb, Eli Lilly and Company, AbbVie, Novartis

PC05 Pilar Garrido Spain Speakers Bureau Roche, Merck, Bristol‐Meyers Squibb, Pfizer

PC05 Pilar Garrido Spain Supported/Contracted Research/Grant Guardant

PC05 Luis Ubillos Uruguay Speakers Bureau Roche, Tecnofarma

PC05 Luis Ubillos Uruguay Speakers or Advisory Board Roche, Tecnofarma, Servier, Bayer

Faculty

PC05.00 Advanced NSCLC Introduction with Poll Questions Luis Ubillos Uruguay Speakers Bureau Roche, Tecnofarma

PC05.00 Advanced NSCLC Introduction with Poll Questions Luis Ubillos Uruguay Speakers or Advisory Board Roche, Tecnofarma, Servier, Bayer

PC05.01 Advanced NSCLC Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS ‐ Point of View: PFS

Mary O’brien UK Nothing to disclose



PC05.02 Advanced NSCLC Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS ‐ Point of View: OS

Yu Shyr USA Speakers or Advisory Board Roche

PC05.03 Discussion

PC05.04 Advanced NSCLC Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting ‐ YES

Maurice Pérol France Advisory Board Roche, Eli Lilly, Pfizer, Boehringer‐Ingelheim, MSD, Bristol‐Myers Squibb, Novartis, Astra‐Zeneca, Takeda


Maurice Pérol France Honoraria Eli Lilly, Roche, Astra‐Zeneca, Pfizer, Amgen, Boehringer‐Ingelheim, Bristol‐Myers Squibb, Takeda


Maurice Pérol France Contracted/Support Research Grant Roche, Astra‐Zeneca

PC05.05 Advanced NSCLC Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting ‐ NO

Rathi Pillai USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb

PC05.05 Advanced NSCLC Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting ‐ NO

Rathi Pillai USA Speakers or Advisory Board AstraZeneca

PC05.06 Discussion

PC05.07 Advanced NSCLC Let's Not Forget Chemo‐Regret Patricia Hollen USA Nothing to disclose

PC05.08 Discussion

Session MA15: Colliding Approaches ‐ EGFR and Immunotherapy


Planner










Chairs

MA15 Heather Wakelee USA Honoraria ACEA, Genentech, Novartis, AstraZeneca

MA15 Heather Wakelee USA Supported/Contracted Research/Grant Clovis, Exelixis, AstraZeneca, MedImmune, Genentech, Roche, Bristol‐Meyers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Eli Lilly, Acea, Merck

MA15 Heather Wakelee USA Speakers or Advisory Board ACEA Biosyciences, Pfizer, Novartis, Genentech, Roche, AstraZeneca, Merck

MA15 Naiyer Rizvi USA Honoraria Roche, AstraZeneca, Novartis, Merck, Pfizer, Lilly, Bristol‐Meyers Squibb

MA15 Naiyer Rizvi USA Ownership Interest (stocks or stock options, or other ownership interest


MA15 Naiyer Rizvi USA Speakers or Advisory Board Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

MA15 Naiyer Rizvi USA Consultant Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

Faculty

MA15.01 Targeted Therapy Strong PD‐L1 Expression Predicts Poor Response and de Novo Resistance to EGFR TKIs Among Non‐Small Cell Lung Cancer Patients with EGFR

Shan Su China Nothing to disclose

MA15.02 Targeted Therapy Long‐Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

Charles Rudin USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Genentech, Harpoon, Genetics

MA15.02 Targeted Therapy Long‐Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

Charles Rudin USA Consultant Bristol‐Meyers Squibb, AbbVie, Seattle Genetics, Harpoon Therapeutics, Genentech Roche, AstraZeneca

MA15.03 Targeted Therapy PD‐L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR‐TKIs in the FLAURA Trial

Suresh Ramalingam USA Consultant AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

MA15.03 Targeted Therapy PD‐L1 Expression in Untreated EGFRm Advanced NSCLC and Response to Osimertinib and SoC EGFR‐TKIs in the FLAURA Trial

Suresh Ramalingam USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

MA15.04 Targeted Therapy Discussant ‐ MA 15.01, MA 15.02, MA 15.03 Adrian Sacher Canada Nothing to disclose

MA15.05 Targeted Therapy The Mutational Profiles of EGFR 19 Exon Deletion and 21 Exon L858R Mutation and Their Association with Primary Response to EGFR‐TKIs

Wenhua Liang China Nothing to disclose

MA15.06 Targeted Therapy Circulating Tumor DNA Portrays the Resistance Landscape to a Novel Third Generation EGFR Inhibitor, AC0010

Yi‐Chen Zhang China Nothing to disclose

MA15.07 Targeted Therapy Different Responses to Osimertinib in Primary and Acquired EGFR T790M‐Mutant NSCLC Patients


MA15.08 Targeted Therapy Discussant ‐ MA 15.05, MA 15.06, MA 15.07 Charu Aggarwal USA Speakers or Advisory Board Celgene, Bristol‐Meyers Squibb

MA15.09 Targeted Therapy Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated with First‐Line EGFR‐TKIs

Chunxia Su China Nothing to disclose

MA15.10 Targeted Therapy Loss of T790M Mutation is Associated with Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M

Sha Zhao China Nothing to disclose

MA15.11 Targeted Therapy Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR‐TKIs

Anne Chiang USA Speakers or Advisory Board AstraZeneca, AbbVie


Anne Chiang USA Consultant AstraZeneca




Anne Chiang USA Supported/Contracted Research/Grant AstraZeneca, AbbVie


Anne Chiang USA Speakers Bureau Bristol‐Meyers Squibb

MA15.12 Targeted Therapy Discussant ‐ MA 15.09, MA 15.10, MA 15.11 Joel Neal USA Consultant Ariad, Takeda, AstraZeneca, Genentech, Roche, Eli Lilly

MA15.12 Targeted Therapy Discussant ‐ MA 15.09, MA 15.10, MA 15.11 Joel Neal USA Speakers or Advisory Board Ariad, Takeda, AstraZeneca, Genentech, Roche, Eli Lily, Clovis

MA15.12 Targeted Therapy Discussant ‐ MA 15.09, MA 15.10, MA 15.11 Joel Neal USA Supported/Contracted Research/Grant Boehringer Ingelheim, Exelixis, Genentech, Roche, Merck, Nektar Therapeutics, Novartis, Ariad, Takeda

Session MA16: Novel Mechanisms for Molecular Profiling


Planner










Chairs

MA16 Makoto Nishio Japan Speakers Bureau Ono Pharmaceu cal, Bristol Myers Squibb,, Pfizer, Chugai Pharmaceu cal, Eli Lilly, Taiho Pharmaceu cal, AstraZeneca, Boehringer‐ingelheim, MSD, Novar s

MA16 Makoto Nishio Japan Advisory Board Novar s, Daiichi Sankyo Healthcare, Taiho Pharmaceu cal, Bristol Myers Squibb, Boehringer‐ingelheim, Ono Pharmaceu cal, Eli Lilly, Chugai Pharmaceu cal, AstraZeneca, Merck Serono, MSD, Pfize

MA16 Makoto Nishio Japan Contracted/Support Research Grant MSD, Novartis, Ono Pharmaceutical, Chugai Pharmaceutical, Bristol Myers Squibb, Taiho Pharmaceutical, Eli Lilly, AstraZeneca, Pfizer, Astellas,

MA16 Mustapha Tehfe Canada Speakers Bureau BMS MERCK Celegen Taiho AstraZeneka

MA16 Mustapha Tehfe Canada Advisory Board BMS MERCK Celegen Takeda Taiho AstraZeneka

MA16 Mustapha Tehfe Canada Other(please specify) Research Grant Celegen

Faculty

MA16.01 Advanced NSCLC Frequency and Genomic Context of Emerging Markers for Molecular Testing in Lung Adenocarcinoma in Cell‐Free DNA NGS Analysis

Vincent Lam USA Nothing to disclose

MA16.02 Advanced NSCLC Prospective Clinical Validation of the InVisionFirst™ ctDNA Assay for Molecular Profiling of Patients with Advanced NSCLC

Ramaswamy Govindan USA Speakers or Advisory Board Merck, Baxalta, Roche, Boehringer Ingleheim, Novartis, Pfizer, Celgene, AstraZeneca, MSK, AbbVie Inivata, Pfizer, NeoHealth, Bristol‐Meyers Squibb, Nektar, GlaxcSmithKline


Ramaswamy Govindan USA Consultant Genentech, Ariad, Astellas, Bristol‐Meyers Squibb, INC Research, AbbVie


Ramaswamy Govindan USA Honoraria AbbVie, Genentech, Boehringer Ingelheim

MA16.03 Advanced NSCLC Discussant ‐ MA 16.01, MA 16.02 Geoffrey Oxnard USA Speakers or Advisory Board Inivata, GRAIL, DropWorks, AstraZeneca, Takeda/Ariad

MA16.03 Advanced NSCLC Discussant ‐ MA 16.01, MA 16.02 Geoffrey Oxnard USA Consultant Loxo, Inivata, AstraZeneca

MA16.03 Advanced NSCLC Discussant ‐ MA 16.01, MA 16.02 Geoffrey Oxnard USA Royalty, Intellectual Property/Patent Holder Co‐author of patent held by DFCI describing a plasma genotyping approach

MA16.03 Advanced NSCLC Discussant ‐ MA 16.01, MA 16.02 Geoffrey Oxnard USA Honoraria Guardant, Sysmex

MA16.04 Advanced NSCLC Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations.

Michael Offin USA Nothing to disclose

MA16.05 Advanced NSCLC MET Kinase Domain Rearrangements (KDRE) in Non‐Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP)

Sai‐Hong Ou USA Speakers Bureau Roche, Genentech, AstraZeneca, Takeda


Sai‐Hong Ou USA Speakers or Advisory Board Pfizer, Roche, Genentech, Novartis, AstraZeneca, Takeda, Foundation Medicine


Sai‐Hong Ou USA Honoraria Pfizer, Genentech, Roche, Ariad, Takeda, Novartis, AstraZeneca, Foundation Medicine


Sai‐Hong Ou USA Ownership Interest (stocks or stock options, or other ownership interest

TP Therapeutics


Sai‐Hong Ou USA Supported/Contracted Research/Grant Pfizer, Roche, MedImmune, AstraZeneca, Clovis Oncology, Ariad, Ignyta, Peregrine Pharma, GlaxoSmithKline, Astellas Pharma, Chugai Pharma

MA16.06 Advanced NSCLC EGFR Clonality and Tumor Mutation Burden (TMB) by Circulating Tumor DNA (ctDNA) Sequencing in Advanced Non‐Small Cell Lung Cancer (NSCLC)

Xinghao Ai China Nothing to disclose

MA16.07 Advanced NSCLC Discussant ‐ MA 16.04, MA 16.05, MA 16.06 Ben Solomon Australia Speakers or Advisory Board AstraZeneca, Bristol‐Myers Squibb, Merck, Pfizer, Roche, Genentech, Novartis

MA16.07 Advanced NSCLC Discussant ‐ MA 16.04, MA 16.05, MA 16.06 Ben Solomon Australia Honoraria Bristol‐Myers Squibb, AstraZeneca

MA16.07 Advanced NSCLC Discussant ‐ MA 16.04, MA 16.05, MA 16.06 Ben Solomon Australia Supported/Contracted Research/Grant Pfizer

MA16.07 Advanced NSCLC Discussant ‐ MA 16.04, MA 16.05, MA 16.06 Ben Solomon Australia Royalty, Intellectual Property/Patent Holder Veristrat

MA16.07 Advanced NSCLC Discussant ‐ MA 16.04, MA 16.05, MA 16.06 Ben Solomon Australia Consultant AstraZeneca, Roche, Merck, Bristol‐Myers Squibb, Novartis



MA16.08 Targeted Therapy Clinical Utility of Detecting ROS1 Genetic Alterations in Plasma Ibiayi Dagogo‐Jack USA Honoraria Foundation Medicine

MA16.08 Targeted Therapy Clinical Utility of Detecting ROS1 Genetic Alterations in Plasma Ibiayi Dagogo‐Jack USA Consultant Boehringer Ingelheim

MA16.09 Advanced NSCLC Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non‐Small Cell Lung Cancer

Aurélie Swalduz France Supported/Contracted Research/Grant Pfizer, Boehringer Ingelheim

MA16.09 Advanced NSCLC Feasibility, Clinical Relevance of ALK/ROS1 Fusion Variant Detection by Liquid Biopsy in Advanced Non‐Small Cell Lung Cancer

Aurélie Swalduz France Speakers or Advisory Board Roche

MA16.10 Advanced NSCLC Clinical Utility of Cerebrospinal Fluid Cell‐Free DNA for Clarifying Genetic Features of Leptomeningeal Metastases in ALK Rearrangement NSCLC

Meimei Zheng China Nothing to disclose

MA16.11 Advanced NSCLC Discussant ‐ MA 16.08, MA 16.09, MA 16.10 Robert Doebele USA Ownership Interest (stocks or stock options, or other ownership interest

Rain Therapeutics

MA16.11 Advanced NSCLC Discussant ‐ MA 16.08, MA 16.09, MA 16.10 Robert Doebele USA Speakers or Advisory Board Ignyta, AstraZeneca, Bayer, Takeda, Bristol‐Meyers Squibb, Ariad

MA16.11 Advanced NSCLC Discussant ‐ MA 16.08, MA 16.09, MA 16.10 Robert Doebele USA Supported/Contracted Research/Grant Ignyta

MA16.11 Advanced NSCLC Discussant ‐ MA 16.08, MA 16.09, MA 16.10 Robert Doebele USA Consultant Pfizer, OncoMed, Trovagene, Ignyta, GreenPeptide, AstraZeneca, Ignyta, Ariad, Guardant Health

MA16.11 Advanced NSCLC Discussant ‐ MA 16.08, MA 16.09, MA 16.10 Robert Doebele USA Honoraria Pfizer, AstraZeneca, Ariad, Guardant Health, Takeda, Spectrum Pharmas, Trovagene

MA16.11 Advanced NSCLC Discussant ‐ MA 16.08, MA 16.09, MA 16.10 Robert Doebele USA Royalty, Intellectual Property/Patent Holder Abbott Molecular, Rain Therapeutics, Igynta

MA16.12 Advanced NSCLC Q&A

Session MA17: New Methods to Improve Lung Cancer Patients Outcomes


Planner







Chairs

MA17 Massey Nematollahi Canada Nothing to disclose

MA17 Rossie Navon Israel Nothing to disclose

Faculty

MA17.01 Nursing and Allied Professionals A Sense of Understanding and Belonging When Life Is at Stake – Operable Lung Cancer Patients’ Lived Experiences of Participation in Exercise

Malene Missel Denmark Nothing to disclose

MA17.02 Nursing and Allied Professionals Early Accrual to a Precision Lung Cancer Survivorship Intervention: The Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program

Jamie Studts USA Nothing to disclose

MA17.03 Nursing and Allied Professionals Shared Decision‐Making for Patients with Advanced Non‐Small Cell Lung Cancer

Mette Jensen Denmark Nothing to disclose

MA17.04 Nursing and Allied Professionals Discussant ‐ MA 17.01, MA 17.02, MA 17.03 Anne Fraser New Zealand Nothing to disclose

MA17.05 Nursing and Allied Professionals Development of a Telephone Clinic for Patients Undergoing Long Term Follow‐Up After Thoracic Surgery

Jenny Mitchell UK Nothing to disclose

MA17.06 Nursing and Allied Professionals The Specialist Lung Cancer Nurse and Self‐Management for People Living with Lung Cancer: A Model of Engagement

Vanessa Brunelli Australia Nothing to disclose

MA17.07 Nursing and Allied Professionals Nurse‐Led Telehealth Clinic in Treatment Monitoring and Follow Up Sarah Cubbin UK Nothing to disclose

MA17.08 Nursing and Allied Professionals Discussant ‐ MA 17.05, MA 17.06, MA 17.07 Melissa Culligan USA Nothing to disclose

MA17.09 Nursing and Allied Professionals Remote Symptom Reporting for Tele‐Nursing Team in Thoracic Oncology Clinics: Environmental Scan and Stakeholder Engagement

Simranjit Kooner Canada Nothing to disclose

MA17.10 Nursing and Allied Professionals The Use of Technology in the Delivery of Supportive Care of Lung Cancer Patients After Treatment

Pamela Rose UK Nothing to disclose

MA17.11 Nursing and Allied Professionals Multi‐Centred, Prospective, Audit to Identify Readmission Causes and Complications Within 30 of Primary Lung Cancer Surgery

Amy Kerr UK Nothing to disclose

MA17.12 Nursing and Allied Professionals Discussant ‐ MA 17.09, MA 17.10, MA 17.11 Mary Duffy Australia Nothing to disclose

Session MA18: Modelling, Decision‐Making and Population‐Based Outcomes


Planner









Chairs

MA18 Fabio Moraes Brazil Nothing to disclose

MA18 Alexander Louie Canada Honoraria Varian Medical Systems, AstraZeneca

Faculty


Non‐Small Cell Lung Cancer Risk Assessment with Artificial Neural Networks

Tafadzwa Chaunzwa USA Nothing to disclose


How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience



How in the Real World Are Lung Cancer Patients Treated? The Ontario, Canada Experience



Discussant ‐ MA 18.01, MA 18.03 Shalini Vinod Australia Nothing to disclose


Characteristics and Long‐Term OS of Non‐Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment

Michael Bergqvist Sweden Nothing to disclose


Patterns of Lung Cancer Care in the United States: Developments and Disparities

Erik Blom Netherlands Nothing to disclose


Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors

Lawson Eng Canada Nothing to disclose


Discussant ‐ MA 18.05, MA 18.06, MA 18.07 Vera Hirsh Canada Nothing to disclose


Predictors of Health Utility Scores (HUS) in Advanced EGFR‐Mutated NSCLC.

Shirley Jiang Canada Nothing to disclose


Evolving Immunotherapy Practice Patterns in Advanced NSCLC: Analysis of an Online Treatment Decision Tool

David Gandara USA Honoraria AstraZeneca, Celgene, Genentech, Guardant Health, Eli Lilly, Liquid Genomics, Nant Health



David Gandara USA Consultant Genentech, AstraZeneca, Celgene, Guardant Health, Eli Lilly, Liquid Genomics



David Gandara USA Supported/Contracted Research/Grant AstraZeneca, Genentech



David Gandara USA Speakers or Advisory Board AstraZeneca, Celgene, Genentech, Gaurdant Health, Eli Lilly, Liquid Genomics, Nant Health


Implementing a Comprehensive National Audit of Lung Cancer Surgery: The English Lung Cancer Clinical Outcomes Publication (LCCOP) Project

Doug West UK Nothing to disclose


Discussant ‐ MA 18.09, MA 18.10, MA 18.11 Martin Stockler Australia Supported/Contracted Research/Grant AbbVie, Amgen, AstraZeneca, Bayer, Bristol‐Meyers Squibb, Celgene, Merck, Pfizer, Roche

MA18.12a Treatment in the Real World ‐ Support, Survivorship, Systems Research

Q&A

Session MS16: Implementation of Lung Cancer Screening


Planner

MS16 Screening and Early Detection Christine Berg USA Honoraria Medial Early Sign LLC, GRAIL

MS16 Screening and Early Detection Stephen Lam Canada Nothing to disclose

MS16 Screening and Early Detection Denise Aberle USA Nothing to disclose

MS16 Screening and Early Detection John Field UK Speakers Bureau Roche

MS16 Screening and Early Detection John Field UK Speakers or Advisory Board Epigenomics, VisonGate

MS16 Screening and Early Detection John Goffin Canada Nothing to disclose

MS16 Screening and Early Detection Harry Groen Netherlands Consultant Roche‐Genentech, Merck, Novartis, Bristol‐Meyers Squibb

MS16 Screening and Early Detection Norihiko Ikeda Japan Honoraria AstraZeneca, Chugai, Merck, Ono Pharma, Taiho, Eli Lilly, Pfizer, Johnson & Johnson

MS16 Screening and Early Detection Garth Nicholas Canada Nothing to disclose

MS16 Screening and Early Detection Nir Peled Israel Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

MS16 Screening and Early Detection Nir Peled Israel Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

MS16 Screening and Early Detection Heidi Schmidt Canada Nothing to disclose

MS16 Screening and Early Detection Betty Tong Speakers or Advisory Board Medtronic

Chairs

MS16 Harry Groen Netherlands Consultant Roche‐Genentech, Merck, Novartis, Bristol‐Meyers Squibb

MS16 Garth Nicholas Canada Nothing to disclose

Faculty

MS16.01 Screening and Early Detection CMS Approved ACR Lung Cancer Screening Registry in the United States Ella Kazerooni USA Nothing to disclose

MS16.02 Screening and Early Detection NELCIN B3 Screening Program in China Qinghua Zhou China Nothing to disclose



MS16.03 Screening and Early Detection Recruitment Strategies for the Lung Cancer Screening

MS16.04 Screening and Early Detection National Lung Screening Program in Taiwan Pan‐Chyr Yang Taiwan Nothing to disclose

MS16.05 Screening and Early Detection Optimal Approach to Integrate Smoking Cessation into Screening Program Matthew Callister UK Nothing to disclose

MS16.06 Q&A

Session MS17: Life After Lung Cancer: Survivorship


Planner



















Gilead

































Chairs

MS17 David Dawe Canada Nothing to disclose

MS17 Jhanelle Gray USA Supported/Contracted Research/Grant AstraZeneca, Celgene, Eli Lilly, Janssen, Merck, Genentech, Boehringer Ingelheim, Bristol‐Meyers Squibb, Array

MS17 Jhanelle Gray USA Speakers or Advisory Board AstraZeneca

MS17 Jhanelle Gray USA Honoraria Celgene, Eli Lilly, Janssen, AstraZeneca

Faculty


Unmet needs and QOL of Lung Cancer Survivors Meredith Giuliani Canada Nothing to disclose


Financial Toxicity and Out of Pocket Costs Bishal Gyawali USA Nothing to disclose


Surveillance & Second Primary Malignancies in Lung Cancer Survivors Virginie Westeel France Speakers Bureau BMS, Roche, AZ


Surveillance & Second Primary Malignancies in Lung Cancer Survivors Virginie Westeel France Advisory Board BMS, Roche, AZ


Surveillance & Second Primary Malignancies in Lung Cancer Survivors Virginie Westeel France Other(please specify) BMS, Roche, AZ, Boehringer Ingelheim (support for meeting attendance)


How Important Is Tobacco Cessation as Part of Lung Cancer Treatment? Clarissa Baldotto Brazil Nothing to disclose

MS17.05 Discussion



Session MS18: Management of SCLC Patients Not Represented in Clinical Trials


Planner

MS18 Small Cell Lung Cancer/NET Fiona Blackhall UK Nothing to disclose

MS18 Small Cell Lung Cancer/NET Peter Ellis Canada Honoraria AbbVie, AstraZeneca

MS18 Small Cell Lung Cancer/NET Peter Ellis Canada Consultant Celegene, Mylan

MS18 Small Cell Lung Cancer/NET Jeffrey Bogart USA Nothing to disclose

MS18 Small Cell Lung Cancer/NET Lauren Byers USA Nothing to disclose

MS18 Small Cell Lung Cancer/NET Quincy Chu Canada Nothing to disclose

MS18 Small Cell Lung Cancer/NET Eric Lim UK Speakers Bureau Abbott Molecular, Pfizer, Roche, Eli Lily, Boehringer Ingelheim, Ethicon

MS18 Small Cell Lung Cancer/NET Eric Lim UK Supported/Contracted Research/Grant Medela, ScreenCell, Clearbridge Biomedics, Illumina, Guardant Health

MS18 Small Cell Lung Cancer/NET Francoise Mornex France Nothing to disclose

MS18 Small Cell Lung Cancer/NET Charles Rudin USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Genentech, Harpoon, Genetics

MS18 Small Cell Lung Cancer/NET Charles Rudin USA Consultant Bristol‐Meyers Squibb, AbbVie, Seattle Genetics, Harpoon Therapeutics, Genentech Roche, AstraZeneca

MS18 Small Cell Lung Cancer/NET Ben Slotman Netherlands Nothing to disclose

MS18 Small Cell Lung Cancer/NET Sumitra Thongprasert Thailand Nothing to disclose

MS18 Small Cell Lung Cancer/NET Jie Wang China Nothing to disclose

MS18 Small Cell Lung Cancer/NET Mauro Zukin Brazil Nothing to disclose

Chairs

MS18 Everett Vokes USA Consultant Genentech

MS18 Jie Wang China Nothing to disclose

Faculty

MS18.01 Small Cell Lung Cancer/NET Treatment of Patients with Poor Performance Status (ECOG 3‐4) Luiz H. Araujo Brazil Nothing to disclose

MS18.02 Small Cell Lung Cancer/NET Treatment of Elderly Patients with SCLC Karen Kelly USA Speakers or Advisory Board AbbVie, AstraZeneca, Genentech, Janssen, Eli Lilly, Merck

MS18.02 Small Cell Lung Cancer/NET Treatment of Elderly Patients with SCLC Karen Kelly USA Supported/Contracted Research/Grant AbbVie, Celgene, Merck, Five Prime, Genentech, Eli Lilly, Lycera, Novartis, Regeneron, Transgene

MS18.02 Small Cell Lung Cancer/NET Treatment of Elderly Patients with SCLC Karen Kelly USA Royalty, Intellectual Property/Patent Holder UpToDate

MS18.02 Small Cell Lung Cancer/NET Treatment of Elderly Patients with SCLC Karen Kelly USA Honoraria Merck

MS18.02 Small Cell Lung Cancer/NET Treatment of Elderly Patients with SCLC Karen Kelly USA Consultant AbbVie, Genentech, Eli Lilly, Merck, UpToDate

MS18.03 Small Cell Lung Cancer/NET Treatment of SCLC transformed from EGFR Mutant Adenocarcinoma Nicolas Marcoux Canada Nothing to disclose

MS18.04 Small Cell Lung Cancer/NET Retreatment with Platinum and Etoposide and Treatment Beyond Second Line

Charles Butts Canada Honoraria Pfizer, Boehringer Ingelheim, AstaZeneca, Bristol‐Meyers Squibb, Merck, Takeda

MS18.04 Small Cell Lung Cancer/NET Retreatment with Platinum and Etoposide and Treatment Beyond Second Line

Charles Butts Canada Speakers or Advisory Board Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Merck, Takeda

MS18.05 Q&A

Session MS19: Pulmonary Dilemmas with Immunotherapy


Planner

MS19 Interventional Diagnostics/Pulmonology Kazuhiro Yasufuku Canada Speakers or Advisory Board Concordia, Olympus America

MS19 Interventional Diagnostics/Pulmonology Kazuhiro Yasufuku Canada Supported/Contracted Research/Grant Olympus Corporation, Siemens, Veran Medical Technologies, Novadaq

MS19 Interventional Diagnostics/Pulmonology Kazuhiro Yasufuku Canada Consultant Intuitive Surgical, Medtronic, Johnson & Johnson, Auris Surgical Robotics

MS19 Interventional Diagnostics/Pulmonology Kwun Fong Australia Nothing to disclose

MS19 Interventional Diagnostics/Pulmonology Jason Agulnik Canada Honoraria Merck, Pfizer, Bristol‐Meyers Squibb, AstraZeneca

MS19 Interventional Diagnostics/Pulmonology Nicole Bouchard Canada Supported/Contracted Research/Grant Pfizer, Bristol‐Meyers Squibb, Merck

MS19 Interventional Diagnostics/Pulmonology Nicole Bouchard Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche

MS19 Interventional Diagnostics/Pulmonology Eric Edell Canada Nothing to disclose

MS19 Interventional Diagnostics/Pulmonology Wael Hannah Canada Nothing to disclose



MS19 Interventional Diagnostics/Pulmonology Felix Herth Germany Nothing to disclose

MS19 Interventional Diagnostics/Pulmonology Hojoong Kim Korea Nothing to disclose

MS19 Interventional Diagnostics/Pulmonology Moishe Liberman Canada Nothing to disclose

MS19 Interventional Diagnostics/Pulmonology Navneet Singh India Nothing to disclose

MS19 Interventional Diagnostics/Pulmonology Egbert Smit Netherlands Nothing to disclose

Chairs

MS19 Benjamin Shieh Canada Nothing to disclose

MS19 Luis Raez USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Roche, Genentech, Syndax, Novartis

Faculty

MS19.01 Interventional Diagnostics/Pulmonology Drug‐Induced Pneumonitis with IO: How worried should we be for our Lung Cancer Patients

Desiree Hao Canada Nothing to disclose

MS19.02 Interventional Diagnostics/Pulmonology What Are the Clinical Features of IO Progression/Pseudoprogression and Radiation Fibrosis vs Recurrence

Chong‐Kin Liam Malaysia Nothing to disclose

MS19.03 Interventional Diagnostics/Pulmonology Diagnostic Approaches Suspected IO Progression/Pseudoprogression and What/When to Rebiospy for TT Progression

Kasia Czarnecka‐Kujawa Canada Nothing to disclose

MS19.04 Q&A

Session OA11: Thymic and Other Thoracic Tumours: Targeted Therapies, Biomarkers and Neo/Adjuvant Radiotherapy


Planner







Chairs

OA11 Mojgan Taremi Canada Nothing to disclose

OA11 Yaron Shargall Canada Nothing to disclose

Faculty

OA11.01 Thymoma/Other Thoracic Malignancies Role of Post‐Operative Radiation in Different Histologic Subgroups of Thymoma: Result Based on National Cancer Data Base (NCDB)

Tithi Biswas USA Nothing to disclose

OA11.02 Thymoma/Other Thoracic Malignancies A Population‐Based Study of Incidence and Survival Trends of 1,588 Thymic Malignancies: Results from the California Cancer Registry

David Benjamin USA Nothing to disclose

OA11.03 Thymoma/Other Thoracic Malignancies Discussant ‐ OA 11.01, OA 11.02 Andrew Hope Canada Nothing to disclose

OA11.04 Thymoma/Other Thoracic Malignancies A Comparative Study of PD‐L1 Immunohistochemical Assays with Four Reliable Antibodies in Thymic Carcinoma

Tadashi Sakane Japan Nothing to disclose

OA11.05 Thymoma/Other Thoracic Malignancies Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum‐Based Chemotherapy (KOSMIC Trial)

Se Hyun Kim Korea Nothing to disclose

OA11.06 Thymoma/Other Thoracic Malignancies Two BRM Promoter Polymorphisms Do Not Predict Susceptibility or Prognosis of Thymoma

Nathan Kuehne Canada Nothing to disclose

OA11.07 Thymoma/Other Thoracic Malignancies Discussant ‐ OA 11.04, OA 11.05, OA 11.06 Giuseppe Giaccone USA Nothing to disclose

OA11.08 Thymoma/Other Thoracic Malignancies Q&A

Session PC06: Controversies in Immunobiomarker Testing


Planner

PC06 Pathology Ming Tsao Canada Honoraria Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Roche, Ventana

PC06 Pathology Ming Tsao Canada Supported/Contracted Research/Grant Merck, Pfizer, Roche, Ventana, AstraZeneca

PC06 Pathology Ming Tsao Canada Speakers or Advisory Board AstraZeneca, Pfizer, Merck, Roche, Ventana, Bristol Myers Squibb, AbbVie, Celgene

PC06 Pathology Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune

PC06 Pathology Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche

PC06 Pathology Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen



PC06 Pathology Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

PC06 Pathology Alan Borczuk USA Nothing to disclose

PC06 Pathology Lukas Bubendorf Switzerland Nothing to disclose

PC06 Pathology Sanja Dacic USA Speakers or Advisory Board Bristol‐Meyers Squibb, Astra‐Zeneca

PC06 Pathology Sanja Dacic USA Honoraria Bristol‐Meyers Squibb, AstraZeneca

PC06 Pathology David Hwang Canada Honoraria Merck, Pfizer, Takeda

PC06 Pathology David Hwang Canada Speakers or Advisory Board Merck

PC06 Pathology Keith Kerr UK Consultant Bristol‐Meyers Squibb

PC06 Pathology Keith Kerr UK Speakers or Advisory Board AstraZeneca, Bristol Meyers Squibb, Merck, Roche, Pfizer

PC06 Pathology Sylvie Lantuejoul France Nothing to disclose

PC06 Pathology John Longshore USA Speakers Bureau Roche, AstraZeneca, Bristol‐Meyers Squibb, Merck, Genentech

PC06 Pathology John Longshore USA Speakers or Advisory Board Roche, AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer

PC06 Pathology John Longshore USA Supported/Contracted Research/Grant Roche, AstraZeneca

PC06 Pathology Mari Mino‐Kenudson USA Consultant Merrimack Pharmas, H3 Biomedicine

PC06 Pathology Mari Mino‐Kenudson USA Honoraria Merrimac Pharmas, H3 Biomedicine

PC06 Pathology Andre Moreira USA Nothing to disclose

PC06 Pathology Andrew Nicholson UK Consultant Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Bristol‐Meyers Squibb, Roche, AbbVie

PC06 Pathology Andrew Nicholson UK Supported/Contracted Research/Grant Pfizer, Roche

PC06 Pathology Andrew Nicholson UK Speakers or Advisory Board Pfizer, Abbvie

PC06 Pathology Andrew Nicholson UK Ownership Interest (stocks or stock options, or other ownership interest

Merck

PC06 Pathology Yasushi Yatabe Japan Consultant Merck, Chugai‐Pharma, AstraZeneca, Bristol‐Meyers Squibb, Pfizer, Roche, ThermoFisher, Dako

PC06 Pathology Yasushi Yatabe Japan Honoraria AstraZeneca, Merck, Bristol Myers, Chugai‐pharma, Pfizer, Roche

Chairs

PC06 Christian Couture Canada Advisory Board AstraZeneca, Merck, BMS, Pfizer

PC06 Christian Couture Canada Honoraria AstraZeneca, Merck, BMS, Pfizer

PC06 Christian Couture Canada Contracted/Support Research Grant Merck, BMS, Pfizer

PC06 Erik Thunnissen Netherlands Speakers or Advisory Board Pfizer, Bristol‐Meyers Squibb, Merck

PC06 Erik Thunnissen Netherlands Consultant Diaceutics

PC06 Erik Thunnissen Netherlands Supported/Contracted Research/Grant Pfizer

PC06 Erik Thunnissen Netherlands Honoraria Oncologia, Histogenix, AstraZeneca, Ventana

Faculty

PC06.01 Pathology Laboratory Developed Test ‐ PRO Dara Aisner USA Consultant AbbVie, Genentech, Bristol‐Meyers Squibb

PC06.01 Pathology Laboratory Developed Test ‐ PRO Dara Aisner USA Honoraria AbbVie, Bristol Meyers Squibb, Inivata

PC06.02 Pathology Laboratory Developed Test ‐ CON Mari Mino‐Kenudson USA Consultant Merrimack Pharmas, H3 Biomedicine

PC06.02 Pathology Laboratory Developed Test ‐ CON Mari Mino‐Kenudson USA Honoraria Merrimac Pharmas, H3 Biomedicine

PC06.03 Pathology Tumor Mutation Burden ‐ PRO Lynette Sholl USA Honoraria Foghorn Therapeutics

PC06.04 Pathology Tumor Mutation Burden ‐ CON Lukas Bubendorf Switzerland Speakers or Advisory Board Roche, Bristol‐Meyers Squibb, AbbVie, AstraZeneca, Novartis, Pfizer, Takeda, Merck

PC06.04 Pathology Tumor Mutation Burden ‐ CON Lukas Bubendorf Switzerland Honoraria Roche, Pfizer, Bristol‐Meyers Squibb, Merck

PC06.04 Pathology Tumor Mutation Burden ‐ CON Lukas Bubendorf Switzerland Supported/Contracted Research/Grant Roche, Merck

PC06.04 Pathology Tumor Mutation Burden ‐ CON Lukas Bubendorf Switzerland Consultant Roche, Roche, Pfizer, Bristol‐Meyers Squibb

PC06.04 Pathology Tumor Mutation Burden ‐ CON Lukas Bubendorf Switzerland Ownership Interest (stocks or stock options, or other ownership interest

Roche, Novartis

PC06.04 Pathology Tumor Mutation Burden ‐ CON Lukas Bubendorf Switzerland Employee Roche, Pfizer, Bristol‐Meyers Squibb, Merck

PC06.04 Pathology Tumor Mutation Burden ‐ CON Lukas Bubendorf Switzerland Financial Support from Tobacco Company(ies)

Merck, Roche, Novartis

PC06.05 Q&A

Session PC07: The Future of Cytotoxic Chemotherapy in Advanced NSCLC




Planner











Gatekeeper Pharmas












Chairs

PC07 Stephanie Brule Canada Nothing to disclose

PC07 Terufumi Kato Japan Advisory Board AstraZeneca, BI, Eli Lilly, MSD

PC07 Terufumi Kato Japan Contracted/Support Research Grant Abbvie, AstraZeneca, Astellas, Chigai, Eli Lilly, Kyowa‐Kirin, Merck Serono, MSD, Ono, Pfizer

PC07 Terufumi Kato Japan Honoraria Abbvie, AstraZeneca, BI, BMS, Chugai, Eli Lilly, MSD, Novartis, Ono, Pfizer, Taiho, Quintiles

Faculty

PC07.01 Advanced NSCLC Debate 2: Chemotherapy Will Become a Thing of the Past in the Management of Advanced NSCLC ‐ For

Suresh Ramalingam USA Consultant AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

PC07.01 Advanced NSCLC Debate 2: Chemotherapy Will Become a Thing of the Past in the Management of Advanced NSCLC ‐ For

Suresh Ramalingam USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Genentech, Roche, Nektar, Takeda, Loxo, Eli Lilly, Merck, Novartis

PC07.02 Advanced NSCLC Debate 2: Chemotherapy Will Become a Thing of the Past in the Management of Advanced NSCLC ‐ Against

Keunchil Park Korea Consultant Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Hanmi, Kyowa Kakko Kirin, Novartis, Ono Pharma, Roche, Bristol‐Meyers Squibb, GlaxoSmithKline, Merck, GlaxoSmithKline


Keunchil Park Korea Supported/Contracted Research/Grant AstraZeneca


Keunchil Park Korea Speakers or Advisory Board AstraZeneca, Astellas, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Hanmi, KHK, Merck, Novartis, Roche

PC07.03 Advanced NSCLC Debate 1: For Wild‐Type NSCLC, Which Will Be the Preferred Strategy: IO Alone versus Chemo + IO ‐ IO Alone

Leora Horn USA Consultant AbbVie, AstraZeneca, Genentech, Merck, Incyte, Xcovery, Roche

PC07.03 Advanced NSCLC Debate 1: For Wild‐Type NSCLC, Which Will Be the Preferred Strategy: IO Alone versus Chemo + IO ‐ IO Alone

Leora Horn USA Supported/Contracted Research/Grant Xcovery Holding Company, Bristol‐Meyers Squibb, Boehringer Ingelheim, AbbVie, Genentech, Merck

PC07.04 Advanced NSCLC Debate 1: For Wild‐Type NSCLC, Which Will Be the Preferred Strategy: IO Alone versus Chemo + IO ‐ Chemo + IO

Federico Cappuzzo Italy Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, AstraZeneca, Pfizer, Roche

PC07.05 Q&A

Session PC08: The Great Oligometastatic Debates


Planner

PC08 Oligometastatic NSCLC David Palma Canada Nothing to disclose

PC08 Oligometastatic NSCLC Joseph Salama USA Nothing to disclose

PC08 Oligometastatic NSCLC Hak Choy USA Speakers Bureau AstraZeneca

PC08 Oligometastatic NSCLC Hak Choy USA Honoraria AstraZeneca, Merck



PC08 Oligometastatic NSCLC Laurie Gaspar USA Nothing to disclose

PC08 Oligometastatic NSCLC Matthias Guckenberger Switzerland Nothing to disclose

PC08 Oligometastatic NSCLC David Jones USA Nothing to disclose

PC08 Oligometastatic NSCLC Mary Macneil Canada Nothing to disclose

PC08 Oligometastatic NSCLC Boris Sepesi USA Nothing to disclose

Chairs

PC08 Stephen Harrow UK Honoraria AstraZeneca

PC08 Stephen Harrow UK Speakers or Advisory Board AstraZeneca

PC08 Melissa Johnson USA Supported/Contracted Research/Grant BerGenBio, Eli Lilly, Merck Serono, Janssen, Mirati Therapeutics, Genmab, Pfizer, AstraZeneca, Genentech, Roche, Stemcentrix, Novartis, Checkpoint Therapeutics, Array BioPharma, Regeneron, Apexigen, AbbVie, Tarveda, Adaptimmune, Syndax, Neovia, Boehringer Ingelheim, Sanofi, Hengrui Therapeutics, Daiichi – Sankyo, Lycera, G1 Therapeutics, Dynavax, OncoMed,

PC08 Melissa Johnson USA Speakers or Advisory Board Astellas, Otsuka Pharmas, Genentech, Roche, Celgene, Boehringer Ingelheim, Sanofi, Mirati, Loxo, AstraZeneca, Mersana

PC08 Melissa Johnson USA Consultant Astellas, Otsuka Pharmas, Roche

Faculty

PC08.01 Oligometastatic NSCLC Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastese (PRO)

Howard West USA Consultant Ariad, Genentech, Roche, Takeda


Howard West USA Speakers Bureau Ariad, Bristol‐Myers Squibb, Eli Lilly


Howard West USA Speakers or Advisory Board AbbVie, Ariad, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Merck, Roche, Genentech, Takeda, Spectrum

PC08.02 Oligometastatic NSCLC Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastese (CON)

Puneeth Iyengar USA Nothing to disclose

PC08.03 Discussion

PC08.04 Oligometastatic NSCLC Debate #2: Optimal Therapy for OM Disease: Thoracic Surgery Should Be the Treatment of Choice Whenever Possible

David Jones USA Nothing to disclose

PC08.05 Oligometastatic NSCLC Debate #2: Keep Calm and Beam On: Thoracic Radiation Obviates the Need for Surgery

Matthias Guckenberger Switzerland Nothing to disclose

PC08.06 Discussion

PC08.07 Oligometastatic NSCLC Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (PRO)

Mark Doherty Canada Nothing to disclose

PC08.08 Oligometastatic NSCLC Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (CON)

Marta Scorsetti Italy Nothing to disclose

PC08.09 Discussion

Session ES03: How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy


Planner

ES03 Mesothelioma Anna Nowak Australia Speakers or Advisory Board Bayer, AstraZeneca, Sellas Life Sciences, Trizell, Boehringer Ingelheim, Epizyme, Roche, Merck

ES03 Mesothelioma Anna Nowak Australia Consultant AstraZeneca, Boehringer Ingelheim, Epizyme

ES03 Mesothelioma Anna Nowak Australia Supported/Contracted Research/Grant AstraZeneca, Douglas Pharma

ES03 Mesothelioma Marc DePerrot Canada Nothing to disclose

ES03 Mesothelioma Paul Baas Netherlands Nothing to disclose

ES03 Mesothelioma Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer

ES03 Mesothelioma Michele Carbone USA Nothing to disclose

ES03 Mesothelioma John Cho Canada Nothing to disclose

ES03 Mesothelioma Lauren Donohoe Canada Nothing to disclose

ES03 Mesothelioma Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche

ES03 Mesothelioma Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex

ES03 Mesothelioma Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca

ES03 Mesothelioma Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

ES03 Mesothelioma Seiki Hasegawa Japan Nothing to disclose

ES03 Mesothelioma Christopher Lee Canada Nothing to disclose

ES03 Mesothelioma Isabelle Opitz Switzerland Nothing to disclose

ES03 Mesothelioma Nick Pavlakis Australia Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Astra Zeneca, Roche, Novartis, Boehringer Ingelheim, Merck, Pfizer, Ipsen, Amgen

ES03 Mesothelioma Nick Pavlakis Australia Supported/Contracted Research/Grant Bayer

ES03 Mesothelioma Kenneth Rosenzweig USA Nothing to disclose



Chairs

ES03 Marc de Perrot Canada Nothing to disclose

ES03 Rolf Stahel Switzerland Speakers Bureau AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Roche

ES03 Rolf Stahel Switzerland Speakers or Advisory Board AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Pfizer, Roche

Faculty

ES03.01 Mesothelioma Diagnosis of Mesothelioma Based on Cytology Alone Jennifer Sauter USA Nothing to disclose

ES03.02 Mesothelioma Role of CT Scan to Follow Pleural Plaques Demetris Patsios Canada Nothing to disclose

ES03.03 Mesothelioma When to Repeat Pleural Biopsies Catherine Labbe Canada Honoraria Bristol‐Meyers Squibb, Merck

ES03.04 Mesothelioma Role of Chemotherapy in Mesothelioma with Minimal Bulk Disease Christopher Lee Canada Nothing to disclose

ES03.05 Mesothelioma Role of Surgery in T0 Mesothelioma Seiki Hasegawa Japan Nothing to disclose

ES03.06 Q&A

Session ES04: Liquid Biopsies in Lung Cancer


Planner

ES04 Targeted Therapy Janessa Laskin Canada Honoraria Roche, Boehringer Ingelheim, AstraZeneca

ES04 Targeted Therapy Janessa Laskin Canada Supported/Contracted Research/Grant AstraZeneca, Roche, Pfizer

ES04 Targeted Therapy Tony Mok China Speakers or Advisory Board AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Bristol‐Meyers Squibb, Taiho, Takeda Oncology Serono, SFJ Pharma, ACEA Biosciences, Vertex Pharma, geneDecode, OncoGenex Technologies, Celgene, Ignyta, Cirina, Fishawack Facilitate, Janssen, ChiMed

ES04 Targeted Therapy Tony Mok China Honoraria AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, SFJ Pharma, ACEA Biosciences, Vertex Pharma, Bristol‐Meyers Squibb, OncoGenex Pharma, Celgene, Ignyta, Fishawack Facilitate, Takeda Oncology, Janssen, Cirina, Chimed

ES04 Targeted Therapy Tony Mok China Ownership Interest (stocks or stock options, or other ownership interest

Sanomics, Cirina

ES04 Targeted Therapy Tony Mok China Consultant Roche., IASLC, ASCO, ChiMed, Chinese Lung Cancer Research Foundation, Chinese Society of Clinical Oncology, Hong Kong Cancer Therapy Society

ES04 Targeted Therapy Tony Mok China Supported/Contracted Research/Grant AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmas Group, Roche, Merck, Clovis Oncology, Bristol‐Meyers Squibb, Taiho Pharma, Eisai

ES04 Targeted Therapy Tony Mok China Employee (full time or part time) The Chinese University of Hong Kong

ES04 Targeted Therapy Ross Camidge USA Honoraria Takeda, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, AstraZeneca, Arrys/Kyn, Genoptix, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera, Lycera, Revolution Med, Orion, Clovis, Celegene, Novartis

ES04 Targeted Therapy Ross Camidge USA Supported/Contracted Research/Grant Ariad, Takeda, Pfizer

ES04 Targeted Therapy Ross Camidge USA Speakers or Advisory Board AstraZeneca, Takeda, Arrys/Kyn, Genoptix, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, Takeda, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera DSMB, Lycera, Revolution Med

ES04 Targeted Therapy Alexander Drilon USA Speakers or Advisory Board Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

ES04 Targeted Therapy Alexander Drilon USA Honoraria TP Therapeutics, Loxo, Ignyta, Roche, Genentech, Pfizer

ES04 Targeted Therapy Alexander Drilon USA Supported/Contracted Research/Grant Foundation Medicine

ES04 Targeted Therapy Alexander Drilon USA Consultant Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

ES04 Targeted Therapy Enriqueta Felip Spain Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb Celgene, Eli Lilly, Guardant Health, Novartis, Pfizer, Roche, Takeda, Merck

ES04 Targeted Therapy Enriqueta Felip Spain Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, AstraZeneca, Bristol‐Meyers Squibb, Novartis, AbbVie, Takeda, Celegene, Guardant Health, Merck

ES04 Targeted Therapy Enriqueta Felip Spain Speakers Bureau AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, MSD, Novartis, Pfizer, Roche, Takeda, AbbVie, Merck, Celegne, Eli Lilly, Guardant Health

ES04 Targeted Therapy Pilar Garrido Spain Consultant Roche, Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol‐Meyers Squibb, Eli Lilly and Company, AbbVie, Novartis

ES04 Targeted Therapy Pilar Garrido Spain Speakers Bureau Roche, Merck, Bristol‐Meyers Squibb, Pfizer

ES04 Targeted Therapy Pilar Garrido Spain Supported/Contracted Research/Grant Guardant

ES04 Targeted Therapy Shun Lu China Supported/Contracted Research/Grant AstraZeneca

ES04 Targeted Therapy Shun Lu China Speakers or Advisory Board Eli Lilly, Hutchison MediPharma, Simcere, Bristol‐Meyers Squibb, Roche, Pfizer, AstraZeneca

ES04 Targeted Therapy Zofia Piotrowska USA Consultant AstraZeneca, Boehringer Ingelheim, Ariad, Novartis, Guardant Health, Takeda, AbbVie

ES04 Targeted Therapy Zofia Piotrowska USA Speakers or Advisory Board AstraZeneca, Ariad, Takeda, Novartis, Boehringer Ingelheim, AbbVie

ES04 Targeted Therapy Zofia Piotrowska USA Supported/Contracted Research/Grant Novartis

ES04 Targeted Therapy Zofia Piotrowska USA Honoraria Guardant Health

ES04 Targeted Therapy Karen Reckamp USA Consultant Amgen, Ariad, Astellas Pharma, Euclises, Tesaro, Boehringer Ingelheim, Takeda

ES04 Targeted Therapy Karen Reckamp USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Novartis, Ariad, Clovis Oncology, Xcovery, Gilead Sciences, Pfizer, Adaptimmune, Genentech, Roche, Boehringer Ingelheim, AbbVie

ES04 Targeted Therapy Lecia Sequist USA Speakers or Advisory Board AstraZeneca, Genentech, Pfizer, Bristol‐Meyers Squibb, Merrimack Pharma, Blueprint Medicines

ES04 Targeted Therapy Lecia Sequist USA Consultant Merrimack, Novartis, Boehringer Ingelheim



ES04 Targeted Therapy Lecia Sequist USA Supported/Contracted Research/Grant AstraZeneca, Novartis, Genentech, Boehringer Ingelheim, Merck, Merrimack, Guardant Health

ES04 Targeted Therapy Benjamin Solomon Australia Speakers or Advisory Board AstraZeneca, Bristol‐Myers Squibb, Merck, Pfizer, Roche, Genentech, Novartis

ES04 Targeted Therapy Benjamin Solomon Australia Honoraria Bristol‐Myers Squibb, AstraZeneca

ES04 Targeted Therapy Benjamin Solomon Australia Supported/Contracted Research/Grant Pfizer

ES04 Targeted Therapy Benjamin Solomon Australia Royalty, Intellectual Property/Patent Holder Veristrat

ES04 Targeted Therapy Benjamin Solomon Australia Consultant AstraZeneca, Roche, Merck, Bristol‐Myers Squibb, Novartis

ES04 Targeted Therapy James Chih‐Hsin Yang Taiwan Consultant Boehringer Ingelheim, Eli Lilly, Bayer, Roche, Genentech, Chugai, Astellas, Merck, Novartis, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, Takeda, AstraZeneca, Hansoh Pharma

ES04 Targeted Therapy James Chih‐Hsin Yang Taiwan Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Roche, Genentech, Chugai, Astellas, Merck, Pfizer, Novartis, Takeda, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, AstraZeneca, Hansoh Pharma

ES04 Targeted Therapy James Chih‐Hsin Yang Taiwan Honoraria Novartis, Roche, Genentech, Eli Lilly and Company, Merck, Celgene, Pfizer, Ono Pharma, Bristol‐Myers Squibb, Hansoh, Takeda, Boehringer Ingelheim, Astellas, Merimack, Yuhan Pharma

Chairs

ES04 Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune

ES04 Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche

ES04 Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen

ES04 Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

ES04 Sai‐Hong Ou USA Speakers Bureau Roche, Genentech, AstraZeneca, Takeda

ES04 Sai‐Hong Ou USA Speakers or Advisory Board Pfizer, Roche, Genentech, Novartis, AstraZeneca, Takeda, Foundation Medicine

ES04 Sai‐Hong Ou USA Honoraria Pfizer, Genentech, Roche, Ariad, Takeda, Novartis, AstraZeneca, Foundation Medicine

ES04 Sai‐Hong Ou USA Ownership Interest (stocks or stock options, or other ownership interest

TP Therapeutics

ES04 Sai‐Hong Ou USA Supported/Contracted Research/Grant Pfizer, Roche, MedImmune, AstraZeneca, Clovis Oncology, Ariad, Ignyta, Peregrine Pharma, GlaxoSmithKline, Astellas Pharma, Chugai Pharma

Faculty

ES04.00 Targeted Therapy Introduction with Poll Questions Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune

ES04.00 Targeted Therapy Introduction with Poll Questions Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche

ES04.00 Targeted Therapy Introduction with Poll Questions Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen

ES04.00 Targeted Therapy Introduction with Poll Questions Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

ES04.01 Targeted Therapy Liquid Biopsies in Lung Cancer Ming Tsao Canada Honoraria Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Roche, Ventana

ES04.01 Targeted Therapy Liquid Biopsies in Lung Cancer Ming Tsao Canada Supported/Contracted Research/Grant Merck, Pfizer, Roche, Ventana, AstraZeneca

ES04.01 Targeted Therapy Liquid Biopsies in Lung Cancer Ming Tsao Canada Speakers or Advisory Board AstraZeneca, Pfizer, Merck, Roche, Ventana, Bristol Myers Squibb, AbbVie, Celgene

ES04.02 Targeted Therapy Mechanisms of Resistance to Targeted Therapy Sai‐Hong Ou USA Speakers Bureau Roche, Genentech, AstraZeneca, Takeda

ES04.02 Targeted Therapy Mechanisms of Resistance to Targeted Therapy Sai‐Hong Ou USA Speakers or Advisory Board Pfizer, Roche, Genentech, Novartis, AstraZeneca, Takeda, Foundation Medicine

ES04.02 Targeted Therapy Mechanisms of Resistance to Targeted Therapy Sai‐Hong Ou USA Honoraria Pfizer, Genentech, Roche, Ariad, Takeda, Novartis, AstraZeneca, Foundation Medicine

ES04.02 Targeted Therapy Mechanisms of Resistance to Targeted Therapy Sai‐Hong Ou USA Ownership Interest (stocks or stock options, or other ownership interest

TP Therapeutics

ES04.02 Targeted Therapy Mechanisms of Resistance to Targeted Therapy Sai‐Hong Ou USA Supported/Contracted Research/Grant Pfizer, Roche, MedImmune, AstraZeneca, Clovis Oncology, Ariad, Ignyta, Peregrine Pharma, GlaxoSmithKline, Astellas Pharma, Chugai Pharma

ES04.03 Targeted Therapy Overcoming Resistance by Improving Treatment Compliance Felipe Gomes Brazil Nothing to disclose

ES04.04 Targeted Therapy Guiding Second Line Treatment in ALK + Patients (Sequence of Drugs, Rebiopsy?)

Enriqueta Felip Spain Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb Celgene, Eli Lilly, Guardant Health, Novartis, Pfizer, Roche, Takeda, Merck


Enriqueta Felip Spain Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, AstraZeneca, Bristol‐Meyers Squibb, Novartis, AbbVie, Takeda, Celegene, Guardant Health, Merck


Enriqueta Felip Spain Speakers Bureau AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, MSD, Novartis, Pfizer, Roche, Takeda, AbbVie, Merck, Celegne, Eli Lilly, Guardant Health

ES04.05 Q&A

Session ES05: Collaboration Between Stakeholders to Improve Lung Cancer Research


Planner

ES05 Advocacy Paul Wheatley‐Price Canada Speakers or Advisory Board AstraZeneca, Novartis, Eli Lilly Oncology, Bristol‐Meyers Squibb, Merck, Takeda

ES05 Advocacy Jesme Fox UK Nothing to disclose

ES05 Advocacy Bonnie Addario USA Nothing to disclose

ES05 Advocacy Andrea Ferris USA Nothing to disclose

ES05 Advocacy Kazuo Hasegawa Japan Nothing to disclose



ES05 Advocacy Kim Norris USA Speakers or Advisory Board Takeda

ES05 Advocacy Kim Norris USA Consultant Takeda

ES05 Advocacy Silvia Novello Italy Speakers or Advisory Board Takeda

ES05 Advocacy Silvia Novello Italy Speakers Bureau Boehringer Ingelheim, AstraZeneca, Roche, Merck, Bristol‐Meyers Squibb, Eli Lilly, Takeda, Pfizer

ES05 Advocacy Christina Sit Canada Nothing to disclose

ES05 Advocacy Howard (Jack) West USA Consultant Ariad, Genentech, Roche, Takeda

ES05 Advocacy Howard (Jack) West USA Speakers Bureau Ariad, Bristol‐Myers Squibb, Eli Lilly

ES05 Advocacy Howard (Jack) West USA Speakers or Advisory Board AbbVie, Ariad, AstraZeneca, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Merck, Roche, Genentech, Takeda, Spectrum

Chairs

ES05 Bonnie Addario USA Nothing to disclose

ES05 Toshiyujki Sawa Japan Nothing to disclose

Faculty

ES05.01 Advocacy Linking the Stakeholders: Can Patient Groups, Clinical Researchers and the Pharmaceutical Industry Collaborate to Accelerate Research?

Janet Freeman‐Daily USA Nothing to disclose

ES05.02 Advocacy Can Patient Groups and Regulatory Bodies Work Together to Make Clinical Research Easier?

Andrea Ferris USA Nothing to disclose

ES05.03 Advocacy Discrepancies and Sustainable Access to Innovative Therapies: Transforming Patient Experience in to Patient Voice

Jesme Fox UK Nothing to disclose

ES05.04 Advocacy Challenges and Solutions in Engaging with the Health Technology Assessment Process in Canada

Christina Sit Canada Nothing to disclose

ES05.05 Q&A

Session GR02: Management of N2 NSCLC ‐ A Case Based Discussion


Planner

GR02 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Supported/Contracted Research/Grant Merck, AstraZeneca, Elekta

GR02 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Consultant Merck, AstraZeneca, Elekta, Pfizer, Respective Meeting‐Related Travel Support

GR02 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers or Advisory Board Pfizer, Merck

GR02 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Honoraria AstraZeneca, Merck

GR02 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers Bureau AstraZeneca, Merck

GR02 Treatment of Locoregional Disease ‐ NSCLC Paula Ugalde Canada Nothing to disclose

GR02 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Honoraria Pfizer, Boehringer Ingelheim, AstaZeneca, Bristol‐Meyers Squibb, Merck, Takeda

GR02 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Speakers or Advisory Board Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Merck, Takeda

GR02 Treatment of Locoregional Disease ‐ NSCLC Hiroshi Date Japan Nothing to disclose

GR02 Treatment of Locoregional Disease ‐ NSCLC Dirk De Ruysscher Netherlands Nothing to disclose

GR02 Treatment of Locoregional Disease ‐ NSCLC Rui Haddad Brazil Nothing to disclose

GR02 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Speakers Bureau Varian Medical

GR02 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Honoraria Varian Medical

GR02 Treatment of Locoregional Disease ‐ NSCLC Jocelyne Martin Canada Nothing to disclose

GR02 Treatment of Locoregional Disease ‐ NSCLC Gaetano Rocco Italy Speakers Bureau Baxter, Medtronic

GR02 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers or Advisory Board AbbVie, AstraZeneca, Spiration

GR02 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers Bureau Synthes

GR02 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Consultant Spiration, Olympus

Chairs

GR02 Linda Coate Ireland Nothing to disclose

GR02 Tomasz Grodzki Poland Nothing to disclose

Faculty

GR02.01 Treatment of Locoregional Disease ‐ NSCLC Case 1: Single Zone N2 (No Pneumonectomy Necessary) Anna Wrona Poland Nothing to disclose

GR02.02 Treatment of Locoregional Disease ‐ NSCLC Panel Discussion Kathy Albain USA Advisory Board Geneutech/Roche, Genomic Health



GR02.03 Treatment of Locoregional Disease ‐ NSCLC Case 2: Multiple N2 Bulky Primary Megan Daly USA Nothing to disclose

GR02.04 Panel Discussion Kathy Albain USA Advisory Board Geneutech/Roche, Genomic Health

GR02.05 Treatment of Locoregional Disease ‐ NSCLC Case 3: Post Operative Management of Incidentally Found N2 Disease Masaya Yotsukura Japan Nothing to disclose

GR02.06 Panel Discussion Kathy Albain USA Advisory Board Geneutech/Roche, Genomic Health

Session MA19: Genomic Markers of IO Response


Planner










Chairs

MA19 Parneet Cheema Canada Speakers or Advisory Board Pfizer, AstraZeneca, Roche, Merck, Novartis, Takeda, Boehringer Ingelheim, Bristol‐Meyers Squibb

MA19 Rafael Rosell Spain Nothing to disclose

Faculty

MA19.01 Immunooncology Efficacy and Genomic Correlates of Response to Anti‐PD1/PD‐L1 Blockade in Non‐Small Cell Lung Cancers Harboring Targetable Oncogenes

Natalie Vokes USA Consultant Genentech

MA19.03 Immunooncology Discussant ‐ MA 19.01 Jonathan W. Goldman USA Speakers or Advisory Board Genentech, Roche, Bristol‐Meyers Squibb, Eli Lilly, Pfizer

MA19.03 Immunooncology Discussant ‐ MA 19.01 Jonathan W. Goldman USA Consultant Genentech, Roche, Bristol‐Meyers Squibb

MA19.03 Immunooncology Discussant ‐ MA 19.01 Jonathan W. Goldman USA Speakers Bureau Merck

MA19.03 Immunooncology Discussant ‐ MA 19.01 Jonathan W. Goldman USA Honoraria AstraZeneca

MA19.03 Immunooncology Discussant ‐ MA 19.01 Jonathan W. Goldman USA Supported/Contracted Research/Grant AstraZeneca, MedImmune, Bristol‐Meyers Squibb, Genentech, Roche, Eli Lilly, Merck

MA19.04 Immunooncology The Clinical Implication of Frameshift Indel Mutation Burden in Non‐Small Cell Lung Cancer (NSCLC)

Young Kwang Chae USA Nothing to disclose

MA19.05 Immunooncology Difference of Tumor Mutational Burden Is Associated with Distinct Immune Microenviroment in the T Cell‐Inflamed Lung Adenocarcinoma

Takahiro Karasaki Japan Nothing to disclose

MA19.06 Immunooncology Blood Based Biomarkers: RNA, KRAS and PD‐L1 Strongly Matching with Tissue and Showing Correlation with Clinical Responses In NSCLC Patient’s

Luis Raez USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Roche, Genentech, Syndax, Novartis

MA19.07 Immunooncology Discussant ‐ MA 19.04, MA 19.05, MA 19.06 Claudia Poleri Argentina Nothing to disclose

MA19.08 Immunooncology Detection of Primary Immunotherapy Resistance to PD‐1 Checkpoint Inhibitors (PD1CI) in 2nd Line NSCLC

Joachim Aerts Netherlands Ownership Interest (stocks or stock options, or other ownership interest

Amphera


Joachim Aerts Netherlands Speakers or Advisory Board Bristol‐Meyers Squibb, Merck Oncology, Boehringer Ingelheim, Eli‐Lilly, Roche, Ampera


Joachim Aerts Netherlands Speakers Bureau AstraZeneca, Verastem


Joachim Aerts Netherlands Supported/Contracted Research/Grant Genentech, AstraZeneca


Joachim Aerts Netherlands Royalty, Intellectual Property/Patent Holder Tumor cell lysate for dendritic cell loading

MA19.09 Immunooncology Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD‐(L)1 Blockade in Patients with NSCLC Despite High TMB

Kathryn Arbour USA Nothing to disclose

MA19.10 Immunooncology Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes with Chemo‐Immunotherapy in Non‐Squamous NSCLC

Ferdinandos Skoulidis USA Nothing to disclose

MA19.11 Immunooncology Discussant ‐ MA 19.08, MA 19.09, MA 19.10 Lynette Sholl USA Honoraria Foghorn Therapeutics

MA19.12 Immunooncology Q&A

Session MA20: Implementation of Lung Cancer Screening


Planner

















Chairs

MA20 Stephen Lam Canada Nothing to disclose

MA20 Christine Berg USA Honoraria Medial Early Sign LLC, GRAIL

Faculty

MA20.01 Screening and Early Detection Lung Cancer Screenee Selection by USPSTF versus PLCOm2012 Criteria – Preliminary ILST Findings

Martin Tammemägi Canada Nothing to disclose

MA20.02 Screening and Early Detection “Reduced” HUNT Lung Cancer Model for Predicting Lung Cancer in the Prospective Danish Lung Cancer Screening Study ‐ Comparison with the

Oluf Røe Norway Nothing to disclose

MA20.03 Screening and Early Detection Surprising Implications of Proposed Risk‐Thresholds for Selecting US Ever‐Smokers into CT Lung‐Cancer Screening

Hormuzd Katki USA Nothing to disclose

MA20.04 Screening and Early Detection Discussant ‐ MA 20.01, MA 20.02, MA 20.03 Amanda Tufman Germany Nothing to disclose

MA20.05 Screening and Early Detection Who Gets Screened for Lung Cancer? A Simple Adjustment to Current Guidelines to Reduce Racial Disparities

Melinda Aldrich USA Nothing to disclose

MA20.06 Screening and Early Detection Lung Cancer Screening Pilot for People at High Risk: Early Results on Cancer Detection and Staging


MA20.07 Screening and Early Detection Lung Cancer Screening for Limited‐Resource Patients: Preliminary Findings from a Low‐dose CT Pilot Program

Lesley Watson USA Nothing to disclose

MA20.08 Screening and Early Detection Discussant ‐ MA 20.05, MA 20.06, MA 20.07 Annette McWilliams Australia Nothing to disclose

MA20.09 Screening and Early Detection Improved Lung Cancer and Mortality Prediction Accuracy Using Survival Models Based on Semi‐Automatic CT Image Measurements

Anton Schreuder Netherlands Nothing to disclose

MA20.10 Screening and Early Detection Lung Cancer Prediction Using Deep Learning Software: Validation on Independent Multi‐Centre Data

Peter Van Ooijen Netherlands Nothing to disclose

MA20.12 Screening and Early Detection Discussant ‐ MA 20.09, MA 20.10 Heidi Schmidt Canada Nothing to disclose

MA20.12a Screening and Early Detection Q&A

Session MA21: Molecular Subtyping, CBL3, and Non Coding RNA


Planner





Rain Therapeutics















Chairs

MA21 Luis Montuenga Spain Nothing to disclose



MA21 Yuko Minami Japan Nothing to disclose

Faculty

MA21.01 Biology Cbl Mutations (mt) as Important Mediators of Oncogenic RTK Signaling in NSCLC

Rebecca Feldman USA Nothing to disclose

MA21.02 Biology Identification of an E2 Ubiquitin Conjugase CDC34 That Competes With E3 Ligase c‐Cbl to Stabilize EGFR and Promotes Lung Carcinogenesis

Guangbiao Zhou China Nothing to disclose

MA21.03 Biology Heterogeneity in MET Copy Number and Intratumoural Subsets in Pleomorphic Lung Carcinoma: Implications for MET Directed Therapy in

Adam Januszewski UK Nothing to disclose

MA21.04 Biology Discussant ‐ MA 21.01, MA 21.02, MA 21.03 Ravi Salgia USA Nothing to disclose

MA21.05 Biology Comprehensive Genomic Characterization and Prognostic Nomogram Developed by 295‐Gene Panel Targeted Sequencing

Bin Zhang China Nothing to disclose

MA21.06 Biology Proteins Associated with Survival Differ Depending on Molecular Subtypes, and Mutational‐ and Smoking‐Status In NSCLC Biopsies

Ann Halvorsen Norway Nothing to disclose

MA21.07 Biology A Nation‐Wide Population‐Based Mapping of Targetable Alterations in Smoking‐Independent Lung Cancer

Maria Planck Sweden Nothing to disclose

MA21.08 Biology Discussant ‐ MA 21.05, MA 21.06, MA 21.07 Siddhartha Devarakonda USA Nothing to disclose

MA21.09 Biology Differential Gene Expression in Tumor and Normal Tissue Reveals New Insights in the Biology of Non‐Small Cell Lung Carcinoma.

Alan Spatz Canada Nothing to disclose

MA21.10 Biology Large‐Scale Discovery of Novel Human Oncofetal Transcripts in Lung Brenda Minatel Canada Nothing to disclose

MA21.11 Biology Epigenomic Mapping of Cell‐Free DNA in Patients with Non‐Small Cell Lung Cancer

Christine Bestvina USA Nothing to disclose

MA21.12 Biology Discussant ‐ MA 21.09, MA 21.10, MA 21.11 Geoffrey Liu Canada Honoraria AstraZeneca, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie, Pfizer, Merck

MA21.12 Biology Discussant ‐ MA 21.09, MA 21.10, MA 21.11 Geoffrey Liu Canada Speakers Bureau AstraZeneca

MA21.12 Biology Discussant ‐ MA 21.09, MA 21.10, MA 21.11 Geoffrey Liu Canada Speakers or Advisory Board AstraZeneca, Roche, Merck, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie

Session MA22: New Therapeutics, Pathology, and Brain Metastases for Small Cell and Neuroendocrine Tumour


Planner

MA22 SCLC/Thymoma/Mesothelioma Marc De Perrot Canada Nothing to disclose

MA22 SCLC/Thymoma/Mesothelioma Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer

MA22 SCLC/Thymoma/Mesothelioma Quincy Chu Canada Nothing to disclose

MA22 SCLC/Thymoma/Mesothelioma Anthony Brade Canada Speakers or Advisory Board AstraZeneca

MA22 SCLC/Thymoma/Mesothelioma Anthony Brade Canada Consultant Eli Lilly

MA22 SCLC/Thymoma/Mesothelioma Gail Darling Canada Nothing to disclose

Chairs

MA22 Medhat El‐Mallah Canada Nothing to disclose

MA22 Eduardo Richardet Argentina Nothing to disclose

Faculty

MA22.01 Small Cell Lung Cancer/NET PARP Inhibitor Radiosensitization of Small Cell Lung Cancer Differs by PARP Trapping Potency

Benjamin Lok USA Nothing to disclose

MA22.02 Small Cell Lung Cancer/NET Activation of MAPK Suppresses Neuroendocrine Transcription Factors and Causes Transdifferentiation of Small Cell Lung Cancer

Yusuke Inoue Canada Nothing to disclose

MA22.03 Small Cell Lung Cancer/NET SCLC Circulating Tumour Cell Derived Explants: The Clinical Characteristics of Patients Whose Samples Generate CDX

Alexander Vickers UK Nothing to disclose

MA22.04 Small Cell Lung Cancer/NET Discussant ‐ MA 22.01, MA 22.02, MA 22.03 Céline Mascaux France Honoraria Boehringer Ingelheim, Eli Lilly, Bristol‐Meyers Squibb, Roche, AstraZeneca

MA22.04 Small Cell Lung Cancer/NET Discussant ‐ MA 22.01, MA 22.02, MA 22.03 Céline Mascaux France Consultant Roche, Kephren, AstraZeneca, Merck

MA22.04 Small Cell Lung Cancer/NET Discussant ‐ MA 22.01, MA 22.02, MA 22.03 Céline Mascaux France Speakers or Advisory Board AstraZeneca, Roche, Kephren

MA22.05 Small Cell Lung Cancer/NET Impact of Tumor Spread Through Air Spaces (STAS) in Lung Neuroendocrine Tumors (NETs)

Katsura Emoto USA Nothing to disclose

MA22.06 Small Cell Lung Cancer/NET Preinvasive Multifocal Neuroendocrine Lesions with Primary Typical Carcinoid Lung Tumors: A Negative Prognostic Factor?

Niccolo Daddi Italy Nothing to disclose

MA22.07 Small Cell Lung Cancer/NET Prognostic Value of Distant Organ‐Specific Metastases in Newly Diagnosed Lung Neuroendocrine Tumors: A Population‐Based Study

Min Fan China Nothing to disclose

MA22.08 Small Cell Lung Cancer/NET Discussant ‐ MA 22.05, MA 22.06, MA 22.07 Giuseppe Pelosi Italy Nothing to disclose

MA22.09 Small Cell Lung Cancer/NET Should Stereotactic Radiosurgery be Considered for Salvage of Intracranial Recurrence in Small Cell Lung Cancer?

Brooklyn Mazure Canada Nothing to disclose

MA22.10 Small Cell Lung Cancer/NET Prevalence and Risk Factors of Brain Metastases in Limited Stage Small Cell Lung Cancer Immediately Before Prophylactic Cranial Irradiation

Zhengfei Zhu China Nothing to disclose

MA22.11 Small Cell Lung Cancer/NET Risk of Hippocampal Metastases in Small Cell Lung Cancer: Implications for Hippocampal Sparing Cranial Irradiation

Rachel Effeney Australia Nothing to disclose

MA22.12 Small Cell Lung Cancer/NET Discussant ‐ MA 22.09, MA 22.10, MA 22.11 Houda Bahig Canada Contracted/Support Research Grant Varian Medical System Reserach Grant

Session MS20: Innovative and Evolving Strategies in Diagnosis and Management of Stage I NSCLC




Planner




















Chairs

MS20 Bob Li USA Consultant Genentech, Roche, Thermo Fischer Scientific, Guardant Health

MS20 Bob Li USA Speakers or Advisory Board Genentech, Guardant Health, Mersana Therapeutics

MS20 Kazuhiro Yasufuku Canada Speakers or Advisory Board Concordia, Olympus America

MS20 Kazuhiro Yasufuku Canada Supported/Contracted Research/Grant Olympus Corporation, Siemens, Veran Medical Technologies, Novadaq

MS20 Kazuhiro Yasufuku Canada Consultant Intuitive Surgical, Medtronic, Johnson & Johnson, Auris Surgical Robotics

Faculty

MS20.01 Treatment of Early Stage/Localized Disease Robotic and Innovative Surgery Waël Hanna Canada Nothing to disclose

MS20.02 Treatment of Early Stage/Localized Disease The Future of Stereotactic Ablative Radiotherapy (SABR) Billy Loo USA Ownership Interest (stocks or stock options, or other ownership interest

TibaRay

MS20.02 Treatment of Early Stage/Localized Disease The Future of Stereotactic Ablative Radiotherapy (SABR) Billy Loo USA Supported/Contracted Research/Grant Varian Medical Systems, RaySearch Laboratories

MS20.03 Treatment of Early Stage/Localized Disease Immunotherapy and Surgery: Neoadjuvant or Adjuvant? Is It Safe? Jamie Chaft USA Consultant Genentech, Roche, AstraZeneca, MedImmune, Merck, Bristol‐Meyers Squibb

MS20.03 Treatment of Early Stage/Localized Disease Immunotherapy and Surgery: Neoadjuvant or Adjuvant? Is It Safe? Jamie Chaft USA Supported/Contracted Research/Grant Genentech, Roche, Bristol‐Meyers Squibb, AstraZeneca, MedImmune

MS20.03 Treatment of Early Stage/Localized Disease Immunotherapy and Surgery: Neoadjuvant or Adjuvant? Is It Safe? Jamie Chaft USA Speakers or Advisory Board Genentech, Bristol‐Meyers Squibb, Merck, AstraZeneca

MS20.04 Treatment of Early Stage/Localized Disease Prediction of Clinical Outcome in NSCLC Using Integrative Genomics: Implications for Adjuvant Chemotherapy

Phillippe Broet France Nothing to disclose

MS20.05 Treatment of Early Stage/Localized Disease Beyond Surgery ‐ Support of the Surgical Patient Kate Kuhns USA Nothing to disclose

MS20.06 Treatment of Early Stage/Localized Disease Less Is More: Segmentectomy in the Management of Early Stage NSCLC Shun‐ichi Watanabe Japan Nothing to disclose

Session OA12: Novel Therapies in MET, RET and BRAF


Planner












Chairs

OA12 Yoshihisa Kobayashi Japan Speakers Bureau Boehringer Ingelheim

OA12 Yoshihisa Kobayashi Japan Supported/Contracted Research/Grant The Japan Society for the Promotion of Science, Osaka Cancer Society, Novartis

OA12 Nick Pavlakis Australia Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Astra Zeneca, Roche, Novartis, Boehringer Ingelheim, Merck, Pfizer, Ipsen, Amgen

OA12 Nick Pavlakis Australia Supported/Contracted Research/Grant Bayer

Faculty

OA12.01 Targeted Therapy Phase II Data for the MET Inhibitor Tepotinib in Patients with Advanced NSCLC and MET Exon 14‐Skipping Mutations

Enriqueta Felip Spain Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb Celgene, Eli Lilly, Guardant Health, Novartis, Pfizer, Roche, Takeda, Merck


Enriqueta Felip Spain Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, AstraZeneca, Bristol‐Meyers Squibb, Novartis, AbbVie, Takeda, Celegene, Guardant Health, Merck


Enriqueta Felip Spain Speakers Bureau AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, MSD, Novartis, Pfizer, Roche, Takeda, AbbVie, Merck, Celegne, Eli Lilly, Guardant Health

OA12.02 Targeted Therapy Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14‐Altered Advanced Non‐Small Cell Lung Cancer

Alexander Drilon USA Speakers or Advisory Board Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene


Alexander Drilon USA Honoraria TP Therapeutics, Loxo, Ignyta, Roche, Genentech, Pfizer


Alexander Drilon USA Supported/Contracted Research/Grant Foundation Medicine


Alexander Drilon USA Consultant Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

OA12.03 Targeted Therapy Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.

Denis Moro‐Sibilot France Speakers or Advisory Board Roche, Eli Lilly, Sanofi, Novartis, Amgen, Pfizer, AstraZeneca, Clovis Oncology, Merck, Ariad, AbbVie, Bristol‐Meyers Squibb, Boehringer Ingelheim, Takeda

OA12.04 Targeted Therapy Discussant ‐ OA 12.01, OA 12.02, OA 12.03 Mark Awad USA Consultant Genentech, Merck, Pfizer, Boehringer Ingelheim, AbbVie, AstraZeneca, MedImmune, Clovis Oncology, Nektar, Bristol‐Meyers Squibb, Ariad, Foundation Medicine, Syndax, Novartis

OA12.05 Targeted Therapy Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcSé Trial.

Julien Mazieres France Consultant Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca, Pfizer, Novartis


Julien Mazieres France Supported/Contracted Research/Grant Roche, Genentech, AstraZeneca, Bristol‐Meyers Squibb


Julien Mazieres France Speakers or Advisory Board Novartis, Roche, Pfizer, Bristol‐Meyers Squibb, Eli Lilly, Merck, AstraZeneca

OA12.06 Targeted Therapy Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure

Anastasios Dimou USA Nothing to disclose

OA12.07 Targeted Therapy Clinical Activity of LOXO‐292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non‐Small Cell Lung Cancer

Geoffrey Oxnard USA Speakers or Advisory Board Inivata, GRAIL, DropWorks, AstraZeneca, Takeda/Ariad


Geoffrey Oxnard USA Consultant Loxo, Inivata, AstraZeneca


Geoffrey Oxnard USA Royalty, Intellectual Property/Patent Holder Co‐author of patent held by DFCI describing a plasma genotyping approach


Geoffrey Oxnard USA Honoraria Guardant, Sysmex

OA12.08 Targeted Therapy Discussant ‐ OA 12.05, OA 12.06, OA 12.07 Thomas Newsom‐Davis UK Speakers Bureau Astra Zeneca, BMS, MSD, Roche

OA12.08 Targeted Therapy Discussant ‐ OA 12.05, OA 12.06, OA 12.07 Thomas Newsom‐Davis UK Advisory Board Astra Zeneca, BMS, MSD, Pfizer, Roche, Takeda

OA12.08 Targeted Therapy Discussant ‐ OA 12.05, OA 12.06, OA 12.07 Thomas Newsom‐Davis UK Honoraria Astra Zeneca, BMS, MSD, Pfizer, Roche, Takeda

Session MS21: Giants in Thoracic Oncology


Planner

MS21 Natasha Leighl Canada Supported/Contracted Research/Grant Novartis

MS21 Natasha Leighl Canada Honoraria Merck, Bristol‐Meyers Squibb

MS21 Natasha Leighl Canada Consultant Novartis, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Canadian Agency for Drugs and Technologies in Health

MS21 Gail Darling Canada Nothing to disclose

MS21 Andrea Bezjak Canada Nothing to disclose

MS21 Frances Shepherd Canada Honoraria Bristol‐Myers Squibb, Eli Lilly, AstraZeneca, Roche, Genentech, Merck, Novartis, Pfizer

MS21 Frances Shepherd Canada Other Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack

MS21 Frances Shepherd Canada Ownership Interest (stocks or stock options, or other ownership interest


MS21 Frances Shepherd Canada Speakers or Advisory Board Eli Lilly, AstraZeneca, Merck

Chairs

MS21 Ronald Feld Canada Nothing to disclose



MS21 Miyako Satouchi Japan Honoraria AstraZeneca, Chugai, BMS, MSD, Eli Lilly, Ono, Pfizer, Novartis, Taiho, Boehringer Ingelheim

MS21 Miyako Satouchi Japan Contracted/Support Research Grant AstraZeneca, BMS, Chugai, Eli Lilly, MSD, Novartis, Ono Pfizer, Astellas

Faculty

MS21.01 Surgery and its Evolution Paul Van Schil Belgium Nothing to disclose

MS21.02 Chemotherapy through the 21st Century David Johnson USA Nothing to disclose

MS21.03 Revolution in Radiation Ben Slotman Netherlands Nothing to disclose

MS21.04 Targeted Therapy ‐ The Second Revolution Frances Shepherd Canada Honoraria Bristol‐Myers Squibb, Eli Lilly, AstraZeneca, Roche, Genentech, Merck, Novartis, Pfizer

MS21.04 Targeted Therapy ‐ The Second Revolution Frances Shepherd Canada Consultant Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack

MS21.04 Targeted Therapy ‐ The Second Revolution Frances Shepherd Canada Ownership Interest (stocks or stock options, or other ownership interest


MS21.04 Targeted Therapy ‐ The Second Revolution Frances Shepherd Canada Speakers or Advisory Board Eli Lilly, AstraZeneca, Merck

MS21.05 Quality of Life ‐ Are we Paying Enough Attention? Richard Gralla USA Nothing to disclose

MS21.06 Immunotherapy ‐ Sequence or Combination? Roy Herbst USA Speakers or Advisory Board AstraZeneca, Eli Lilly, Genentech, Roche, Merck, NextCure, Novartis, Pfizer

MS21.06 Immunotherapy ‐ Sequence or Combination? Roy Herbst USA Supported/Contracted Research/Grant AstraZeneca, Eli Lilly, Merck, Genentech

MS21.07 The Growing Role of Biomarkers in Treatment Selection: “The Tissue is the Issue”

Fred Hirsch USA Consultant AstraZeneca, Genentech, HTG Molecular Diagnostics, Eli Lilly, Merck, Clovis Oncology, Ventana Medical Systems, Bristol‐Meyers Squibb, Pfizer, Roche


Fred Hirsch USA Royalty, Intellectual Property/Patent Holder University of Colorado Cancer Center


Fred Hirsch USA Supported/Contracted Research/Grant Eli Lilly, Genentech, Amgen, Bristol‐Meyers Squibb, Celgene


Fred Hirsch USA Speakers or Advisory Board AbbVie, AstraZeneca, Biocept, Bristol‐Meyers Squibb, HTG, Eli Lilly, Loxo, Merck, Novartis, Pfizer, Roche, Genentech, Ventana, Bayer

MS21.08 Where will we be in 10 years? Paul Bunn, Jr. USA Consultant AstraZeneca, Bristol‐Meyers Squibb, Genentech, Eli Lilly, Pfizer, Merck, Novartis, Merrimack, Daiichi

MS21.08 Where will we be in 10 years? Paul Bunn, Jr. USA Supported/Contracted Research/Grant Genentech, Roche

MS21.08 Where will we be in 10 years? Paul Bunn, Jr. USA Honoraria AstraZeneca, Guardant Health

MS21.08 Where will we be in 10 years? Paul Bunn, Jr. USA Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Genentech, Merck, MerckSerono, Takeda

MS21.09 Discussion

Session MTE19: How I Treat Advanced Stage Thymic Malignancy Patients

Wednesday, September 26 ‐ 07:00 ‐ 08:00

Planner

MTE19 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Honoraria ACEA, Genentech, Novartis, AstraZeneca

MTE19 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Supported/Contracted Research/Grant Clovis, Exelixis, AstraZeneca, MedImmune, Genentech, Roche, Bristol‐Meyers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Eli Lilly, Acea, Merck

MTE19 Thymoma/Other Thoracic Malignancies Heather Wakelee USA Speakers or Advisory Board ACEA Biosyciences, Pfizer, Novartis, Genentech, Roche, AstraZeneca, Merck

MTE19 Thymoma/Other Thoracic Malignancies Meinoshin Okumura Japan Nothing to disclose

MTE19 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Speakers or Advisory Board AstraZeneca

MTE19 Thymoma/Other Thoracic Malignancies Anthony Brade Canada Consultant Eli Lilly

MTE19 Thymoma/Other Thoracic Malignancies Wentao Fang China Nothing to disclose

MTE19 Thymoma/Other Thoracic Malignancies Pier Luigi Filosso Italy Nothing to disclose

MTE19 Thymoma/Other Thoracic Malignancies Nicolas Girard France Consultant Bristol‐Meyers Squibb, Merck Roche, AstraZeneca

MTE19 Thymoma/Other Thoracic Malignancies Shaf Keshavjee Canada Nothing to disclose

MTE19 Thymoma/Other Thoracic Malignancies Robert Korst USA Nothing to disclose

MTE19 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Supported/Contracted Research/Grant Varian Medical Systems, Boehringer Ingelheim, AstraZeneca, Pfizer

MTE19 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Honoraria Varian Medical Systms, Bristol‐Meyers Squibb, AstraZeneca, Pfizer, Merck

MTE19 Thymoma/Other Thoracic Malignancies Andreas Rimner USA Speakers or Advisory Board AstraZeneca, Merck

MTE19 Thymoma/Other Thoracic Malignancies DAvid Waller UK Nothing to disclose

Faculty

MTE19.01 Thymoma/Other Thoracic Malignancies How I Treat Advanced Stage Thymic Malignancy Patients Heather Wakelee USA Honoraria ACEA, Genentech, Novartis, AstraZeneca

MTE19.01 Thymoma/Other Thoracic Malignancies How I Treat Advanced Stage Thymic Malignancy Patients Heather Wakelee USA Supported/Contracted Research/Grant Clovis, Exelixis, AstraZeneca, MedImmune, Genentech, Roche, Bristol‐Meyers Squibb, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, Eli Lilly, Acea, Merck

MTE19.01 Thymoma/Other Thoracic Malignancies How I Treat Advanced Stage Thymic Malignancy Patients Heather Wakelee USA Speakers or Advisory Board ACEA Biosyciences, Pfizer, Novartis, Genentech, Roche, AstraZeneca, Merck



Session MTE20: Molecular Testing in Small Samples


Planner

MTE20 Pathology Ming Tsao Canada Honoraria Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Roche, Ventana

MTE20 Pathology Ming Tsao Canada Supported/Contracted Research/Grant Merck, Pfizer, Roche, Ventana, AstraZeneca

MTE20 Pathology Ming Tsao Canada Speakers or Advisory Board AstraZeneca, Pfizer, Merck, Roche, Ventana, Bristol Myers Squibb, AbbVie, Celgene

MTE20 Pathology Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune

MTE20 Pathology Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche

MTE20 Pathology Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen

MTE20 Pathology Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

MTE20 Pathology Alan Borczuk USA Nothing to disclose

MTE20 Pathology Lukas Bubendorf Switzerland Nothing to disclose

MTE20 Pathology Sanja Dacic USA Speakers or Advisory Board Bristol‐Meyers Squibb, Astra‐Zeneca

MTE20 Pathology Sanja Dacic USA Honoraria Bristol‐Meyers Squibb, AstraZeneca

MTE20 Pathology David Hwang Canada Honoraria Merck, Pfizer, Takeda

MTE20 Pathology David Hwang Canada Speakers or Advisory Board Merck

MTE20 Pathology Keith Kerr UK Consultant Bristol‐Meyers Squibb

MTE20 Pathology Keith Kerr UK Speakers or Advisory Board AstraZeneca, Bristol Meyers Squibb, Merck, Roche, Pfizer

MTE20 Pathology Sylvie Lantuejoul France Nothing to disclose

MTE20 Pathology John Longshore USA Speakers Bureau Roche, AstraZeneca, Bristol‐Meyers Squibb, Merck, Genentech

MTE20 Pathology John Longshore USA Speakers or Advisory Board Roche, AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer

MTE20 Pathology John Longshore USA Supported/Contracted Research/Grant Roche, AstraZeneca

MTE20 Pathology Mari Mino‐Kenudson USA Consultant Merrimack Pharmas, H3 Biomedicine

MTE20 Pathology Mari Mino‐Kenudson USA Honoraria Merrimac Pharmas, H3 Biomedicine

MTE20 Pathology Andre Moreira USA Nothing to disclose

MTE20 Pathology Andrew Nicholson UK Consultant Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Bristol‐Meyers Squibb, Roche, AbbVie

MTE20 Pathology Andrew Nicholson UK Supported/Contracted Research/Grant Pfizer, Roche

MTE20 Pathology Andrew Nicholson UK Speakers or Advisory Board Pfizer, Abbvie

MTE20 Pathology Andrew Nicholson UK Ownership Interest (stocks or stock options, or other ownership interest

Merck

MTE20 Pathology Yasushi Yatabe Japan Consultant Merck, Chugai‐Pharma, AstraZeneca, Bristol‐Meyers Squibb, Pfizer, Roche, ThermoFisher, Dako

MTE20 Pathology Yasushi Yatabe Japan Honoraria AstraZeneca, Merck, Bristol Myers, Chugai‐pharma, Pfizer, Roche

Faculty

MTE20.01 Pathology Molecular Testing in Small Samples John Longshore USA Speakers Bureau Roche, AstraZeneca, Bristol‐Meyers Squibb, Merck, Genentech

MTE20.01 Pathology Molecular Testing in Small Samples John Longshore USA Speakers or Advisory Board Roche, AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer

MTE20.01 Pathology Molecular Testing in Small Samples John Longshore USA Supported/Contracted Research/Grant Roche, AstraZeneca

MTE20.02 Pathology Molecular Testing in Small Samples Jin‐Haeng Chung Korea Nothing to disclose

Session MTE21: Can I Treat Brain Metastasis with Immunotherapy?


Planner

MTE21 Immunooncology Desiree Hao Canada Nothing to disclose

MTE21 Immunooncology Solange Peters Switzerland Speakers or Advisory Board Amgen, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Roche, Janssen, Merck, Pfizer, Regeneron, Takeda

MTE21 Immunooncology Myung‐Ju Ahn Korea Consultant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Merck, Novartis, Alpha BioPharmas

MTE21 Immunooncology Myung‐Ju Ahn Korea Speakers or Advisory Board AstraZeneca, Eli Lilly, Bristol‐Meyers Squibb, Merck, Ono Pharma, Roche

MTE21 Immunooncology Fabrice Barlesi France Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda

MTE21 Immunooncology Fabrice Barlesi France Consultant Roche, Genentech., AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda



MTE21 Immunooncology Fabrice Barlesi France Supported/Contracted Research/Grant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda

MTE21 Immunooncology Fabrice Barlesi France Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda, Serono

MTE21 Immunooncology Julie Brahmer USA Speakers or Advisory Board Merck, Genetech, Bristol‐Meyers Squibb, Syndax, AstraZeneca, Celgene, Amgen Oncology

MTE21 Immunooncology Julie Brahmer USA Consultant Celgene, Eli Lilly, MedImmune, AstraZeneca, Bristol‐Meyers Squibb

MTE21 Immunooncology Julie Brahmer USA Supported/Contracted Research/Grant Medimmune, AstraZeneca, Bristol‐Meyers Squibb

MTE21 Immunooncology Edward Garon USA Consultant Bristol‐Meyers Squibb, Eli Lilly, AstraZeneca, Genentech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax

MTE21 Immunooncology Edward Garon USA Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Genetech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax

MTE21 Immunooncology Edward Garon USA Supported/Contracted Research/Grant Merck, Genentech, AstraZeneca, Novartis, Pfizer, Eli Lilly, Bristol‐Meyers Squibb, Boehringer Ingelheim, Mirati Therapeutics, Dyanvax

MTE21 Immunooncology Rina Hui Australia Honoraria Bristol‐Meyers Squibb, Boehringer Ingelheim, Merck, AstraZeneca, Novartis, Roche

MTE21 Immunooncology Rina Hui Australia Speakers or Advisory Board AstraZeneca, Merck, Novartis, Pfizer, Roche, Bristol‐Meyers Squibb

MTE21 Immunooncology Rina Hui Australia Consultant Merck, AstraZeneca, Novartis, Roche, Bristol‐Meyers Squibb, Boehringer Ingelheim, Pfizer

MTE21 Immunooncology Rosalyn Juergens Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Amgen, Novartis, AstraZeneca, Takeda

MTE21 Immunooncology Rosalyn Juergens Canada Honoraria Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, AstraZeneca, MedImmune, Eli Lilly, Takeda, Novartis, Amgen Pfizer

MTE21 Immunooncology Rosalyn Juergens Canada Speakers Bureau Amgen

MTE21 Immunooncology Rosalyn Juergens Canada Consultant Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Amgen, Roche, AstraZeneca, MedImmune,

MTE21 Immunooncology Rosalyn Juergens Canada Supported/Contracted Research/Grant AstraZeneca, MedImmune, Merck, Bristol‐Meyers Squibb

MTE21 Immunooncology Martin Reck Germany Speakers Bureau Roche, Eli Lilly, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Merck, Boehringer‐Ingelheim, Novartis, Pfizer, Abbot

MTE21 Immunooncology Martin Reck Germany Speakers or Advisory Board Roche, Eli Lilly, AstraZeneca, Bristol‐Meyers Squibb, Celgene, Merck, Boehringer Ingelheim, Novartis, Pfizer, Abbot

MTE21 Immunooncology Martin Reck Germany Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Lilly, Merck, Practa, Roche

MTE21 Immunooncology Martin Reck Germany Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Celgene, Eli Lilly, Merck, Pfizer, Proacta, Novartis, Roche, Abbott

MTE21 Immunooncology Naiyer Rizvi USA Honoraria Roche, AstraZeneca, Novartis, Merck, Pfizer, Lilly, Bristol‐Meyers Squibb

MTE21 Immunooncology Naiyer Rizvi USA Ownership Interest (stocks or stock options, or other ownership interest


MTE21 Immunooncology Naiyer Rizvi USA Speakers or Advisory Board Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

MTE21 Immunooncology Naiyer Rizvi USA Consultant Merck, AstraZeneca, Roche, Bristol‐Meyers Squibb, Novartis, Pfizer, Eli Lilly, AbbVie, Regeneron

MTE21 Immunooncology Adrian Sacher USA Nothing to disclose

MTE21 Immunooncology Ross Soo Singapore Supported/Contracted Research/Grant AstraZeneca

MTE21 Immunooncology Ross Soo Singapore Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Celgene, Ignyta, Roche, Taiho

MTE21 Immunooncology Yi‐Long Wu China Speakers or Advisory Board AstraZeneca, Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, Sanofi

MTE21 Immunooncology Yi‐Long Wu China Speakers Bureau AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi

MTE21 Immunooncology Yi‐Long Wu China Honoraria AstraZeneca, Eli Lilly, Pfizer, Roche

MTE21 Immunooncology Yi‐Long Wu China Consultant AstraZeneca, Boehringer Ingelheim, Merck, Roche

MTE21 Immunooncology Yi‐Long Wu China Supported/Contracted Research/Grant Boehringer Ingelheim, Roche

Faculty

MTE21.01 Immunooncology Can I Treat Brain Metastasis with Immunotherapy? Sarah Goldberg USA Supported/Contracted Research/Grant AstraZeneca

MTE21.01 Immunooncology Can I Treat Brain Metastasis with Immunotherapy? Sarah Goldberg USA Honoraria AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Boehringer Ingelheim

MTE21.01 Immunooncology Can I Treat Brain Metastasis with Immunotherapy? Sarah Goldberg USA Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Boehringer Ingelheim Daiichi

MTE21.02 Immunooncology Can I Treat Brain Metastasis with Immunotherapy? Caroline Chung USA Nothing to disclose

Session MTE22: Incorporation of Smoking Cessation in Clinical Care


Planner

MTE22 Prevention and Tobacco Control Matthew Steliga USA Nothing to disclose

MTE22 Prevention and Tobacco Control Michael Cummings USA Nothing to disclose

MTE22 Prevention and Tobacco Control Eric Bedard Canada Nothing to disclose

MTE22 Prevention and Tobacco Control Wanda De Kanter Netherlands Nothing to disclose

MTE22 Prevention and Tobacco Control Carolyn Dresler USA Nothing to disclose



MTE22 Prevention and Tobacco Control Rayjean Hung Canada Nothing to disclose

MTE22 Prevention and Tobacco Control Jacek Jassem Poland Nothing to disclose

MTE22 Prevention and Tobacco Control Jamie Ostroff USA Nothing to disclose

MTE22 Prevention and Tobacco Control Emily Stone Australia Nothing to disclose

MTE22 Prevention and Tobacco Control Nise Yamaguchi Brazil Nothing to disclose

MTE22 Prevention and Tobacco Control Li Zhang China Speakers or Advisory Board Merck, Boehringer Ingelheim

Faculty

MTE22.01 Prevention and Tobacco Control Integration of Cessation and Lung Cancer Screening Matthew Steliga USA Nothing to disclose

MTE22.02 Prevention and Tobacco Control Cessation and Clinical Lung Cancer Care Jamie Ostroff USA Nothing to disclose

Session MTE23: Surgical Considerations Following Induction Therapy for Stage IIIA Disease


Planner

MTE23 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Supported/Contracted Research/Grant Merck, AstraZeneca, Elekta

MTE23 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Consultant Merck, AstraZeneca, Elekta, Pfizer, Respective Meeting‐Related Travel Support

MTE23 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers or Advisory Board Pfizer, Merck

MTE23 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Honoraria AstraZeneca, Merck

MTE23 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers Bureau AstraZeneca, Merck

MTE23 Treatment of Locoregional Disease ‐ NSCLC Paula Ugalde Canada Nothing to disclose

MTE23 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Honoraria Pfizer, Boehringer Ingelheim, AstaZeneca, Bristol‐Meyers Squibb, Merck, Takeda

MTE23 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Speakers or Advisory Board Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Merck, Takeda

MTE23 Treatment of Locoregional Disease ‐ NSCLC Hiroshi Date Japan Nothing to disclose

MTE23 Treatment of Locoregional Disease ‐ NSCLC Dirk De Ruysscher Netherlands Nothing to disclose

MTE23 Treatment of Locoregional Disease ‐ NSCLC Rui Haddad Brazil Nothing to disclose

MTE23 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Speakers Bureau Varian Medical

MTE23 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Honoraria Varian Medical

MTE23 Treatment of Locoregional Disease ‐ NSCLC Jocelyne Martin Canada Nothing to disclose

MTE23 Treatment of Locoregional Disease ‐ NSCLC Gaetano Rocco Italy Speakers Bureau Baxter, Medtronic

MTE23 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers or Advisory Board AbbVie, AstraZeneca, Spiration

MTE23 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers Bureau Synthes

MTE23 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Consultant Spiration, Olympus

Faculty

MTE23.01 Treatment of Locoregional Disease ‐ NSCLC Surgical Considerations Following Induction Therapy for Stage IIIA Disease Eric Vallieres USA Speakers or Advisory Board AbbVie, AstraZeneca, Spiration

MTE23.01 Treatment of Locoregional Disease ‐ NSCLC Surgical Considerations Following Induction Therapy for Stage IIIA Disease Eric Vallieres USA Speakers Bureau Synthes

MTE23.01 Treatment of Locoregional Disease ‐ NSCLC Surgical Considerations Following Induction Therapy for Stage IIIA Disease Eric Vallieres USA Consultant Spiration, Olympus

MTE23.02 Treatment of Locoregional Disease ‐ NSCLC Surgical Considerations Following Induction Therapy for Stage IIIA Disease Jonathan Spicer Canada Consultant Bristol‐Myers Squibb

MTE23.02 Treatment of Locoregional Disease ‐ NSCLC Surgical Considerations Following Induction Therapy for Stage IIIA Disease Jonathan Spicer Canada Speakers or Advisory Board Bristol‐Myers Squibb, AstraZeneca

MTE23.02 Treatment of Locoregional Disease ‐ NSCLC Surgical Considerations Following Induction Therapy for Stage IIIA Disease Jonathan Spicer Canada Honoraria AstraZeneca

Session MTE24: Multiple Lung Nodules; Resect, Radiate or Watch?


Planner

MTE24 Treatment of Early Stage/Localized Disease Hisao Asamura Japan Honoraria Lecturer of seminar ‐ Johnson & Johnson, Covidien, Eli Lilly, Taiho, Boehringer Ingelheim, Ono Pharmaceuticals

MTE24 Treatment of Early Stage/Localized Disease Patrick Cheung Canada Nothing to disclose

MTE24 Treatment of Early Stage/Localized Disease Thomas D'Amico USA Consultant Consultant for Scanlan Instruments



MTE24 Treatment of Early Stage/Localized Disease Jessica Donington USA Honoraria AstraZeneca

MTE24 Treatment of Early Stage/Localized Disease Janet Edwards Canada Nothing to disclose

MTE24 Treatment of Early Stage/Localized Disease Bob Li USA Consultant Genentech, Roche, Thermo Fischer Scientific, Guardant Health

MTE24 Treatment of Early Stage/Localized Disease Bob Li USA Speakers or Advisory Board Genentech, Guardant Health, Mersana Therapeutics

MTE24 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Speakers or Advisory Board Eli LIlly

MTE24 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Supported/Contracted Research/Grant Eli Lilly, Boehringer Ingelheim, AstraZeneca, Chugai, The Japan Society for the Promotion of Science

MTE24 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Consultant Bristol‐Meyers Squibb, Ono Pharma

MTE24 Treatment of Early Stage/Localized Disease Tetsuya Mitsudomi Japan Speakers Bureau AstraZeneca, Chug, Pfizer, Boehringer Ingelheim

MTE24 Treatment of Early Stage/Localized Disease Luis Raez USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Roche, Genentech, Syndax, Novartis

MTE24 Treatment of Early Stage/Localized Disease Ramon Rami‐Porta Spain Nothing to disclose

MTE24 Treatment of Early Stage/Localized Disease Tomohito Saito Japan Supported/Contracted Research/Grant Ono Pharma, Bristol‐Myers Squibb

MTE24 Treatment of Early Stage/Localized Disease Tomohito Saito Japan Consultant Ono Pharma

MTE24 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Speakers or Advisory Board AstraZeneca, Eli Lilly, Merck

MTE24 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Employee (full time or part time) VU University Medical Center

MTE24 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Honoraria Eli Lilly

MTE24 Treatment of Early Stage/Localized Disease Suresh Senan Netherlands Supported/Contracted Research/Grant Varian Medical Systems, ViewRay

Faculty

MTE24.01 Treatment of Early Stage/Localized Disease Surgery vs SABR for Early NSCLC Thomas D'Amico USA Consultant Consultant for Scanlan Instruments

MTE24.01 Treatment of Early Stage/Localized Disease Surgery vs SABR for Early NSCLC Thomas D'Amico USA Speakers or Advisory Board Scanlon

MTE24.02 Treatment of Early Stage/Localized Disease Small Lung Tumours: High Risk Lesions and Contraindications to Stereotactic Ablative Body Radiotherapy (SABR)

David Ball Australia Nothing to disclose

Session MTE25: Enhancing the Care of Your Older Adult Population with Lung Cancer


Planner

MTE25 Nursing and Allied Professionals Massey Nematollahi Canada Nothing to disclose

MTE25 Nursing and Allied Professionals Patricia Hollen USA Nothing to disclose

MTE25 Nursing and Allied Professionals Beth Eaby‐Sandy USA Speakers Bureau Helsinn, Merck, AstraZeneca, Takeda

MTE25 Nursing and Allied Professionals Beth Eaby‐Sandy USA Consultant Consultant‐ AbbVie

MTE25 Nursing and Allied Professionals Kathleen Gamblin USA Nothing to disclose

MTE25 Nursing and Allied Professionals Maria Guerin UK Speakers or Advisory Board AstraZeneca

MTE25 Nursing and Allied Professionals Maria Guerin UK Honoraria AstraZeneca

MTE25 Nursing and Allied Professionals Pippa Labuc UK Nothing to disclose

MTE25 Nursing and Allied Professionals Naz Nouriany Canada Nothing to disclose

MTE25 Nursing and Allied Professionals Dianne Zawisza Canada Nothing to disclose

Faculty

MTE25.01 Nursing and Allied Professionals Enhancing the Care of Your Older Adult Population with Lung Cancer Martine Puts Canada Nothing to disclose

Session MTE26: New Paradigms in Symptom Management in Lung Cancer


Planner

MTE26 Treatment in the Real World ‐ Support, Survivorship, Systems Research




















Gilead

































Faculty

MTE26.01 Treatment in the Real World ‐ Support, Survivorship, Systems Research

Treatment of Cancer Related Symptoms Patricia Rivera USA Nothing to disclose


Symptoms and IO Toxicity Management Jarushka Naidoo USA Supported/Contracted Research/Grant Merck, AstraZeneca


Symptoms and IO Toxicity Management Jarushka Naidoo USA Consultant Bristol‐Meyers Squibb, Takeda, AstraZeneca

Session MTE27: Controversies in Radiotherapy for SCLC


Planner

MTE27 Small Cell Lung Cancer/NET Fiona Blackhall UK Nothing to disclose

MTE27 Small Cell Lung Cancer/NET Peter Ellis Canada Honoraria AbbVie, AstraZeneca

MTE27 Small Cell Lung Cancer/NET Peter Ellis Canada Consultant Celegene, Mylan

MTE27 Small Cell Lung Cancer/NET Jeffrey Bogart USA Nothing to disclose

MTE27 Small Cell Lung Cancer/NET Lauren Byers USA Nothing to disclose

MTE27 Small Cell Lung Cancer/NET Quincy Chu Canada Nothing to disclose

MTE27 Small Cell Lung Cancer/NET Eric Lim UK Speakers Bureau Abbott Molecular, Pfizer, Roche, Eli Lily, Boehringer Ingelheim, Ethicon

MTE27 Small Cell Lung Cancer/NET Eric Lim UK Supported/Contracted Research/Grant Medela, ScreenCell, Clearbridge Biomedics, Illumina, Guardant Health

MTE27 Small Cell Lung Cancer/NET Francoise Mornex France Nothing to disclose

MTE27 Small Cell Lung Cancer/NET Charles Rudin USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Genentech, Harpoon, Genetics

MTE27 Small Cell Lung Cancer/NET Charles Rudin USA Consultant Bristol‐Meyers Squibb, AbbVie, Seattle Genetics, Harpoon Therapeutics, Genentech Roche, AstraZeneca

MTE27 Small Cell Lung Cancer/NET Ben Slotman Netherlands Nothing to disclose

MTE27 Small Cell Lung Cancer/NET Sumitra Thongprasert Thailand Nothing to disclose

MTE27 Small Cell Lung Cancer/NET Jie Wang China Nothing to disclose

MTE27 Small Cell Lung Cancer/NET Mauro Zukin Brazil Nothing to disclose

Faculty

MTE27.01 Small Cell Lung Cancer/NET Radiotherapy in ES‐SCLC Elizabeth Gore USA Nothing to disclose



Session MTE28: Lessons from the Past‐What I Would Not Do Again in Diagnostic and Therapeutic IP


Planner

MTE28 Interventional Diagnostics/Pulmonology Kazuhiro Yasufuku Canada Speakers or Advisory Board Concordia, Olympus America

MTE28 Interventional Diagnostics/Pulmonology Kazuhiro Yasufuku Canada Supported/Contracted Research/Grant Olympus Corporation, Siemens, Veran Medical Technologies, Novadaq

MTE28 Interventional Diagnostics/Pulmonology Kazuhiro Yasufuku Canada Consultant Intuitive Surgical, Medtronic, Johnson & Johnson, Auris Surgical Robotics

MTE28 Interventional Diagnostics/Pulmonology Kwun Fong Australia Nothing to disclose

MTE28 Interventional Diagnostics/Pulmonology Jason Agulnik Canada Honoraria Merck, Pfizer, Bristol‐Meyers Squibb, AstraZeneca

MTE28 Interventional Diagnostics/Pulmonology Nicole Bouchard Canada Supported/Contracted Research/Grant Pfizer, Bristol‐Meyers Squibb, Merck

MTE28 Interventional Diagnostics/Pulmonology Nicole Bouchard Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche

MTE28 Interventional Diagnostics/Pulmonology Eric Edell Canada Nothing to disclose

MTE28 Interventional Diagnostics/Pulmonology Wael Hannah Canada Nothing to disclose

MTE28 Interventional Diagnostics/Pulmonology Felix Herth Germany Nothing to disclose

MTE28 Interventional Diagnostics/Pulmonology Hojoong Kim Korea Nothing to disclose

MTE28 Interventional Diagnostics/Pulmonology Moishe Liberman Canada Nothing to disclose

MTE28 Interventional Diagnostics/Pulmonology Navneet Singh India Nothing to disclose

MTE28 Interventional Diagnostics/Pulmonology Egbert Smit Netherlands Nothing to disclose

Faculty

MTE28.01 Interventional Diagnostics/Pulmonology Lessons from the Past‐What I Would Not Do Again in Diagnostic and Therapeutic IP

Navneet Singh India Nothing to disclose

MTE28.02 Interventional Diagnostics/Pulmonology Lessons from the Past‐What I Would Not Do Again in Diagnostic and Therapeutic IP




Planner







SH03 Frances Shepherd Canada Other Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack




Chairs

SH03 Christina Sit Canada Nothing to disclose

SH03 Andrew Bang Canada Nothing to disclose

Faculty

SH03.01 Thymoma & Outcomes Shirish Gadgeel USA Speakers or Advisory Board Astra‐Zeneca, Genentech, Roche, Ariad, Takeda, AbbVie, Bristol Meyers‐Squibb

SH03.02 Targeted Alice Shaw USA Speakers or Advisory Board Pfizer, Novartis, Genentech, Roche, Ariad, Takeda, Ignyta, Blueprint Medicines, Loxo, Daiichi Sankyo, Merck, Taiho Pharma, KSQ Therapeutics, Natera

SH03.02 Targeted Alice Shaw USA Honoraria Pfizer, Novartis, Roche, Genentech, Foundation Medicine, Takeda

SH03.02 Targeted Alice Shaw USA Supported/Contracted Research/Grant Pfizer, Novartis, Roche, Genentech

SH03.03 Biology Glen Reid Australia Nothing to disclose

SH03.04 Screening Stephen Lam Canada Nothing to disclose

SH03.05 Q&A





Planner







SH04 Frances Shepherd Canada Other Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack




Chairs

SH04 Pilar Garrido Spain Consultant Roche, Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol‐Meyers Squibb, Eli Lilly and Company, AbbVie, Novartis

SH04 Pilar Garrido Spain Speakers Bureau Roche, Merck, Bristol‐Meyers Squibb, Pfizer

SH04 Pilar Garrido Spain Supported/Contracted Research/Grant Guardant

SH04 Simron Singh Canada Advisory Board Novartis, IPSEN

SH04 Simron Singh Canada Employee Astra Zeneca (spouse)

SH04 Simron Singh Canada Honoraria Novartis, IPSEN

SH04 Simron Singh Canada Contracted/Support Research Grant Novartis

Faculty

SH04.01 SCLC/NET Melissa Johnson USA Supported/Contracted Research/Grant BerGenBio, Eli Lilly, Merck Serono, Janssen, Mirati Therapeutics, Genmab, Pfizer, AstraZeneca, Genentech, Roche, Stemcentrix, Novartis, Checkpoint Therapeutics, Array BioPharma, Regeneron, Apexigen, AbbVie, Tarveda, Adaptimmune, Syndax, Neovia, Boehringer Ingelheim, Sanofi, Hengrui Therapeutics, Daiichi – Sankyo, Lycera, G1 Therapeutics, Dynavax, OncoMed,

SH04.01 SCLC/NET Melissa Johnson USA Speakers or Advisory Board Astellas, Otsuka Pharmas, Genentech, Roche, Celgene, Boehringer Ingelheim, Sanofi, Mirati, Loxo, AstraZeneca, Mersana

SH04.01 SCLC/NET Melissa Johnson USA Consultant Astellas, Otsuka Pharmas, Roche

SH04.02 Surgery Biniam Kidane Canada Nothing to disclose

SH04.03 Locally Advanced/IO Edgardo Santos USA Speakers Bureau Genentech, Pfizer, Novartis, Amgen, Takeda, Boehringer Ingelheim, Celgene, Merck, AstraZeneca

SH04.04 Survivorship & Radiation Chad Rusthoven USA Honoraria Takeda

SH04.05 Q&A

Session PL03: Call to Action ‐ Challenges Ahead


Planner







PL03 Frances Shepherd Canada Other Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack




Chairs


PL03 Nagahiro Saijo Japan Nothing to disclose



Faculty

PL03.01 From Bench to Bedside Charles Swanton UK Ownership Interest ACHILLES (CO‐FOUNDER)

PL03.01 From Bench to Bedside Charles Swanton UK Honoraria CELGENE, GENENTECH, ROCHE VENTANA, NOVARTIS, BMS

PL03.01 From Bench to Bedside Charles Swanton UK Contracted/Support Research Grant PFIZER, ASTRAZENECA

PL03.01 From Bench to Bedside Charles Swanton UK Other(please specify) STOCK OPTIONS IN APOGEN BIOTECH AND EPIC BIOSCIENCES AND GRAIL

PL03.02 Host Immunity ‐ No Longer a Passive Bystander Julie Brahmer USA Speakers or Advisory Board Merck, Genetech, Bristol‐Meyers Squibb, Syndax, AstraZeneca, Celgene, Amgen Oncology

PL03.02 Host Immunity ‐ No Longer a Passive Bystander Julie Brahmer USA Consultant Celgene, Eli Lilly, MedImmune, AstraZeneca, Bristol‐Meyers Squibb

PL03.02 Host Immunity ‐ No Longer a Passive Bystander Julie Brahmer USA Supported/Contracted Research/Grant Medimmune, AstraZeneca, Bristol‐Meyers Squibb

PL03.03 Beaming into the Future David Palma Canada Nothing to disclose

PL03.04 A Cut Above Yolonda Colson USA Contracted/Support Research Grant Canon USA

PL03.05 It's All In The Tissue Keith Kerr UK Consultant Bristol‐Meyers Squibb

PL03.05 It's All In The Tissue Keith Kerr UK Speakers or Advisory Board AstraZeneca, Bristol Meyers Squibb, Merck, Roche, Pfizer

PL03.06 The Future of Targeted Therapy Tetsuya Mitsudomi Japan Speakers or Advisory Board Eli LIlly

PL03.06 The Future of Targeted Therapy Tetsuya Mitsudomi Japan Supported/Contracted Research/Grant Eli Lilly, Boehringer Ingelheim, AstraZeneca, Chugai, The Japan Society for the Promotion of Science

PL03.06 The Future of Targeted Therapy Tetsuya Mitsudomi Japan Consultant Bristol‐Meyers Squibb, Ono Pharma

PL03.06 The Future of Targeted Therapy Tetsuya Mitsudomi Japan Speakers Bureau AstraZeneca, Chug, Pfizer, Boehringer Ingelheim

Session ES06: Oligometastatic Disease


Planner

ES06 Oligometastatic NSCLC David Palma Canada Nothing to disclose

ES06 Oligometastatic NSCLC Joseph Salama USA Nothing to disclose

ES06 Oligometastatic NSCLC Hak Choy USA Speakers Bureau AstraZeneca

ES06 Oligometastatic NSCLC Hak Choy USA Honoraria AstraZeneca, Merck

ES06 Oligometastatic NSCLC Laurie Gaspar USA Nothing to disclose

ES06 Oligometastatic NSCLC Matthias Guckenberger Switzerland Nothing to disclose

ES06 Oligometastatic NSCLC David Jones USA Nothing to disclose

ES06 Oligometastatic NSCLC Mary Macneil Canada Nothing to disclose

ES06 Oligometastatic NSCLC Boris Sepesi USA Nothing to disclose

Chairs

ES06 Gaetano Rocco Italy Speakers Bureau Baxter, Medtronic

ES06 Renato Martins USA Contracted/Support Research Grant Merck, Pfizer

Faculty

ES06.01 Oligometastatic NSCLC Current Clinical Trials in Oligometastases Anne‐Marie Dingemans Netherlands Nothing to disclose

ES06.02 Oligometastatic NSCLC Integrating New Systemic Therapy into Trials in OMD Sanjay Popat UK Consultant Boehringer Ingelheim, Epizyme, Bristol‐Meyers Squibb, Clovis Oncology, Roche, Eli Lilly, Takeda, AstraZeneca, Novartis, Pfizer, Merck, Guardant Health, AbbVie

ES06.02 Oligometastatic NSCLC Integrating New Systemic Therapy into Trials in OMD Sanjay Popat UK Honoraria Boehringer Ingelheim, AstraZeneca, Roche, Eli Lilly, Novartis, Takeda, Guardant Health, Bristol‐Meyers Squibb, Pfizer, Chugai Pharma, Merck, Abbvie

ES06.02 Oligometastatic NSCLC Integrating New Systemic Therapy into Trials in OMD Sanjay Popat UK Supported/Contracted Research/Grant Boehringer Ingelheim, Epizyme, Bristol‐Meyers Squibb, Clovis Oncology, Roche, Eli Lilly, Takeda

ES06.02 Oligometastatic NSCLC Integrating New Systemic Therapy into Trials in OMD Sanjay Popat UK Speakers Bureau Pfizer, AstraZeneca, Boehringer Ingelheim, Roche, Merck, Chugai

ES06.02 Oligometastatic NSCLC Integrating New Systemic Therapy into Trials in OMD Sanjay Popat UK Speakers or Advisory Board Boehringer Ingelheim, AstraZeneca, Roche, Novartis, Pfizer, Bristol‐Meyers Squibb, Merck, Guardant Health, AbbVie, Takeda, Chugai

ES06.03 Oligometastatic NSCLC Developments in SBRT in the Oligometastatic Paradigm in NSCLC Patrick Cheung Canada Nothing to disclose

ES06.04 Oligometastatic NSCLC Surgical Considerations in OMD Jessica Donington USA Honoraria AstraZeneca

ES06.05 Q&A

Session MA23: Early Stage Lung Cancer: Present and Future


Planner
















Chairs

MA23 Aman Coonar UK Nothing to disclose

MA23 Roy Decker USA Nothing to disclose

Faculty

MA23.01 Treatment of Early Stage/Localized Disease Buffy Coat Immunooncologic Diagnosis and Prognosis of pStage I Lung Adenocarcinoma

Harvey Pass USA Nothing to disclose

MA23.02 Treatment of Early Stage/Localized Disease Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early‐Stage Lung Cancer

Vincent Lam USA Nothing to disclose

MA23.03 Screening and Early Detection Risk Assessment for Indeterminate Pulmonary Nodules Using a Novel, Plasma‐Protein Based Biomarker Assay

Anil Vachani USA Honoraria MagArray

MA23.04 Treatment of Early Stage/Localized Disease Discussant ‐ MA 23.01, MA 23.02, MA 23.03 Scott Bratman Canada Royalty, Intellectual Property/Patent Holder Roche Molecular Diagnostics

MA23.05 Treatment of Early Stage/Localized Disease Post‐Operative Radiation Improves Overall Survival in Patients with Node‐Positive Non‐Small Cell Lung Cancer Undergoing Sublobar Resections

Karl Fabian Uy USA Nothing to disclose

MA23.06 Treatment of Early Stage/Localized Disease Small Residual Setup Errors After Image‐Guided Radiotherapy Affect Heart Dose and Are Linked to Overall Survival

Alan McWilliam UK Nothing to disclose

MA23.07 Treatment of Early Stage/Localized Disease Defining the Role of Adjuvant Therapy for Early Stage Large Cell Neuroendocrine Lung Cancer

Elliot Wakeam Canada Nothing to disclose

MA23.08 Treatment of Early Stage/Localized Disease Discussant ‐ MA 23.05, MA 23.06, MA 23.07 Kevin Franks UK Nothing to disclose

MA23.09 Treatment of Early Stage/Localized Disease Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy, a Comparison Utilizing the National Cancer Database

Mark Hennon USA Nothing to disclose

MA23.10 Treatment of Early Stage/Localized Disease Cone‐Beam Computed Tomography‐Guided Microcoil Localization of Pulmonary Nodules During Video‐Assisted Thoracic Surgery

Hideki Ujiie Canada Nothing to disclose

MA23.11 Treatment of Early Stage/Localized Disease Lobe‐Specific Nodal Dissection for Clinical Stage I and II Non‐Small Cell Lung Cancer: Japanese Multi‐Institutional Retrospective Study

Tomoyuki Hishida Japan Nothing to disclose

MA23.12 Treatment of Early Stage/Localized Disease Discussant ‐ MA 23.09, MA 23.10, MA 23.11 Giulia Veronesi Italy Speakers or Advisory Board Medtronic

MA23.12 Treatment of Early Stage/Localized Disease Discussant ‐ MA 23.09, MA 23.10, MA 23.11 Giulia Veronesi Italy Honoraria Verbsurgical, Abmedica

Session MA24: Genomic Evolution, KEAP 3 and More Non‐Coding RNA


Planner





Rain Therapeutics

















Chairs

MA24 Ravi Salgia USA Nothing to disclose

MA24 Ping Yang USA Nothing to disclose

Faculty

MA24.01 Biology Genomic Evolution Trajectory Depicts Invasiveness Acquisition from Pre‐invasive to Invasive Adenocarcinoma

Chao Zhang China Nothing to disclose

MA24.02 Biology Genomic Alterations in Lung Adenocarcinoma Precursor Lesions Dennis Wigle USA Nothing to disclose

MA24.03 Treatment of Early Stage/Localized Disease Biologic Profiling of Pre‐Metastatic Niche in Completely Resected Pathological Stage I Non‐Small Cell Lung Cancer

Tomohito Saito Japan Supported/Contracted Research/Grant Ono Pharma, Bristol‐Myers Squibb

MA24.03 Treatment of Early Stage/Localized Disease Biologic Profiling of Pre‐Metastatic Niche in Completely Resected Pathological Stage I Non‐Small Cell Lung Cancer

Tomohito Saito Japan Consultant Ono Pharma

MA24.04 Biology Discussant ‐ MA 24.01, MA 24.02, MA 24.03 Udayan Guha USA Nothing to disclose

MA24.05 Biology Baseline Spatial Heterogeneity of T790M in Tyrosine Kinase Inhibitor Naïve EGFR‐Mutant Lung Adenocarcinomas

Michael Cabanero Canada Nothing to disclose

MA24.06 Biology Long Non‐Coding Rna Expression Patterns Delineate Infiltrating Immune Cells in the Lung Tumour Microenvironment

Adam Sage Canada Nothing to disclose

MA24.07 Biology A Novel cis‐Acting lncRNA Controls HMGA1 Expression in Lung Adenocarcinoma

Adam Sage Canada Nothing to disclose

MA24.08 Biology Discussant ‐ MA 24.05, MA 24.06, MA 24.07 Alice Berger USA Nothing to disclose

MA24.09 Biology Synergy Between the KEAP1/NRF2 and PI3K Pathways Drives Non‐Small Cell Lung Cancer with an Altered Metabolism

Sarah Best Australia Nothing to disclose

MA24.10 Biology Interrogating the Metabolic Effects of Keap1 Inactivation in Adenocarcinoma

Sarah Best Australia Nothing to disclose

MA24.11 Biology Loss of Tumour Suppressors is Adequate and Sufficient to Drive Lung Cancer in CRISPR/Cas9 Mice.

Paola Marignani Canada Nothing to disclose

MA24.12 Biology Discussant ‐ MA 24.09, MA 24.10, MA 24.11 Vladmir Cordeiro De Lima Brazil Nothing to disclose

Session MS22: Biology of the Lung and Lung Cancer


Planner






Rain Therapeutics


























OrigiMed










Chairs

MS22 Matthew Meyerson USA Speakers or Advisory Board OrigiMed

MS22 Matthew Meyerson USA Ownership Interest (stocks or stock options, or other ownership interest

OrigiMed

MS22 Matthew Meyerson USA Supported/Contracted Research/Grant Bayer

MS22 Matthew Meyerson USA Royalty, Intellectual Property/Patent Holder LabCorp

MS22 Geoffrey Liu Canada Honoraria AstraZeneca, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie, Pfizer, Merck

MS22 Geoffrey Liu Canada Speakers Bureau AstraZeneca

MS22 Geoffrey Liu Canada Speakers or Advisory Board AstraZeneca, Roche, Merck, Novartis, Takeda, Bristol‐Meyers Squibb, AbbVie

Faculty

MS22.01 Biology Lung Development and Stem Cells Samuel Rowbotham USA Nothing to disclose

MS22.02 Biology Epigenetic Alterations in Lung Cancer Development Wan Lam Canada Nothing to disclose

MS22.03 Biology Non‐Coding RNA in Lung Cancer Sven Diederichs Germany Ownership Interest (stocks or stock options, or other ownership interest

Biotech, Martinsried

MS22.04 Biology Genomics of Resistance and Response in Lung Cancer Marc Ladanyi USA Consultant Boehringer‐Ingelheim, Afatinib Targeted Therapy

MS22.04 Biology Genomics of Resistance and Response in Lung Cancer Marc Ladanyi USA Speakers or Advisory Board Foundation Medicine

MS22.04 Biology Genomics of Resistance and Response in Lung Cancer Marc Ladanyi USA Supported/Contracted Research/Grant Loxo

MS22.05 Biology Inflammation in Lung Cancer Katerina Politi USA Supported/Contracted Research/Grant AstraZeneca, Roche, Kolltan, Symphogen

MS22.05 Biology Inflammation in Lung Cancer Katerina Politi USA Honoraria AstraZeneca, Merck, Novartis, Tocagen

MS22.05 Biology Inflammation in Lung Cancer Katerina Politi USA Royalty, Intellectual Property/Patent Holder Molecular MD

MS22.06 Biology Transcriptomic‐Metabolomic Reprograming as Resistant Mechanism Patrick Ma USA Speakers Bureau Merck, BMS, Takeda, AstraZeneca

MS22.06 Biology Transcriptomic‐Metabolomic Reprograming as Resistant Mechanism Patrick Ma USA Advisory Board Caris

Session MS23: What's New in Targeted Therapy?


Planner

MS23 Targeted Therapy Janessa Laskin Canada Honoraria Roche, Boehringer Ingelheim, AstraZeneca

MS23 Targeted Therapy Janessa Laskin Canada Supported/Contracted Research/Grant AstraZeneca, Roche, Pfizer

MS23 Targeted Therapy Tony Mok China Speakers or Advisory Board AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, Bristol‐Meyers Squibb, Taiho, Takeda Oncology Serono, SFJ Pharma, ACEA Biosciences, Vertex Pharma, geneDecode, OncoGenex Technologies, Celgene, Ignyta, Cirina, Fishawack Facilitate, Janssen, ChiMed

MS23 Targeted Therapy Tony Mok China Honoraria AstraZeneca, Roche, Genentech, Pfizer, Eli Lilly, Boehringer Ingelheim, Merck, Novartis, SFJ Pharma, ACEA Biosciences, Vertex Pharma, Bristol‐Meyers Squibb, OncoGenex Pharma, Celgene, Ignyta, Fishawack Facilitate, Takeda Oncology, Janssen, Cirina, Chimed

MS23 Targeted Therapy Tony Mok China Ownership Interest (stocks or stock options, or other ownership interest

Sanomics, Cirina

MS23 Targeted Therapy Tony Mok China Consultant Roche., IASLC, ASCO, ChiMed, Chinese Lung Cancer Research Foundation, Chinese Society of Clinical Oncology, Hong Kong Cancer Therapy Society



MS23 Targeted Therapy Tony Mok China Supported/Contracted Research/Grant AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, SFJ Pharmas Group, Roche, Merck, Clovis Oncology, Bristol‐Meyers Squibb, Taiho Pharma, Eisai

MS23 Targeted Therapy Tony Mok China Employee (full time or part time) The Chinese University of Hong Kong

MS23 Targeted Therapy Ross Camidge USA Honoraria Takeda, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, AstraZeneca, Arrys/Kyn, Genoptix, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera, Lycera, Revolution Med, Orion, Clovis, Celegene, Novartis

MS23 Targeted Therapy Ross Camidge USA Supported/Contracted Research/Grant Ariad, Takeda, Pfizer

MS23 Targeted Therapy Ross Camidge USA Speakers or Advisory Board AstraZeneca, Takeda, Arrys/Kyn, Genoptix, G1 Therapeutics, Mersana Therapeutics, Roche, Genentech, Takeda, Ignyta, Daichii Sankyo, Hansoh SRC, Bio‐Thera DSMB, Lycera, Revolution Med

MS23 Targeted Therapy Alexander Drilon USA Speakers or Advisory Board Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

MS23 Targeted Therapy Alexander Drilon USA Honoraria TP Therapeutics, Loxo, Ignyta, Roche, Genentech, Pfizer

MS23 Targeted Therapy Alexander Drilon USA Supported/Contracted Research/Grant Foundation Medicine

MS23 Targeted Therapy Alexander Drilon USA Consultant Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

MS23 Targeted Therapy Enriqueta Felip Spain Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb Celgene, Eli Lilly, Guardant Health, Novartis, Pfizer, Roche, Takeda, Merck

MS23 Targeted Therapy Enriqueta Felip Spain Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Pfizer, Roche, AstraZeneca, Bristol‐Meyers Squibb, Novartis, AbbVie, Takeda, Celegene, Guardant Health, Merck

MS23 Targeted Therapy Enriqueta Felip Spain Speakers Bureau AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, MSD, Novartis, Pfizer, Roche, Takeda, AbbVie, Merck, Celegne, Eli Lilly, Guardant Health

MS23 Targeted Therapy Pilar Garrido Spain Consultant Roche, Merck, AstraZeneca, Boehringer Ingelheim, Pfizer, Bristol‐Meyers Squibb, Eli Lilly and Company, AbbVie, Novartis

MS23 Targeted Therapy Pilar Garrido Spain Speakers Bureau Roche, Merck, Bristol‐Meyers Squibb, Pfizer

MS23 Targeted Therapy Pilar Garrido Spain Supported/Contracted Research/Grant Guardant

MS23 Targeted Therapy Shun Lu China Supported/Contracted Research/Grant AstraZeneca

MS23 Targeted Therapy Shun Lu China Speakers or Advisory Board Eli Lilly, Hutchison MediPharma, Simcere, Bristol‐Meyers Squibb, Roche, Pfizer, AstraZeneca

MS23 Targeted Therapy Zofia Piotrowska USA Consultant AstraZeneca, Boehringer Ingelheim, Ariad, Novartis, Guardant Health, Takeda, AbbVie

MS23 Targeted Therapy Zofia Piotrowska USA Speakers or Advisory Board AstraZeneca, Ariad, Takeda, Novartis, Boehringer Ingelheim, AbbVie

MS23 Targeted Therapy Zofia Piotrowska USA Supported/Contracted Research/Grant Novartis

MS23 Targeted Therapy Zofia Piotrowska USA Honoraria Guardant Health

MS23 Targeted Therapy Karen Reckamp USA Consultant Amgen, Ariad, Astellas Pharma, Euclises, Tesaro, Boehringer Ingelheim, Takeda

MS23 Targeted Therapy Karen Reckamp USA Supported/Contracted Research/Grant Bristol‐Meyers Squibb, Pfizer, Novartis, Ariad, Clovis Oncology, Xcovery, Gilead Sciences, Pfizer, Adaptimmune, Genentech, Roche, Boehringer Ingelheim, AbbVie

MS23 Targeted Therapy Lecia Sequist USA Speakers or Advisory Board AstraZeneca, Genentech, Pfizer, Bristol‐Meyers Squibb, Merrimack Pharma, Blueprint Medicines

MS23 Targeted Therapy Lecia Sequist USA Consultant Merrimack, Novartis, Boehringer Ingelheim

MS23 Targeted Therapy Lecia Sequist USA Supported/Contracted Research/Grant AstraZeneca, Novartis, Genentech, Boehringer Ingelheim, Merck, Merrimack, Guardant Health

MS23 Targeted Therapy Benjamin Solomon Australia Speakers or Advisory Board AstraZeneca, Bristol‐Myers Squibb, Merck, Pfizer, Roche, Genentech, Novartis

MS23 Targeted Therapy Benjamin Solomon Australia Honoraria Bristol‐Myers Squibb, AstraZeneca

MS23 Targeted Therapy Benjamin Solomon Australia Supported/Contracted Research/Grant Pfizer

MS23 Targeted Therapy Benjamin Solomon Australia Royalty, Intellectual Property/Patent Holder Veristrat

MS23 Targeted Therapy Benjamin Solomon Australia Consultant AstraZeneca, Roche, Merck, Bristol‐Myers Squibb, Novartis

MS23 Targeted Therapy James Chih‐Hsin Yang Taiwan Consultant Boehringer Ingelheim, Eli Lilly, Bayer, Roche, Genentech, Chugai, Astellas, Merck, Novartis, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, Takeda, AstraZeneca, Hansoh Pharma

MS23 Targeted Therapy James Chih‐Hsin Yang Taiwan Speakers or Advisory Board Boehringer Ingelheim, Eli Lilly, Roche, Genentech, Chugai, Astellas, Merck, Pfizer, Novartis, Takeda, Celgene, Merrimack, Yuhan Pharma, Bristol‐Meyers Squibb, Ono Pharma, Daiichi Sankyo, AstraZeneca, Hansoh Pharma

MS23 Targeted Therapy James Chih‐Hsin Yang Taiwan Honoraria Novartis, Roche, Genentech, Eli Lilly and Company, Merck, Celgene, Pfizer, Ono Pharma, Bristol‐Myers Squibb, Hansoh, Takeda, Boehringer Ingelheim, Astellas, Merimack, Yuhan Pharma

Chairs

MS23 Vera Hirsh Canada Nothing to disclose

MS23 Alexander Drilon USA Speakers or Advisory Board Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

MS23 Alexander Drilon USA Honoraria TP Therapeutics, Loxo, Ignyta, Roche, Genentech, Pfizer

MS23 Alexander Drilon USA Supported/Contracted Research/Grant Foundation Medicine

MS23 Alexander Drilon USA Consultant Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Roche, Takeda, Helsinn Therapeutics, BeiGene

Faculty

MS23.01 Targeted Therapy Novel Combinations of Targeted Therapies Pasi Jänne USA Consultant Araxes Pharmas, Ariad, AstraZeneca, Boehringer Ingelheim, Chugai, Ignyta, Eli Lilly, Loxo, Merrimack, Mirati Therapeutics, Pfizer, Roche, Dana‐Farber Cancer Institute

MS23.01 Targeted Therapy Novel Combinations of Targeted Therapies Pasi Jänne USA Speakers or Advisory Board AstraZeneca, Boehringer Ingelheim, Pfizer, Merrimack Pharmas, Roche, Genentech, Chugai Pharmas, Acea Biosciences, Ignyta, Loxo, Ariad, Eli Lilly, Araxes Pharmas

MS23.01 Targeted Therapy Novel Combinations of Targeted Therapies Pasi Jänne USA Speakers Bureau Loxo

MS23.01 Targeted Therapy Novel Combinations of Targeted Therapies Pasi Jänne USA Ownership Interest (stocks or stock options, or other ownership interest

Gatekeeper Pharmas

MS23.01 Targeted Therapy Novel Combinations of Targeted Therapies Pasi Jänne USA Supported/Contracted Research/Grant Astellas Pharmas, AstraZenenca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim



MS23.01 Targeted Therapy Novel Combinations of Targeted Therapies Pasi Jänne USA Royalty, Intellectual Property/Patent Holder LabCorp

MS23.02 Targeted Therapy Emerging or Rare Targets ‐ Fusions, Mutational Burden Etc Luis Paz‐Ares Spain Consultant Novartis, Roche, Pfizer, Bristol‐Meyers Squibb, Merck, Boehringer Ingelheim, AstraZeneca, Amgen, Clovis, Takeda

MS23.02 Targeted Therapy Emerging or Rare Targets ‐ Fusions, Mutational Burden Etc Luis Paz‐Ares Spain Honoraria Eli Lilly, Roche, Novartis, Bristol‐Meyers Squibb, Merck, Pfizer, Amgen, Takeda, Boehringer Ingelheim, AstraZeneca, Clovis Oncology, Astillas

MS23.02 Targeted Therapy Emerging or Rare Targets ‐ Fusions, Mutational Burden Etc Luis Paz‐Ares Spain Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, AstraZeneca, Roche, Lilly, Merck, Pfizer, Novartis, Takeda, Incyte, Boehringer Ingelheim, Celgene

MS23.03 Targeted Therapy Management of CNS Mets in the Era of CNS‐Penetrant TKIs (Med Onc and Rad Onco Perspectives)

Marina Garassino Italy Consultant Merck, Bristol‐Meyers Squibb AstraZeneca, Roche

MS23.03 Targeted Therapy Management of CNS Mets in the Era of CNS‐Penetrant TKIs (Med Onc and Rad Onco Perspectives)

Marina Garassino Italy Honoraria Merck, Bristol‐Meyers Squibb, AstraZeneca, Roche, Boehringer Ingelheim

MS23.04 Targeted Therapy Targeting Driver Oncogenes in Stage 1‐3 NSCLC Helena Yu USA Consultant AstraZeneca, Boehringer Ingelheim, Eli Lilly

MS23.04 Targeted Therapy Targeting Driver Oncogenes in Stage 1‐3 NSCLC Helena Yu USA Supported/Contracted Research/Grant AstraZeneca, Astellas Pharma, Eli Lilly, Clovis Oncology, Incyte, Daiichi, Novartis

MS23.05 Targeted Therapy Role of Immunotherapy in Patients with Molecular Driven NSCLC Benjamin Besse France Supported/Contracted Research/Grant Roche, AstraZeneca

MS23.06 Q&A

Session MS24: Global Perspectives on Tobacco Control


Planner












Chairs

MS24 Desmond Carney Ireland Nothing to disclose

MS24 Rui Haddad Brazil Nothing to disclose

Faculty

MS24.01 Prevention and Tobacco Control Tobacco Control Impacting the Effectiveness and Cost of Cancer Care Graham Warren USA Nothing to disclose

MS24.02 Prevention and Tobacco Control Legal Action Against the Tobacco Industry in Europe Paul Baas Netherlands Nothing to disclose

MS24.03 Prevention and Tobacco Control The Importance of Physician Involvement in Tobacco Control Jacek Jassem Poland Nothing to disclose

MS24.04 Prevention and Tobacco Control Challenges of Tobacco Control in China Caicun Zhou China Honoraria Roche, Eli Lilly, Boehringer Ingelheim, Merck, Hengrui, Qiru, Sanofi, Pfizer

MS24.05 Q&A

Session MS25: Genetic and Prognostic Markers in Mesothelioma; Going Beyond the Histology Subtypes


Planner

MS25 Mesothelioma Anna Nowak Australia Speakers or Advisory Board Bayer, AstraZeneca, Sellas Life Sciences, Trizell, Boehringer Ingelheim, Epizyme, Roche, Merck

MS25 Mesothelioma Anna Nowak Australia Consultant AstraZeneca, Boehringer Ingelheim, Epizyme

MS25 Mesothelioma Anna Nowak Australia Supported/Contracted Research/Grant AstraZeneca, Douglas Pharma

MS25 Mesothelioma Marc DePerrot Canada Nothing to disclose

MS25 Mesothelioma Paul Baas Netherlands Nothing to disclose

MS25 Mesothelioma Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer

MS25 Mesothelioma Michele Carbone USA Nothing to disclose

MS25 Mesothelioma John Cho Canada Nothing to disclose



MS25 Mesothelioma Lauren Donohoe Canada Nothing to disclose

MS25 Mesothelioma Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche

MS25 Mesothelioma Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex

MS25 Mesothelioma Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca

MS25 Mesothelioma Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

MS25 Mesothelioma Seiki Hasegawa Japan Nothing to disclose

MS25 Mesothelioma Christopher Lee Canada Nothing to disclose

MS25 Mesothelioma Isabelle Opitz Switzerland Nothing to disclose

MS25 Mesothelioma Nick Pavlakis Australia Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Astra Zeneca, Roche, Novartis, Boehringer Ingelheim, Merck, Pfizer, Ipsen, Amgen

MS25 Mesothelioma Nick Pavlakis Australia Supported/Contracted Research/Grant Bayer

MS25 Mesothelioma Kenneth Rosenzweig USA Nothing to disclose

Chairs

MS25 Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche

MS25 Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex

MS25 Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca

MS25 Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

MS25 Aaron Mansfield USA Speakers or Advisory Board Genentech, Bristol‐Meyers Squibb, AbbVie

MS25 Aaron Mansfield USA Supported/Contracted Research/Grant Novartis, NIH

MS25 Aaron Mansfield USA Consultant Roche

Faculty

MS25.01 Mesothelioma Impact of Tumor Volume on Outcome: What Are the Limitations? Anna Nowak Australia Speakers or Advisory Board Bayer, AstraZeneca, Sellas Life Sciences, Trizell, Boehringer Ingelheim, Epizyme, Roche, Merck

MS25.01 Mesothelioma Impact of Tumor Volume on Outcome: What Are the Limitations? Anna Nowak Australia Consultant AstraZeneca, Boehringer Ingelheim, Epizyme

MS25.01 Mesothelioma Impact of Tumor Volume on Outcome: What Are the Limitations? Anna Nowak Australia Supported/Contracted Research/Grant AstraZeneca, Douglas Pharma

MS25.02 Mesothelioma How Should P16, BAP1, and NF2 Mutations Be Integrated in Therapeutic Algorithms?

Francoise Galateau‐Salle France Nothing to disclose

MS25.03 Mesothelioma Impact of Innate and Adaptive Tumor Infiltrating Cells on Prognosis Thomas John Australia Speakers or Advisory Board Bristol‐Meyers Squibb, AstraZeneca, Boehringher Ingelheim, Takeda, Pfizer, Novartis, Merck, Ignyta

MS25.03 Mesothelioma Impact of Innate and Adaptive Tumor Infiltrating Cells on Prognosis Thomas John Australia Consultant Bristol‐Meyers Squibb, AstraZeneca, Boehringer Ingelheim, Takeda, Pfizer, Novartis, Merck

MS25.04 Mesothelioma Biomarkers in Clinical Practice: Is It Prime Time? Harvey Pass USA Nothing to disclose

MS25.05 Mesothelioma Targeting the Micro‐RNA: A New Therapeutic Venture Nick Pavlakis Australia Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Astra Zeneca, Roche, Novartis, Boehringer Ingelheim, Merck, Pfizer, Ipsen, Amgen

MS25.05 Mesothelioma Targeting the Micro‐RNA: A New Therapeutic Venture Nick Pavlakis Australia Supported/Contracted Research/Grant Bayer

MS25.06 Q&A

Session MS26: From Textbook to Practice Around the World


Planner



















Gilead



































Chairs

MS26 Jarushka Naidoo USA Supported/Contracted Research/Grant Merck, AstraZeneca

MS26 Jarushka Naidoo USA Consultant Bristol‐Meyers Squibb, Takeda, AstraZeneca

MS26 Fabio Moraes Brazil Nothing to disclose

Faculty


Translation of Clinical Data to Real World ‐ Asia Dae Ho Lee Korea Honoraria AstraZeneca, Boehringer Ingelheim, CJ Healthcare, Eli Lilly, Merck, Mundipharma, Novartis, Ono Pharma, Pfizer, Roche, Samyang, STCube Pharmas, Ministry of Food and Drug Safety, National Evidence‐based Collaborating Agency, Korea, National Cancer Control Planning Board, Takeda, Bristol‐Meyers Squibb


Translation of Clinical Data to Real World ‐ Asia Dae Ho Lee Korea Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, CJ Healthcare, Eli Lilly, Merck, Mundipharma, Novartis, Ono Pharma, Pfizer, Roche, Samyang, STCube Pharmas, Ministry of Food and Drug Safety, National Evidence‐based Collaborating Agency, National Cancer Control Planning Board, Takeda


Translation of Clinical Data to Real World ‐ North America Cheryl Ho Canada Supported/Contracted Research/Grant BC Cancer Foundation


Translation of Clinical Data to Real World ‐ North America Cheryl Ho Canada Honoraria AstraZeneca


Translation of Clinical Data to Real World ‐ North America Cheryl Ho Canada Consultant Roche


Translation of Clinical Data to Real World ‐ Europe Fabrice Barlesi France Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda


Translation of Clinical Data to Real World ‐ Europe Fabrice Barlesi France Consultant Roche, Genentech., AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda


Translation of Clinical Data to Real World ‐ Europe Fabrice Barlesi France Supported/Contracted Research/Grant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda


Translation of Clinical Data to Real World ‐ Europe Fabrice Barlesi France Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Clovis Oncology, Eli Lilly, Roche, Novartis, Merck, Pierre Fabre, Pfizer, Takeda, Serono


Translation of Clinical Data to Real World ‐ Latin America/Africa Luis Ubillos Uruguay Speakers Bureau Roche, Tecnofarma


Translation of Clinical Data to Real World ‐ Latin America/Africa Luis Ubillos Uruguay Speakers or Advisory Board Roche, Tecnofarma, Servier, Bayer

MS26.05 Panel Discussion

Session MS27: Therapeutic Implications of Staging Issues


Planner






















Chairs

MS27 Janet Edwards Canada Nothing to disclose

MS27 Masaoki Ito Japan Nothing to disclose

Faculty

MS27.01 Treatment of Early Stage/Localized Disease Staging of Lymph Nodes in Early Stage NSCLC: Therapeutic Implications Raymond Osarogiagbon USA Supported/Contracted Research/Grant Association of Community Cancer Centers

MS27.01 Treatment of Early Stage/Localized Disease Staging of Lymph Nodes in Early Stage NSCLC: Therapeutic Implications Raymond Osarogiagbon USA Ownership Interest (stocks or stock options, or other ownership interest

Foundation Medicine, Pfizer, Eli Lilly

MS27.01 Treatment of Early Stage/Localized Disease Staging of Lymph Nodes in Early Stage NSCLC: Therapeutic Implications Raymond Osarogiagbon USA Royalty, Intellectual Property/Patent Holder Patent

MS27.01 Treatment of Early Stage/Localized Disease Staging of Lymph Nodes in Early Stage NSCLC: Therapeutic Implications Raymond Osarogiagbon USA Consultant Association of Community Cancer Centers

MS27.02 Treatment of Early Stage/Localized Disease Invasive Staging in Medically Inoperable Patients Treated with SBRT: Is It Necessary?

Anand Swaminath Canada Nothing to disclose

MS27.03 Treatment of Early Stage/Localized Disease Multiple Lung Nodules: M1, T4 or T3? Are They Really Different? Frank Detterbeck USA Speakers or Advisory Board Spiration

MS27.03 Treatment of Early Stage/Localized Disease Multiple Lung Nodules: M1, T4 or T3? Are They Really Different? Frank Detterbeck USA Supported/Contracted Research/Grant Medela

MS27.04 Treatment of Early Stage/Localized Disease Therapeutic Implications of AJCC 8th Edition T1 Subsets Laura Donahoe Canada Nothing to disclose

MS27.05 Treatment of Early Stage/Localized Disease The Future of Precision Therapy for Localized Lung Cancer Takashi Seto Japan Honoraria Astellas Pharma, AstraZeneca, Bristol‐Myers Squibb, Chugai Pharma, Eli Lilly, Merck, Nippon Boehringer Ingelheim, Ono Pharma, Pfizer, Taiho Pharma, Takeda

MS27.05 Treatment of Early Stage/Localized Disease The Future of Precision Therapy for Localized Lung Cancer Takashi Seto Japan Supported/Contracted Research/Grant AstraZeneca, Bayer, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Kissei Pharma, Merck, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer

MS27.06 Q&A

Session OA13: Therapeutics and Radiation for Small Cell Lung Cancer


Planner







Chairs

OA13 Stephanie Snow Canada Advisory Board AstraZeneca, BMS, Lilly, Merck, Novartis, Roche

OA13 Theodoros Tsakiridis Canada Nothing to disclose

Faculty

OA13.01 Small Cell Lung Cancer/NET The Impact of [18F]fludeoxyglucose PET/CT in Small‐Cell Lung Cancer: Analysis of the Phase 3 CONVERT Trial

Corinne Faivre‐Finn UK Supported/Contracted Research/Grant Merck, AstraZeneca, Elekta


Corinne Faivre‐Finn UK Consultant Merck, AstraZeneca, Elekta, Pfizer, Respective Meeting‐Related Travel Support


Corinne Faivre‐Finn UK Speakers or Advisory Board Pfizer, Merck


Corinne Faivre‐Finn UK Honoraria AstraZeneca, Merck


Corinne Faivre‐Finn UK Speakers Bureau AstraZeneca, Merck

OA13.02 Small Cell Lung Cancer/NET Two Novel Immunotherapy Agents Targeting DLL3 in SCLC: Trials in Progress of AMG 757 and AMG 119


OA13.02 Small Cell Lung Cancer/NET Two Novel Immunotherapy Agents Targeting DLL3 in SCLC: Trials in Progress of AMG 757 and AMG 119


OA13.03 Small Cell Lung Cancer/NET Anlotinib as Third‐Line or Further‐Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double‐Blind Phase 2 Trial

Ying Cheng China Nothing to disclose

OA13.04 Small Cell Lung Cancer/NET Discussant ‐ OA 13.01, OA 13.02, OA 13.03 Normand Blais Canada Speakers or Advisory Board AstraZeneca, Merck, Sanofi Canada, Bristol‐Meyers Squibb, Roche Canada, Boehringer Ingelheim, Bayer, Pfizer



OA13.05 Small Cell Lung Cancer/NET Prophylactic Cranial Irradiation (PCI) for Limited‐Stage Small‐Cell Lung Cancer: Results from the Phase 3 CONVERT Trial

Cecile Le Pechoux France Speakers or Advisory Board AstraZeneca

OA13.06 Small Cell Lung Cancer/NET Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes in Limited‐stage Small Cell Lung Cancer with Radiation

Xiao Hu China Nothing to disclose

OA13.07 Small Cell Lung Cancer/NET Survival Outcomes After Whole Brain Radiotherapy for Brain Metastases in Elderly Patients with Newly Diagnosed Metastatic Small Cell Carcinoma.

Paul Renz USA Nothing to disclose

OA13.08 Small Cell Lung Cancer/NET Discussant ‐ OA 13.05, OA 13.06, OA 13.07 Inga Grills USA Nothing to disclose

Session PC09: Approaches to Management of Advanced NSCLC


Planner











Gatekeeper Pharmas












Chairs

PC09 Yasushi Goto Japan Nothing to disclose

PC09 Gwyn Bebb Canada Nothing to disclose

Faculty

PC09.01 Advanced NSCLC Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild‐Type NSCLC ‐ Early


PC09.02 Advanced NSCLC Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild‐Type NSCLC ‐ Delayed

Walter Curran, Jr. USA Nothing to disclose

PC09.03 Discussion

PC09.04 Advanced NSCLC Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? ‐ NSCLC

Noemi Reguart Spain Nothing to disclose

PC09.05 Advanced NSCLC Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? ‐ SCLC

Scott Laurie Canada Consultant Bristol‐Meyers Squibb, Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca, BBI

PC09.05 Advanced NSCLC Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? ‐ SCLC

Scott Laurie Canada Honoraria Novartis, Pfizer, Boehringer Ingelheim, AstraZeneca

PC09.06 Discussion

Session ES07: Beyond the Diagnosis ‐ Collaborative Care for Change


Planner

ES07 Nursing and Allied Professionals Massey Nematollahi Canada Nothing to disclose

ES07 Nursing and Allied Professionals Patricia Hollen USA Nothing to disclose



ES07 Nursing and Allied Professionals Beth Eaby‐Sandy USA Speakers Bureau Helsinn, Merck, AstraZeneca, Takeda

ES07 Nursing and Allied Professionals Beth Eaby‐Sandy USA Consultant Consultant‐ AbbVie

ES07 Nursing and Allied Professionals Kathleen Gamblin USA Nothing to disclose

ES07 Nursing and Allied Professionals Maria Guerin UK Speakers or Advisory Board AstraZeneca

ES07 Nursing and Allied Professionals Maria Guerin UK Honoraria AstraZeneca

ES07 Nursing and Allied Professionals Pippa Labuc UK Nothing to disclose

ES07 Nursing and Allied Professionals Naz Nouriany Canada Nothing to disclose

ES07 Nursing and Allied Professionals Dianne Zawisza Canada Nothing to disclose

Chairs

ES07 Maria Guerin UK Speakers or Advisory Board AstraZeneca

ES07 Maria Guerin UK Honoraria AstraZeneca

ES07 Dianne Zawisza Canada Nothing to disclose

Faculty

ES07.01 Nursing and Allied Professionals A Moment in Time for the Unplanned Conversations Kelly McGuigan Canada Nothing to disclose

ES07.02 Nursing and Allied Professionals Special Needs and Wellness in Lung Cancer Patients ‐ Australian Perspective

Maria Ftanou Australia Nothing to disclose

ES07.03 Nursing and Allied Professionals Special Needs and Wellness in Lung Cancer Patients ‐ European Perspective

Rossie Navon Israel Nothing to disclose

ES07.04 Nursing and Allied Professionals Leveraging Social Media to Change the Public Conversation on Lung Cancer Stigma

Lisa Carter‐Harris USA Nothing to disclose

ES07.05 Nursing and Allied Professionals Research Update: Patient’s Perspective on Living with Malignant Pleural Mesothelioma

Angela Tod UK Nothing to disclose

ES07.06 Q&A

Session ES08: The Pathologist ‐ An Essential Member of the Patient Care Team


Planner

ES08 Pathology Ming Tsao Canada Honoraria Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Roche, Ventana

ES08 Pathology Ming Tsao Canada Supported/Contracted Research/Grant Merck, Pfizer, Roche, Ventana, AstraZeneca

ES08 Pathology Ming Tsao Canada Speakers or Advisory Board AstraZeneca, Pfizer, Merck, Roche, Ventana, Bristol Myers Squibb, AbbVie, Celgene

ES08 Pathology Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune

ES08 Pathology Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche

ES08 Pathology Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen

ES08 Pathology Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

ES08 Pathology Alan Borczuk USA Nothing to disclose

ES08 Pathology Lukas Bubendorf Switzerland Nothing to disclose

ES08 Pathology Sanja Dacic USA Speakers or Advisory Board Bristol‐Meyers Squibb, Astra‐Zeneca

ES08 Pathology Sanja Dacic USA Honoraria Bristol‐Meyers Squibb, AstraZeneca

ES08 Pathology David Hwang Canada Honoraria Merck, Pfizer, Takeda

ES08 Pathology David Hwang Canada Speakers or Advisory Board Merck

ES08 Pathology Keith Kerr UK Consultant Bristol‐Meyers Squibb

ES08 Pathology Keith Kerr UK Speakers or Advisory Board AstraZeneca, Bristol Meyers Squibb, Merck, Roche, Pfizer

ES08 Pathology Sylvie Lantuejoul France Nothing to disclose

ES08 Pathology John Longshore USA Speakers Bureau Roche, AstraZeneca, Bristol‐Meyers Squibb, Merck, Genentech

ES08 Pathology John Longshore USA Speakers or Advisory Board Roche, AbbVie, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer

ES08 Pathology John Longshore USA Supported/Contracted Research/Grant Roche, AstraZeneca

ES08 Pathology Mari Mino‐Kenudson USA Consultant Merrimack Pharmas, H3 Biomedicine

ES08 Pathology Mari Mino‐Kenudson USA Honoraria Merrimac Pharmas, H3 Biomedicine

ES08 Pathology Andre Moreira USA Nothing to disclose

ES08 Pathology Andrew Nicholson UK Consultant Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Bristol‐Meyers Squibb, Roche, AbbVie



ES08 Pathology Andrew Nicholson UK Supported/Contracted Research/Grant Pfizer, Roche

ES08 Pathology Andrew Nicholson UK Speakers or Advisory Board Pfizer, Abbvie

ES08 Pathology Andrew Nicholson UK Ownership Interest (stocks or stock options, or other ownership interest

Merck

ES08 Pathology Yasushi Yatabe Japan Consultant Merck, Chugai‐Pharma, AstraZeneca, Bristol‐Meyers Squibb, Pfizer, Roche, ThermoFisher, Dako

ES08 Pathology Yasushi Yatabe Japan Honoraria AstraZeneca, Merck, Bristol Myers, Chugai‐pharma, Pfizer, Roche

Chairs

ES08 Claudia Poleri Argentina Nothing to disclose

ES08 Prodipto Pal Canada Nothing to disclose

Faculty

ES08.01 Pathology Targeted Therapy Yasushi Yatabe Japan Consultant Merck, Chugai‐Pharma, AstraZeneca, Bristol‐Meyers Squibb, Pfizer, Roche, ThermoFisher, Dako

ES08.01 Pathology Targeted Therapy Yasushi Yatabe Japan Honoraria AstraZeneca, Merck, Bristol Myers, Chugai‐pharma, Pfizer, Roche

ES08.02 Pathology Immunotherapy Sylvie Lantuejoul France Nothing to disclose

ES08.03 Pathology Mesothelioma, Thymic Epithelial Tumors and Others Andrew Nicholson UK Consultant Merck, Boehringer Ingelheim, Novartis, AstraZeneca, Bristol‐Meyers Squibb, Roche, AbbVie

ES08.03 Pathology Mesothelioma, Thymic Epithelial Tumors and Others Andrew Nicholson UK Supported/Contracted Research/Grant Pfizer, Roche

ES08.03 Pathology Mesothelioma, Thymic Epithelial Tumors and Others Andrew Nicholson UK Speakers or Advisory Board Pfizer, Abbvie

ES08.03 Pathology Mesothelioma, Thymic Epithelial Tumors and Others Andrew Nicholson UK Ownership Interest (stocks or stock options, or other ownership interest

Merck

ES08.04 Pathology Neoadjuvant Therapy Ignacio Wistuba USA Consultant Genentech, Roche, Eli Lilly, Bristol‐Myers Squibb, Ariad, HTG Molecular Diagnostics, Asuragen, Pfizer, AstraZeneza, MedImmune

ES08.04 Pathology Neoadjuvant Therapy Ignacio Wistuba USA Speakers Bureau Pfizer, Boehringer Ingelheim, Merck, Bristol‐Myers Squibb, Genentech, Roche

ES08.04 Pathology Neoadjuvant Therapy Ignacio Wistuba USA Supported/Contracted Research/Grant Genentech, Merck, OncoPlex Diagnostics, Myriad Genetics, HTG Molecular Diagnostics, Silicon Biosystems, Adaptimmune, Pfizer, MedImmune, DepArray, Bristol‐Myers Squibb, Adaptive, Takeda, Amgen

ES08.04 Pathology Neoadjuvant Therapy Ignacio Wistuba USA Speakers or Advisory Board Genentech, Roche, Bristol‐Myers Squibb, AstraZeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Bayer

ES08.05 Q&A

Session LA01: IASLC Lectureship Award Session


Planner

LA01 Natasha Leighl Canada Supported/Contracted Research/Grant Novartis

LA01 Natasha Leighl Canada Honoraria Merck, Bristol‐Meyers Squibb

LA01 Natasha Leighl Canada Consultant Novartis, AstraZeneca, Bristol‐Meyers Squibb, Merck, Pfizer, Canadian Agency for Drugs and Technologies in Health

LA01 Gail Darling Canada Nothing to disclose

LA01 Andrea Bezjak Canada Nothing to disclose

LA01 Frances Shepherd Canada Honoraria Bristol‐Myers Squibb, Eli Lilly, AstraZeneca, Roche, Genentech, Merck, Novartis, Pfizer

LA01 Frances Shepherd Canada Other Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack

LA01 Frances Shepherd Canada Ownership Interest (stocks or stock options, or other ownership interest


LA01 Frances Shepherd Canada Speakers or Advisory Board Eli Lilly, AstraZeneca, Merck

Chairs

LA01 Giorgio Scagliotti Italy Honoraria AstraZeneca, Roche, Pfizer, Merck, Eli Lilly, AbbVie, Novartis, Clovis

LA01 Giorgio Scagliotti Italy Speakers or Advisory Board Eli Lilly, Merck

LA01 Giorgio Scagliotti Italy Speakers Bureau Eli Lilly, Merck

LA01 Giorgio Scagliotti Italy Consultant Bayer

LA01 Fred Hirsch USA Consultant AstraZeneca, Genentech, HTG Molecular Diagnostics, Eli Lilly, Merck, Clovis Oncology, Ventana Medical Systems, Bristol‐Meyers Squibb, Pfizer, Roche

LA01 Fred Hirsch USA Royalty, Intellectual Property/Patent Holder University of Colorado Cancer Center

LA01 Fred Hirsch USA Supported/Contracted Research/Grant Eli Lilly, Genentech, Amgen, Bristol‐Meyers Squibb, Celgene

LA01 Fred Hirsch USA Speakers or Advisory Board AbbVie, AstraZeneca, Biocept, Bristol‐Meyers Squibb, HTG, Eli Lilly, Loxo, Merck, Novartis, Pfizer, Roche, Genentech, Ventana, Bayer

LA01 Tetsuya Mitsudomi Japan Speakers or Advisory Board Eli LIlly

LA01 Tetsuya Mitsudomi Japan Supported/Contracted Research/Grant Eli Lilly, Boehringer Ingelheim, AstraZeneca, Chugai, The Japan Society for the Promotion of Science



LA01 Tetsuya Mitsudomi Japan Consultant Bristol‐Meyers Squibb, Ono Pharma

LA01 Tetsuya Mitsudomi Japan Speakers Bureau AstraZeneca, Chug, Pfizer, Boehringer Ingelheim

Faculty

LA01.01 Clifton F. Mountain Lectureship Award for Staging ‐ Is There Still a Stage for Improvements in Staging?

Johan Vansteenkiste Belgium Supported/Contracted Research/Grant University Hospitals KU Leuven, Merck


Johan Vansteenkiste Belgium Speakers or Advisory Board Apotex, AstraZeneca, Apotex, Boehringer Ingelheim, Merck, Novartis, Roche


Johan Vansteenkiste Belgium Consultant AstraZeneca, Merck, Bristol‐Meyers Squibb, Roche


Johan Vansteenkiste Belgium Honoraria AstraZeneca, Bristol‐Meyers Squibb, Merck, Roche

LA01.02 IASLC Lectureship Award for Radiation Oncology ‐ Defining the Role of Radiotherapy for Lung Cancer: Past, Present and Future

Hak Choy USA Speakers Bureau AstraZeneca

LA01.02 IASLC Lectureship Award for Radiation Oncology ‐ Defining the Role of Radiotherapy for Lung Cancer: Past, Present and Future

Hak Choy USA Honoraria AstraZeneca, Merck

LA01.03 Heine H. Hansen Lectureship Award for Small Cell Lung Cancer ‐ New Opportunities in Small Cell Lung Cancer

Charles Rudin USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Genentech, Harpoon, Genetics

LA01.03 Heine H. Hansen Lectureship Award for Small Cell Lung Cancer ‐ New Opportunities in Small Cell Lung Cancer

Charles Rudin USA Consultant Bristol‐Meyers Squibb, AbbVie, Seattle Genetics, Harpoon Therapeutics, Genentech Roche, AstraZeneca

LA01.04 Adi F. Gazdar Lectureship Award for Translational Research ‐ Genomic Alterations in Human Lung Cancers

Matthew Meyerson USA Speakers or Advisory Board OrigiMed


Matthew Meyerson USA Ownership Interest (stocks or stock options, or other ownership interest

OrigiMed


Matthew Meyerson USA Supported/Contracted Research/Grant Bayer


Matthew Meyerson USA Royalty, Intellectual Property/Patent Holder LabCorp

LA01.05 Tsuguo Naruke Lectureship Award for Surgery ‐ The Value of Naruke Lymph Node Chart and the Creation of IASLC Chart in Lung Cancer

Hisao Asamura Japan Honoraria Lecturer of seminar ‐ Johnson & Johnson, Covidien, Eli Lilly, Taiho, Boehringer Ingelheim, Ono Pharmaceuticals

LA01.06 Daniel C. Ihde Lectureship Award for Medical Oncology ‐ The Intersection of Science and Medicine

David Carbone USA Consultant Genentech


David Carbone USA Supported/Contracted Research/Grant Merck, Bristol‐Meyers Squibb


David Carbone USA Speakers or Advisory Board AbbVie, Adaptimmune, Agenus, Amgen, Ariad, AstraZeneca, Biocept, Boehringer Ingelheim, Bristol‐Meyers Squibb, Celgene, EMD Serono, Inc, Foundation Medicine, Genentech, Roche, Gritstone, Guardant Health, Inovio, Merck, Novartis, Palobiofarma, Pfizer, prIME Oncology, Stemcentrx, Takeda


David Carbone USA Honoraria AbbVie, Adaptimmune, Agenus, Amgen, Ariad, AstraZeneca, Biocept, Boehringer Ingelheim, Bristol‐Meyers Squibb, Celgene, Foundation Medicine, Genentech, Roche, Gritstone, Guardant Health, Inovio, Merck, Novartis, Palobiofarma, Pfizer, prIME Oncology, Stemcentrx, Takeda

LA01.07 Robert J. Ginsberg Lectureship Award for Surgery ‐ Honoring the Tradition of Surgically‐Based Clinical Trials


LA01.07 Robert J. Ginsberg Lectureship Award for Surgery ‐ Honoring the Tradition of Surgically‐Based Clinical Trials


LA01.08 IASLC Lectureship Award for Nursing and Allied Health Professionals ‐ The Right Hand: The Art of Collaboration

Kimberly Rohan USA Speakers Bureau Merck, Genentech, AstraZeneca

LA01.08 IASLC Lectureship Award for Nursing and Allied Health Professionals ‐ The Right Hand: The Art of Collaboration

Kimberly Rohan USA Speakers or Advisory Board AstraZeneca

LA01.09 Q&A

Session MA25: Oligometastasis: Defining, Treating, and Evaluating


Planner














Chairs

MA25 Zishan Allibhai Canada Nothing to disclose

MA25 Joanna Laba UK Nothing to disclose

Faculty

MA25.01 Oligometastatic NSCLC EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC


MA25.02 Oligometastatic NSCLC Searching for a Definition of Synchronous Oligometastatic (sOMD)‐NSCLC: A Consensus from Thoracic Oncology Experts

Anne‐Marie Dingemans Netherlands Nothing to disclose



MA25.03 Oligometastatic NSCLC Defining Oligometastatic Non‐Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion


MA25.04 Oligometastatic NSCLC Discussant ‐ MA 25.01, MA 25.02, MA 25.03 Abraham Wu USA Nothing to disclose

MA25.05 Oligometastatic NSCLC Characteristics & Survival of Resected Stage IV Non‐Small Cell Lung Cancer (NSCLC) in the Mid‐South Quality of Surgical Resection Cohort

Nicholas Faris USA Nothing to disclose

MA25.06 Oligometastatic NSCLC RPA Analysis for Oligometastatic Non‐Small Cell Lung Cancer: Smoking Combine T3/4 Patients May Not Be Benefit from Local Consolidative

Jia‐Tao Zhang China Nothing to disclose

MA25.07 Oligometastatic NSCLC Effectiveness of Systemic Therapy Combined with Thoracic Radiotherapy for Patients with Oligometastatic NSCLC: A Pooled Analysis

Chunyu Wang USA Nothing to disclose

MA25.08 Oligometastatic NSCLC Discussant ‐ MA 25.05, MA 25.06, MA 25.07 Alysa Fairchild Canada Nothing to disclose

MA25.09 Oligometastatic NSCLC M1b Disease in the 8th Edition of IASLC Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcom

Hyesun Park USA Nothing to disclose

MA25.10 Oligometastatic NSCLC Complete Response by PET‐CT After Radical Treatment in Oligometastatic Non‐Small Cell Lung Cancer Predicts Longer Survival

Oscar Arrieta Mexico Nothing to disclose

MA25.11 Biology Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT

Fabio Moraes Canada Nothing to disclose

MA25.12 Oligometastatic NSCLC Discussant ‐ MA 25.09, MA 25.10, MA 25.11 Michael Macmanus Australia Nothing to disclose

Session MA26: New Therapies and Emerging Data in ALK, EGFR and ROS1


Planner










Chairs

MA26 Alice Shaw USA Speakers or Advisory Board Pfizer, Novartis, Genentech, Roche, Ariad, Takeda, Ignyta, Blueprint Medicines, Loxo, Daiichi Sankyo, Merck, Taiho Pharma, KSQ Therapeutics, Natera

MA26 Alice Shaw USA Honoraria Pfizer, Novartis, Roche, Genentech, Foundation Medicine, Takeda

MA26 Alice Shaw USA Supported/Contracted Research/Grant Pfizer, Novartis, Roche, Genentech

MA26 George Simon USA Speakers or Advisory Board Takeda

MA26 George Simon USA Contracted/Support Research Grant Merck

Faculty

MA26.01 Targeted Therapy Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK‐Positive NSCLC

Shun Lu China Supported/Contracted Research/Grant AstraZeneca

MA26.01 Targeted Therapy Accumulation of Concomitant Mutations Involved in Drug Resistance in the Sequential ALK TKI Treatments of ALK‐Positive NSCLC

Shun Lu China Speakers or Advisory Board Eli Lilly, Hutchison MediPharma, Simcere, Bristol‐Meyers Squibb, Roche, Pfizer, AstraZeneca

MA26.02 Targeted Therapy Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.

Elisa Gobbini Italy Nothing to disclose

MA26.03 Targeted Therapy Activity of Osimertinib and the Selective RET Inhibitor BLU‐667 in an EGFR‐Mutant Patient with Acquired RET Rearrangement

Zofia Piotrowska USA Consultant AstraZeneca, Boehringer Ingelheim, Ariad, Novartis, Guardant Health, Takeda, AbbVie


Zofia Piotrowska USA Speakers or Advisory Board AstraZeneca, Ariad, Takeda, Novartis, Boehringer Ingelheim, AbbVie


Zofia Piotrowska USA Supported/Contracted Research/Grant Novartis


Zofia Piotrowska USA Honoraria Guardant Health

MA26.04 Targeted Therapy Discussant ‐ MA 26.01, MA 26.02, MA 26.03 Caroline McCoach USA Honoraria Takeda, Guardant

MA26.05 Targeted Therapy Comprehensive Analysis of Treatment Response and Progression Pattern in Chinese Patients with Different ALK Fusion‐Variants

Meng Qiao China Nothing to disclose

MA26.06 Targeted Therapy Crizotinib‐Treated ALK Immunopositive Metastasized NSCLC is Associated with an Unfavorable Prognosis when FISH Negative

Erik Thunnissen Netherlands Speakers or Advisory Board Pfizer, Bristol‐Meyers Squibb, Merck


Erik Thunnissen Netherlands Consultant Diaceutics


Erik Thunnissen Netherlands Supported/Contracted Research/Grant Pfizer


Erik Thunnissen Netherlands Honoraria Oncologia, Histogenix, AstraZeneca, Ventana

MA26.07 Pathology ROS1 (SP384) Immunohistochemistry Inter‐Reader Precision Between 12 Pathologists

Keith Kerr UK Consultant Bristol‐Meyers Squibb

MA26.07 Pathology ROS1 (SP384) Immunohistochemistry Inter‐Reader Precision Between 12 Pathologists

Keith Kerr UK Speakers or Advisory Board AstraZeneca, Bristol Meyers Squibb, Merck, Roche, Pfizer

MA26.08 Targeted Therapy Discussant ‐ MA 26.05, MA 26.06, MA 26.07 Dong‐Wan Kim Korea Nothing to disclose

MA26.09 Targeted Therapy Lazertinib, a Third Generation EGFR‐TKI, in Patients with EGFR‐TKI‐Resistant NSCLC: Updated Results of a Phase I/II Study

Byoung Chul Cho Korea Honoraria AstraZeneca, Boehringer Ingelheim, Novartis, Ono Pharmas




Byoung Chul Cho Korea Consultant AstraZeneca, Janssen, MedImmune, Merck, Novartis, Ono Pharma, Pfizer, Roche, Yuhan


Byoung Chul Cho Korea Speakers Bureau Novartis

MA26.10 Targeted Therapy CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M‐Positive EGFR‐Mutant NSCLC

Luis Paz‐Ares Spain Consultant Novartis, Roche, Pfizer, Bristol‐Meyers Squibb, Merck, Boehringer Ingelheim, AstraZeneca, Amgen, Clovis, Takeda


Luis Paz‐Ares Spain Honoraria Eli Lilly, Roche, Novartis, Bristol‐Meyers Squibb, Merck, Pfizer, Amgen, Takeda, Boehringer Ingelheim, AstraZeneca, Clovis Oncology, Astillas


Luis Paz‐Ares Spain Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, AstraZeneca, Roche, Lilly, Merck, Pfizer, Novartis, Takeda, Incyte, Boehringer Ingelheim, Celgene

MA26.11 Advanced NSCLC Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation‐Positive NSCLC

Yi‐Long Wu China Speakers or Advisory Board AstraZeneca, Roche, Pfizer, Eli Lilly, Boehringer Ingelheim, Sanofi


Yi‐Long Wu China Speakers Bureau AstraZeneca, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Sanofi


Yi‐Long Wu China Honoraria AstraZeneca, Eli Lilly, Pfizer, Roche


Yi‐Long Wu China Consultant AstraZeneca, Boehringer Ingelheim, Merck, Roche


Yi‐Long Wu China Supported/Contracted Research/Grant Boehringer Ingelheim, Roche

MA26.12 Targeted Therapy Discussant ‐ MA 26.09, MA 26.10, MA 26.11 Liza Villaruz USA Speakers or Advisory Board Pfizer

Session MA27: Novel Drugs and PDX Models


Planner










Chairs

MA27 William Lockwood Canada Nothing to disclose

MA27 Katerina Politi USA Supported/Contracted Research/Grant AstraZeneca, Roche, Kolltan, Symphogen

MA27 Katerina Politi USA Honoraria AstraZeneca, Merck, Novartis, Tocagen

MA27 Katerina Politi USA Royalty, Intellectual Property/Patent Holder Molecular MD

Faculty

MA27.01 Biology Establishment of PDX From Tumors Characterized by EGFR Mutations or ALK Fusion Genes from Resections, Biopsies and Pleural Fluids

Sebastiao Martins‐Filho Canada Nothing to disclose

MA27.02 Biology Hypofractionated Radiotherapy Normalizes Tumor Vasculature in Non‐Small Cell Lung Cancer Xenografts Through p‐STAT3/HIF‐1 Alpha Pathway

Xiaorong Dong China Nothing to disclose

MA27.03 Targeted Therapy Multi‐Omic Characterization of TKI‐Treated Drug‐Tolerant Cell Population in an EGFR‐Mutated NSCLC Primary‐Derived Xenograft

Erin Stewart Canada Nothing to disclose

MA27.04 Targeted Therapy Discussant ‐ MA 27.01, MA 27.02, MA 27.03 Byoung Chul Cho Korea Honoraria AstraZeneca, Boehringer Ingelheim, Novartis, Ono Pharmas

MA27.04 Targeted Therapy Discussant ‐ MA 27.01, MA 27.02, MA 27.03 Byoung Chul Cho Korea Consultant AstraZeneca, Janssen, MedImmune, Merck, Novartis, Ono Pharma, Pfizer, Roche, Yuhan

MA27.04 Targeted Therapy Discussant ‐ MA 27.01, MA 27.02, MA 27.03 Byoung Chul Cho Korea Speakers Bureau Novartis

MA27.05 Targeted Therapy Drug Loaded Mesenchymal Stem Cells for Targeted Lung Cancer Treatment in Mice

YAOJIONG Wu China Nothing to disclose

MA27.06 Targeted Therapy Therapeutic Silencing of Oncogenic KRAS With a Mutant‐Specific Short Interfering RNA

Chad Pecot USA Nothing to disclose

MA27.07 Targeted Therapy Lung Adenocarcinoma Harboring BRAF G469V Mutation is Uniquely Sensitive to EGFR Tyrosine Kinase Inhibitors

Hirotsugu Notsuda Canada Nothing to disclose

MA27.08 Targeted Therapy Discussant ‐ MA 27.05, MA 27.06, MA 27.07 Gwyn Bebb Canada Nothing to disclose

MA27.09 Targeted Therapy Dual Inhibition of BCL‐XL and MCL‐1 is Required to Induce Tumour Regression in Lung Squamous Cell Carcinomas Sensitive to FGFR Inhibition

Marie‐Liesse Asselin‐Labat USA Nothing to disclose

MA27.10 Targeted Therapy EGFR‐Targeted Therapy Alters the Tumor Microenvironment In EGFR‐Driven Lung Tumors: Rationale for Combination Therapies

Yijun Jia China Nothing to disclose

MA27.11 Targeted Therapy Genomic Sequencing and Editing Revealed the GRM8 Signaling Pathway as Potential Therapeutic Targets of Squamous Cell Lung Cancer

Panpan Zhang China Nothing to disclose

MA27.12 Targeted Therapy Discussant ‐ MA 27.09, MA 27.10, MA 27.11 Dave Barbie USA Honoraria Johnson &Johnson, Covidien, Eli Lilly, Taiho, Boehringer Ingelheim, Ono Pharmas

Session MS28: IO Combinations in Advanced NSCLC




Planner








































Chairs

MS28 Corey Langer USA Supported/Contracted Research/Grant Pfizer, Eli Lilly, Genentech, OSI Pharmas, GlaxoSmithKline, Clovis, Merck, Advantagene, Inovio, Takeda, AbbVie, Celgene, Incyte, Macrogenics

MS28 Corey Langer USA Honoraria Bristol‐Meyers Squibb, Imclone Systems, Pfizer, Eli Lilly, AstraZeneca, Merck, Novartis, Genentech, Bayer, Celgene, Abbott Labs, Biodesix, Clariant, CarisDx, Ariad, Boehringer Ingelheim, Synta, Clovis

MS28 Corey Langer USA Consultant Amgen, Synta, Peregrine, SWOG, Incyte, VA, Eli Lilly, PIK, PER, NOCR, CCO, RTP

MS28 Edgardo Santos USA Speakers Bureau Genentech, Pfizer, Novartis, Amgen, Takeda, Boehringer Ingelheim, Celgene, Merck, AstraZeneca

Faculty



MS28.01 Immunooncology Understanding the Rationale for Combining IO Agents Edward Garon USA Consultant Bristol‐Meyers Squibb, Eli Lilly, AstraZeneca, Genentech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax

MS28.01 Immunooncology Understanding the Rationale for Combining IO Agents Edward Garon USA Speakers or Advisory Board AstraZeneca, Bristol‐Meyers Squibb, Eli Lilly, Genetech, Merck, Novartis, Pfizer, Boehringer Ingelheim, Mirati, Dynavax

MS28.01 Immunooncology Understanding the Rationale for Combining IO Agents Edward Garon USA Supported/Contracted Research/Grant Merck, Genentech, AstraZeneca, Novartis, Pfizer, Eli Lilly, Bristol‐Meyers Squibb, Boehringer Ingelheim, Mirati Therapeutics, Dyanvax

MS28.02 Immunooncology Combination IO+IO Myung‐Ju Ahn Korea Consultant AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Merck, Novartis, Alpha BioPharmas

MS28.02 Immunooncology Combination IO+IO Myung‐Ju Ahn Korea Speakers or Advisory Board AstraZeneca, Eli Lilly, Bristol‐Meyers Squibb, Merck, Ono Pharma, Roche

MS28.03 Immunooncology Combinatorial IO + Chemo Rosalyn Juergens Canada Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, Eli Lilly, Pfizer, Amgen, Novartis, AstraZeneca, Takeda

MS28.03 Immunooncology Combinatorial IO + Chemo Rosalyn Juergens Canada Honoraria Bristol‐Meyers Squibb, Merck, Roche, Boehringer Ingelheim, AstraZeneca, MedImmune, Eli Lilly, Takeda, Novartis, Amgen Pfizer

MS28.03 Immunooncology Combinatorial IO + Chemo Rosalyn Juergens Canada Speakers Bureau Amgen

MS28.03 Immunooncology Combinatorial IO + Chemo Rosalyn Juergens Canada Consultant Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Amgen, Roche, AstraZeneca, MedImmune,

MS28.03 Immunooncology Combinatorial IO + Chemo Rosalyn Juergens Canada Supported/Contracted Research/Grant AstraZeneca, MedImmune, Merck, Bristol‐Meyers Squibb

MS28.04 Immunooncology Combination with Targeted Therapies Ross Soo Singapore Supported/Contracted Research/Grant AstraZeneca

MS28.04 Immunooncology Combination with Targeted Therapies Ross Soo Singapore Honoraria AstraZeneca, Bristol‐Meyers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Celgene, Ignyta, Roche, Taiho

MS28.05 Immunooncology Combining IO with Radiation Corinne Faivre‐Finn UK Supported/Contracted Research/Grant Merck, AstraZeneca, Elekta

MS28.05 Immunooncology Combining IO with Radiation Corinne Faivre‐Finn UK Consultant Merck, AstraZeneca, Elekta, Pfizer, Respective Meeting‐Related Travel Support

MS28.05 Immunooncology Combining IO with Radiation Corinne Faivre‐Finn UK Speakers or Advisory Board Pfizer, Merck

MS28.05 Immunooncology Combining IO with Radiation Corinne Faivre‐Finn UK Honoraria AstraZeneca, Merck

MS28.05 Immunooncology Combining IO with Radiation Corinne Faivre‐Finn UK Speakers Bureau AstraZeneca, Merck

MS28.06 Q&A

Session MS29: Selection into Screening Programs: Interplay of Risk Algorithms, Genetic Markers and Biomarkers


Planner

MS29 Screening and Early Detection Christine Berg USA Honoraria Medial Early Sign LLC, GRAIL

MS29 Screening and Early Detection Stephen Lam Canada Nothing to disclose

MS29 Screening and Early Detection Denise Aberle USA Nothing to disclose

MS29 Screening and Early Detection John Field UK Speakers Bureau Roche

MS29 Screening and Early Detection John Field UK Speakers or Advisory Board Epigenomics, VisonGate

MS29 Screening and Early Detection John Goffin Canada Nothing to disclose

MS29 Screening and Early Detection Harry Groen Netherlands Consultant Roche‐Genentech, Merck, Novartis, Bristol‐Meyers Squibb

MS29 Screening and Early Detection Norihiko Ikeda Japan Honoraria AstraZeneca, Chugai, Merck, Ono Pharma, Taiho, Eli Lilly, Pfizer, Johnson & Johnson

MS29 Screening and Early Detection Garth Nicholas Canada Nothing to disclose

MS29 Screening and Early Detection Nir Peled Israel Honoraria AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

MS29 Screening and Early Detection Nir Peled Israel Consultant AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360

MS29 Screening and Early Detection Heidi Schmidt Canada Nothing to disclose

MS29 Screening and Early Detection Betty Tong Speakers or Advisory Board Medtronic

Chairs

MS29 John Goffin Canada Nothing to disclose

MS29 Betty Tong USA Speakers or Advisory Board Medtronic

Faculty

MS29.00 Screening and Early Detection Introduction with Poll Slides John Goffin Canada Nothing to disclose

MS29.01 Screening and Early Detection Assessment of Risk Prediction Algorithms for Entry into Screening Programs


MS29.02 Screening and Early Detection Defining Screening Frequency & Duration Using Risk Prediction Algorithms and CT Image Findings

Kevin Ten Haaf Netherlands Nothing to disclose

MS29.03 Screening and Early Detection Polygenic Risk Score for Risk Assessment Rayjean Hung Canada Nothing to disclose

MS29.04 Screening and Early Detection LuCID Exhaled Breath Analysis Marc Van Der Schee UK Employee (full time or part time) Owlstone Medical

MS29.04 Screening and Early Detection LuCID Exhaled Breath Analysis Marc Van Der Schee UK Royalty, Intellectual Property/Patent Holder Owlstone Medical

MS29.05 Screening and Early Detection Early Detection Biomarker Development: Is Success on the Horizon? Peter Mazzone USA Speakers or Advisory Board Exact Sciences, Grail, Oncimmune



MS29.05 Screening and Early Detection Early Detection Biomarker Development: Is Success on the Horizon? Peter Mazzone USA Supported/Contracted Research/Grant Oncocyte, Veracyte

MS29.06 Q&A

Session MS30: Modern Day RT in LA NSCLC: Where Is the Evidence?


Planner

MS30 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Supported/Contracted Research/Grant Merck, AstraZeneca, Elekta

MS30 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Consultant Merck, AstraZeneca, Elekta, Pfizer, Respective Meeting‐Related Travel Support

MS30 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers or Advisory Board Pfizer, Merck

MS30 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Honoraria AstraZeneca, Merck

MS30 Treatment of Locoregional Disease ‐ NSCLC Corinne Faivre‐Finn UK Speakers Bureau AstraZeneca, Merck

MS30 Treatment of Locoregional Disease ‐ NSCLC Paula Ugalde Canada Nothing to disclose

MS30 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Honoraria Pfizer, Boehringer Ingelheim, AstaZeneca, Bristol‐Meyers Squibb, Merck, Takeda

MS30 Treatment of Locoregional Disease ‐ NSCLC Charles Butts Canada Speakers or Advisory Board Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol‐Meyers Squibb, Merck, Takeda

MS30 Treatment of Locoregional Disease ‐ NSCLC Hiroshi Date Japan Nothing to disclose

MS30 Treatment of Locoregional Disease ‐ NSCLC Dirk De Ruysscher Netherlands Nothing to disclose

MS30 Treatment of Locoregional Disease ‐ NSCLC Rui Haddad Brazil Nothing to disclose

MS30 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Speakers Bureau Varian Medical

MS30 Treatment of Locoregional Disease ‐ NSCLC Feng‐Ming (Spring) Kong USA Honoraria Varian Medical

MS30 Treatment of Locoregional Disease ‐ NSCLC Jocelyne Martin Canada Nothing to disclose

MS30 Treatment of Locoregional Disease ‐ NSCLC Gaetano Rocco Italy Speakers Bureau Baxter, Medtronic

MS30 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers or Advisory Board AbbVie, AstraZeneca, Spiration

MS30 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Speakers Bureau Synthes

MS30 Treatment of Locoregional Disease ‐ NSCLC Eric Vallieres USA Consultant Spiration, Olympus

Chairs

MS30 Fiona Hegi‐Johnson Australia Nothing to disclose

MS30 Yuko Nakayama Japan Speakers or Advisory Board AstraZeneca

Faculty

MS30.01 Treatment of Locoregional Disease ‐ NSCLC Overview of RT Technology in LA NSCLC (IMRT, VMAT, IGRT) Gerard Hanna UK Nothing to disclose

MS30.01 Treatment of Locoregional Disease ‐ NSCLC Introduction with Poll Questions Yuko Nakayama Japan Speakers or Advisory Board AstraZeneca

MS30.02 Treatment of Locoregional Disease ‐ NSCLC What Evidence Is Available to Support RT Technology in LA NSCLC (including Protons)?

Yong Chan Ahn Korea Nothing to disclose

MS30.03 Treatment of Locoregional Disease ‐ NSCLC What Evidence Is Available to Support RT Treatment Intensification in LA NSCLC?

Jeffrey Bradley USA Speakers or Advisory Board AstraZeneca, ViewRay, Varoian

MS30.03 Treatment of Locoregional Disease ‐ NSCLC What Evidence Is Available to Support RT Treatment Intensification in LA NSCLC?

Jeffrey Bradley USA Supported/Contracted Research/Grant Mevion Medical Systems, Viewray

MS30.04 Treatment of Locoregional Disease ‐ NSCLC Perspective Maria Werner‐Wasik USA Nothing to disclose

MS30.05 Treatment of Locoregional Disease ‐ NSCLC Nutritional Management During Radical Radiotherapy Rhys White UK Nothing to disclose

MS30.06 Treatment of Locoregional Disease ‐ NSCLC Q&A with Poll Questions

Session MS31: Clinical Science in Mesothelioma


Planner

MS31 Mesothelioma Anna Nowak Australia Speakers or Advisory Board Bayer, AstraZeneca, Sellas Life Sciences, Trizell, Boehringer Ingelheim, Epizyme, Roche, Merck

MS31 Mesothelioma Anna Nowak Australia Consultant AstraZeneca, Boehringer Ingelheim, Epizyme

MS31 Mesothelioma Anna Nowak Australia Supported/Contracted Research/Grant AstraZeneca, Douglas Pharma

MS31 Mesothelioma Marc DePerrot Canada Nothing to disclose

MS31 Mesothelioma Paul Baas Netherlands Nothing to disclose

MS31 Mesothelioma Penelope Bradbury Canada Honoraria AbbVie, Merck, Pfizer



MS31 Mesothelioma Michele Carbone USA Nothing to disclose

MS31 Mesothelioma John Cho Canada Nothing to disclose

MS31 Mesothelioma Lauren Donohoe Canada Nothing to disclose

MS31 Mesothelioma Dean Fennell UK Speakers or Advisory Board AbbVie, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol‐Meyers Squibb, Clovis, Eli Lilly, Lab21, Oncos, Polaris, Bristol‐Meyers Squibb, Epizyme, Roche

MS31 Mesothelioma Dean Fennell UK Supported/Contracted Research/Grant Boehringer Ingelheim, Bergen Bio, Bayer, Bristol‐Meyers Squibb, Pierre Fabre, Eli Lilly, Roche‐Genentech, Astex

MS31 Mesothelioma Dean Fennell UK Speakers Bureau Boehringer Ingelheim, Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca

MS31 Mesothelioma Dean Fennell UK Honoraria AbbVie, Boehringer Ingelheim, Bayer, Bristol‐Meyers Squibb, Epizyme, Roche, AstraZeneca

MS31 Mesothelioma Seiki Hasegawa Japan Nothing to disclose

MS31 Mesothelioma Christopher Lee Canada Nothing to disclose

MS31 Mesothelioma Isabelle Opitz Switzerland Nothing to disclose

MS31 Mesothelioma Nick Pavlakis Australia Speakers or Advisory Board Bristol‐Meyers Squibb, Merck, Astra Zeneca, Roche, Novartis, Boehringer Ingelheim, Merck, Pfizer, Ipsen, Amgen

MS31 Mesothelioma Nick Pavlakis Australia Supported/Contracted Research/Grant Bayer

MS31 Mesothelioma Kenneth Rosenzweig USA Nothing to disclose

Chairs

MS31 Marc De Perrot Canada Nothing to disclose

MS31 Haining Yang USA Nothing to disclose

Faculty

MS31.01 Mesothelioma Mechanisms and Targets for BAP1 Activity Michele Carbone USA Nothing to disclose

MS31.02 Mesothelioma Clinical Implementation of BAP1 Inhibitors Paul Baas Netherlands Nothing to disclose

MS31.03 Mesothelioma Targeting the Hippo Pathway David Jablons USA Consultant Razor Genomics

MS31.04 Mesothelioma CAR‐T and ADC's in MPM Prasad Adusumilli USA Nothing to disclose

MS31.05 Mesothelioma Vaccination and Antibody‐Based Therapy in Mesothelioma Joachim Aerts Netherlands Speakers or Advisory Board Bristol‐Meyers Squibb, Merck Oncology, Boehringer Ingelheim, Eli‐Lilly, Roche, Ampera

MS31.05 Mesothelioma Vaccination and Antibody‐Based Therapy in Mesothelioma Joachim Aerts Netherlands Speakers Bureau AstraZeneca, Verastem

MS31.05 Mesothelioma Vaccination and Antibody‐Based Therapy in Mesothelioma Joachim Aerts Netherlands Supported/Contracted Research/Grant Genentech, AstraZeneca

MS31.05 Mesothelioma Vaccination and Antibody‐Based Therapy in Mesothelioma Joachim Aerts Netherlands Royalty, Intellectual Property/Patent Holder Tumor cell lysate for dendritic cell loading

MS31.06 Q&A

Session MS32: SCLC ‐ From Benchside to Bedside ‐ Clinical Science Session


Planner

MS32 Small Cell Lung Cancer/NET Fiona Blackhall UK Nothing to disclose

MS32 Small Cell Lung Cancer/NET Peter Ellis Canada Honoraria AbbVie, AstraZeneca

MS32 Small Cell Lung Cancer/NET Peter Ellis Canada Consultant Celegene, Mylan

MS32 Small Cell Lung Cancer/NET Jeffrey Bogart USA Nothing to disclose

MS32 Small Cell Lung Cancer/NET Lauren Byers USA Nothing to disclose

MS32 Small Cell Lung Cancer/NET Quincy Chu Canada Nothing to disclose

MS32 Small Cell Lung Cancer/NET Eric Lim UK Speakers Bureau Abbott Molecular, Pfizer, Roche, Eli Lily, Boehringer Ingelheim, Ethicon

MS32 Small Cell Lung Cancer/NET Eric Lim UK Supported/Contracted Research/Grant Medela, ScreenCell, Clearbridge Biomedics, Illumina, Guardant Health

MS32 Small Cell Lung Cancer/NET Francoise Mornex France Nothing to disclose

MS32 Small Cell Lung Cancer/NET Charles Rudin USA Speakers or Advisory Board AbbVie, Amgen, AstraZeneca, Bristol‐Meyers Squibb, Genentech, Harpoon, Genetics

MS32 Small Cell Lung Cancer/NET Charles Rudin USA Consultant Bristol‐Meyers Squibb, AbbVie, Seattle Genetics, Harpoon Therapeutics, Genentech Roche, AstraZeneca

MS32 Small Cell Lung Cancer/NET Ben Slotman Netherlands Nothing to disclose

MS32 Small Cell Lung Cancer/NET Sumitra Thongprasert Thailand Nothing to disclose

MS32 Small Cell Lung Cancer/NET Jie Wang China Nothing to disclose

MS32 Small Cell Lung Cancer/NET Mauro Zukin Brazil Nothing to disclose



Chairs

MS32 Jason Pantarotto Canada Nothing to disclose

MS32 Alex Adjei USA Nothing to disclose

Faculty

MS32.01 Small Cell Lung Cancer/NET Genetic Mouse Models (GEMMS) Trudy Oliver USA Nothing to disclose

MS32.02 Small Cell Lung Cancer/NET Patient Derived Models (PDX & CTC‐Derived) Anna Farago USA Supported/Contracted Research/Grant AbbVie, Stemcentrx, PharmaMar, Ignyta, Bristol‐Meyers Squibb, Merck, AstraZeneca, Novartis, Bayer, Loxo

MS32.02 Small Cell Lung Cancer/NET Patient Derived Models (PDX & CTC‐Derived) Anna Farago USA Honoraria Foundation Medicine

MS32.02 Small Cell Lung Cancer/NET Patient Derived Models (PDX & CTC‐Derived) Anna Farago USA Consultant AbbVie, PharmaMar, Takeda, Stemcentrx, Loxo, Bayer

MS32.02 Small Cell Lung Cancer/NET Patient Derived Models (PDX & CTC‐Derived) Anna Farago USA Speakers or Advisory Board AbbVie, Loxo, Pharmamar

MS32.03 Small Cell Lung Cancer/NET Liquid Biopsies for Drug Development in SCLC Caroline Dive UK Employee Cancer Research UK

MS32.03 Small Cell Lung Cancer/NET Liquid Biopsies for Drug Development in SCLC Caroline Dive UK Honoraria AstraZeneca

MS32.03 Small Cell Lung Cancer/NET Liquid Biopsies for Drug Development in SCLC Caroline Dive UK Contracted/Support Research Grant AstraZeneca, Astex Pharmaceuticals, Bioven, Amgen, Carrick Therapeutics, Merck AG, Taiho Oncology, Clearbridge Biomedicals, Angle PLC, Menarini Diagnostics, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene

MS32.04 Small Cell Lung Cancer/NET Molecular Phenotypes of SCLC Adi Gazdar USA Nothing to disclose

MS32.05 Small Cell Lung Cancer/NET Targeting DNA Damage and Repair Lauren Byers USA Nothing to disclose

MS32.06 Small Cell Lung Cancer/NET Epigenetic Targets John Poirier USA Nothing to disclose

Session PL04: Take Action ‐ Key Messages from WCLC 2018 and Goals for 2019


Planner







PL04 Frances Shepherd Canada Other Bristol‐Myers Squibb, Eli Lilly, Pfizer, AstraZeneca, MedImmune, Roche, Merrimack




Chairs




PL04 Robert Pirker Austria Speakers Bureau Boehringer Ingelheim

PL04 Robert Pirker Austria Speakers or Advisory Board Boehringer Ingelheim, AstraZeneca, Eli Lilly

PL04 Robert Pirker Austria Honoraria Merck, Genmab and Regeneron

Faculty

PL04.01 Immunotherapy David Gandara USA Honoraria AstraZeneca, Celgene, Genentech, Guardant Health, Eli Lilly, Liquid Genomics, Nant Health

PL04.01 Immunotherapy David Gandara USA Consultant Genentech, AstraZeneca, Celgene, Guardant Health, Eli Lilly, Liquid Genomics

PL04.01 Immunotherapy David Gandara USA Supported/Contracted Research/Grant AstraZeneca, Genentech

PL04.01 Immunotherapy David Gandara USA Speakers or Advisory Board AstraZeneca, Celgene, Genentech, Gaurdant Health, Eli Lilly, Liquid Genomics, Nant Health

PL04.02 Biomarkers Ming Tsao Canada Honoraria Merck, AstraZeneca, Bristol Myers Squibb, Pfizer, Roche, Ventana

PL04.02 Biomarkers Ming Tsao Canada Supported/Contracted Research/Grant Merck, Pfizer, Roche, Ventana, AstraZeneca

PL04.02 Biomarkers Ming Tsao Canada Speakers or Advisory Board AstraZeneca, Pfizer, Merck, Roche, Ventana, Bristol Myers Squibb, AbbVie, Celgene

PL04.03 Surgery Ramon Rami‐Porta Spain Nothing to disclose

PL04.04 Radiation Oncology Jose Belderbos Netherlands Nothing to disclose

PL04.05 Clinical Research in Latin America Clarissa Mathias Brazil Nothing to disclose



PL04.06 Targeted Therapy Michael Boyer Australia Honoraria Roche, Bristol‐Meyers Squibb, Merck, AstraZeneca, Novartis

PL04.06 Targeted Therapy Michael Boyer Australia Speakers or Advisory Board Merck, Amgen, Roche, Bristol‐Meyers Squibb, Pfizer, AstraZeneca

PL04.06 Targeted Therapy Michael Boyer Australia Contracted/Support Research Grant Merck, Amgen, Genentech, Roche, Bristol‐Meyers Squibb, AstraZeneca, Novartis, Pfizer

Documents

WCLC 2018 - Disclosure Information - Faculty and Planners · 11/1/2018 · WCLC 2018 - Disclosure Information - Faculty and Planners Final Pr.No. Topic Presentation Title Pres. FirstName